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ABSTRACT: 
This thesis examines both humoral and cellular adaptive immune 
responses to varicella vaccination (up to 18 months post immunisation), in 
an ethnically diverse population of healthcare workers. Using two 
parameters of humoral immunity at six weeks post first vaccination; 
(avidity readings 60%, and a TRFIA reading 400mIU/mL) a cut-off of 
130mIU/mL was defined for a more sensitive in house immuno assay 
(TRFIA), in this vaccinated adult population. Using these cut-offs, three 
patterns of antibody responses were identified; primary responders who 
seroconverted following vaccination, secondary responders who had pre-
existing immunity and subjects who responded poorly to vaccination. 
Demographic and immunological characteristics of each subset were 
examined. An association between black ethnicity and lower antibody titre 
to vaccination in primary responders was identified, whilst Caucasians 
were more likely to have a history and pre-existing immunity, in keeping 
with the epidemiology of chickenpox in temperate climates. The follow-up 
study revealed that affinity maturation to VZV can take longer than 18 
months in response to vaccination. At follow-up, 25% of subjects recruited 
at this time point were seronegative by TRFIA. Seroconversion after two 
doses of vaccine and a TRFIA titre of <500mIU/ml after two doses were 
significantly associated with waning antibody titre over time. Positive IFN- 
ELISPOT responses at 18 months did not necessarily correspond with 
TRFIA seropositive status.  
 
3 
 
ACKNOWLEDGEMENTS AND DEDICATION: 
First, I would like to thank my supervisor, Prof. Judy Breuer, for giving me 
the opportunity to undertake this PhD and for the immeasurable amount of 
time and energy she has invested in this adventure; for her continued 
support, encouragement and guidance throughout. I would also like to 
thank my second supervisor, Prof. Ping Wang.  
 
Thanks to Dr. Dan Pennington and Dr. Sourenna Kiani for their helpful 
comments and advice with this thesis, and for their support and belief in 
me over the last few years. Thanks also to Dr. Jon Dodd (Imperial College) 
for comments and advice with the introduction chapter of this thesis. I 
would also like to thank Dr. Rav Kanda, Mrs. Fiona Scott, Miss Christine 
Tomlins and Dr. Alison Steele for proof reading parts of this thesis.  
 
I would like to thank all the ROVE study participants; without their samples 
this study would not have been possible. I would also like to say a special 
thanks to Mrs. Fiona Scott for coordinating the ROVE study and carrying 
out sample collection; and Mr. Mahmoud Al-Bassam, Miss Ingrid Green 
and Mr. Gavin Wall for technical assistance with processing ROVE 
samples. I would like to thank collaborators who have assisted with the 
ROVE study; Dr. Chris Maple (HPA; London) for his assistance with 
serology; Dr. Paul Sinnott and Mr. Sharham Hemmatpour (Bart‟s and the 
London NHS Trust) for assistance with Luminex HLA typing; Dr. Graham 
Ogg and Dr. Louise Jones (University of Oxford) for their assistance with 
tetramer assays and Sharon Steinberg in the lab of Prof. Anne Gershon 
(Columbia University, USA) for carrying out FAMA assays. For general 
statistical assistance, I would like to thank Mrs. Mary Leedham Green, as 
well as Dr. Nick Andrews (HPA; London) and Dr. Karen Ayres (University 
of Reading) for their invaluable advice with mixture modelling and 
probability density curves and ROC analysis respectively.  
 
I would like to pay a special tribute to the members of the Breuer 
Laboratory, past and present; for the vast amount of support along the 
way; Dr. Mark Quinlivan; Dr. Inga Dry; Dr. Nitu Sengupta, Dr. Karin 
4 
 
Averbeck, Dr. Manuraj Singh, Dr. Meleri Jones and Mr. Forrest Ran along 
with members of the Wang laboratory past and present; Dr. Vassia Sofra 
and Dr. Salah Mansour, Major Dr. Bo Zhu, Dr. Alistair Symonds and Dr. 
Martine Barel. I would also like to thank Dr. Gary Warnes for his 
assistance with FACS and imaging techniques over the last few years. 
 
I would like to say a special thank you to colleagues (too numerous to 
mention by name) at Bart‟s and the London School of Medicine and 
Dentistry, in the Centre of Infectious Diseases, the Centre of Adult and 
Paediatric Gastroenterology (and the many other departments I have 
infiltrated), for immeasurable amounts of advice and support over the 
years. Thank you all for creating such a wonderful and happy environment 
to carry out my PhD; many of the friendships I have made at the Institute 
of Cell and Molecular Science will last a lifetime, and I was blessed to 
share the journey with you. 
 
I would like to say a special thank you for the continued love and support I 
have received from my friends and family over the last four years; many of 
whom didn‟t realise what completing a PhD entailed, but have been 
supportive, patient and forgiving nonetheless. I would also like to take this 
opportunity to apologise to all of them, for having seen a lot less of me 
over the last few years, and for having to endure a grumpy monster most 
of the time when they have seen me.  I would like to extend that apology 
to the ladies of Jamaica St. over the years, and say thank you for helping 
to make a lovely nest to come home too. 
 
Lastly, I would like to thank my Mum and my Nan for their financial support 
over the last few months and my concluding thanks are to them, my Sister 
and my Brother-in-law, for their never ending emotional support.  
 
This thesis is dedicated to an autodidactic biologist; my Granddad.
5 
 
CONTENTS: 
 
DECLARATION        2 
ABSTRACT         2 
ACKNOWLEDGEMENTS AND DEDICATION    3 
TABLE OF CONTENTS       5 
LIST OF FIGURES        13 
LIST OF TABLES        18 
LIST OF ABBREVIATIONS       20 
 
CHAPTER 1:  INTRODUCTION   
1.1   Varicella Zoster Virus in Context     29                                                     
1.2   Classification and Virus Structure     29 
1.2.1  Structure and Morphology of the Varicella Zoster Virus  32           
1.3   Genomic Structure and Organisation     33 
1.4   Functions and Properties of Key VZV Proteins  39 
1.4.1   Glycoproteins and Structural Proteins   39 
1.4.2   Proteins Involved in Replication    44 
1.5   VZV Infection at a Cellular Level    47 
1.5.1   Cell Attachment and Entry     47 
1.5.2   Initial Events in Viral Replication     52 
1.5.2.1  Viral DNA Replication      52 
1.5.3   Protein Synthesis      54 
1.5.4   Virion Assembly      56 
1.5.4.1   The Nucleocapsid      56 
1.5.4.2  Acquisition of Tegument Proteins    59 
1.5.4.3  Glycoprotein Synthesis and Trafficking   60 
1.5.4.4  Envelopment and Virion Morphogenesis   62 
1.5.5   Egress and Cell-to-Cell Spread    67 
1.6   The Natural History of VZV Infection    70 
1.6.1   Pathogenesis of Varicella     70 
1.6.1.1  Rash Formation and the Host Immune Response  76 
1.6.1.2  The Role of Individual VZV Proteins in Varicella  
Pathogenesis       78 
1.6.2   Pathogenesis of Latency and Reactivation   86 
1.6.2.1  The Role of Individual VZV Proteins in the Pathogenesis  
of  Latency       90 
6 
 
 
1.7 Host Immune Responses to VZV, and Immune  
Modulation and Evasion by the Virus    92 
1.7.1 NK Cell Mediated Immunity and VZV Induced Immune    
Modulation        93 
1.7.2   Immune Modulation of Dendritic Cells   94 
1.7.3   Modulation of Apoptosis     95 
1.7.4   Immune Modulation of Adhesion Molecules   96 
1.7.5   VZV Modulation of the Major Histocompatibility  
Complexes  (MHC-I and MHC-II)    96 
1.7.6 Cytokines Induced by VZV Infection, and the  
Immune Modulation of Cytokine Pathways by VZV   100                                                 
1.7.6.1  Type I (IFN-) and Type II (IFN- and IFN-)  
Interferons       103 
1.7.7   Modulation of the NFB Transactivation Pathway  105 
1.8   Prevention and Treatment     106 
1.8.1   Antiviral Therapy      106 
1.8.2   Varicella Vaccination      107 
1.8.2.1  Development of the Varicella Oka Vaccine   107 
1.8.2.2  Comparison of POka and VOka Viruses   107 
1.8.2.3  Vaccine Virus Attention     108 
1.8.2.4  Uses of the Varicella Vaccine    110 
1.8.2.5  Vaccine Efficacy       111 
1.8.2.6  The Aim of Universal Vaccination and Achievements  
Ten Years Post Introduction      111 
1.8.2.7  The Effect of Varicella Vaccination on Rates of  
Zoster        112 
1.8.3   Development of the Zoster Vaccine    113 
 
CHAPTER 2:  MATERIALS AND METHODS 
2.1   List of Buffers and Reagents     115 
2.2  Patient Recruitment and Sample Collection   115 
2.2.1   ROVE (Response to Oka Vaccine Evaluation) Study 115 
2.2.2  Sample Collection in the Case of ROVE Rash  
Development, Post Vaccination    118 
2.3   Sample Processing and Storage    118 
2.3.1   ROVE Blood Samples     118 
7 
 
2.3.2   Whole Blood       118 
2.3.3   Plasma Isolation      118 
2.3.4   Serum Isolation      118 
2.3.5   Peripheral Blood Mononuclear Cells (PBMC) Separation 119 
2.3.6   DNA Extraction      119 
2.3.7   Cell Freezing       120 
2.3.8  Thawing Cell Aliquots      120 
2.3.9  Viable Cell Counts      120 
2.3.10  Sample Storage      121 
2.4   Serology Based Assays     121 
2.4.1   ELISA Based Assays      121 
2.4.1.1  VZV IgG TRFIA       121 
2.4.1.2  VZV IgG Avidity (EUROIMMUN) Assay    122    
2.4.2  SDS-PAGE and Western Blotting     123 
2.4.2.1  Coomassie Staining      125 
2.4.2.2  Bradford Assay      125 
2.4.3   Fluorescent Antibody to Membrane Antigen (FAMA)  
Technique       125 
2.5   Cell Based Assays      126 
2.5.1  IFN- ELISPOT      126 
2.5.1.1   Ex Vivo Overnight Stimulation on ROVE HCW PBMCs  
Using Whole VZV Lysate as Antigen    126 
2.5.1.2       Assessing PBMC Aggregation at Various Incubation  
Temperatures for ELISPOT Optimisation   127 
2.5.2   DRB1*1501 Specific Peptide Stimulation of PBMCs  
T Cell Lines       128 
2.5.3   Flow Cytometry Analysis      128 
2.5.3.1  Flow Cytometry Analysis of DRB1*1501 Tetramer and  
Surface  Staining on ROVE PBMCs    128 
2.6   PCR Based Assays      130 
2.6.1   PCR on Vaccine Associated Rash DNA   130 
2.7   Statistical Analysis      130 
2.7.1   Mixture Modelling      130 
2.7.2   ROC analysis       130 
2.7.3  Calculating the Accurarcy of Serological Assays  131 
2.7.4   All Other Statistical Analysis     131 
 
8 
 
CHAPTER 3:  HUMORAL IMMUNE RESPONSES TO VACCINATION 
Chapter Summary      132 
3.1   INTRODUCTION      132 
3.1.1   Antibody Structure and Function    132 
3.1.1.1  Antibody Structure and Primary Diversification of  
Antibody Repertoire      132 
3.1.1.2  Secondary Diversification of the Antibody Repertoire 134 
3.1.1.2.1 Affinity Maturation of Antibodies    137 
3.1.1.2.2  Antibody Class Switching     138 
3.1.1.3  Sources of Antibody Following Primary Antigen  
Challenge        138 
3.1.1.4  Kinetics of Antibody Responses    138 
3.1.1.5  Biological Functions of Antibodies    139 
3.1.1.5.1  Biological Activity of Different Subclasses of IgG  140 
3.1.2   Antibodies to VZV      140 
3.1.2.1  The Role of VZV-Specific Antibodies in the Prevention  
of  Reinfection       142 
3.1.2.2  The Roles of Different Classes and Subclasses of  
Antibodies in VZV Infection     143 
3.1.2.2.1  Immunoglobulin G      143 
3.1.2.2.2  Immunoglobulin A      144 
3.1.3   Targets of Humoral Immunity to VZV    145 
3.1.3.1  Glycoproteins       145 
3.1.3.2  Capsid and Tegument Proteins    153 
3.1.4   Avidity Studies      153 
3.1.5   Differences in the Magnitude of the Humoral Immune  
Response to VZV Vaccine     155 
3.1.5.1  Genetic Factors      155 
3.1.5.2  Age of Infection      155 
3.1.5.3  Vaccination Verses Natural Infection    155 
3. 1.5.4  Factors Affecting Vaccine Seroconversion Rates  156 
3.1.6   Antibodies as a Measure of VZV Immunity and  
Breakthrough Infection     158  
3.1.7   Methodologies for Serology Testing    160 
3.1.7.1  Cell and Bead Based Assays     160 
3.1.7.2  Enzyme-Linked Immuno Sorbent Assays (ELISAs)  161 
3.1.7.3  Time Resolved Fluorescence Immuno Assay (TRFIA)  164 
9 
 
3.2   AIMS AND HYPOTHESIS      166 
3.3   RESULTS        166 
3.3.1   Characteristics of the ROVE Study Population  166 
3.3.1.1  Summary of ROVE Study Participants Demographics  167 
3.3.1.2  Characteristics of Humoral Immune Responses to  
Vaccination       170 
3.3.2 Evaluation of UK Reference VZV IgG Antibody Assay  
for Detection of Vaccine Induced Antibody and Low  
Level Antibody      171 
3.3.2.1  Assay Characteristics of TRFIA and Avidity 
(EUROIMMUN)      172 
3.3.2.2 Correlation of TRFIA and Avidity Values Six Weeks  
Post Vaccination        173 
3.3.2.3 Extrapolating a VZV-Specific IgG TRFIA Cut-Off  
from an Adult Population Using Vaccination as a Tool 
 to Assess Naturally Derived VZV-specific Antibody     177 
3.3.2.3.1  Defining a Cut-off Using Mixture Modelling      179 
3.3.2.3.2  Comparison between the Six Week Post Vaccination  
and the Mixture Modelling Defined Cut-offs, Using  
Probability Density Curves     180 
3.3.2.3.3  Using ROC Analysis to Evaluate an Optimum Cut-Off 181 
3.3.3   Assessing Humoral Immune Responses to  
Vaccination Using the TRFIA Cut-Off of 130mIU/mL     184 
3.3.3.1  The Characteristics of the Humoral Immune  
Response  Following Vaccination and at Follow-Up     185 
3.3.3.1.1  Demographic Characteristics for each Subset  191 
3.3.3.1.2  Characteristics of Primary Responders   194 
3.3.3.1.2.1   Characteristics of Primary Responders who  
Seroconverted Following Vaccination (NSC1 and NSC2) 194 
3.3.3.1.2.2 Characteristics of Primary Responders who Made  
Low Level Responses to Vaccine (NLR and PLR)   194 
3.3.3.1.2.3   NLRs: Response to a Third Dose of Vaccine   196 
3.3.3.1.2.4  NLRs: Responses to Natural Infection   196 
3.3.3.1.2.5  Secondary Humoral Immune Responses to  
Vaccination (PI  and NI)     197 
3.3.3.2 Correlation Between FAMA and TRFIA in Vaccinated  
Adults; Benchmarking Humoral Subsets   197 
10 
 
3.3.3.3      Benchmarking the Subsets Against a History of  
Varicella at  Enrolment     203 
3.3.3.4      Antibody Boosting and Waning Immune Responses  
at 18 Months Post Vaccination    204 
3.3.3.4.1 Characteristics of Subjects who Retained  
Seropositive TRFIA Status at 18 Months Post  
Vaccination       207 
3.3.3.4.2  Waning Humoral Immunity     207 
3.3.3.4.3  Antibody Boosting      213 
3.3.4   Failure to Undergo IgG Antibody Affinity Maturation,  
18 Months Post Vaccination     214 
3.3.5   Western Blotting of Serum from Varicella Vaccinees 218 
3.4   DISCUSSION       223 
3.4.1   Summary of Main Findings     223 
3.4.2   Defining a TRFIA Cut-Off in an Adult  
Population Using Vaccination as a Tool to Assess  
Naturally Derived VZV-Specific Antibodies   224 
3.4.3   Study Population Demographics    225 
3.4.4   Failure to Seroconvert Following Two Doses of  
Vaccine in Primary Responders    225 
3.4.5 Humoral Immune Responses and an Association  
with Ethnicity       227 
3.4.6   Negative immune (NI) Humoral Responders   228 
3.4.7   Failure to Undergo Antibody Affinity Maturation at 18  
Months Post-Vaccination     229 
3.4.8 Loss of Seropositive Status 18 Months Post  
Vaccination and the Risk of Breakthrough Infection  231 
3.4.9   Implications of Antibody Boosting at Follow-Up  232 
3.4.10  Future work       233 
 
CHAPTER 4: CELL MEDIATED IMMUNE RESPONSES TO VACCINATION  
Chapter Summary      234 
4.1   INTRODUCTION      234 
4.1.1   An Introduction to Adaptive Cell Mediate Immunity (CMI) 234 
4.1.2 The Role of Adaptive Cell Mediated Immunity in Varicella   
and Herpes Zoster      236 
 
11 
 
4.1.3 Variation in T Cell Responses and Factors that Affect T  
Cell Responses in Individuals    238 
4.1.3.1  Age        238 
4.1.3.2  Gender       239 
4.1.3.3  Immunosuppression      239 
4.1.3.4  Genetic Factors      241 
4.1.3.5   Relative Antigen Content of Varicella Vaccine  243 
4.1.4   Nature of the T Cell Response to VZV   243 
4.1.4.1  The Role of CD8+ T Cells in VZV Infection   245 
4.1.4.2  The Role of CD4+ T Cells in VZV Infection   247 
4.1.4.3  Targets of CD4+ T Cells     247 
4.1.4.3.1  Glycoproteins       247 
4.1.4.3.2  Tegument Proteins      249 
4.1.4.3.3 Other Targets       250 
4.1.5   Measuring CMI Responses to Vaccination and  
Naturally Acquired Infection     255 
4.2   AIMS        255 
4.3   RESULTS       256 
4.3.1   Ex Vivo VZV-Specific IFN- ELISPOTs   256 
4.3.1.1  Optimizing the Number of PBMCs Available for  
ELISPOT Assays After Thawing    258 
4.3.2 Ex Vivo VZV-Specific IFN- Responses at the 18  
Month Post Vaccination     258  
4.3.2.1 Comparison Between VZV-Specific IFN- Responses  
and VZV-Specific IgG Titres at 18 Months Post  
Vaccination       261 
4.3.2.1.1  Positive ELISPOT      261 
4.3.2.1.2 Negative ELISPOT      263 
4.3.3   Ex Vivo and Cultured IE63 and gE Epitope Tetramer  
Specific  CD4+ T Cell Responses    265 
4.3.3.1  Comparison between IFN- Responses and Tetramer  
Staining       267 
4.3.3.2  Examining the Frequency of CD4+ Tetramer+ Cells  
in Low Numbers of PBMCs     267 
4.4   DISCUSSION       278 
4.4.1  Summary of Results      278 
12 
 
4.4.2  VZV-Specific IFN- ELISPOT Responses and  
Corresponding TRFIA Titres at 18 Months Post  
Vaccination       279 
4.4.3   Problems Encountered with Measurement of CMI  
after VOka Vaccination      282 
4.4.3.2  Low Frequencies of IE63 and gE DRB1*1501  
Tetramer Specific CD4+ T Cells Identified in this  
Study        282 
4.4.3.2.1 Specificity of Tetramer Staining    283 
4.4.4   Discrepant TRFIA and Tetramer Assay Results  284 
4.4.5   Correlation Between Clinical Protection and CMI  286 
4.4.6   Concluding Remarks      287 
 
CHAPTER 5: SUMMARY OF KEY FINDINGS AND FUTURE  
STUDIES         288 
 
CHAPTER 6:  BIBLIOGRAPHY      291 
 
CHAPTER 7: APPENDIX       347 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
LIST OF FIGURES: 
 
CHAPTER 1 
Figure 1.1  Phylogenetic Tree for Selected Mammalian  
Herpesviruses       30 
Figure 1.2  Structure of the Varicella Zoster Virus Particle  33 
Figure 1.3  A Schematic of the VZV Genome    34 
Figure 1.4  VZV Isomers       35 
Figure 1.5  VZV Open Reading Frames (ORFs)    36 
Figure 1.6 Viral Attachment and Cell Entry    51 
Figure 1.7  An Overview of Events in the Nucleus; Viral DNA  
        Replication, Protein Synthesis and DNA Packaging  55 
Figure 1.8 A Proposed Model of VZV Capsid Assembly  58 
Figure 1.9  Proposed Assembly and Envelopment of VZV  64 
Figure 1.10  The Harson and Grose Model of Envelopment and  
Egress of VZV Particles     66 
Figure 1.11  Proposed Model for the Formation and Release of 
„Light‟Particles During Viral Replication   68 
Figure 1.12 Pathogenesis of Varicella; Based on the Mouse Pox  
Model        71 
Figure 1.13  A Model of the Pathogenesis of Primary VZV  
Infection       75 
Figure 1.14  A Model of VZV Dissemination Following Primary  
Inoculation       77 
Figure 1.15  Schematic of the Sites of VZV-Mediated Disruption  
of IFN- Induced MHC-II Expression    101 
Figure 1.16  Attenuation of P-Oka to V-Oka and the Differences in  
Attenuation Between the Biken, GSK and Merck  
Vaccines       108 
 
CHAPTER 2 
Figure 2.1 Schematic of TRFIA Reaction    123 
 
CHAPTER 3 
Figure 3.1  Structure of Immunoglobulin     133 
Figure 3.2  Schematic Representation of a Germinal Centre, and  
its Location within the Lymph Node    135 
14 
 
Figure 3.3  The Structure of Glycoprotein E and the Position of  
Known Antibody Epitopes     152 
Figure 3.4  Age at Baseline (Enrolment) for ROVE Study  
Participants       167 
Figure 3.5  Ethnicity of ROVE Study Participants   168 
Figure 3.6  Comparison of TRFIA VZV-Specific Antibody Titres at  
Each Study Visit      170 
Figure 3.7  Correlation between VZV-Specific IgG Measured by  
TRFIA  and EUROIMMUN Assays    173 
Figure 3.8  Avidity Maturation Seen After Each Dose of Vaccine  
and at the Follow-up Visit  for Study Participants with  
Six Week Avidity <60%.     175 
Figure 3.9  Scatter Plot to Show the Relationship Between TRFIA  
Titres and Avidity Levels at Six Weeks After the First  
Vaccination (Visit 2)      176 
Figure 3.10  Observed and Fitted Positive and Negative  
Distributions of Baseline Samples Classified by  
Avidity Readings and TRFIA Titres After the First  
Dose of Vaccine (Six Weeks)     178 
Figure 3.11  Observed and Fitted Counts of ROVE Baseline  
(Visit 1) Log10 TRFIA Readings Using Mixture  
Modelling       179 
Figure 3.12  Comparison of Probability Density Curves for  
Positive and Negative Distributions of Baseline  
(Visit 1) Samples Using Either Mixture Modelling, 
or Avidity Cohorts Defined After the First Dose of  
Vaccine (Six Weeks)      181 
Figure 3.13  ROC Analysis of Baseline TRFIA Readings  
Classified by Immune Status According to  
Corresponding Six Week Avidity Cut-off (60%)  182 
Figure 3.14  Comparison between TRFIA Negative (%) at Each  
Study Visit, Classified by Three TRFIA Cut-Offs  184 
Figure 3.15  Schematic of Humoral Subset Classification   186 
Figure 3.16 Clustering of each Humoral Subset After the First  
Dose of  Vaccine      188 
Figure 3.17  Summary of Humoral Immune Responses Following  
Two Doses of Vaccine, for Each Subset   189 
15 
 
Figure 3.18 Log10 TRFIA titres at Baseline and after Each Dose  
of Vaccine for Study Participants Classified as Low 
 Responders       190 
Figure 3.19  Summary of Ethnicity, Gender and Age for Each  
Humoral Subset      191 
Figure 3.20 Summary of Ethnicity, Gender and Age for Subsets  
which were Classified as Seroconverters, Low  
Responders or Secondary Responders   193 
Figure 3.21  Log10 VZV-Specific IgG TRFIA Titres Following Two  
Doses of  Vaccine for Primary Humoral Responders  
who were TRFIA Negative at Baseline   195 
Figure 3.22 Correlation between FAMA Assay Negative and  
Positive Status and Log10 TRFIA Titres   200 
Figure 3.23 Correlation between FAMA Scores and Log10 TRFIA  
Readings       200 
Figure 3.24 Correlation between TRFIA Titres at 12 Weeks and  
18 Months for Study Participants who Lost or  
Retained Seropositive Status     205 
Figure 3.25  Comparison between Log10TRFIA Antibody Titres  
Following Two  Doses of Vaccine (12 Weeks) and 18  
Months Post Vaccination for Each Humoral Subset  206 
Figure 3.26  Comparison between Study Participants who  
Retained  or Lost  TRFIA Seropositive Status at 18  
Months Post Vaccination     208 
Figure 3.27 Comparison in TRFIA Titres at Each Visit for Subjects  
who were Seropositive or Seronegative 18 Months  
Post Vaccination who were Either Classified as  
Seroconverting After One or Two Dose(s) of Vaccine 211 
Figure 3.28 Comparison between 12 week TRFIA (Visit 3) Titres  
for Study Participants who Serconverted after One or  
Two Doses and were Either TRFIA Positive or  
Negative at Follow-Up (Visit 4)    213 
Figure 3.29 Comparisons of Avidity Readings and Log10 TRFIA  
Titres at Each Time Point for Each Humoral Subset  216 
Figure 3.30  Coomassie Staining of Lystaes and Markers used  
for Western Blotting      218 
 
16 
 
Figure 3.31 Schematic of VZV-Specific Bands Identified in Sera  
from Subjects with a History of Varicella under  
Reducing Conditions      219 
Figure 3.32 Western Blot of VZV-Infected Cell and Uninfected  
Cell Lysate with Multiple VZV-Specific Monoclonal 
 Antibodies       220 
Figure 3.33  Examples of Antibody Detection Using ROVE  
Follow-Up  Serum Samples of Varying Avidity  221 
Figure 3.34  Serial Two Fold Dilution of Vaccinees Serum  
Sample to Deduce the Limit of VZV-Specific IgG that  
this Western Blotting System could be used to Detect 222 
 
CHAPTER 4 
Figure 4.1  Glycoprotein E CD4+ T Cell Epitopes and their HLA  
Restriction, Identified in Naturally Immune, Adult  
Donors       252 
Figure 4.2  Glycoprotein I CD4+ T Cell Epitopes in Naturally  
Immune Adult Donors      253 
Figure 4.3  IE62 CD4+ T Cell Epitopes Identified in Either Healthy  
Naturally Immune, or Vaccinated Donors, or in  
Patients with VZV-Induced Uveitis    254 
Figure 4.4 Optimisation of IFN- ELISPOT Using PBMCs from  
Naturally Immune Healthy Adults    257 
Figure 4.5 Representative Image of an Ex Vivo IFN- ELISPOT  
Generated Using Responsive PBMCs Which Produced  
a VZV-Specific IFN- Response Following Overnight  
Stimulation       259 
Figure 4.6  Representative Image of an Ex Vivo IFN- Negative  
ELISPOT Response After Overnight Stimulation   264 
Figure 4.7 Representative Images of Ex vivo IE63- and gE- 
Tetramer-Specific CD4+ T Cells in Populations of  
Live, CD14-, CD19- T Lymphocytes in a Healthy  
Adult HLA-DRB1*1501 Negative/VZV-Seropositive  
Donor and a Healthy Adult HLA-DRB1*1501Positive/ 
VZV-Seronegative Donor     266 
 
17 
 
Figure 4.8 Comparison between Ex Vivo VZV-Specific IFN-  
Responses (ELISPOT) and Frequencies of Tetramer- 
Specific CD4+ T Cells Using PBMCs from a 
 DRB1*1502 Naturally Immune Donor   268 
Figure 4.9 Representative Images of Low Frequency, Brightly  
Stained IE63 Tetramer-Specific CD4+ T Cells  
Identified in Small Populations of Live, CD14-, CD19-  
T Lymphocytes      269 
Figure 4.10 Glycoprotein E and IE63 Tetramer-Specific CD4+ T  
Cell  Staining at 12 weeks (visit 3) for ROVE 1018  275 
Figure 4.11 IE63 and gE Tetramer Specific CD4+ T Cell Staining  
at 18 Months Post Vaccination for ROVE Study  
Participant 1001      276 
Figure 4.12 IE63 and Glycoprotein E Tetramer Specific CD4+ T  
Cell Staining at Baseline for ROVE Study Participant  
1067        277 
Figure 4.13 Glycoprotein E Tetramer Specific CD4+ T Cell  
Staining at Baseline and Follow-up for ROVE Study  
Participant 1067      278 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
LIST OF TABLES: 
 
CHAPTER 1 
Table 1.1 Classification of the Eight Human Herpes Virus, Along 
with Some of the Most Common Mamalian  
Herpesviruses       31 
Table 1.2  Genes of VZV to which a Function has been  
Assigned       37 
Table 1.3  Summary of Properties of Some Key VZV Proteins  40 
Table 1.4  VZV Proteins Involved in DNA Replication   54 
Table 1.5  VZV Capsid Proteins Closely Related to HSV  
Capsid Proteins      56 
Table 1.6  Essentiality of VZV ORFs for Replication in Skin  
and T-cells In Vitro and In Vivo (SCID-Hu Mouse Model) 80 
 
CHAPTER 2 
Table 2.1  Summary of ROVE Visits Timings, Vaccine Schedule  
and Sample Collection     117 
Table 2.2  Antibodies Used for Surface Staining of PBMCs Prior  
to Flow Cytometry Analysis     129 
 
CHAPTER 3 
Table 3.1  Function of VZV Proteins which Induce Antibody  
Responses       146 
Table 3.2  Known Antibody Epitopes of gB and gI   147 
Table 3.3  Sensitivity and Specificity of Merck gpELISA,  
Behring and Diamedix Assays in Comparison to TRFIA 165 
Table 3.4  Sensitivity and Specificity of the Two TRFIA Cut-Offs 
in Naturally Immune Adults     165 
Table 3.5  Summary of the Country of Birth, Migration to the UK,  
History and Previous Vaccination for Caucasian and  
Non-Caucasian Study Participants    169 
Table 3.6  Summary of Humoral Response Subset Classification 187 
Table 3.7 Comparison of Positive and Negative Status between  
FAMA and TRFIA.      198 
 
 
19 
 
Table 3.8 FAMA, TRFIA and Avidity Readings for Study  
Participants with Multiple Assay Discrepancies  
Throughout the Study        202 
Table 3.9 Summary of Subjects who Reported a History of  
Chickenpox, or a Previous Varicella Vaccination, at  
Enrolment       203 
Table 3.10  Percentage of Each Subset with Low, Intermediate  
or High Avidity Antibodies at Each Visit    217 
 
CHAPTER 4 
Table 4.1  VZV Proteins which are Targets of T Cell Immune  
Responses       245 
Table 4.2  HLA-A*0201 Restricted CD8+T Cell IE62 Epitopes    247 
Table 4.3 Glycoprotein B, ORF4 and IE63 CD4+ T Cell Epitopes  
Identified in Naturally Immune Donors    251 
Table 4.4  Loss of Live PBMCs Due to Cell Aggregation, after 30  
Minuets Incubation at Various Temperatures   258 
Table 4.5 HCWs who had VZV-Specific IFN- Responses at  
the 18 Month Follow-Up Visit      260 
Table 4.6  Summary of the ELISPOT and TRFIA Assay Status  
at 18 Months Post Vaccination    261 
Table 4.7  Study Participants who had No Measurable VZV- 
Specific IFN-  Response at the 18 Month Follow-Up  
Visit        263 
Table 4.8 Percentage of IE63 and gE Tetramer+, CD4+ T Cells  
Quantified Ex Vivo and Following Short Term (10  
Day) Culture with the Corresponding Peptide   270  
 
 
 
 
 
 
 
 
 
20 
 
ABBREVIATIONS: 
   
aa   Amino acid 
A   Adenine 
ACIP    Advisory committee on immunization practices  
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Af   African 
AID   Activation-induced deaminase 
APC   Antigen presenting cell 
APC   Allophycocyanin (fluorochrome) 
ADCC   Antibody dependent cellular cytotoxicity 
AP-1   Activator protein 1 
BHV-1   Bovine herpes virus-1 
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B7.1 and B7.2 
CD80   B7.1, a costimulatory molecule, binds to CD28 and CTLA-4 
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CIITA     MHC-II transactivator 
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CTLA-4  Cytotoxic T-lymphocyte antigen 4 (CD152) 
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receptor 1; BLR1) 
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DMF    N,N-Dimethylformamide 
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DTT    Dithiothreitol 
dTTP   Deoxythymidine triphosphate 
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EBV   Epstein-Barr virus 
ECM    Extra cellular matrix  
EDTA    Ethylenediaminetetraacetic Acid  
EIA    Enzyme Immunoassay  
eIF-2   Eukaryotic initiation factor 2  
EHV   Equine herpes virus  
ELCHA  East London and the city health authority 
ELISA   Enzyme-linked immunosorbent assay 
ELISPOT  Enzyme-linked immunosorbent spot assay 
EM   Electron microscopy 
ER   Endoplasmic reticulum 
ERK   Extracellular Signal-Regulated Kinase  
EU/mL   European units/mL 
F   Forward (primer) 
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Fas (CD95) Apoptosis inducing receptor; interacts with Fas 
ligand on activated T cells.  
FAMA   Fluorescent antibody membrane antigen 
FACS   Fluorescent activated cell sorter 
FBS   Foetal bovine serum 
Fc   Constant fragment of antibody 
FcR   Fc receptors (FcR binds IgA; FcR bind IgG and so)   
FDC   Follicular dendritic cell  
FITC   Fluorescein isothiocyanate (fluorochrome) 
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g   Gravitational force 
gB   Glycoprotein B 
gC   Glycoprotein C 
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HHV-1   Human herpes virus 1 (HSV-1) 
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HSV   Herpes simplex virus  
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HVS   Herpesvirus Saimiri 
HZ   Herpes zoster 
IE (genes)  Immediate early (genes) 
ICAM-1  Intercellular adhesion molecule-1 (CD54) 
ICFC   Intracellular cytokine flow cytometry  
ICMS   Institute of Cell and Molecular Science 
ICOS   Inducible costimulator 
ICP   Infected cell protein (HSV protein nomenclature) 
IDE   Insulin-degrading enzyme 
IFN   Interferon 
Ig   Immunoglobulin 
IB    Inhibitor of NFB 
IL   Interleukin 
Ind (Ind Sub)  Indian subcontinent 
IQR   Interquartile range 
IRF-1    Interferon regulatory factor -1 
IRL   Internal repeat long 
IRS   Inverted repeat short 
IU   International units 
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J   Joining segment 
JAK    Janus kinases   
JNK/SAPK   Jun NH2-terminal kinase/stress-activated protein kinase   
Kb   Kilo bases 
KCl   Potassium chloride 
KDa   Kilo Dalton 
KOAc   Potassium acetate 
KSHV   Kaposi sarcoma herpes virus 
L (genes)  Late (genes) 
L   Light chain (antibody) 
LA   Latex agglutination  
LAT   Latency associate transcript 
LFA   Leukocyte function associated antigen 
LPA   Lymphocyte proliferation assay 
M   Molar 
mAb   Monoclonal antibody 
Man 6-P  Mannose-6-phosphate 
MAPK   Mitogen-activated protein kinase 
MCMV   Murine cytomegalovirus 
MDV   Marek‟s Disease Virus 
MEM   Minimum Essential (Eagles) Medium 
MeWo   Melanoma cell line 
MFI   Medain/mean fluorescence intensity 
MgCL2   Magnesium chloride 
Mg(OAc)2  Magnesium acetate 
MHC   Major histocompatability complex 
MIP-3β   Macrophage inflammatory protein-3β  
mIU/mL  Mili international unit/mililitre 
mL   Mililitre 
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MMR   Measles, Mumps, Rubella (vaccine) 
MPR   Mannose 6-phosphate receptor 
MRC5   Human lung fibroblast cell line  
mRNA   Messenger ribonucleic acid 
NA   Not applicable 
NHS   National Health Service 
NFB   Nuclear Factor B 
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ng   Nanogram 
NI Negative-immune (Negative baseline TRFIA, secondary 
responder) 
NK   Natural killer cell 
NLR   Negative (TRFIA baseline) Low Responder 
NSC1 Negative (TRFIA baseline) Seroconverted after one dose 
of vaccine 
NSC2  Negative (TRFIA baseline) Seroconverted after two doses 
of vaccine 
nm   Nanometer 
OBP   Origin of replication binding protein 
Oct-1   Octamer-binding protein 1 
OD   Optical density 
ORF   Open reading frame 
Oris   Origin of replication (short) 
p38/MAPK    p38 mitogen-activated protein kinase  
PACS-1  Phosphofurin acidic cluster sorting protein 1 
P‟Blue   Pacific Blue (fluorochrome)  
PBMC   Peripheral blood mononuclear cell 
PBG   Peptide binding groove 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PCT   Primary care trust 
PE   Phycoerythrin (fluorochrome) 
PerCP   Peridinin-chlorophyll-protein (fluorochrome) 
pfu   Plaque forming unit 
PHA   Phytohaemoglutinin (T cell mitogen) 
Phil   Filipino  
PHLS   Public health laboratory service 
PHN   Postherpetic neuralgia 
pi   Post infection 
PI Positive (TRFIA baseline) Immune (secondary responder) 
PKR    Double-stranded RNA-activated protein kinase  
PLR   Positive (TRFIA baseline) Low Responder 
PM   Plasma membrane 
PMSF    Phenylmethanesulphonylfluoride  
POka   Parental Oka strain of VZV 
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PRV   Pseudorabies virus 
R   Reverse (primer) 
R Retained (TRFIA 130mIU/mL at 12 weeks and 18 
months) 
RAG   Recombination activating 
RAI   Relative avidity index 
RANTES Regulated on activation normal T cell expressed and 
secreted (chemokine) 
RCF   Responder cell frequency 
RER   Rough endoplasmic reticulum 
RNA   Ribonucleic acid 
ROC   Receiver (or relative) operating characteristic  
ROVE   Response to Oka vaccine evaluation (study) 
rpm   Revolutions per minute  
RPMI   Roswell Park Memorial Institute medium 
RT   Room Temperature 
R1-5   Repeat region 1-5 
SAPE   Streptavidin (SA)/phycoerythrin (PE) 
SC   Seroconverted 
SCID-Hu Severe combined immunodeficient mouse with human 
xenograft 
SD   Standard deviation 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SER   Smooth endoplasmic reticulum 
SFUs   Spot forming units 
SHM   Somatic hypermutation 
SIEVE   Society of independent European vaccination experts 
SLE   Systemic lupus erythematosus 
SNP   Single nucleotide polymorphism 
Sp1   Specificity factor 1 
STAT     Signal transducers and activators of transcription  
SVV   Simian varicella virus 
T   Thymine 
Tc   Cytotoxic T cell 
TCM   Central memory T cell 
TCR   T Cell Receptor 
TGN   Trans-Golgi network 
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TEM   Transmission electron microscopy 
TEM    Effector memory T cell 
TFH   CD4
+ T follicular helper cell 
Th1   CD4+ T helper 1 cell 
Th2   CD4+ T helper 2 cell 
TK   Thymidine kinase 
TLR    Toll like receptor  
TNF   Tumour Necrosis Factor   
Treg   T regulatory cell 
TRFIA   Time resolved fluorescence immunoassay  
TRL   Terminal repeat long 
TRS   Terminal repeat short 
U   Uracil 
UL   Unique long (also used for HSV protein nomenclature) 
US   Unique short 
USA   United States of America 
USF   Upstream stimulatory factor 
UV   Ultraviolet 
V   Variable region 
V1   Visit 1 of the ROVE study (baseline) 
V2 Visit 2 of the ROVE study (six weeks post first dose of 
vaccine)  
V3 Visit 3 of the ROVE study (12 weeks post 1st dose, six 
weeks post second dose of vaccine)  
V4 Visit 4 of the ROVE study (approximately 18 month follow 
up, post first dose) 
VCAM Vascular cell adhesion molecule 
Visit 1   See V1 
Visit 2   See V2 
Visit 3   See V3 
Visit 4   See V4 
VLP   Virus like particle 
VOka   Oka vaccine virus 
VP   Virion Protein (HSV protein nomenclature) 
VRE   Vaccine related event 
VTM   Viral transport medium 
VZIG   Varicella zoster immune globulin 
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VZV   Varicella zoster virus 
WFS   Withdrew from study 
WT   Wild type 
7AAD   7-aminoactinomycin D (fluorochrome) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
CHAPTER 1: INTRODUCTION 
 
1.1 Varicella Zoster Virus in Context: 
Varicella zoster virus (VZV) is a highly contagious ubiquitous human 
pathogen that causes varicella (chickenpox) upon primary infection. In 
temperate climates approximately 90% of the population are seropositive 
by 10-14 years of age (Vyse et al., 2004; Waclawski et al., 2002; 
Vandersmissen, et al., 2000; Nardone, 2003). The virus establishes life 
long latency in dorsal root ganglia and in around 25% of infected 
individuals will later reactivate along the ganglia to cause herpes zoster 
(shingles). About 15% of all zoster patients experience postherpetic 
neuralgia (PHN); defined as the dermatomal pain associated with shingles 
persisting beyond one month after resolution of the rash. 
  
1.2 Classification and Virus Structure: 
Varicella zoster virus (VZV), also known as human herpesvirus 3 (HHV3), 
is one of eight members of the herpesviridae family known to infect 
humans. The family is classified into three subfamilies alphaherpesviriae, 
betaherpesviriae and gammaherpesviriae (figure 1.1 and table 1.1).  
Members of the alphaherpesviriae subfamily infect birds, reptiles, 
amphibians, molluscs and mammals, whereas betaherpesvirinae and 
gammaherpesviriae are members are only known to infect mammalian 
hosts.  
 
Classification of the Herpesviridae family was originally based on the 
biological characteristics of members of the same subfamilies; in particular 
their sites of latency. Alphaherpesviruses are characterized by 
establishment of latency in host ganglia; betaherpesviruses in host 
haematopoietic cells and gammaherpesviruses in host lymphocytes, 
(Winkler et al., 2000; Baxi et al., 1995; Borchers et al., 1999; Welch et al., 
1992; Kennedy et al., 2004; Romero et al., 2003; Croen et al., 1988; Huff 
and Barry, 2003; Hahn et al., 1998; Koffron et al., 1998; Kondo et al., 
2002; Kempf et al., 1998; MacSween et al., 2003; Tibbetts et al., 2003 and 
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Schulz, 2000; Cohen et al., 2007b). Gene content and sequence 
similarities are now also used to define classification (Roizman, 1992).   
 
VZV is a member of the alphaherpesvirus subfamily, which is further 
characterized by a relatively short reproductive cycle, rapid cell-to-cell 
spread and cytolysis (Mori and Nishiyama, 2005; Arvin, 2001c; Cohen et 
al., 2007b).  Based on phylogenetic analysis of conserved herpesvirus 
genes the mammalian alphaherpesvirus subfamily is delineated as 1 and 
2 lineages, corresponding to the genera simplexvirus and varicellovirus, 
respectively (McGeoch, 1989; McGeoch et al., 1995; McGeoch et al., 
2000), (see table 1.1).  
 
 
Figure 1.1: Phylogenetic Tree for Selected Mammalian Herpesviruses.  
This was deduced by McGeoch et al., (1995) from the combined amino 
acid sequences encoded by several well conserved genes. A proposed 
timescale is shown inferred from host palaeontology. The oldest part of the 
tree is shown as a broken line, indicating lower confidence. Key: HSV-1, 
herpes simplex virus 1; HSV-2, herpes simplex virus 2; HCMV, human 
cytomegalovirus; HHV-6, human herpes virus 6; HVS, herpesvirus saimiri; 
EBV, Epstein-Barr virus (Adapted from Davison, 2000; with permission).  
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Sub Family 
Genus and 
Lineage 
Species Other Names 
Alphaherpesviriae 
Simplexvirus (1 
lineage) 
 
 
Human 
Herpesvirus 1 
(HHV1) 
Herpes Simplex 
Virus 1 (HSV-1) 
Human 
Herpesvirus 2 
(HHV2) 
Herpes Simplex 
Virus 2 (HSV-2) 
Bovine 
Herpesvirus 2 
(BHV2) 
Bovine Mamillitis 
Virus, 
Allerton Virus, 
Pseudolumpy Skin 
Disease Virus 
Herpes B Virus 
(HBV)
a
 
Cercopithecine 
Herpesvirus 1 
Herpes Simiae virus 
3 
Varicellovirus (2 
lineage) 
Human 
Herpesvirus 3 
(HHV3) 
Varicella-Zoster 
Virus (VZV) 
Bovine 
Herpesvirus 1 
(BHV1) 
Infectious Bovine 
Rhinotracheitis Virus 
Equid Herpesvirus 
1 (EHV1) 
Equine Abortion 
Herpesvirus 
Equid Herpesvirus 
4 (EHV4) 
Equine 
Rhinopneumonitis 
Virus 
Simian Varicella 
Virus (SVV) 
 
Pseudorabies 
Virus (PRV) 
Suid Herpes Virus 1 
Aujeszky‟s Disease 
Virus 
Betaherpesviriae 
Cytomegalovirus 
(CMV) 
Human 
Herpesvirus 5 
(HHV5) 
Human 
Cytomegalovirus 
(HCMV) 
Muromegalovirus 
Mouse 
Cytomegalovirus 1 
(MCMV1) 
Murid Herpesvirus 
Roseolovirus 
Human 
Herpesvirus 6A 
(HHV6A)
b
 
 
Human 
Herpesvirus 6B 
(HHV6B)
b
 
Human 
Herpesvirus 7 
(HHV7) 
Gammaherpesviriae 
Lymphocryptovirus 
Human 
Herpesvirus 4 
(HHV4) 
Epstein-Barr Virus 
(EBV) 
Radinovirus 
Human 
Herpesvirus 8 
(HHV8) 
Kaposi‟s Sarcoma-
Associated 
Herpesvirus 
Table 1.1: Classification of the Eight Human Herpes Virus, Along with Some of the Most Common 
Mamalian Herpesviruses. NB: 
a
HBV which is endemic in macaque monkeys is the only one of 35 
identified non-human primate herpes viruses that is highly pathogenic for humans (Whitley and 
Hillard, 2007). 
b
Although not formally recognized as such, the HHV-6 variants (HHV-6A and HHV-
6B) satisfy the requirements for recognition as separate herpes viruses (Dominguez et al., 1999). 
(Adapted from Quinlivan and Breuer, 2006; with permission).   
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Varicella-zoster virus is the only member of the varicellovirus genus that 
infects humans (Davison, 2000).  Other members of this genus include 
bovine herpesvirus 1 (BHV1), equid herpesvirus 1 (EHV1), equid 
herpesvirus 4 (EHV4), simian varicella virus (SVV) and pseudorabies virus 
(PRV).  The simplexvirus genus consists of human herpesvirus 1 and 2 
(HHV1, HHV2) (otherwise known as herpes simplex virus 1 and 2 (HSV-1, 
HSV-2)), bovine herpesvirus 2 (BHV2) and herpes B virus (HBV), (table 
1.1). 
 
1.2.1 Structure and Morphology of the Varicella Zoster Virus: 
The VZ virus is approximately 175nm in diameter (Nagler and Rake, 1948; 
Rake et al., 1948). VZV, like all herpesviruses, consists of four major 
elements: The core, nucleocapsid, tegument and envelope (see figure 
1.2).  The core contains one copy of the linear double stranded DNA 
genome (approximately 125kb) (Davidson and Scott, 1986), which is 
incorporated into each virion.  This has been described as a loose fibrillar 
cage of strands surrounding a dense cylindrical core of DNA fibers 
(Puvion-Dutilleul et al., 1987). The nucleocapsid is an assemblage of 162 
capsomeres with a 5:3:2 axial symmetry in which pentameric proteins form 
the vertices of an 80-120nm icosahedron and hexameric elements 
comprise its facets (Almeida et al., 1962). The tegument is an amorphous 
protein material that bridges the nucleocapsid and the envelope. The 
tegument also includes enzymes controlling virus replication and 
immediate early proteins, (IE proteins) encoded by open reading frame 
(ORF) ORF4, ORF62 and ORF63 (Kinchington et al., 1992) as well as 
numerous other proteins (see table 1.2). The nucleocapsid assembles 
within patches of host cellular membranes, that have been modified to 
display virally encoded glycoproteins (in order of abundance: gE, gB, gH, 
gI, gC, and gL) to form its envelope (Asano et al., 1980a). VZV encodes 
nine membrane glycoproteins, which in addition to those listed above 
include gK, gM and gN, (Davison and Scott 1986, Davison et al., 1986; 
Grose, 1990; Gomi et al., 2002; Storlie et al., 2008; Yamagishi et al., 
2008). These three glycoproteins have not been fully characterised, but 
recently gM has been shown to be expressed in the viral envelope 
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(Yamagishi et al., 2008), whilst gK is postulated to be incorporated into the 
virion envelope, although this is yet to be experimentally determined (Hall 
et al., 2007).  
 
 
Figure 1.2: Structure of the Varicella Zoster Virus Particle.  
Note: glycoproteins are of various lengths. (Quinlivan and Breuer, 2005; 
reprinted with permission). 
 
1.3 Genomic Structure and Organisation: 
The complete genome of the Dumas strain of VZV, which was isolated in 
the Netherlands, was determined in 1986 by Davison and Scott. VZV has 
the smallest genome of all the human herpesviruses; the virus is 
comprised of 72 ORFs, of which at least 69 are unique. These 72 ORFs 
actually encode only 71 genes as the transcripts of ORFs 42 and 45 are 
spliced and thus translate into a single protein product (Davison and Scott, 
1986). The genome is a linear double stranded DNA molecule, 124,884bp 
in length.  
 
The genome consists of a unique long region (UL) of 104,836bp which is 
flanked by the inverted repeat regions: The terminal repeat long (TRL) and 
internal repeat long (IRL) both of which are 88.5bp in length; and a unique 
short region (US) of 5,232bp. This in turn is flanked by the internal repeat 
regions terminal repeat short (TRS) and the inverted repeat short (IRS), 
both of which are 7,319.5bp in length, (see figure 1.3). The inverted repeat 
structure of the VZV genome has been verified using electron microscopy 
of VZV DNA molecules (Ecker and Hyman, 1982; Gilden et al., 1982b; 
Straus et al., 1982).  The viral genome is usually present as a linear 
molecule within the virion, but there are four isotypes; of which two 
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predominate (Kinchington et al., 1985; Straus et al., 1981; Davison 1984) 
(see figure 1.4).  
 
 
 
 
 
Figure 1.3: A Schematic of the VZV Genome. Key: TRL-Terminal repeat 
long, UL-unique long, IRL-Internal repeat long, IRS-inverted repeat short, 
US-unique short region, TRS-terminal repeat short. (Adapted from Cohen 
et al., 2007, with permission). 
 
The genome contains five regions with repeat elements R1-R5 (Davison 
and Scott, 1986; Hondo and Yogo, 1988); see figure 1.5.  R1-R4 are 
guanine-cytosine (G-C) rich and R1, 2 and 3 regions are located in UL 
segments of genomes. The R1 region is located within ORF11 and 
consists of four separate repeated elements (Kinoshita et al., 1988). The 
R2 region, present within the glycoprotein C gene consists of 42bp repeats 
(which differ among different strains of VZV) (Kinchington et al., 1986). 
The R3 region is the largest repeat region, about 1,000bp in length and 
encoded by ORF22 (Davison, 1984). The R4 region is located in both IRS 
and TRS regions between ORFs 62 and 63 and ORFs 70 and 71 and 
consists of multiple 27bp elements (Casey et al., 1985). Finally the R5 
region is located between ORFs 60 and 61 and consists of 88 and 24bp 
repeats and is adenine-thymine (A-T) rich (Hondo and Yogo, 1988). The 
Dumas strain of VZV has only one copy of the R5 repeats whereas other 
strains of VZV have multiple R5 repeats.  Indeed the R1-5 repeats differ in 
length and have been used to distinguish different strains of VZV by 
restriction endonuclease analysis (Hayakawa et al., 1986; Hondo and 
Yogo, 1988; Straus et al., 1983). The variability in the number of repeats 
implies that the different strains of VZV have differing overall lengths of 
their genome. 
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Figure 1.4: VZV Isomers. Two linear isomeric forms predominate; 
circularized forms are rare. The direction of the US and UL sequences 
differs between isotypes. Each end of the linear genome has a single 
unpaired complementary nucleotide (C-G), which may base pair to form 
circular isoforms. 
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As mentioned previously, the genome contains at least 69 unique genes, 
three of which are present in two copies in the IRS and TRS regions (see 
figure 1.5). Eleven of the VZV genes are thought to have overlapping 
reading frames (Davison and Scott, 1986). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: VZV Open Reading Frames (ORFs). ORF transcripts are 
numbered and shown as arrows. ORFs 69 to 71 are duplications of ORFs 
62 to 64. Repeats (R1-R5) are indicated by filled rectangles. The origins of 
DNA replication (oris are shown.) (Reprinted from Cohen et al., 2007b, with 
permission).   
 
A large portion of the VZV genome is colinear with HSV-1 genome (see 
table 1.2). Only five VZV genes in the UL regions do not have HSV-1 
homologues: ORFs 1, 2, 13, 32 and 57. Four ORFs (1, 2, 32 and 57) have 
homologues in equine herpesvirus 1 (Telford et al., 1992) whilst 29 VZV 
genes have EBV homologues (Baer et al., 1984; McGeoch and Davison, 
1986; Davison and Taylor, 1987). These conserved genes include 
transcriptional, regulatory, viral enzyme and glycoprotein genes (Davison 
and Taylor, 1987). The gene which is encoded by ORF13 is the viral 
enzyme thymidylate synthase, which is not present in any other 
alphaherpesvirus (Honess et al., 1986, Richter et al., 1988).  
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Gene Function HSV-1 homologue 
1 Membrane protein No homologue 
3 Unknown function UL55 
4 
Transcriptional activator, multifunctional regulatory 
protein  
UL54  
5 Glycoprotein K (gK) UL53  
6 DNA replication; DNA helicase/primase component UL52 
7 Myrisolated protein  UL51 
8 
Nucleotide metabolism; Deoxyuridine 
triphosphatase (dUTPase) 
UL50 
9 Complexes with gE, Interacts with IE62  UL49 
9A 
Stearoylated membrane protein (syncytia formation) 
(gN) 
UL49A 
10 Transcriptional activator  UL48  
11 Unknown No homologue 
12 Unknown UL46 
13 Thymidylate synthetase No homologue 
14 Glycoprotein C (gC) UL44  
15 Integral membrane protein UL43 
16 DNA replication; Associated with DNA polymerase UL42 
17 Host shut-off UL41 
18 Ribonucleotide reductase small subunit UL40  
19 
Nucleotide metabolism; Ribonucleotide reductase 
large subunit 
UL39  
20 Minor capsid binding protein UL38 
21 Associated with developing nuclearcapsid ♦  UL37 
22 Large tegument protein UL36 
23 Small capsid binding protein, Hexon tips UL35 
24 Role in nuclear egress UL34 
25 DNA packaging protein (putative) UL33 
26 Capsid protein; DNA packaging protein (putative) UL32 
27 Nuclear maturation, capsid nuclear egress UL31 
28 DNA replication; DNA polymerase UL30 
29 
DNA replication; Single stranded DNA binding 
protein  
UL29 
30 
Virion maturation; DNA cleveage; terminase subunit 
homologue 
UL28 
31 Glycoprotein B (gB) UL27 
32 Capsid scaffold No homologue 
33 Capsid scaffold protease UL26 
33.5 Scaffold/Assembly protein UL26.5 
34 
Capsid associated tegument protein; DNA 
packaging protein (putative) 
UL25 
 
Table 1.2: Genes of VZV to Which a Function has Been Assigned, (continued; 1 of 2) 
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Gene Function HSV-1 homologue 
35 Nuclear protein, role in cell-to-cell fusion UL24 
36 Pyrimidine deoxyribonucleotide kinase UL23 
37 Glycoprotein H (gH) UL22 
38 Unknown UL21 
39 
Virion egress, Co-localizes with gK, suggested role 
in envelopment 
UL20 
40 Major nucleocapsid antigen UL19 
41 Minor capsid protein UL18 
42 
DNA packaging protein; terminase subunit 
homologue 
UL15 
43 DNA packaging protein UL17 
44 Unknown UL16 
45 Terminase subunit homologue   
46 Myristoylated protein  UL14 
47 Protein kinase ♦  UL13 
48 Virion maturation; Deoxyribonuclease UL12 
49 Myristoylated protein UL11 
50 Glycoprotein M (gM) UL 10 
51 Origin of replication (ori) binding protein UL9 
52 
DNA replication; Component of DNA 
helicase/primase 
UL8 
53 Tegument protein UL7 
54 
Minor capsid protein; DNA packaging protein 
(putative) 
UL6 
55 
DNA replication; Component of DNA 
helicase/primase 
UL5 
56 Unknown function UL4 
57 Virion egress No homologue 
58 Unknown UL3 
59 Nucleotide metabolism; Uracil-DNA glycosylase UL2 
60 Glycoprotein L (gL) UL1 
61 Transcriptional activator/repressor ICPO 
62, 71 Transcriptional activator  ICP4 
63, 70 Transcriptional activator  US1 
64 Unknown US10 
65 Membrane protein, axonal transport; US9 
66 Protein kinase ♦  US3 
67 Glycoprotein I (gI) US7 
68 Glycoprotein E (gE) US8 
Table 1.2: Genes of VZV to Which a Function has Been Assigned.            (2 of 2) 
 
Key: immediate early protein; early protein; late protein, class unknown, (virion-
associated protein  (tegument protein; , transcribed during latency 
(McDonald and Breuer, 2008; adapted with permission).  
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1.4 Functions and Properties of Key VZV Proteins: 
This section summarizes what is known about the function of some of the 
VZV proteins which are known to be of biological importance. For some 
VZV proteins, functional studies have been carried out, whilst for others, 
functions have been extrapolated from what is known of their HSV 
homologues. Table 1.3 summarises some of the main characteristics of 
these proteins. For some proteins, little else is known besides these main 
characteristics and thus these proteins are not discussed further in the 
text. Whether VZV proteins are essential for infection and replication 
(either in vitro or in the SCID-Hu mouse model), or the establishment of 
latency (in the cotton rat model) is discussed in section 1.6.1.2 and section 
1.6.2.1. 
 
1.4.1 Glycoproteins and Structural Proteins: 
VZV glycoproteins, like their HSV-1 homologues, are involved in virion 
attachment, entry, envelopment, cell-to-cell spread, and egress (Cohen et 
al., 2007b), discussed in section 1.5. Glycoprotein B, the second most 
abundant glycoprotein, is important for entry into the cell (Keller et al., 
1986) and binds cell surface heparan sulphate (Jacquet et al., 1998). This 
glycoprotein, (along with gC, gE and gH); is a type-1 membrane protein 
which contains a signal peptide. This particular protein is a heterodimer, 
linked by disulphide bonds and has been shown to have great fusogenic 
properties in the presence of gE (Maresova et al., 2001). The DNA 
sequence for gB encodes for a polypeptide of 868aa residues, comprising 
as mentioned above; an 8aa signal peptide, the main body of the protein, 
and a hydrophobic anchor region (aa 699-743), followed by a positively 
charged C-terminal domain (Keller et al., 1986). Two tyrosine based motifs 
within the cytoplasmic domain of gB are required for endocytosis into the 
Golgi network (Heineman and Hall, 2001; Heineman et al., 2000), a 
process during which gB associates with clathrin, (Pasieka et al., 2003a), 
discussed in more detail in section 1.5.1. It is the 36aa at the carboxy-
terminus of gB that are required for normal trafficking of this glycoprotein 
to the golgi and for normal viral egress (Heineman and Hall, 2002). 
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Gene 
Classification 
IE, E, L 
ORF Name 
Size 
(kDa) 
HSV-1 
Homologue 
Number 
of aa 
Transcribed 
During 
Latency 
Location 
within 
virus 
Additional 
References 
IE 
4 IE4 51 ICP27  452 Yes Tegument 
Cohen et al., 2005b; 
Sadzot-Delvaux and 
Rentier, 2001 
61 IE61 62-65 ICP0 467   
Not 
tegument 
Stevenson et al., 1992 
62/71 IE62 175 ICP4 1,310 Yes Tegument 
Cohrs and Gilden, 
2006 
63/70 IE63 45 
US1.5 is expressed 
colinearly with 
ICP22 (US1) 
278 Yes Tegument 
Kennedy et al., 2000, 
Lungu et al., 1998, 
Mahalingam et al., 
1996 
E 
29 
 DNA binding 
protein 
130 ICP8 (UL29) 1,204 Yes   Cohen et al., 2007a 
47 
 Serine/threonine 
protein kinase 
54 UL13 510   Tegument 
Kinchington et al., 
1992 
66 
Serine/threonine 
protein kinase  
48 US3 393 Yes Tegument 
 
Table 1.3: Summary of Properties of Some Key VZV Proteins.           (1 of 2) 
Key: NR; non-reducing conditions, R; reducing conditions, IE; immediate early, E; Early, L; Late, NCP; Nuclear capsid protein, 
abbreviations in parentheses are the former names of glycoproteins. Referenced from Davison and Scott, 1986. 
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Gene 
Classification  
IE, E, L 
ORF Name Size (kDa) 
HSV-1 
Homologue 
Number 
of aa 
Transcribed 
During  
Latency 
Location 
within virus 
Additional 
References 
L 
5 gK 40 UL53 340   
Postulated as 
envelope 
Govero et al., 2007; Mo 
et al., 1999 
10  50 VP16 (UL48) 410   Tegument Moriuchi et al., 1993b 
14 
gC 
(gpV) 
80-170 
(Dependent on 
strain) 
UL44 560   Envelope 
Kinchington et al., 1990; 
Kinchington et al., 1986; 
Ling et al., 1991 
31 
gB 
(gpII) 
20-140 (NR) 60-
70 (R) 
UL27 868   Envelope Keller et al., 1986 
37 
gH 
(gpIII) 
118 UL22 841   Envelope Keller et al., 1987 
40 NCP 155 UL19 1,396   Capsid  
50 gM 20 UL10 435   Envelope Yamagishi et al., 2008 
60 
gL 
(gpVI) 
20 UL1 159   Envelope 
 
67 
gI 
(gpIV) 
62 US7 354   Envelope 
 
68 
gE 
(gpI) 
98 US8 623   Envelope 
 
(„Properties of Some Key VZV Proteins‟) continued                          2 of 2
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The size of glycoprotein C ranges between VZV strains from 80–170kDa, 
which as mentioned above, is due to the different number of R2 repeat 
units located in the coding sequence of this protein. The amount of mRNA 
transcribed, along with the level of protein expressed within infected cells 
also varies depending on the strain of VZV (Kinchington et al., 1990; 
Kinchington et al., 1986; Ling et al., 1991).   
 
The most abundantly produced glycoprotein in VZV infected cells is gE 
(Montalvo et al., 1985).  Expression of this glycoprotein in epithelial cells 
induces formation of tight junctions whilst enhancing establishment of 
trans-epithelial resistance, which results in increased cell-to-cell contact 
(Mo et al., 2002). This glycoprotein has been shown to bind to the Fc 
fragment of IgG (Edson et al., 1985a; Litwin et al., 1992; Litwin et al., 
1990; Yao et al., 1993b) and is known to form a complex with gI by a non-
covalent link (Vafai et al., 1989; Yao et al., 1993a). Glycoprotein I is 
required for normal maturation of gE and for efficient distribution of gE to 
the cell surface.  A study by Kimura (et al., 1997) demonstrated that the 
entire gE:gI complex could be immunoprecipitated using monoclonal 
antibodies to either gE or gI and this complex requires the amino terminus 
of gI for its interaction (Kimura et al., 1997); along with residues 168-208 in 
the cysteine-rich region of the gE ectodomain (Berarducci et al., 2009). 
The unique N-terminal region of gE is required for viral replication, cell-to-
cell spread and secondary envelopment (Berarducci et al., 2006). This 
region also binds to the VZV receptor insulin-degrading enzyme (IDE) (Li 
et al., 2007). The C-terminal is essential for TGN and plasma membrane 
trafficking (Moffat et al., 2004).  Recently gE has been shown to form a 
complex with ORF9 protein in vitro (Che et al., 2008).  
 
Glycoprotein H is the third most abundant VZV glycoprotein and unlike 
other VZV glycoproteins, is secreted into the medium of cells in culture 
(Shiraki and Takahashi, 1982). This glycoprotein associates with gL to 
form the gH:gL complex (Forghani et al., 1994), which allows processing 
in the Golgi network and subsequent transport to the cell surface (Duus et 
al., 1995). VZV gH is a fusogen that is important for cell-to-cell spread of 
43 
 
the virus (Rodriquez et al., 1993); gE enhances fusion mediated by gH 
(Maresova et al., 2001), and these glycoproteins can also form a complex 
in virus infected cells (Maresova et al., 2005; Pasieka et al., 2004). VZV 
glycoprotein H has two hydrophobic domains, one at the N-terminus and 
the other at the C-terminus (Keller et al., 1987). Like gB, gH endocytosis is 
clathrin dependent (Pasieka et al., 2003a). 
 
Glycoprotein K is conserved among alphaherpesviruses but the highly 
hydrophobic nature of the protein has made it difficult to study and thus it 
has not been fully characterized. This glycoprotein is a multiply inserted 
type-3 membrane protein which consists of four transmembrane domains, 
containing a signal peptide (Govero et al., 2007). It is found in enveloped 
virions and is evenly distributed in the cytoplasm in infected cells (Mo et 
al., 1999). During infection, the ORF39 protein and gK tightly co-localize 
with VZV envelope glycoproteins B, E and H (Govero et al., 2007). The 
half-life of gK is considerably shorter than that of other VZV glycoproteins 
including gB, gE and gH (Hall et al., 2007).  
 
Knowledge of glycoprotein M is limited, but recent studies using gM 
deletion mutants in MRC5 cells demonstrated that this protein was 
expressed on the viral envelope, and functions in virus cell-to-cell spread 
(Yamagishi et al., 2008).  
 
The VZV ORF10 protein is a structural component of the viral tegument 
(Moriuchi et al., 1993b). Following transfection into cells it is expressed 
diffusely in the cytoplasm, but is localized to the TGN with either co-
transfection of gI or after viral infection (Wang et al., 2001). VZV ORF10 
transactivates the IE VZV ORF62 gene promoters in transient expression 
assays but is unable to transactivate the VZV IE ORF4 and ORF61 
promoters (Che et al., 2007).   
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1.4.2 Proteins Involved in Replication: 
The ORF4 protein is a transcriptional activator that influences several 
promoters from each of the three classes of genes (Defechereux et al., 
1993). The ORF4 protein transactivates expression of its own promoter as 
well as VZV IE promoters ORF61, ORF62, early promoters ORF29, 
ORF36 and late promoter ORF67. ORF4 does not transactivate 
expression of IE ORF63 or early ORF28 promoters, (Defechereux et al., 
1996; Defechereux et al., 1997). The ORF4 protein works cooperatively 
with ORF62 to function at both transcriptional and post-transcriptional 
levels (Schoonbroodt et al., 1996). Furthermore, in transient expression 
assays ORF4 synergizes with ORF62 to transactivate expression of IE 
promoters (ORF4, ORF61), early promoters (ORF36) and late promoters 
(ORF14, ORF67 and ORF68) (Moriuchi et al., 1994a). The ORF4 protein 
has recently been shown to be essential in vitro (Zhang et al., 2007) and 
have an important role in the establishment of latency (Cohen et al., 
2005b; Sadzot-Delvaux and Rentier, 2001).   
 
The ORF29 protein promoter binds to the gI promoter in vitro (Boucaud et 
al., 1998). The ORF29 protein is secreted from VZV infected cells in vitro, 
where it can be endocytosed by neurons (Annunziato et al., 2000).  
Absence or over-expression of the ORF29 protein impairs late gene 
expression and reduces latency in a rodent model (Cohen et al., 2007a). 
BAG3, Hsp70/Hsc70 and Hsp90 (cytosolic molecular chaperones which 
prevent protein misfolding and aggregation) co-localize with the ORF29 
protein in nuclear transcription/replication factories during lytic replication 
of VZV and this interaction is crucial for viral replication (Kyratsous and 
Silverstein 2007). Localization of the ORF29 protein to the nucleus or 
cytoplasm correlates with whether VZV infection is lytic or latent 
respectively and the ubiquitination and degradation of this protein 
implicates the proteasome as one of the determinants of this protein‟s 
localization (Stallings et al., 2006). Proteins expressed during latency are 
discussed in more detail in section 1.6.2.1. 
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The protein product of ORF47 is a serine/threonine protein kinase and 
tegument component. The ORF47 protein autophosphorylates and 
phosphorylates the major IE transactivator proteins IE62 (Kinchington et 
al., 1992; Ng et al., 1994) and IE63 (Kenyon et al., 2001), gE (ORF68) 
(Kenyon et al., 2002, Montalvo and Grose, 1986b) and ORF32 (Reddy et 
al., 1998a). Glycoprotein E requires ORF47 phosphorylation to mediate 
cell fusion and TGN trafficking for virion assembly (Kenyon et al., 2002). 
Recently, ORF47 kinase was shown to be important in the activation of the 
Akt signaling cascade (Rahaus et al., 2007); which has an important role 
in the regulation of cell survival.  
 
The ORF61 protein optimizes the availability of cellular factors involved in 
gene expression and can either enhance or repress activation of other 
VZV genes by IE4 and IE62, but is dependent on the cell lines and 
transfection conditions used (Moruchi et al., 1993a; Nagpal and Ostrove, 
1991; Perera et al., 1992b). This protein has been shown to contain a 
RING finger domain which is required for its transregulatory functions 
(Moriuchi et al., 1994b). Phosphorylation occurs in the N- and, to a lesser 
extent, C-terminal portions of this protein. The C-terminal region directs 
transport of the protein to the nucleus, whereas the N-terminal region, 
which contains a potential zinc-binding domain, is responsible for a 
punctate distribution (Stevenson et al., 1992). This protein has recently 
been shown to facilitate the nuclear import of IE63 within guinea pig 
enteric neurons (Walters et al., 2008). The VZV ORF61 protein has been 
suggested to play an important role in the fine-regulation and activation of 
the MAPK pathways and their downstream targets (Rahaus et al., 2005).  
 
IE62 is also known to transactivate VZV immediate early (ORF4, ORF61), 
early (ORF36) and late (ORF67, 68) gene promoters in transient 
expression assays (Inchauspé and Ostrove, 1989; Perera et al., 1992a; 
Perera et al., 1992b). Co-expression of the IE62 tegument protein with the 
ORF66 protein  results in cytoplasmic accumulation of IE62 (Kinchington 
et al., 2000) and is required for localization within virions in cultured cells, 
(Kinchington et al., 2001) but not VZV-infected primary T cells (Schaap-
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Nutt et al., 2006). IE62 is known to activate its own promoter in 
lymphocytes and neural cells but represses its own promoter in simian 
cells (Disney and Everett, 1990; Felser et al., 1988; Perera et al., 1992a).  
This protein has also been shown to be transcribed during latency (Cohrs 
and Gilden, 2006).  This protein is a substrate for CDK1/cyclin B1 and 
recent data indicate that binding to IE62 leads to the incorporation of 
cellular kinase into the tegument (Leisenfelder et al., 2008). IE62 also 
binds to ORF9 at IE62 residues 1-43 (Cilloniz et al., 2007) and to the 
proteins encoded by ORF47 (Besser et al., 2003) and ORF4 (Spengler et 
al., 2000). 
 
IE63 binds to, and co-localizes with, IE62 in infected cells (Lynch et al., 
2002). The IE62 binding site that lies within IE63 has been mapped to 
IE63 amino acids 55 to 67, with R59/L60 being critical residues (Baiker et 
al., 2004b). In IE63 mutant viruses, ORF47 kinase protein and 
glycoprotein E (gE) synthesis were reduced, indicating that IE63 
contributed to optimal expression of early and late gene products (Baiker 
et al., 2004b). IE63 is important in the establishment of latency (see 
section 1.6.2.1).  
 
The ORF66 product is a serine/threonine protein kinase that 
phosphorylates nuclear egress lamina proteins and mediates 
phosphorylation of cellular and viral proteins, including IE62 (Eisfeld et al., 
2006). This leads to the cytoplasmic accumulation of IE62 late in infection 
(Cohrs et al., 2003b). ORF66 affects several host cell signalling pathways, 
which have been shown to play an important role in viral immune evasion, 
(Abendroth et al., 2001a; Eisfeld et al, 2007; Schapp et al., 2005; Rahaus 
et al., 2007; Schaap-Nutt et al., 2006; Schaap et al., 2005) which is 
discussed in section 1.7. 
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1.5 VZV Infection at a Cellular Level: 
Knowledge of VZV replication is somewhat limited, but extrapolation from 
what is known for other human herpes viruses, along with mammalian 
alphaherpesviruses, has helped with our understanding of this process. In 
order to replicate the virus must first attach to the host cell surface to 
facilitate entry. The viral genome must then be released from the capsid 
and translocate into the nucleus, where replication (aided by the host‟s 
own cellular machinery) commences. Newly synthesised DNA is then 
packaged within newly synthesised nucleocapsids and exported from the 
nucleus. The encapsidated DNA must then acquire tegument proteins and 
an envelope before the resulting progeny virus exits the host cell. Kinetic 
studies of VZV-infected cells which were used to inoculate uninfected 
cells, demonstrated that viral proteins were expressed as early as 1h post 
infection (Reichelt et al., 2009) and progeny virus spreads to neighbouring 
cells as early as 8h post infection (Asano and Takahashi, 1980). 
 
1.5.1 Cell Attachment and Entry: 
Like other herpesviruses, VZV particles are presumed to enter cells by 
fusion of the virion envelope with the plasma membrane or by 
endocytosis, (Cohen et al., 2007b). As with all of the human herpes 
viruses, VZV glycoproteins are presumed to be involved in virion 
attachment and entry, (as well as envelopment, cell-to-cell spread, and 
egress), (Roizman and Knipe 2001; Heldwein and Krummenacher, 2008). 
VZV attaches to the host cell surface via an interaction between gB and 
heparan sulphate constituents on the host cell surface proteoglycans 
(heparan sulphate proteoglycan (HSPG)), (Zhu et al., 1995; Jaquet, 1998), 
see figure 1.6A. Glycoproteins H and I which are embedded in the outer 
envelope of the virus also appear to be important in the interaction of VZV 
with HSPG (Cohen and Nguyen, 1997; Rodriguez et al., 1993). VZV entry 
is likely to be a two-stage process in which initial binding to HSPG 
stabilizes VZV on the plasmalemma of target cells, enabling subsequent 
viral entry. 
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It has been proposed that following attachment, mannose 6-phosphate 
(Man 6-P) residues in N-linked complex oligosaccharide chains (Gabel et 
al., 1989) (present on at least four of the viral glycoproteins ectodomains: 
gB, gE, gH and gI) interact with Man 6-P receptors on the host cell surface 
and initiate viral entry (Wang et al., 2000; Gershon et al., 1994b), see 
figure 1.6B.  Chen (et al., 2004) demonstrated that the cation-independent 
mannose 6-phosphate receptor (MPRci) is required for infection of cell-free 
VZV, but not cell-associated VZV. MPRci is a type-I transmembrane 
protein with multiple functions, one of which is the delivery of proteins from 
the trans-Golgi network (TGN) and extracellular space to late endosomes. 
Endosomes are thought to play a role in several stages of viral replication 
and are discussed in the text where appropriate. 
 
It was suggested that gE may also be involved in viral entry and cell-to-cell 
spread because gE deletion viruses are not stable (Mo et al., 2002) and 
gE antibodies neutralize virus in vitro (Lowry et al., 1992). Li (et al., 2006) 
found that IDE is a cellular receptor for both cell-free and cell-associated 
VZV.  Although IDE is located in the cytoplasm of cells, it is (along with 
MPRci), also expressed on the cell surface and within endosomes, see 
figure 1.6B and C.  The region of VZV gE required to bind IDE has 
recently been defined as residues 24-71 in the extracellular domain, 
located immediately after the predicted signal peptide, (Li et al., 2007). 
Chimeric HSV-2/VZV gE proteins used in the study also demonstrated that 
the secondary structure of gE is critical for its interaction with IDE. As IDE 
is a soluble protein it would appear to require a membrane-anchoring 
adaptor molecule (or co-receptor); but such a molecule has yet to be 
identified. It has been suggested that MPRci and IDE may interact to 
facilitate virus infection, and that there are also likely to be unidentified 
receptors involved in the process of viral entry, as blocking IDE results in 
only a 25-75% reduction of VZV infection and cell-to-cell spread (Li et al., 
2006).  
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Recent work by Hambleton (et al., 2007) has highlighted the importance of 
membrane cholesterol in the establishment of VZV infection in vitro. 
Cholesterol is a major constituent of lipid rafts and entry of both EBV and 
HSV have previously been shown to be cholesterol dependent, (Bender et 
al., 2003; Katzman and Longnecker, 2003). Based on analogy to HSV 
entry, it is possible that lipid rafts are also involved in VZV entry through 
the participation of gB in the fusion of the viral envelope with cellular 
membranes. This glycoprotein has been shown to play a role in VZV-
induced membrane fusion, (Maresova et al., 2001) and is one of the most 
conserved amongst the human herpesviruses. In the case of HSV, a 
physical association between gB and host cell lipid rafts has been 
demonstrated and it has been suggested that cholesterol plays a role in 
that fusion process (Bender et al., 2003). 
 
The work of Hambleton and colleagues also suggested that clathrin-
mediated endocytosis is a major route of viral entry into several human 
cell types in vitro. Although MPRci trafficking is generally clathrin mediated, 
and depletion of cholesterol has been demonstrated to affect the 
distribution of MPRci (Miwako et al., 2001), the internalization of the MPRci 
from the cell surface does not require cholesterol (Hambleton et al., 2007). 
The researchers proposed that after binding to MPRci, VZV undergoes 
receptor-mediated endocytosis and is subsequently delivered to an 
intracellular compartment (see figure 1.6B and C). Here, fusion is triggered 
by unknown factors, possibly co-receptors, such as IDE. Recently it has 
shown that VZV entry into Chinese hamster ovary (CHO) cells is 
dependent on an acidic compartment (Finnen et al., 2006) and thus it has 
been proposed that there is a possibility that the same endosomal 
conditions that have been shown to inactivate outgoing virions, could be 
responsible for triggering the fusion between incoming viruses and the 
endosomal membrane. 
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Once the virus has entered the cell, to spread within this new environment, 
it is believed that VZV utilizes proteins within the host cells cytoskeleton 
(Cilloniz et al., 2007; Che et al., 2008), (this process is also believed to be 
used during cell-to-cell spread; see section 1.5.5). The cytoskeleton is 
composed of three types of protein structures, known as microfilaments, 
microtubules and the intermediate fibre system, (Henderson and Weber, 
1981). Microfilaments mainly consist of the globular protein actin, which 
once assembled into fibres are important for the maintenance of cell 
morphology. Microtubules, which are comprised of - and -tubulin 
subunits, perform general functions within cells including organelle 
movement and cargo transport (Nogales, 2000).  During the VZV 
replication cycle in vitro, tubulin and actin networks undergo significant 
changes including fibre elongation (Khun et al., 2005). It was 
demonstrated that when these networks were destroyed intentionally, viral 
replication was diminished, which suggested that these systems are vital 
for efficient infection and viral replication (Khun et al., 2005).  Recently it 
was demonstrated that the ORF9 protein binds to -tubulin, suggesting 
that this protein may attach to microtubules and play a role in the 
intracellular transport of non-enveloped virions (Cilloniz et al., 2007). Many 
herpes viruses including HSV and CMV are also known to use the host 
cells microtubular network during replication (Sodeik et al., 1997; Dohner 
et al., 2004).  
 
The contents of the viral particle are released into the host cell cytoplasm 
via fusion of the viral and endosomal envelopes. Tegument proteins and 
the nucleocapsid migrate to and enter the host cell nucleus (see figure 
1.6D and E). Controversy surrounds the mechanisms that are utilized by 
herpesviruses to translocate DNA into the nucleus (Cohen et al., 2007b), 
and the mechanisms for VZV are not known. However, with HSV-1 it has 
been demonstrated that capsids are transported from the site of de-
envelopment to the nuclear pore along the microtubular network 
(Kristensson et al., 1986; Sodeik et al., 1997; Topp et al., 1994). The 
capsid then binds to the nuclear pore and releases viral DNA in the 
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presence of an energy source (Ojala et al., 2000). Simultaneously 
tegument proteins are released into the cytosol, of which VP1-2 (UL36) 
(the VZV homologue ORF22) migrates with the capsid to the nuclear pore, 
whilst VP16 (UL48) (the VZV homologue ORF10) travels to the nucleus 
independently (Batterson and Roizman, 1983). Upon entry of the viral 
genome into the nucleus, DNA replication commences.   
 
 
 
 
Figure 1.6: Viral Attachment and Cell Entry. VZV enters the cells by 
attaching to HSPG (A) and binding to receptors (M6PRci via gB, IDE via 
gE) on the plasma membrane, and undergoes clathrin dependent 
endocytosis (B). The virus is engulfed in an endosome (C), in which the 
virus and the endosome undergo membrane fusion (D), which releases 
tegument proteins and the nucleocapsid. NB: nuclear entry via fusion with 
the nuclear membrane is extrapolated from the HSV model (E). Not to 
scale; adapted from Hambleton et al., 2007 and Cohen et al., 2007 with 
permission. 
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1.5.2 Initial Events in Viral Replication:  
Transactivation can be defined as stimulation of transcription, by 
transcription factors binding to DNA and activating adjacent proteins.  Five 
viral proteins are capable of transactivating (and/or transrepressing) 
specific VZV gene promoters. These proteins are encoded by genes of the 
immediate early (IE) class that lie within ORF4, ORF62, ORF63, and 
ORFs 10 and 61, (Baudoux et al., 2000). Apart from the IE61, all of these 
proteins are structural components of the virion tegument (Kinchington et 
al., 1992; Kinchington et al., 1995), see figure 1.7A. The IE62 protein is 
the major viral transactivator and is known to induce expression of all 
classes of VZV genes (Disney et al., 1990; Inchauspe et al., 1989; Perera 
et al., 1992b). In addition to the viral transactivators, several cellular 
transcription factors have been shown to play an important role in viral 
gene transactivation, including specificity factor 1 (Sp1), upstream 
stimulatory factor (USF), activator protein 1 (AP-1), octamer-binding 
protein 1 (Oct-1), and TATA element (Jones et al., 2005; Meier and 
Straus, 1995; Moriuchi et al., 1995b; Rahaus and Wolff, 1999; Ruyechan 
et al., 2003).  USF is particularly important for VZV replication, due to the 
direct physical interaction that occurs between this cellular transcription 
factor and IE62 (Meier and Straus, 1995; Rahaus et al., 2003; Yang et al., 
2004). Recently it was demonstrated that the activation domain of USF1 is 
sufficient for synergistic activation with IE62 (Yang et al., 2006). In 
conjunction with the IE62 protein, USF transactivates the promoters of IE4 
and ORF10 in reporter plasmid assays (Michael et al, 1998).  
Approximately 25% of the putative regulatory elements that control 
expression of the 71 VZV ORFs contain USF consensus binding sites, 
indicating that USF is likely to play a key role in VZV replication (Ruyechan 
et al., 2003).  
 
1.5.2.1 Viral DNA Replication: 
The machinery that enters the nucleus and replicates viral DNA is 
composed of early proteins; including the DNA helicase/primase (encoded 
by ORF6, 52 and 55); the large subunit of DNA polymerase encoded by 
ORF28; (the small subunit is thought to be encoded by ORF16) and the 
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single stranded DNA binding protein (encoded by ORF29), (Zweerink et 
al., 1981); see table 1.4 and figure 1.7C. By analogy with HSV; VZV 
ORF6, 52 and 55 are predicted to form a heterotrimeric complex exhibiting 
both helicase and primase activity. The model of VZV DNA replication is 
based on elements of a general mechanism proposed for HSV DNA 
replication and on VZV specific data. Recently it has been demonstrated in 
vitro that formation of DNA replication compartments begins 4-6h post 
infection (Reichelt et al., 2009). Unwinding of the DNA origin is thought to 
occur via the ORF29 encoded single-stranded DNA binding protein 
(Kinchington et al., 1988), see figure 1.7B. Replication is then initiated at 
one of two origin of replication (short) (Oris) loci by binding of the ORF51 
encoded origin of replication binding protein (OBP) (Stow et al., 1990; 
Chen and Olivo, 1994) and possibly cellular factor(s). The remainder of 
the replication proteins are then recruited to the origin; see figure 1.7C. 
Five additional VZV DNA binding proteins have been identified ranging 
from 21-175kDa (Roberts et al., 1985). Like HSV-1, the VZV genome has 
single nucleotide extensions (Mocarski and Roizman 1982; Davison, 
1984). These extensions are presumed to mediate circularisation of the 
genomes via direct ligation of the termini (Davison, 1984), after their entry 
into the host cell nucleus, (see figure 1.7C). Viral protein synthesis 
(discussed in section 1.5.3), is initiated by tegument proteins binding to the 
circularised viral DNA, see figure 1.7D. By analogy with HSV; a nick 
introduced into the replicating DNA shifts replication into a rolling circle 
mechanism, (Ruyechan and Hay, 2000). This form of replication generates 
head-to-tail concatamers which are cleaved by specific nucleases to 
generate linear DNA for packaging (see figure 1.7E). Based on sequence 
comparison to HSV, VZV encodes homologues for each of the seven 
essential genes whose protein products are responsible for the cleavage 
and packaging of viral DNA into capsids. The putative DNA encapsidation 
genes are encoded by VZV ORFs 25, 26, 30, 34, 43, 45/42 and 54 
(Sheaffer et al., 2001). Capsid formation is discussed in section 1.5.4.1 
and figure 1.7F. 
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Table 1.4: VZV Proteins Involved in DNA Replication. The functions of the 
proteins encoded by VZV ORFs 6, 16, 52 and 55 are based on the 
properties of their HSV homologues.  
 
1.5.3 Protein Synthesis: 
As mentioned above, viral protein synthesis is initiated by tegument 
proteins that bind to the circularised VZV DNA. By analogy with cells 
infected with HSV and other herpesviruses, VZV protein expression is 
believed to be a tightly regulated cascade of events that occurs in three 
stages which are classified based on the time course of their expression 
after virus entry (Cohen et al., 2007b). Each stage is dependent on the 
host cell ribonucleic acid (RNA) polymerase and may also be regulated by 
the RNA cleavage activity of VZV ORF17 (Sato et al., 2002a). The first 
genes transcribed are the immediate early genes. Products of these genes 
include transcriptional activator and transcription repressor proteins. 
These proteins are expressed in the host cell cytoplasm but are 
translocated back into the nucleus to down regulate further immediate 
early gene transcription and to initiate synthesis of the early proteins. Early 
proteins enter the nucleus to facilitate viral DNA replication (see figure 
1.7C). The third class of VZV proteins to be expressed are the late 
proteins. These encode the structural proteins that act as the building 
blocks for the assembly of new virions and include the viral glycoproteins 
(Davison and Scott, 1986), see figure 1.7. 
 
As achievable titres of cell-free VZV are too low to permit synchronous 
infections of cultured cells, kinetic studies which have been conducted for 
other herpesviruses are lacking. However, a recent study was conducted 
that examined the kinetics of VZV protein expression in vitro using 
different fluorescent cell dyes to label VZV-infected inoculum cells and 
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uninfected cells (Reichelt et al., 2009). Newly infected human fibroblast 
cells were evaluated by confocal immunofluorescence and electron 
microscopy at specific time points, at the single-cell level. This study 
revealed that IE62 and IE61 appeared within 1h post infection whilst late 
proteins such as the ORF23 capsid protein were detectable at 9h. 
Surprisingly, although gE is classified as a late protein, accumulation in 
the Golgi compartment was seen as early 4h post infection, whilst 
substantial gE expression on plasma membranes was only evident at 9h. 
 
 
 
 
Figure 1.7: An Overview of Events in the Nucleus; Viral DNA Replication, 
Protein Synthesis and DNA Packaging. (A): Transactivation by both viral 
and cellular transcription factors occurs; (B): Unwinding of DNA is 
facilitated by ORF29 protein, binding of ORF51 initiates DNA replication 
and recruitment of other DNA replication proteins encoded by ORFs 6, 16, 
28, 52 and 55; (C): Rolling circle replication ensues; (D): Messenger RNAs 
are transcribed, transported to the cytoplasm and translated. The encoded 
proteins are then transported back to the nucleus; (E): Head-to-tail 
concatamers are cleaved by specific nucleases to generate linear DNA for 
packaging. The putative DNA encapsidation proteins are encoded by VZV 
ORFs 25, 26, 30, 34, 43, 45/42 and 54; (F): Nucleocapsids are assembled 
in the nucleus. Key: IE; immediate early, E; early, L; late, RNA; ribonucleic 
acid. Not to scale, adapted from Cohen et al., 2007, with permission.  
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1.5.4 Virion Assembly: 
1.5.4.1 The Nucleocapsid: 
The nucleocapsids of VZV (Gershon et al., 1994; Harson and Grose, 
1995); and indeed HSV (Nii et al., 1968), and PRV (Whealy, 1991), are 
assembled in the nuclei of infected cells. Recent kinetic experiments in 
vitro have shown that these structures are present within the nucleus at 9h 
post infection (Reichelt et al., 2009). Capsid assembly is a complex 
process involving interactions between multiple proteins in both the 
cytoplasm and in the nucleus. Like other alphaherpesviruses, the 
formation of VZV capsids is predicted to require the products of VZV ORFs 
20, 23, 33, 33.5, 40, and 41 (Gibson and Roizman, 1972; Kut and 
Rasschaert, 2004). Direct information about VZV capsid proteins is limited, 
but assuming conservation of function with HSV (see table 1.5 below), the 
outer capsid shell comprises of ORF20, ORF23, ORF40 and ORF41. 
 
 
VZV 
Capsid 
Protein 
HSV Capsid 
Protein 
Homologue 
         Function and Property of HSV 
Homologue 
ORF20 VP19C (UL38) 
Forms a triplex complex with VP23; part 
of the outer capsid; interacts and 
stabalizes adjacent capsomers  
ORF23 VP26 (UL35) 
Smallest capsid protein (SCP), covers 
the top of hexons of the outer surface of 
the capsid shell; homologue of UL48/49 
in HCMV 
ORF33 VP24/VP21 Minor scaffolding proteins 
ORF33.5 Pre-VP22a 
Scaffolding protein, protease which self 
cleaves 
ORF40 VP5 (UL19) Major HSV-1 capsid protein;  
ORF41 VP23 (UL18) 
Forms all capsomers; and thus the outer 
capsid; see VP19C  
 
Table 1.5: VZV Capsid Proteins Closely Related to HSV Capsid Proteins. 
(Additional HCMV reference form Lai and Britt, 2003). 
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Like HSV-1, (Rixon et al., 1996), not all of the VZV capsid proteins have a 
nuclear localization capacity. This is restricted to the ORF23 and ORF33.5 
protein products and has been mapped to residues 229-234 in the C-
terminus of the ORF23 protein product (Chaudhuri et al., 2008). The 
ORF40 protein is predominantly translocated to the nucleus by the ORF23 
protein, and to a lesser extent by the ORF33.5 protein in vitro. However as 
ORF23 has been shown to be essential for replication in vivo, ORF33.5 
cannot compensate for the loss of ORF23 in vivo (Chaudhuri et al., 2008). 
It is also noteworthy that although ORF23 is not essential for replication in 
melanoma cells in vitro, growth kinetics and capsid formation are severely 
disrupted in the absence of this protein; however, this was not the case in 
a fibroblast cell line. Using recombinant capsid protein GFP fusion 
constructs the intracellular trafficking of the individual proteins revealed 
that neither ORF23 nor ORF33.5 could facilitate the transport of ORF20 or 
ORF41 from the cytoplasm to the nucleus. Chaudhuri and colleagues 
have proposed a model based on analogy with HSV capsid assembly (see 
figure 1.8). In HSV-1, the ORF20 and ORF41 homologues are known to 
form a trimeric complex, which is transported into the nucleus upon 
binding to VP5; the major capsid protein and ORF40 homologue. Thus, 
this may also be the case for VZV. A similar trimeric complex may form in 
the cytoplasm, composed of ORF20 and ORF41, bound to ORF40. This 
larger complex may then translocate into the nucleus to allow for the final 
assembly of capsomeres through ORF40 binding to either ORF23 or 
ORF33.5.  
 
Encapsidated viral DNA then exits the nucleus, and in doing so, acquires a 
primary envelope as it passes through the inner nuclear membrane. This 
enveloped structure then enters the perinuclear cisterna, which is 
continuous with the RER, (this mechanism is accepted for all of the 
alphaherpesviruses, (Mettenleiter, 2002)). In order to achieve intimate 
contact with the inner nuclear membrane, the nuclear lamina has to be 
softened and at least partially dissolved; in HSV-1, PRV, EBV and MCMV, 
this requires two virally encoded proteins, which are both structurally and 
functionally conserved in Herpesviridae, (Reynolds et al., 2004; Fuchs et 
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al., 2002; Gonnella et al., 2005; Lotzerich et al., 2006). The VZV 
homologues of these two proteins (pUL31 and pUL34) are ORFs 27 and 
24 respectively. Homologues of pUL34 are predicted type-II 
transmembrane proteins that complex with pUL31. Complex formation is 
important for correct positioning at the nuclear membrane, which is a 
prerequisite for primary envelopment. In the absence of either protein, 
nuclear egress has been demonstrated to be drastically impaired.  For the 
alphaherpesviruses examined to date (HSV-1 and BHV-1) nucleocapsids 
subsequently gain access to the cytoplasm by fusion of their primary 
envelope with the outer nuclear membrane, however the exact 
mechanisms for this are still unclear (Leuzinger et al., 2005). 
 
 
 
 
Figure 1.8: A Proposed Model of VZV Capsid Assembly. (Based on 
analogy of HSV capsid assembly); not to scale; adapted from Chaudhuri 
et al., 2008, with permission. 
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Following encapsidation and subsequent egress from the nucleus, 
acquisition of both the tegument and a glycoprotein studded envelope in 
the cytoplasm must occur. Two models which incorporate these concepts 
have been proposed (Gershon et al., 1994; Harson and Grose 1995) and 
will be discussed in detail in section 1.5.4.4.  
 
1.5.4.2 Acquisition of Tegument Proteins: 
Knowledge of the events that occur during VZV tegumentation is limited, 
but in the case of HSV-1, tegumentation (and secondary envelopment) are 
driven by a highly ordered network of protein–protein interactions in the 
cytoplasm (Vittone et al., 2005), and the proteins involved are conserved 
in the Herpesviridae family. Final tegumentation of HSV-1 can initiate at 
two distinct sites; the capsid and the future envelope, which then combine 
to produce a mature virion. The capsid-proximal tegument contains the 
conserved pUL36 and pUL37 (homologous to VZV ORFs 22 and 21), 
which form a physical complex, pUS3 (VZV ORF66), and presumably, also 
contains the conserved pUL25 (VZV ORF34). This structure is either 
reassembled immediately after nuclear egress, or remains associated with 
the capsid during this process (Wolfstein et al., 2006; Luxton et al., 2005; 
Zhou et al., 1999).   
 
In the case of VZV, the mechanism by which the IE62 protein is 
incorporated into the viral tegument is largely unknown. However, the viral 
kinases present in the viral tegument (encoded by VZV ORF47 and 
ORF66) have been shown to be capable of phosphorylating IE62. ORF47 
kinase function is known to be important for normal VZV virion assembly 
(Besser et al., 2004), is critical for replication in human immature Dendritic 
cells (DCs), (Hu and Cohen, 2005) and has been shown to form a stable 
complex with IE62 (Besser et al., 2003; Kenyon et al., 2003). 
Phosphorylation of IE62 by ORF66 kinase is required for the redistribution 
and exclusion of IE62 from the nucleus to the cytoplasm.  Recently it was 
suggested that the ORF9 protein may also play a role in viral tegument 
formation via the recruitment of IE62 and possibly ORF47 kinase to 
complexes within the cytoplasm (Cilloniz et al., 2007; Che et al., 2008). 
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ORF9,  which is essential for replication in vitro (Che et al., 2008), 
interacts with IE62 via the central portion of the ORF9 protein (aa 117 to 
186) and the N-terminal half of the IE62 acidic activation domain (Cilloniz 
et al., 2007). In the cytoplasm, IE62 co-localizes with the ORF9 protein in 
filamentous structures leading to the incorporation of IE62 into the viral 
particle (Kinchington et al., 2000; Cilloniz et al., 2007). 
 
The process of VZV tegumentation is not addressed in the Harson and 
Grose model, but according to the Gershon model, nucleocapsids lose 
their nuclear derived envelopes when they fuse with the RER, releasing 
naked nucelocapsids into the cytoplasm (figure 1.9A); which is consistent 
with what is seen with HSV. Subsequently, naked nucelocapsids are 
enveloped in the TGN where they acquire both tegument proteins and a 
mature envelope (see section 1.5.4.4 for more details). The Gershon 
model was based upon transmission electron microscopy (TEM) studies 
and recent TEM experiments in HELF cells (Reichelt et al., 2009) add 
support to the model of tegumentation (and envelopment) of viral 
nucleocapsids by the c-shaped cisternae of the TGN.   
 
1.5.4.3 Glycoprotein Synthesis and Trafficking;  
Both models agree that the VZV glycoproteins are synthesized and 
processed in the rough endoplasmic reticulum (RER) and are transported 
to the Golgi apparatus independently of the newly assembled 
nucleocapsids, (Gershon et al., 1994; Harson and Grose, 1995). Once 
transcribed, glycoprotein mRNA is translocated out of the nucleus and into 
the cytoplasm where it is translated by polyribosomes associated with the 
RER. The glycoprotein polypeptides then cross the RER membrane and 
enter the RER lumen. As the peptides migrate through the RER, they 
become glycosylated and acquire Man 6-P (Gabel et al., 1989), (see figure 
1.9A). Recent experiments by Storlie (et al., 2006) have shown that gE, gI, 
gH, and gB are synthesized within 4-6h postinfection in cultured cells, and 
travel via the TGN to the outer cell membrane. 
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For their transport to the TGN, some glycoproteins use TGN-specific aa 
targeting patches in their cytoplasmic tails. For gE, gB and gI, these 
sequences have been identified as AYRV and a second acidic aa rich 
sequence, the putative signal patch, (Zhu et al., 1996), YSRV and YMTL 
(Heineman et al., 2000), and TIREE (Wang et al.,  1998) respectively. The 
acidic cluster of gE interacts with the connector protein, phosphofurin 
acidic cluster sorting protein 1 (PACS-1), and directs VZV gE from 
endosomes to the TGN, (Wang et al., 1998 and Wang et al., 2001). VZV 
gE is phosphorylated on its cytoplasmic tail (Grose et al., 1989, Montalvo 
and Grose 1986b, Olson et al., 1997) and differential phosphorylation of 
the gE acidic cluster targets endocytosed gE to either the TGN for viral 
assembly or to the cell surface for cell-to-cell spread (Kenyon et al., 2002). 
Glycoprotein E is an essential protein in vitro (Mo et al., 2002) and both 
the YAGL motif and the first 16 residues of the unique N-terminal region of 
this protein have been shown to be essential for VZV replication in vitro 
(Moffat et al., 2004; Berarducci et al., 2006). However, the gE-AYRV 
mutant which interferes with TGN targeting was found to be associated 
with substantial attenuation in skin (Moffat et al., 2004).  
 
Because those VZV glycoproteins that lack targeting sequences (gC, gH 
and gL) concentrate in the TGN of infected cells, it has been proposed that 
gE and gI, serve as navigators, forming complexes that direct the signal-
deficient glycoproteins to the TGN (Gershon and Gershon 1999; Alconda 
et al., 1998; Duus and Grose, 1996). These glycoproteins also rely on 
these mechanisms for their transport to the infected cell membrane and/or 
retrieval from this site back to the TGN for their incorporation into new 
virions (Heineman and Hall 2002; Alconda et al., 1998; Gershon and 
Gershon, 1999; Duus and Grose, 1996; Duus et al., 1995; Kenyon et al., 
2002; Pasieka et al., 2003). Duus and Grose (1996) have reported that gE 
can interact with gH, and Pasieka (et al., 2004) reported on a gE:gH 
complex shuttling gH to the TGN after internalisation of the complex 
through the trafficking motif in the long gE tail. Preliminary observations 
have suggested that gI can also redirect the gH:gL complex to the TGN 
(Wang et al.,  2000).  
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VZV gE is transported to the cell plasma membrane (PM) from where it is 
selectively retrieved by endocytosis, and returned to the TGN, before 
being recycled back to the PM (Olson and Grose 1997; Olson and Grose 
1998; Wang et al., 2000). As a recombinant VZV genome lacking only 
endocytosis-competent gE cannot replicate, this supports the conclusion 
that endocytosis is an essential glycoprotein trafficking mechanism 
(Maresova et al., 2005, Moffat et al., 2004). Glycoprotein K is also 
transported to the PM of infected cells where it is efficiently endocytosed 
(Hall et al., 2007), however, the half-life of gK is considerably shorter than 
that of other VZV glycoproteins including gB, gE and gH (Hall et al., 2007).  
Glycoprotein I is also transported to the PM, but in some cells, some gI is 
retained in the TGN (Wang et al., 1998). Glycoprotein I can, but does not 
always form a complex with gE. Complex formation, which is presumed to 
occur in the RER, (Gershon and Gershon, 1999) requires the gI N-
terminus (Kimura et al., 1997) whilst the gI binding domain on gE was 
recently mapped to aas 163-208 (Li et al., 2007). Complex formation also 
enhances the exit of gI from the RER and the targeting of gI to the TGN 
(Gershon and Gershon, 1999; Wang et al., 1998; Olson and Grose, 1998).  
In the absence of gI, VZV-infected cells show an unusual punctuate 
distribution of gE on plasma membranes, reduced syncytium formation 
and diminished synthesis of the mature form of gE (Mallory et al., 1997).  
 
1.5.4.4 Envelopment and Virion Morphogenesis: 
The hypothesis of VZV envelopment in the TGN is similar to that originally 
proposed for PRV and later extended to HSV and other herpes viruses 
(Whealy, 1991; Card et al., 1993; Mettenleiter, 2006). According to the 
Gershon model (1994b), the sacs of the TGN flatten and curve to acquire 
the shape of the letter „c‟ which envelops a VZV nucleocapsid (figure 
1.9B). Viral glycoproteins are segregated to the inner face of these 
cisternae, while MPRs and other cellular proteins are restricted to the 
opposing outer face of the same c-shaped cisternae (Gershon et al., 
1994), (figure 1.9B). The cytoplasmic tails of all three major VZV 
glycoproteins, gE, gH, and gB, harbour functional tyrosine-based 
endocytosis motifs that mediate internalization (Maresova et al., 2005).  
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Figure 1.9: Proposed Assembly and Envelopment of VZV. 
 
(A) Nucleocapsids lose their nuclear derived envelopes when they fuse with the RER, releasing naked nucleocapsids into the 
cytoplasm. Glycoproteins are synthesized on the RER and delivered to the TGN independently of nucleocapsids and tegument.   
 
(B) The TGN forms C-shaped cisternae, each of which envelops a VZV nucleocapsid (for ease of diagrammatic representation, 
only one C-shaped cisterna is shown). Viral glycoproteins are segregated to the inner (concave) face of these cisternae, while 
MPRs and other cellular proteins are restricted to the outer (convex) face of the same C-shaped cisterna.  
 
(C) The encroaching arms of the TGN fuse with the creation of a double membrane bound structure. The inner (concave) face 
becomes the glycoprotein-containing-VZV-envelope, while the outer (convex) face functions as a transport vesicle. 
 
(D) In most cell types the transport vesicle facilitates MPR-dependent delivery of VZV to late endosomes.  
 
Key: CGN: Cis-Golgi network; TGN: trans-Golgi newtork; PM; Plasma membrane; RER; rough endoplasmic reticulum, MPR; 
Mannose-6- phosphate receptor.  Not to scale; adapted from Hambleton et al., 2004, with permission.  
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This segregation of viral glycoproteins and MPRs may serve to organise 
viral assembly and egress and, possibly, to permit cellular MPRs to 
interact with glycoproteins of the VZV envelope (Gershon et al., 1994b, 
Zhu et al., 1995).  
 
The encroaching arms of the TGN fuse, creating a double membrane 
bound structure. The inner membrane becomes the glycoprotein-
containing-VZV-envelope, while the outer membrane functions as a 
transport vesicle (see figure 1.9C). Accumulation of MPRs on the outer 
membrane of the wrapping cisternae is thought to route viral particles from 
the cell secretory pathway to endosomes (Dahms et al., 1989; Westlund et 
al., 1991; Gershon et al., 1994b), (figure 1.9D). TGN-derived vesicles 
containing MPRs are preferentially sorted to late endosomes (Dahms et 
al., 1989; Griffiths et al., 1988) and VZV-containing vacuoles have been 
found to contain a lysosomal acid phosphatase enzyme (Gershon et al., 
1973).  The de-envelopment and subsequent re-envelopment of VZV has 
been proposed to be a mechanism which enables tegument proteins that 
lack signal sequences and thus are synthesised in the cytosol, to be 
incorporated into mature viral particles. 
 
The model proposed by Harson and Grose (1995), (see figure 1.10), was 
formulated from experiments in melanoma cells (MeWo) and lung diploid 
cells (MRC5) and suggests that nucleocapsids acquire and then retain 
their envelopes as they bud through the inner nuclear membrane, (figure 
1.10A). Although these authors acknowledged the presence of naked 
nucleocapsids in the cytoplasm, they stated this to be a rare event. From 
here they travel through the perinuclear space into a SER vacuole which 
pinches off and enters the cytoplasm, (figure 1.10B). The virion envelopes 
are glycosylated when the SER vacuole fuses with Golgi-derived vesicles, 
laden with glycoproteins, (figure 1.10C and 1.10D). This model also 
suggests that late in infection, some particles re-enter the nucleus. Whilst 
residing in the perinuclear space, some particles appear to travel back 
through the inner nuclear membrane, and thus also acquire their envelope 
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from the inner membrane, (Figure 1.10F); accounting for the phenomenon 
that enveloped capsids are seen within the nucleus. 
 
 
Figure 1.10: The Harson and Grose Model of Envelopment and Egress of 
VZV Particles. (A) Nucleocapsids in the nucleoplasm bud through the 
inner nuclear membrane and in doing so, acquire an envelope and travel 
through the perinuclear space into the Smooth Endoplasmic Reticulum 
(SER) (B) The SER vacuole pinches off and enters the cytoplasm. (C) 
Golgi derived vesicles containing VZV glycoproteins fuse with the SER 
vacuole. (D) The vesicles fuse to form a large vacuole containing complete 
viral particles. (E) Some vacuoles fuse with the Plasma membrane and 
enveloped viruses emerge on the surface of the infected cell. (G) Some 
vacuoles fuse with prelysosomes, leading to partial degradation of viral 
particles. (F) Late in infection, some particles re-enter the nucleus. Key: 
RER; Rough endoplasmic reticulum, SER; smooth endoplasmic reticulum. 
Not to scale; adapted from Harson and Grose, 1995 and Cohen et al., 
2007b with permission. 
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It is important to note that the main discrepancy between these two 
models (ie: whether there is a de-envelopment and subsequent re-
envelopment of VZV) may be explained by the difference of virion 
morphogenesis seen in different cell types in vitro. It has thus been 
suggested that VZV envelopment is not a uniform process in all 
susceptible cell types. The Harson and Grose model is based on the 
hypothesis that the melanocyte is a preferred cell type for replication as 
the virus usurps the cell machinery used for melanin production.  
 
1.5.5 Egress and Cell-to-Cell Spread: 
According to both models, most particles are either transported to the cell 
surface for release (figure 1.10E), or to prelysosomes (figure 1.10G), 
within which the particles are partially degraded before release. This leads 
to an abundance of defective progeny VZV being released. Recently it has 
been demonstrated that aberrant „light‟ particles that lack a core capsid, 
but contain equivalent gB, gE and gI content to infectious progeny, 
comprise the majority (75 to 85%) of all egressed particles from melanoma 
cells in vitro (Carpenter et al., 2008) and in comparison to infectious virus 
particles are produced at a ratio of approximately 40,000:1 (Carpenter et 
al., 2009). This implies a dissociation between events in the nucleus 
related to capsid formation and the subsequent envelopment processes in 
the cytoplasm of VZV infected cells, (see figure 1.11 for a proposed model 
of light particle assembly and release). Although controversy surrounds 
both the site of envelopment and the pathway leading to the release of the 
VZV particle from the cell, unenveloped nucleocapsids in the cytosol of 
infected cells are a feature of infection with any alphaherpesvirus 
(Mettenleiter, 2002). With both models, although virion degradation takes 
place, pathways that avoid prelysosomes must exist in humans for efficient 
spread of infection.  
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Figure 1.11: Proposed Model for the Formation and Release of „Light‟ 
Particles During Viral Replication. This is based on the HSV model and 
recent work by Carpenter et al., 2008.  Key: CGN: Cis-Golgi network, 
TGN; trans-Golgi newtork; PM; Plasma membrane. Not to scale; adapted 
from Mettenleiter et al., 2006, with permission. 
 
Fusion between the TGN-derived transport vesicle membrane and the 
plasma membrane releases mature virions from the cell surface (Johnson 
and Huber, 2002).  No unique combination of membrane proteins has 
been identified as a minimum fusion unit. Instead, several VZV proteins, 
individually and in various combinations, have been observed to induce 
cellular fusion. Cell-to-cell fusion has been suggested as the prominent 
mechanism by which VZV spreads to new host cells (Cole and Grose, 
2003), but although syncytia formation is a hallmark of VZV, recent 
experiments in HELF cells demonstrated that initial infection of 
neighbouring cells does not require cell-to-cell fusion (Reichelt et al., 
2009). However, cell-to-cell fusion (which was first seen in vitro at 9h post 
infection), is likely to substantially amplify VZV replication. Membrane 
fusion is mediated by gH and gL or gB and gE (Cole and Grose, 2003; 
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Rodriguez et al., 1993; Duus and Grose, 1996). While expression of gH or 
gB alone induce a modest amount of fusion, expression of gE alone is not 
sufficient for fusion unless it is co-expressed with gB (Maresova et al., 
2001). Cell fusion has been shown to be regulated by VZV gH endocytosis 
(Pasieka et al., 2004) and VZV gK (based on analogy to its HSV-1 
homologue) is believed to participate in membrane fusion (and 
cytoplasmic virion morphogenesis), (Maresova et al., 2005; Hall et al., 
2007). As mentioned earlier, virus spreads to neighbouring cells as early 
as 8-12h post infection (Asano and Takahashi, 1980; Reichelt et al., 
2009).  
 
It is also believed that VZV utilize proteins within the host cells 
cytoskeleton in order to facilitate its cell-to-cell spread (Mo et al., 2000; 
Cilloniz et al., 2007; Che et al., 2008).  Expression of VZV gE has been 
shown to induce changes in the organization of microfilaments in polarized 
epithelial cells and it has been hypothesized that it is the rearrangement of 
the actin filaments that facilitates the cell-to-cell spread of VZV (Mo et al., 
2000). Co-immunoprecipitation experiments have recently demonstrated 
that ORF9 binds to gE, (Che et al., 2008) as well as to -tubulin (Colloniz 
et al., 2007).  
 
Experiments carried out in MeWos demonstrated that VZV emerges from 
an infected cell surface in a distinctive pattern described as viral highways 
(Harson and Grose, 1995; Padilla et al., 2003). These structures consist of 
thousands of particles arranged in linear pathways across the syncytial 
surface. This egress pattern has not been seen with the five other human 
herpesviruses investigated to date or with PRV (Padilla et al., 2003). 
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1.6 The Natural History of VZV Infection: 
VZV is highly contagious and causes annual epidemics among susceptible 
individuals during late winter and spring in temperate climates (Cohen et 
al., 2007b). Unique amongst the human herpes viruses, VZV is thought to 
be spread by inhalation of aerosolized virus particles (Brunell, 1989; Tsolia 
et al., 1990; Sawyer et al., 1994; Arvin et al., 1996). The virus is 
transmitted in the human population, (its only natural reservoir), either by 
direct contact with infectious virus in varicella or zoster skin lesions, or by 
respiratory secretions (Arvin et al., 1996; Cohen et al., 2007b). 
 
Primary VZV infection is associated with viraemia and a diffuse cutaneous 
rash recognized as varicella, (chickenpox). VZV establishes latency in 
sensory ganglia and during periods of impaired cellular immunity, 
reactivation from latency allows the virus to migrate down the nerves to the 
skin (Esiri and Tomlinson, 1972) and cause herpes zoster (shingles). 
 
1.6.1 Pathogenesis of Varicella: 
The restricted infectivity of VZV for non-human species has been a major 
obstacle in the study of VZV pathogenicity and disease progression.   
Originally theories of VZV pathogenesis was based upon similarities to the 
mousepox model (Grose, 1981b). According to this model (see figure 
1.12), VZV is presumed to infect mononuclear cells in regional lymph 
nodes, causing a primary viraemia that carries the virus to 
reticuloendothelial organs, such as the liver, for a phase of viral 
amplification, which is followed by a secondary viraemia in the late 
incubation period that results in VZV transport to the skin. 
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Figure 1.12: Pathogenesis of Varicella; Based on the Mouse Pox Model. 
According to this model, the incubation period includes two episodes of 
viraemia: Following virus replication at a local focus, primary viraemia 
seeds internal organs. A more prolonged secondary viraemia leads to 
widespread cutaneous infection and characteristic exanthema, which 
occurs when high titre virus is released from internal sites of multiplication. 
Not to scale. (Adapted from Grose 1981b, with permission). 
 
Clinical observations of varicella have indicated that VZV is transported 
from respiratory sites of inoculation (Sawyer et al., 1994) to the skin via a 
cell associated viraemia (Ozaki et al., 1984; Asano et al., 1990; Ozaki et 
al., 1994). As with the mousepox model, these observations have also 
suggested that this viraemia was biphasic, with an asymptomatic phase 
preceding the onset of the skin rash. Viraemia leads to the dissemination 
of the virus to the lungs, spleen, liver and other organs, and can cause life-
threatening varicella in immunocompromised children, (Asano et al., 1993; 
LaRussa et al., 2000).  Using culture techniques, viraemia has been 
detected in patients between five days prior and one day post, rash 
development in several studies (Asano et al., 1985a; Asano et al., 1985b; 
Ozaki et al., 1984). Detection immediately prior to disease onset was 
suggested to correspond to secondary viraemia. In the same studies, 
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viraemia disappeared two days after disease onset and was undetectable 
when specific immunity to VZV developed (Asano et al., 1985a; Ozaki et 
al., 1986). However, using PCR amplification viral DNA was detected for 
longer periods (Ozaki et al., 1994). Although virus could not be isolated 
from the blood early in the incubation period using culture techniques, viral 
DNA was detected at the same stage by PCR amplification and was 
assumed to represent primary viraemia, (Ozaki et al., 1994).  
 
The relatedness of VZV and simian varicella virus (SVV) and the 
similarities in the clinical symptoms and pathogenesis of human and 
simian varicella, make SVV infection of non-human primates an excellent 
animal model to investigate VZV pathogenesis (and latency), (Gray, 2004). 
SVV is a neurotropic alphaherpesvirus that causes a natural, varicella-like 
disease in several monkey species including African Green (Gray, 2003; 
Mahalingam et al., 1998b; Kennedy et al., 2004), St. Kitts vervet (Gray et 
al 1998; Ou et al., 2007) and Cynomolgus monkeys (Mahalingam et al., 
2007) as well as Rhesus macaques (Kolappaswamy et al., 2007). The 
genomes of SVV and VZV are similar in size and structure, co-linear with 
respect to gene organization and share 70-75% DNA homology. 
Experimental infection of African Green monkeys is followed by a 7-10 day 
incubation period during which a viraemia disseminates the virus 
throughout the host (Gray, 2003). Clinical disease is characterized by 
fever and a vesicular skin rash and is highly contagious. Pneumonia and 
hepatitis may occur during more severe infections. Examination of acutely 
infected tissues reveals histopathology including necrosis and 
haemorrhage in the skin, lung, liver, and spleen. Host immune responses 
are induced which resolve the acute infection within 14-21 days 
(Mahalingam et al., 2007). However, research with this model has only 
been carried out in a limited number of laboratories, due to both the lack of 
availability of appropriate facilities and the economic burden associated 
with working with such a model. 
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In addition to simian models, several small laboratory animals (rats, rabbits 
and guinea pigs) have been used as models of VZV pathogenesis; (Myers 
et al., 1980; Matsunaga et al., 1982). However, animal-to-animal spread, 
viraemia, and exanthem have only been demonstrated in guinea pigs, 
(Myers and Connelly, 1992).  The combined use of guinea pigs and 
guinea pig adapted viral strains is a good model of VZV pathogenesis as 
(providing the guinea pigs body temperature (39.3oC) is kept below the 
viral replication shut-off temperature (39oC)), replicating viruses can reach 
the skin and cause lesions (Myers and Connelly, 1992; Yamanishi et al., 
1980).  Various guinea pig strains including Weanling, Hartley, strain-2 
and hairless have proved useful (Yamanishi et al., 1980; Lowry et al., 
1993; Sabella et al., 1993) and viraemia is detectable during primary 
infection in about half of animals used regardless of the strain of guinea 
pig. Experiments in Weanling guinea pigs demonstrated that animals 
inoculated intranasally or subcutaneously with VZV shed virus from the 
nasopharynx (Yamanishi et al., 1980). 
 
However, the development of the SCID-Hu mouse model for VZV (Moffat 
et al., 1995) greatly enhanced knowledge of VZV pathogenicity, and has 
led to a new model being proposed (see figure 1.13). Due to their 
immunodeficient state, SCID-Hu mice cannot reject human tissue 
xenografts and also lack the capacity to develop an adaptive immune 
response against the VZV infection within the engrafted tissues. This has 
made it possible to evaluate VZV interactions in human target cells located 
within an intact tissue microenvironment. Recently the use of this model 
was combined with the emerging technique of live whole-animal imaging 
(Zhang et al., 2007; Oliver et al., 2008).  This technique allows for the 
measurement of proteins expressed in vivo using luminescence and will 
undoubtedly lead to a greater understanding of VZV pathogenesis in the 
future. 
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However thus far, the use of the VZV SCID-Hu model has demonstrated 
that lesions in skin xenografts involve the epidermis and dermis; typical of 
the patterns observed in biopsies of varicella and zoster lesions. In 
addition, both human CD8+ and CD4+ T cells in human fetal thymus/liver 
xenografts support VZV replication (Moffat et al., 1995) as well as 
epithelial cells in human skin xenografts.  By analogy to the mousepox 
model (Grose, 1981b) it is believed following inhalation by the host, the 
virus infects the mucous membranes in the respiratory tract. Respiratory 
epithelial cells cover tonsil surfaces and penetrate into tonsillar tissues, 
forming „crypts‟. These crypts are adjacent to foci of mononuclear cells 
which contain activated memory T cells. Ku (et al., 2002) found that tonsil 
T cells in the SCID-Hu mouse model are highly susceptible to VZV 
infection. Furthermore, memory CD4+ T cells that express skin homing 
markers, cutaneous leucocyte antigen (CLA) and chemokine receptor 4 
(CCR4), are most likely to be infected. As well as tonsils, other lymphoid 
tissues of the upper respiratory tract, such as the adenoids, contain this 
subset of T cells, which may become infected when VZV infects 
respiratory mucosa (Ku et al., 2004). 
 
Memory T cells that express these receptors carry out immune 
surveillance by trafficking through the skin, thus the increased 
susceptibility of this subset of memory T cells to VZV infection may further 
enhance their role in VZV pathogenesis (Ku et al., 2004). According to the 
model in figure 1.13 tonsillar T cells infected with VZV enter the circulation 
and transport the virus to the skin shortly thereafter; it is the viral spread to 
the skin that causes the lesions that constitute the characteristic rash of 
varicella (Arvin et al., 1996).  When SCID-Hu mice were inoculated via the 
tail vein with VZV-infected tonsil T cells, it took only 24 hours for the 
human T cells to appear in the skin xenografts, with an early distribution 
around the hair follicles (Ku et al., 2004). 
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As a clinical correlate, VZV dissemination to skin may be modulated in 
young children, who have few memory T cells, whereas adults with 
varicella who have <75% memory CD4+ T cells usually develop many 
cutaneous lesions (Arvin, 2001c). This is also seen with vaccine-related 
rashes (discussed in section 1.8); in most children, cases consist of fewer 
than 10 lesions, but in adults this can be up to 50 (Weibel et al., 1984; 
Arbeter et al., 1986). 
  
 
 
Figure 1.13. A Model of the Pathogenesis of Primary VZV Infection. T cells 
within the local lymphoid tissue of the respiratory tract may become 
infected by transfer of VZV from its initial site of inoculation in respiratory 
epithelial cells. T cells may then traffic the virus to the skin immediately 
and release infectious VZV. The remainder of the 10–21 day incubation 
period appears to be the interval required for VZV to overcome the innate 
IFN-α response in enough epidermal cells to create the typical vesicular 
lesions containing cell-free virus at the skin surface. The signaling of 
enhanced IFN-α production in adjacent skin cells may prevent a rapid, 
uncontrolled cell-to-cell spread of VZV. Secondary “crops” of varicella 
lesions may result when T cells traffic through early stage cutaneous 
lesions become infected and produce a secondary viraemia. Intact host 
immune responses appear to be required to trigger up-regulation of 
adhesion molecules, facilitating the clearance of VZV by adaptive 
immunity. Not to scale. (Ku et al., 2004, reprinted with permission) 
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Recent data from Sri Lankan adults hospitalized with varicella 
demonstrated that the clinical disease severity score increased 
significantly with advancing age and that there was a positive correlation 
between age and peripheral blood viral load during disease. Patients with 
>500 skin lesions had significantly higher viral loads than patients with 
fewer lesions, and thus the number of skin lesions appears to be a good 
clinical indicator of viral loads in peripheral blood (Malavige et al., 2008b). 
The number of lesions has also been demonstrated to correlate with the 
maximum body temperature and duration of fever (Asano et al., 1990). 
 
In healthy individuals, the estimated proporrtion of PBMCs infected varies 
depending on the experimental technique but ranges from 0.01% to 
0.001% (Koropchak et al., 1989; Koropchak et al., 1991; Mainka et al., 
1998). In guinea pig models the frequency of VZV-infected PBMCs is 
estimated to be at least 1 in 200,000, which is comparable to that 
observed in human infection (Lowry et al., 1993). Data from in vitro studies 
has shown that VZV also infects B cells, monocytes, (Koenig and Wolff, 
2003) macrophages, (Arbeit et al., 1982), hepatocytes (Shiraki et al., 
2003) as well as mature (Morrow et al., 2003) and immature (Abendroth et 
al., 2001b) dendritic cells (DCs). These observations have led to the 
suggestion that it may be the ability of the virus to infect immature DCs of 
the respiratory mucosa, which subsequently transport virus to the T cell-
rich draining lymph nodes, which results in T-lymphocyte infection and 
subsequent dissemination of virus to other sites (Abendroth et al., 2001b), 
see figure 1.14. 
 
1.6.1.1 Rash Formation and the Host Immune Response: 
The characteristic chickenpox rash develops after an incubation period of 
10 to 21 days (Arvin, 2001c; Cohen et al., 2007b). The remainder of this 
incubation period could be the interval required for VZV to overcome the 
innate IFN- response in enough epidermal cells to create the typical 
vesicular lesions at the skin surface (Ku et al., 2004). (See section 1.7.6.1 
for more details on the role of IFN- in VZV infection). Signalling of 
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enhanced IFN- production in adjacent skin cells prevents a rapid, 
uncontrolled cell-to-cell spread of VZV. Additional “crops” of varicella 
lesions may result when T cells traffic through early-stage cutaneous 
lesions, become infected, and produce a secondary viraemia. This 
process continues until host immune responses trigger the up-regulation of 
adhesion molecules (such as ICAM-1, VCAM-1 and E-selectin) and 
mediate the clearance of the virus by VZV-specific antiviral T cells. 
 
 
 
Figure 1.14: A Model of VZV Dissemination Following Primary Inoculation. 
The virus enters the host at respiratory mucosa and subsequently infects 
dendritic cells which are then triggered to migrate to the regional lymph 
nodes. It is here that the infected DCs interact with T cells, resulting in 
virus transmission and productive infection of these T cells. Following T 
cell infection the virus continues to replicate and is disseminated to other 
sites of the body, infecting cutaneous epithelial cells with the formation of 
the characteristic vesicular rash of varicella. Not to scale. (Bosnjak et al., 
2005; adapted with permission) 
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Data on the incidence and severity of vaccine-related rashes in 
immunocompromised compared to immunocompetent children also lends 
support to the role of the host immune system in controlling rash 
formation. The frequency of vaccine-related-rashes in healthy children is 
about five percent, but most consist of fewer than 10 lesions (Weibel et al., 
1984). However up to 40-50% of leukaemic children receiving 
chemotherapy develop a vaccine associated rash, (usually maculopapular 
and vesicular) with around 80 lesions, although there have been cases of 
up to 1,000 lesions (Arvin and Gershon 1996; Gershon and Steinberg 
1989; Gershon et al., 1992; LaRussa et al., 1996). In addition to this, 
severe, disseminated life-threatening infections have occurred when the 
varicella vaccine has been inadvertently administered to 
immunocompromised children (Kramer et al., 2001; Sharrar et al., 2000; 
Ghaffar et al., 2000; Levy et al., 2003). 
 
1.6.1.2 The Role of Individual VZV Proteins in Varicella Pathogenesis: 
Table 1.6 summarizes what is known to date about the requirement of 
different VZV proteins for replication either in vitro or in skin and T cells in 
the SCID-Hu mouse model (in vivo). Of the VZV proteins investigated so 
far in the SCID-Hu mouse model, products of ORF23, IE62, gE and gI are 
essential for skin replication, and without these proteins virus cannot be 
recovered, whilst ORF47, IE62, IE63, gE and gI are essential for 
replication in T cells, whilst numerous proteins are important „virulence 
factors‟ for growth and replication (see table 1.6 for references).  If VZV 
pathogenesis depends on the assembly and release of virions from T cells 
then the infected cells must survive long enough to transport VZV from 
respiratory sites of inoculation to the skin. ORF66 protein kinase appears 
to have a unique role in viral replication in T cells. This protein supports 
VZV T cell tropism by contributing to immune evasion and enhancing 
survival of infected T cells (Schaap et al., 2005). Preventing ORF66 
protein kinase expression impairs the growth of virus in SCID-Hu T cell 
xenografts, and increases the susceptibility of infected T cells to apoptosis 
(Schaap et al., 2005). For more details on the role of ORF66 in immune 
evasion see section 1.7.3. 
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Findings by Besser (et al., 2004) using ORF47 deletion mutant viruses 
suggest a differential requirement for cell fusion and virion formation in the 
pathogenesis of VZV infection in skin and T cells. Evaluation of two 
recombinants of the Oka strain of VZV showed that ORF47 kinase function 
was necessary for optimal viral replication in human skin xenografts in 
SCID mice, but not T cells. Although virion assembly was reduced and no 
virion transport to cell surfaces was observed, epidermal cell fusion 
persisted, and VZV polykaryocytes were generated by both mutants in 
skin.  
 
Normal VZV virion assembly requires ORF47 kinase function. Thus, cell 
fusion was induced by ORF47 mutants in skin, and cell-to-cell spread 
occurred even though virion formation was deficient. VZV-infected T cells 
did not undergo cell fusion, and impaired virion assembly by ORF47 
mutants was associated with a complete elimination of T cell infectivity. 
However, ORF35 has also been demonstrated to be required for efficient 
infection of both skin and T cell xenographs, but is dispensable for viral 
replication (Ito et al., 2005). 
 
ORF63 is expressed in neurons during both productive and latent 
infection. Most mutations of ORF63 made with the VZV cosmid system 
prove lethal for infectivity. The few IE63 changes that are tolerated result 
in VZV mutants with an impaired capacity to replicate in vitro. However, 
the IE63 mutants are attenuated in skin but not T cells in the SCID-Hu 
mouse model indicating that the contribution of the IE63 
tegument/regulatory protein to VZV pathogenesis depends upon the 
differentiated human cell type which is targeted for infection within the 
intact tissue microenvironment (Baiker et al., 2004b). A recent study by 
Hood (et al., 2006) showed that ORF63 can suppress apoptosis of 
neurons. This may play a significant role in viral pathogenesis by 
promoting neuron survival during primary and reactivated infections. 
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ORF Function 
Replication in T cells Replication in Skin Virus Transfer 
from T cells to 
Skin 
Establishment 
of Latency 
References 
In vitro In vivo  In vitro In vivo  
0 
Putative 
membrane 
Protein 
Not 
Investigated 
Not 
Investigated 
Virulence 
factor2 
Virulence 
factor2 
Not 
Investigated  
Not Investigated Zhang et al., 2007 
1 
Membrane 
protein 
No1 
Not 
Investigated 
No1/2 No2 No1 No 
Sato et al., 2003b; 
Soong et al., 2000; 
Cohen and Seidel, 
1995; Zhang et al., 
2007 
2 Unknown 
Not 
Investigated 
Not 
Investigated 
No2  No2 
Not 
Investigated 
No 
Sato et al., 2002b; 
Zhang et al., 2007 
3 Unknown 
Not 
Investigated 
Not 
Investigated 
No2  No2  
Not 
Investigated 
Not Investigated Zhang et al., 2007 
4 
Transcriptional 
regulator 
Not 
Investigated 
Not 
Investigated 
Yes2 
Not 
Investigated 
Not 
Investigated 
No (Impaired)* 
Cohen et al., 2005b; 
Sato et al., 2003d; 
Zhang et al., 2007 
5 Glycoprotein K 
Not 
Investigated 
Not 
Investigated 
Yes2 
Not 
Investigated 
Not 
Investigated 
Not Investigated 
Mo et al., 1999; 
Cohen and Seidel, 
1994b 
9 Virion  Yes 
Not 
Investigated 
Yes 
Not 
Investigated 
Not 
Investigated 
Not Investigated 
Tischer et al., 2007; 
Che et al., 2008 
10 
Transcriptional 
regulator 
Noa No1/2 No1/a 
Virulence 
factora 
Not 
Investigated 
No 
Che et al., 2006; Sato 
et al., 2003b; Cohen 
and Seidel, 1994a 
Table 1.6 „Essentiality of VZV ORFs for Replication in Skin and T Cells‟ Continued              (1of 5) 
 
 81 
 
ORF Function 
Replication in T cells Replication in Skin Virus Transfer 
from T cells to 
Skin 
Establishment 
of Latency 
References 
In vitro In vivo  In vitro In vivo  
11 Unknown Noa 
Not 
Investigated 
Noa 
Virulence 
factora 
Not 
Investigated 
Not Investigated Che et al., 2008 
12 Unknown Noa 
Not 
Investigated 
Noa (No)a 
Not 
Investigated 
Not Investigated Che et al., 2008 
13 
Thymidylate 
synthetase 
No1 
Not 
Investigated 
No1 
Not 
Investigated 
No1 No 
Sato et al., 
2003b; Soong et 
al., 2000; Cohen 
and Seidel, 1993 
14 Glycoprotein C 
Not 
Investigated 
Not 
Investigated 
 No1/2 
Virulence 
factor 2 
Not 
Investigated 
No 
Moffat et al., 
1998a; Grinfield 
et al., 2004b  
19 
Ribonucleoltide 
reductase 
Not 
Investigated 
Not 
Investigated 
Virulence 
factor2 
Not 
Investigated 
Not 
Investigated 
Not Investigated 
Heineman and 
Cohen, 1994 
21 Unknown 
Not 
Investigated 
Not 
Investigated 
Not 
Investigated 
Not 
Investigated 
Not 
Investigated 
No Xia et al., 2003 
23 Capsid protein 
Not 
Investigated 
Not 
Investigated 
No (Capsid 
assembly 
disrupted) 
Yes 
Not 
Investigated  
No 
Chaudhuri et al., 
2008 
29 
SS-DNA binding 
protein 
Not 
Investigated 
Not 
Investigated 
Yes2 
Not 
Investigated 
Not 
Investigated 
No (Impaired)♦ 
Cohen et al., 
2007a 
Table 1.6 „Essentiality of VZV ORFs for Replication in Skin and T Cells‟ Continued               (2of 5) 
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ORF Function 
Replication in T cells Replication in Skin Virus 
Transfer from 
T cells to 
Skin 
Establishment 
of Latency 
References 
In vitro In vivo  In vitro In vivo  
32 Unknown No1 
Not 
Investigated 
No  
Not 
Investigated 
No2 No 
Sato et al., 2003b; Soong 
et al., 2000; Ito et al., 2005; 
Reddy et al., 1998 
35 Unknown No2 
Not 
Investigated 
Yes2 No2 
Not 
Investigated 
Not Investigated Ito et al., 2005 
47£ 
Serine-
threonine 
kinase 
Virulence 
factor 
Yesb/1 No1 
Virulence 
factor 1/4 
Virulence 
factor 
No 
Sato et al., 2003b; Soong 
et al., 2000; Moffat et al., 
1998b; Heinman and 
Cohen, 1995; Reddy et al., 
1998a; Besser et al., 2003; 
Besser et al., 2004 
50 gM 
Not 
Investigated 
Not 
Investigated 
 Virulence 
factor; 
MRC5 
Not 
Investigated 
Not 
Investigated 
Not Investigated Yamagishi et al., 2008 
57 Unknown No1 
Not 
Investigated 
No2 
Not 
Investigated 
No2 No 
Soong et al., 2000;Cox et 
al., 1998; Sato et al., 2003b 
Table 1.6 „Essentiality of VZV ORFs for Replication in Skin and T Cells‟ Continued              (3 of 5) 
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ORF Function 
Replication in T cells Replication in Skin Virus Transfer 
from T cells to 
Skin 
Establishment 
of Latency 
References 
In vitro In vivo  In vitro In vivo  
58 Unknown 
Not 
Investigated 
Not 
Investigated 
No2 (MRC5) 
Not 
Investigated 
Not 
Investigated 
Not Investigated  Yoshii et al., 2008 
61 
Transcriptional 
regulator 
Not 
Investigated 
Not 
Investigated 
Virulence 
factor 
Not 
Investigated 
Not 
Investigated 
No 
Cohen and 
Nguyen, 1998; 
Sato et al., 2003c 
62/71c 
Transcriptional 
regulator 
Not 
Investigated 
Yes2 Yes2 Yes2/ 
Not 
Investigated 
Not Investigated Sato et al., 2003a;  
63 
Transcriptional 
regulator 
No2 No7 Yes7/2 
Virulence 
factor7 
Not 
Investigated 
Yes 
Cohen et al., 
2005a; Baiker et 
al., 2004b; 
63/70 
Transcriptional 
regulator 
Not 
Investigated 
Yes2 Yes2 
Not 
Investigated 
Not 
Investigated 
Yes§ 
Cohen et al., 
2004; Baiker et 
al., 2004b; 
Sommer et al., 
2001 
64 Unknown No 
Not 
Investigated 
Not 
Investigated 
Not 
Investigated 
Not 
Investigated 
Not Investigated 
Sommer et al., 
2001 
64/69d Unknown No 
Not 
Investigated 
Not 
Investigated 
Not 
Investigated 
Not 
Investigated 
Not Investigated 
Sommer et al., 
2001 
65 Unknown 
Not 
Investigated 
No2 No2 No2 
Not 
Investigated 
Not Investigated 
Cohen et al., 
2001; Niizuma et 
al., 2003 
Table 1.6 „Essentiality of VZV ORFs for Replication in Skin and T Cells‟ Continued               (4 of 5) 
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aDeletion mutant virus lacking either; ORF 10, 11, 12 or (10/11); (11/12); or (10/11/12) were dispensible for replication in skin in 
vitro; ORFs 11, 12 or (10/11/12)  were dispensable T cell tropism in vitro, ORF 11, (10/11) and (11/12) were virulence factors in 
skin in vivo, ORF12 alone was dispensable for replication in skin in vivo, but (10/11/12) was essential for skin infection in vivo (Che 
et al., 2008).    
bAlso important for replication in immature DCs;   
cAt least one copy of diploid gene required;   
dNeither copy of diploid gene required;    
*Cotton rats inoculated with VZV lacking ORF4 showed reduced frequency of latency compared to animals infected with the 
parental or ORF4-rescued virus. Ganglia were infected at the same rate as WT, but lack the ability to persist in ganglia, (Cohen et 
al., 2005b).   
£ORF47 kinase activity which is essential for infection and replication in human skin in vivo, is due to the formation of complexes 
between the ORF47 and IE62 proteins (Besser et al., 2003).  
Viruses with both genes deleted, but with rescued vOka62 or pOka62 were not infectious in vivo or replicated to a very limited 
extent in only one implant of all of the skin xenografts that were inoculated with these viruses (Sato et al., 2003a). 
19 of 22 changes in the coding sequence were lethal for VZV replication in vitro   
ORF63 is not required for VZV to enter ganglia but is critical for establishment of latency.   
♦Cotton rats infected with the ORF29 deletion mutant, or a virus over-expressing ORF29 had markedly reduced frequency of latent 
infection in dorsal root ganglia compared to those infected with parental virus, indicating that regulation of ORF29 at appropriate 
levels is critical for VZV latency in the rodent model (Cohen et al., 2007a). 
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ORF Function 
Replication in T cells Replication in Skin Virus Transfer 
from T cells to 
Skin 
Establishment 
of Latency 
References 
In vitro In vivo  In vitro In vivo  
66 
Serine-
threonine 
kinase 
Virulence 
factor 
Virulence 
factor1 
No1/2 
Virulence 
factor1 
Virulence 
factor1 
No 
Soong et al., 2000;  Sato 
et al., 2003b;  Schaap et 
al., 2005;  Schaap-Nutt et 
al., 2006;  Moffat et al., 
1998b;  
Heinman et al., 1996 
67 Glycoprotein I No3 Yes2 
 
 
No2/8 
   Not 
investigated 
Yes2/3 
Not 
Investigated 
No 
Grinfield et al., 2004b; 
Cohen et al., 1997;  Mo et 
al., 2002;  Moffat et al., 
2002;  Ito et al., 2003;  
Mallory et al., 1997;  
68 
Glycoprotein 
E 
Not 
Investigated 
Yes2/5 Yes6 Yes6 
Not 
Investigated 
Not Investigated 
Mo et al., 2002;  Mallory et 
al., 1997; Berarducci et al., 
2006; Moffat et al., 2004a 
Table 1.6 Essentiality of VZV Open Reading Frames for Replication in Skin and T Cells In Vitro and In Vivo (SCID-Hu Mouse Model).     (5 of 5) 
Key:  Yes: gene is essential (no virus is recovered if this gene is deleted, or stop codon inserted); No; gene is not essential (very 
little effect, if any, on viral growth and replication); Virulence factor: Infection/replication/growth is possible without this gene, but is 
severely reduced/impaired;   1Stop codon inserted into gene;  2Gene deleted;   3Mutation in promoter site that binds 
cellular transcription factors;   4Point mutation in conserved kinase motif;    5Point mutation in endocytotic signal motif/deletion of C-
terminal domain;   6Mutation in gE trans-Golgi network targeting motif/gE phosphorylation motif;   7Mutation in IE63 single 
putative phosphorylation sites or deletion of IE63 nuclear localisation signal.   8 VZV gI is not essential for viral replication in 
vitro, but impaired cell-to-cell spread and altered posttranslational modification and trafficking of gE were shown in cells infected 
with VZV gI deletion mutant. 
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The ORF10 protein is required for efficient viral replication, virion 
assembly, and cell-to-cell spread in human skin in the SCID-Hu mouse 
model, but is not required for replication in T cells in this model, (Che et 
al., 2006).  The cellular transcription factor USF is required as a co-factor 
with IE62 to produce the ORF10 protein in infected cells in vitro and is a 
direct determinant of VZV skin virulence in the SCID-Hu mouse model 
(Che et al., 2007). In vitro, ORFs 10, 11 and 12 are dispensable for 
replication in melanoma and T cells and appear to have no role in 
nucleocapsid formation and virion assembly. Deletion of all three ORFs 
simultaneously has no effect on growth kinetics or infectivity in vitro. 
However, in the SCID-Hu mouse model ORF12 is also dispensable, 
whereas ORF11 is an important virulence factor for skin. When both 
ORF10 and ORF11 were deleted along with ORF12, this resulted in a 
complete loss of infectivity. This indicates that compensating mechanisms, 
which permit some replication when ORF10 and ORF11 are deleted, do 
not overcome the incremental effect of deleting ORF12 from the VZV 
genome.  However ORF9 is essential for replication in vitro.  It has been 
suggested that this maybe because ORF9 has critical functions at different 
steps of VZV virion assembly; through its interactions with gE as well as 
IE62, (Che et al., 2008). 
 
1.6.2 Pathogenesis of Latency and Reactivation: 
VZV establishes latency in the primary afferent neurons of dorsal root and 
cranial nerve ganglia, (Hope-Simpson, 1965) and in neurons of the enteric 
nervous system (Gershon et al., 2008).  The distribution of zoster lesions 
typically involves trigeminal and thoracic dermatomes which are in the 
anatomical regions where the majority of varicella lesions appear (on the 
face and trunk), (Ragozzino et al, 1982). This clinical observation indicates 
that during varicella, the virus spreads directly by retrograde axonal 
transport from infected epidermal and dermal tissues to the dorsal root 
ganglia (Straus and Oxman, 1999). In addition, studies of vaccine-
associated zoster have demonstrated that reactivation commonly occurs 
at or near the vaccine injection site, suggesting that latency was 
established in sensory ganglia serving that particular dermatome (Hardy et 
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al., 1991; Lawrence et al., 1988). However in cases of fatal varicella, 
analysis of ganglia recovered at autopsy, suggest that the virus may reach 
the dorsal root ganglia via systemic viraemia (Cheatham et al., 1956). In 
such cases, satellite cells positive for virus have been found surrounding 
neurons which are virus negative (Croen et al., 1988). This suggests that 
had the virus travelled through the sensory neuron and spread through the 
ganglia to the neighbouring satellite cells, both cell populations would have 
been virus positive.  
 
However, recent data from a model of lytic infection, latency and 
reactivation in enteric neurons from adult guinea pigs and foetal mice, 
suggested the former hypothesis of retrograde spread from the epidermis 
to be correct, (Gershon et al., 2008).  In this newly developed model, 
latency was established when neurons were infected by cell-free virus in 
the absence of fibroblasts or other cells. Whilst in contrast, lytic infection 
occurred either when fibroblasts were present, or when the enteric 
neurons were infected by cell-associated VZV. Based on these 
observations, and previous studies (Chen et al., 2004), the authors 
suggested that as abundant cell-free virus is only produced in the 
epidermis, and the sensory nerves which serve this site are present as 
naked nerve fibres; in VZV-infected regions of skin, nerve fibres would be 
infected by the cell-free virus, (Gershon et al., 2008).  
 
As mentioned earlier, the onset of zoster is caused by reactivation of latent 
VZV from the dorsal root ganglia, where the virus multiplies and spreads 
within the ganglion. This causes neuronal necrosis and intense 
inflammation, often resulting in severe neuralgia. The virus then spreads 
antidromically down the sensory nerve, causing intense neuritis. The virus 
is subsequently released from sensory nerve endings in the skin where it 
spreads to produce the characteristic cluster of zoster vesicles. Typically, 
this results in a unilateral vesicular rash within a single cutaneous 
dermatome. The rash is often accompanied by debilitating acute pain that 
can last for several weeks.  
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Latency (and in some cases reactivation) have been studied in various 
models, including SVV in the simian model.  SVV establishes life-long 
latent infection, as indicated by detection of viral DNA within neural 
ganglia. Subsequently, SVV may reactivate to cause secondary disease 
and spread the virus to susceptible monkeys (Mahalingam et al., 2007). 
Studies of guinea pig enteric neurons (Chen et al., 2003; Stallings et al., 
2006; Walters, 2008) have also been carried out and have demonstrated 
that VZV gene sequences are detectable in ganglia tissue for at least 80 
days after infection (Lowry et al., 1993).  More recently human ganglionic 
explants in SCID-Hu mice have been used (Zerboni et al., 2005b; Zerboni 
et al., 2007) but a vast quantity of knowledge has been gained from earlier 
studies in the cotton rat model. 
 
In the cotton rat model, latency is characterized by a long-lasting presence 
of the viral genome and selected viral gene transcription in the dorsal root 
ganglia (Sadzot-Delvaux et al., 1990). Many similarities with latency in 
humans have been found, including the persistence of the virus in the 
ganglia for at least two years (Grinfeld et al., 2004a), the largely neuronal 
localization of the virus, and the expression of a similar subset of genes in 
both systems during ganglionic latency (Kennedy et al., 2000; Kennedy et 
al., 2001; Sadzot-Delvaux et al., 1995). However, it is important to note 
that there are many differences. For example, more satellite cells are 
found to be positive in infected ganglia in the rat model than in human 
latency, (Kennedy et al., 2001) as well as in axons (Debrus et al., 1995), 
something not observed in human ganglia. Unlike in humans, the late VZV 
gene encoded by ORF40 has been shown to be expressed in the rat 
model (Kennedy et al., 2001). VZV reactivation has not been obtained in 
rats in vivo which is an important criterion of viral latency, but can be 
induced ex vivo after repeated stresses (Sadzot-Delvaux et al., 1995). 
Despite the shortcomings of this model it has been widely used to evaluate 
the contribution of virus genes in the establishment of putative ganglionic 
latency (Grinfeld et al., 2004b, Cohen et al., 2005a, Cohen et al., 2005b; 
Grinfeld et al., 2007a; Annunziato et al., 2001; Sato et al. 2003c and 
2003d; Hoover et al., 2006;  Cohen et al., 2007). 
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As mentioned above, the SCID-Hu mouse model has also been used to 
study latency; when human dorsal root ganglia (DRG) were successfully 
transplanted, clinical isolates of VZV persisted in the ganglia without any 
requirement for VZV-specific adaptive immunity (Zerboni et al., 2005b). 
This was associated with continued transcription of the ORF63 regulatory 
gene. The live attenuated varicella vaccine virus exhibited the same 
pattern of short-term replication, persistence of viral DNA and prominent 
ORF63 transcription, comparable to clinical isolates. VZV-infected T cells 
transferred virus from the circulation into DRG, suggesting that VZV 
lymphotropism facilitates its neurotropism. 
 
Recently a more detailed study of the cellular tropisms and mechanisms of 
neuropathogenesis during acute infection of human DRG xenografts has 
been carried out in this model using multiscale correlative 
immunofluorescence-electron microscopy (Reichelt et al., 2008). The 
observations from this study suggest a model in which the first event in the 
acute infection of sensory ganglia, caused by VZV reactivation from 
latency is viral replication in a single neuron. This leads to polykaryon 
formation with adjacent satellite cells and the subsequent release of 
virions which infect nearby satellite cells which surround other neuronal 
cell bodies. This process leads to further polykaryon formation and it is 
polykaryon formation between these secondarily infected satellite cells and 
their neuronal cell bodies which enhances access of virions to neuronal 
axons for transport to skin sites of replication. This model predicts that 
most neurons become infected by virions that are released into the DRG 
by productively infected satellite cells, not by the simultaneous reactivation 
of latent VZV genomes harboured by multiple neurons within the affected 
ganglion. 
 
Another model to aid in our understanding of latency is infection in human 
intact explant DRG which has recently been developed (Gowrishankar et 
al., 2007). This model enables VZV infection of ganglionic cells to be 
studied in the context of intact DRG, but results in cell free VZV being 
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released from infected DRG, rather than remaining highly cell associated 
(Gowrishankar et al., 2007). 
 
1.6.2.1 The Role of Individual VZV Proteins in the Pathogenesis of 
Latency: 
Various studies designed to determine the extent of VZV transcription in 
latently infected human ganglia have yielded different results. In situ 
hybridization using gene-specific oligonucleotide probes detected 
transcripts from VZV genes 4, 18, 21, 29, 40, 62, and 63 but not genes 28 
or 61 (Kennedy et al., 1999; Kennedy et al., 2000). However, using 
sequence analysis from RNA extracted from latently infected human 
ganglia, Cohrs and colleagues detected transcripts mapping to only five 
VZV genes: 21, 29, 62, 63, and 66 but not to VZV genes 4, 10, 40, 51, or 
61 (Cohrs et al., 1996; Cohrs and Gilden, 2003).  Proteins encoded by 
ORFs 4, 21, 29, 62 and 63 have been detected in human ganglia in a 
separate report (Lungu et al., 1998). In studies to date only the ORF21 
protein has not been shown to induce an immune response; see section 
3.1.3 (chapter 3) and 4.1.4 (chapter 4) for more details. Prevalence and 
abundance of multiple VZV gene transcripts in human ganglia has also 
produced conflicting results (Cohrs et al., 2000, Cohrs and Gilden, 2007). 
Looking at ganglia samples from the same individuals, the 2000 study 
found VZV gene 63 transcripts were detected in either or both ganglia from 
all of 11 subjects (100%), VZV gene 29 transcripts were detected in 2 of 
11 (18%), and VZV gene 21 transcripts were detected in 4 of 11 (36%) 
subjects. Compared to VZV gene 21 transcripts, VZV gene 63 and 29 
transcripts were 22 and 26 fold more abundant. In the more recent study, 
analysis of 28 trigeminal ganglia (from 14 humans) revealed that the most 
prevalent transcript found was VZV gene 63 (78%), followed by gene 66 
(43%), gene 62 (36%), and gene 29 (21%), (Cohrs and Gilden, 2007). 
Interestingly, despite the use of PCR primers and probes identical to those 
used in a previous study, VZV gene 21 transcripts were not detected in 
any of the 28 ganglia in this study. Both studies confirmed that VZV gene 
63 is the most prevalent and abundant transcript, and revealed that VZV 
gene 29 transcripts are detected more often than VZV gene 21 transcripts. 
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This suggests that gene 63 may be more important for the maintenance of 
virus latency than the less abundantly transcribed and randomly detected 
VZV genes 21, 29, 62, and 66. 
 
Thus far only ORFs 4 and 63 have been shown to be essential to the 
establishment of latency (Cohen et al., 2005b; Cohen et al., 2004). This 
was demonstrated via use of the cotton rat model infected with mutant 
viruses, with either the ORF 4 gene or >90% of both copies of the ORF63 
genes respectively deleted. ORFs 2, 14, 21, 47, 61, 66 and 67 have been 
shown to be dispensable for the establishment of latency: (Xia et al., 2003; 
Sato et al., 2003c; Sato et al., 2002b; Grinfeld et al., 2004b; Sato et al., 
2003d), whilst ORF29 has recently been shown to be dispensable for the 
initial infection of DRG, but important in the establishment of latency in the 
cotton rat model (Cohen et al., 2007). Some establishment of latency still 
occurs with ORF29 deleted VZV mutants, but this is markedly reduced 
compared to that seen in the parental virus. The proteins transcribed 
during latency are localised in the cytoplasm of infected neurons of dorsal 
root ganglia (Lungu et al., 1998). This sharply contrasts with the nuclear 
localisation of these VZV proteins during reactivation, (Lungu et al., 1998). 
ORF21 is the only transcript which has not been shown to invoke an 
immune response. 
 
Some of these VZV proteins may restrict regulatory proteins from entering 
the nucleus, thereby maintaining a latent state in the presence of the 
essential immediate-early protein product of ORF62, an efficient 
transactivator of VZV gene transcription. The protein kinase encoded by 
ORF66 (66-pk), phosphorylates the protein product of ORF62, leading to 
its cytoplasmic accumulation (Cohrs et al., 2003b).  Prevention of IE62 
import to the nucleus by VZV 66-pk phosphorylation is one possible 
mechanism by which VZV latency is maintained (Cohrs et al., 2003b). 
Another mechanism is the ability of ORF63 to downregulate ORF62 
transcription, which may play an important role in virus replication and 
latency (Hoover et al., 2006). ORF61 is also thought to play an important 
role in viral reactivation. In the rodent enteric neuron model, when latency 
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was established, reactivation was accomplished by expression of ORF61p 
(or its HSV homologue ICP0), (Gershon et al., 2008).    
 
Recent experiments in the SCID-Hu mouse model demonstrated that DRG 
xenografts with a VZV mutant that lacked gI resulted in highly restricted 
VZV replication, demonstrating the effect of attenuated cell-to-cell spread 
in this model (Zerboni et al., 2007). The authors suggested that altered 
intracellular trafficking of gE (when gI is lacking), is likely to be the 
mechanism for impaired VZV infection of DRG, as gE–gI complexes have 
been shown to potentiate polykaryon formation (Maresova et al., 2001). 
Infection with this particular mutant also caused a prolonged infectious 
process during which VZV DNA synthesis, transcription and translation of 
both IE and late genes, and production of infectious virions continued for 
at least 70 days. This is in contrast to DRG infected with intact VZV, where 
there was an early transition to persistence (Zerboni et al., 2007). 
 
1.7 Host Immune Responses to VZV, and Immune Modulation and 
Evasion by the Virus: 
Adaptive cell mediated immunity and antibody responses to VZV are 
discussed at length in chapters 3 and 4. Here, innate immune responses 
and subsequent modulation of the innate (and the adaptive) immune 
response are discussed. Innate immune responses are non-specific and 
lack the ability to improve with each successive exposure.  The cellular 
response is produced primarily by leucocytes such as natural killer (NK) 
cells, macrophages and neutrophils. The humoral arm of the innate 
immune system is composed mainly of complement and innate cytokines 
(Murphy et al., 2008). The early host responses to viruses in particular, 
involve NK and cytokines such as type-I interferons. They function to 
restrict virus replication and spread (Arvin, 1996a).  However, the innate 
immune system is unable to prevent progressive disease. The adaptive 
immune response is subsequently activated with the clonal expansion of 
VZV-specific T and B cells that interfere with viral replication and spread of 
the virus, (see chapters 3 and 4).  
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1.7.1 NK Cell Mediated Immunity and VZV Induced Immune Modulation: 
NK cells are a population of innate lymphocytes, which are also referred to 
as large granular lymphocytes (LGLs) and express neither B nor T cell 
receptors. These cells have the capacity to recognise the surface changes 
that occur on virally infected cells which have down regulated their MHC. 
These cells are able to kill target cells coated with IgG antibodies via their 
IgG Fc receptors (FcRIII: CD16) a process known as antibody dependent 
cellular cytotoxicity (ADCC) which is discussed in more detail in chapter 3, 
section 3.1.1.5. 
 
NK cells have been shown to lyse VZV-infected fibroblasts in vitro and 
these cytotoxic effects are enhanced by incubating NK cells with IL-2 
(Bowden et al., 1985; Ihara et al., 1984; Hayward et al., 1986a).  In one 
report, IFN- (secreted by HLA-DR+ cells) was found to contribute to NK 
cell-mediated lysis of VZV infected cells (Oh, et al., 1987). Granulysin is an 
antiviral protein produced by NK cells (and CTLs) and has been shown to 
have potent activity against VZV-infected cells (Hata et al., 2001).  
Granulysin acts to overcome VZV-induced inhibition of apoptosis in 
infected cells, which can be expected to reduce viral load during acute 
infection (Hata et al., 2001).  
 
Severe herpes virus infections, including varicella, have been reported in 
cases of NK deficiency (Biron et al., 1989). Indeed, recurrent acute 
varicella has proved fatal in the case of a child who had an NK cell 
deficiency (Etzioni et al., 2005) and in a separate study of five cases of life 
threatening varicella; reported in children with no history of recurrent 
infection or immunodeficiency, it was found that NK cells (and CD8+ T 
cells) were absent from their circulation during active infection (Vossen et 
al., 2005a). However, in the four patients who recovered both subsets of 
cells reappeared in the circulation, suggesting that VZV has the unique 
capability to sequester NK (and CD8+ T cells) from the circulating 
lymphocyte pool.  
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1.7.2 Immune Modulation of Dendritic Cells: 
The impact of VZV infection on Dendritic cell (DC) maturation and function 
is emerging as another immune evasion tactic adopted by VZV.  In brief, 
DCs are professional antigen presenting cells that play an important role in 
the induction of adaptive immune responses to protein antigens. Immature 
DCs can be found in the epithelia of skin and respiratory sites and express 
low levels of surface molecules such as MHC and co-stimulatory 
molecules which are needed to efficiently activate T cells. The main 
function of immature DCs is to capture antigen and translocate to the 
nearest draining lymph node. During migration to the lymph node, the 
immature DCs mature to become extremely efficient at antigen 
presentation. In their mature state, DCs are capable of stimulating naïve T 
cells (Murphy et al., 2008). Huch and colleagues (Huch et al., 2006) 
reported that VZV infection of immature DCs prevented DC maturation in 
vitro. Even LPS induced maturation was strongly inhibited by VZV 
infection, as demonstrated by a failure to upregulate the cell surface 
expression of MHC-I, CD86, CD80 and CD83 (CD86; also known as B7.2, 
and CD80; also known as B7.1, are both essential co-stimulatory 
molecules which bind to CD28 (or CTLA-4), whilst CD83 is involved in 
antigen presentation). Induction of cytokines IL-12, IL-10 and TNF was 
inhibited compared to mock infected counterparts, and VZV infection also 
resulted in a significant decrease in DC migration in response to 
chemokines such as macrophage inflammatory protein-3 (MIP-3). In 
addition the authors found that CCR7 expression was absent on the 
majority of VZV infected DCs, thus they would be unable to migrate to the 
nearest draining lymph node.  VZV infected mature DCs have also been 
shown to down regulate co-stimulation molecules CD80, CD83 and CD86 
(Morrow et al., 2003). More importantly, VZV infection of this cell type 
significantly reduced the ability of the infected DCs to stimulate the 
proliferation of allogeneic T cells (Morrow et al., 2003).   
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1.7.3 Modulation of Apoptosis: 
Apoptosis is a process of cell death characterised by nuclear condensation 
and fragmentation and plasma membrane blebbing which leads to 
phagocytosis of the cell without inducing an inflammatory response 
(Murphy et al., 2008). VZV has been shown to elicit anti-apoptosis within 
various infected cells in vitro. Hu and Cohen (2005) found that VZV-
infected DCs have reduced cell surface expression of Fas (CD95); an 
apoptosis inducing receptor, which would thus reduce the likelihood of 
apoptosis of the cell.  Recently, several viral proteins have been shown to 
play a role in anti-apoptosis in vitro. VZV infection of T cells is associated 
with modulation of apoptosis via the ORF66 protein (Schaap et al., 2005). 
Preventing the protein‟s expression increased the susceptibility of infected 
T cells to apoptosis (and reduced the capacity of the virus to interfere with 
induction of the interferon pathway by exposure to IFN-). ORF66 protein 
appears to have a unique role that supports VZV T cell tropism by 
contributing to immune evasion and enhancing survival of infected T cells 
(Schaap et al., 2005). A later study in human neuronal cells demonstrated 
that mutant viruses lacking one copy of the diploid gene encoded by 
ORF63, induced apoptosis, whilst cells infected with parental virus did not 
undergo apoptosis. The authors suggested that IE63 may play a 
significant role in viral pathogenesis by promoting neuron survival during 
primary and reactivated infections (Hood et al., 2006).   
 
It has also been shown that VZV is able to suppress apoptosis induced by 
the ERK signalling pathway.  Pro-apoptotic functions of a key protein in the 
ERK pathway (Bad) are suppressed by its phosphorylation, and a 10 fold 
increase of phosphorylation was seen in VZV infected melanoma cells 
(Rahaus et al., 2006).  The role of VZV in signalling pathways is discussed 
in section 1.7.6-1.7.7. 
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1.7.4 Immune Modulation of Adhesion Molecules: 
Some of the major adhesion molecules expressed on T cells are members 
of the integrin family. The major functions of T cell integrins are to mediate 
adhesion to professional APCs, endothelial cells and extra cellular matrix 
(ECM) proteins. There are two subfamilies of the integrin family; 1 and 
2. The 2 family consists solely of LFA-1 (Leukocyte function associated 
antigen-1, or CD11a/CD18), which is expressed on 90% of mature T cells, 
B cells, granulocytes and monocytes.  A ligand of LFA-1 is Intercellular 
adhesion molecule-1 (ICAM-1; CD54).  ICAM-1 is a membrane 
glycoprotein that is expressed on a variety of cells including B- and T cells, 
fibroblasts, keratinocytes and endothelial cells.  Surface expression of 
ICAM-1 has been shown to be down regulated in VZV-infected 
keratinocytes, despite the expression of pro-inflammatory cytokines such 
as IFN- and TNF within cutaneous lesions (Nikkels et al., 2004). This 
may hinder interactions of infected cells with LFA-1-bearing T cells. In vitro 
VZV infection is able to inhibit the expression of ICAM-1 in response to 
TNF in infected melanoma cells and fibroblasts and this has been shown 
to be caused by VZV interfering with the NFB pathway (El-Mjiyad et al., 
2007). In addition, treatment of VZV-infected keratinocytes with IFN- in 
vitro has demonstrated that ICAM-1 is upregulated to a much lesser extent 
than in uninfected keratinocytes (Black et al., 2009).  
 
1.7.5 VZV Modulation of the Major Histocompatibility Complexes (MHC-I 
and MHC-II): 
Interference in the expression of MHC-I and MHC-II proteins (required for 
CD4+ and CD8+ T cell recognition; see chapter 4, section 4.1.1) has been 
postulated to be a mechanism by which VZV delays the clearance of virus 
infected cells (Cohen, 1998; Abendroth et al., 2000; Abendroth et al., 
2001a).  MHC-I is present on nearly all nucleated cells of the body, (some 
nucleated cells located in immune privilege sites lack MHC expression). 
Experiments in the SCID-Hu mouse have demonstrated that MHC-I 
expression is down regulated on VZV infected T cells in this model 
(Abendroth et al., 2001a). Down regulation of MHC-I has also been seen 
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in vitro on mature DCs (Morrow et al., 2003), as well as human melanoma 
fibroblasts (Eisfeld et al., 2007). Recent experiments in a human derived 
keratinocyte cell line infected with both parental and vaccine strains of 
VZV, demonstrated that upregulation of MHC-I following IFN-  treatment 
was severely impaired, compared to uninfected controls (Black et al., 
2009) and infected keratinocytes were unable to stimulate antigen specific 
CD8+ T cell responses. 
 
Cohen (1998) demonstrated that there was a reduction in class-I heavy 
chains on the surface of infected cells and suggested this was due to a 
defect in posttranslational processing. Pulse chase experiments and 
immunoprecipitation revealed that VZV down regulates MHC-I by 
impairing its transport from the Golgi to the plasma membranes of infected 
cells (Abendroth et al., 2001a). Transient expression of the ORF66 protein 
kinase has been associated with this decrease in cell surface expression 
(Abendroth et al., 2001a) and more recent experiments in vitro in human 
melanoma fibroblast and T cells, have illustrated that ORF66 kinase 
activity actually delays MHC-I transport through the cis/medial-Golgi 
complex (Eisfeld et al., 2007).  
 
In addition, VZV has ORF66-independent mechanisms that contribute to 
reduced MHC-I surface expression that are yet to be identified (Eisfeld et 
al., 2007). A panel of plasmids expressing VZV ORFs 0, 1, 2, 7,9, 11, 17, 
21, 23, 32, 40, 44, 46, 58, 64, and 65 revealed no ability for any one 
protein to downregulate MHC-I, in fibroblasts in vitro. Further 
investigations into VZV ORF9a protein (putative gN); the orthologue of the 
BHV-1 UL49.5 (a transporter associated with antigen processing inhibition) 
revealed no effects on MHC-I expression in a T cell line. As gN and gM 
complex in PRV the authors investigated the combined effect on VZV 
ORFs 9a:50 (gM) expression, but again found no effect on MHC-I 
expression (Eisfeld et al., 2007). 
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MHC-II expression is predominantly restricted to professional antigen 
presenting cells (APCs) such as B cells, DCs and monocytes/ 
macrophages. IFN- causes the upregulation of MHC-II on APCs and can 
actually induce the expression of MHC-II on non-professional APCs, such 
as fibroblasts (Collins et al., 1984). During primary infection, NK cells 
produce IFN-, and as the VZV-specific T cell response develops, CD4+ T 
cells that produce IFN- are induced (Abendroth et al., 2001). Thus 
inhibiting IFN- induced MHC-II upregulation would allow a window in 
which VZV could replicate in skin.  Abendroth and colleagues (2000) 
demonstrated that fibroblasts infected with VZV and treated with IFN- 
expressed less that half the amount of MHC-II than non-infected 
fibroblasts, and similar results have recently been demonstrated in a 
human keratinocyte cell line, (Black et al., 2009). In addition, when skin 
biopsies of varicella lesions were analyzed by in situ hybridization, MHC 
class-II transcripts were detected in areas around lesions but not in cells 
that were infected with VZV. A later study by Nikkels (et al., 2004) in 
herpes zoster biopsies again showed that MHC-II transcripts were found in 
keratinocytes around vesicles, but not in VZV-infected cells. In addition, 
VZV-infected keratinocytes treated with IFN- have an impaired ability to 
stimulate antigen specific CD4+ T cells in vitro compared with infected or 
uninfected keratinocytes that had not been treated with IFN- and this has 
been shown to be due to inhibition of the IFN- signalling pathway (Black 
et al., 2009). 
 
The engagement of a cytokine (such as IFN-) to its appropriate receptor 
(such as the IFN- receptor) results in the activation of intracellular 
signalling pathways. This leads to either the induction or inhibition of 
transcription of cytokine regulated genes, (such as MHC-II). In brief, 
cytokines initiate intracellular signalling through the ligand induced 
aggregation of their receptor components. The common outcome of 
receptor aggregation is the activation of kinases associated with the 
cytoplasmic domains of these receptors, followed by phosphorylation of 
the cellular substrates. Some of the ultimate cellular responses to a 
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cytokine include cell growth, differentiation and proliferation, apoptosis and 
up or down regulation of surface molecules. The unique function a 
cytokine has on a particular cell type is related to the signalling pathway 
which it activates and the interplay between these pathways (Murphy et 
al., 2008).  
 
A signalling pathway frequently used by IFN- (and type-I Interferon) 
receptors involves enzymes called Janus kinases (JAKs) and transcription 
factors called signal transducers and activators of transcription (STATs). 
Thus the pathway is called the JAK/STAT pathway. There are four 
members of the JAK family; JAK-1, JAK-2, JAK-3 and Tyk2 and seven 
STATs (1-5, -6a, and -6b).  Receptor-associated inactive JAK enzymes, 
which are loosely attached to the cytoplasmic domains of the receptors, 
become activated via transphosphorylation. This leads to the 
phosphorylation of tyrosine residues in the cytoplasmic portions of the 
clustered receptors. STAT proteins bind to the receptors via 
phosphotyrosine residues and are subsequently phosphorylated by the 
receptor-associated JAK kinases. This results in the bound STAT proteins 
dissociating from the receptor, allowing the STAT dimer to migrate to the 
nucleus and activate gene transcription via NFB (Murphy et al., 2008). 
 
Analysis of regulatory events in the IFN- signalling pathway demonstrated 
that VZV infection inhibited transcription of both interferon regulatory factor 
-1 (IRF-1) and the MHC-II transactivator (CIITA), thus enabling the virus to 
inhibit IFN- induction of cell surface MHC-II expression (see figure 1.15 ). 
STAT-1 is known to induce the expression of CIITA and IRF-1 by IFN- 
treatment (Meraz et al., 1996, Piskurich et al., 1998). Abendroth and 
colleagues (2000) found that VZV infection inhibited the expression of both 
STAT-1 and JAK2 proteins but had little effect on JAK1. HCMV and 
MCMV also inhibit MHC-II expression at the level of transcription. In the 
case of HCMV, the virus inhibits MHC-II expression (in human fibroblasts 
in vitro) by blocking JAK/STAT signal transduction through a specific 
decrease in JAK-1 expression (Miller et al., 1998). In contrast, MCMV 
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inhibits IFN- stimulated MHC-II expression (in murine macrophages in 
vitro) by a mechanism that does not involve JAK/STAT signal transduction 
(Heise et al., 1998). The fact that these three herpesviruses all employ 
mechanisms to reduce MHC-II antigen presentation is indicative that they 
have been exposed to a similar immunological selection pressure.   
 
1.7.6 Cytokines Induced by VZV Infection, and the Immune Modulation of 
Cytokine Pathways by VZV: 
Cytokines are small soluble proteins (approximately 8-80kDa) that usually 
act in an autocrine or paracrine, (rather than endocrine), manner to alter 
the behaviour or properties of cells. These proteins are part of an 
extracellular signalling network that controls immune responses. Cytokines 
produced during an innate immune response include TNF, IL-1, IL-6, IL-
12, IFN-, IFN-, IFN- and various chemotactic cytokines (chemokines) 
such as IL-8. Interleukins have a variety of functions, mainly directing other 
cells to divide and differentiate. Interferons are particularly important in 
limiting the spread of viral infections; type-I interferons (IFN- and IFN-) 
are produced by virally infected cells early in infection and induce a state 
of antiviral resistance in uninfected cells. Type-II Interferon (IFN-) is 
produced by NK cells (and activated T cells).  
 
VZV has been shown to modulate host immune responses by modifying 
several signalling pathways such as the Jun NH2-terminal kinase/stress-
activated protein kinase (JNK/SAPK) pathway and the p38 mitogen-
activated protein kinase (p38/MAPK) pathway, (Desloges et al., 2008a). 
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Figure 1.15: Schematic of the Sites of VZV-Mediated Disruption of IFN- 
Induced MHC-II Expression. The proteins which are affected in VZV 
infected cells are crossed out. Key: CIITA - MHC-II transactivator, IFN – 
interferon, IRF-1 - interferon regulatory factor -1, JAK - Janus kinases, Stat 
- signal transducers and activators of transcription. Not to scale. (Adapted 
from Abendroth and Arvin 2001b, with permission).  
 
A range of cytokines are produced in response to VZV infection, and have 
either been measured from patients ex vivo, in vitro, or in skin xenografts 
on the SCID-Hu mouse model. For many of these cytokines, VZV-induced 
modulation of the signalling pathways which lead to their transcription, 
have been investigated. 
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PBMCs obtained from patients during the acute phase of varicella were 
shown to produce significantly higher amounts of IFN-, TNF and IL-12 
compared to healthy individuals (Torigo et al., 2000). Levels of IL-6 and 
IFN- have been shown to be slightly raised in the serum of zoster patients 
at the time of acute disease compared with a group of normal healthy 
subjects (Zak-Prelich et al., 2003). Human monocytes, macrophages and 
keratinocytes have been shown to produce IL-6 (Wang et al., 2005, 
Nikkels et al., 2004). In VZV-infected monocytes, the production of this 
cytokine has been shown to be via Toll Like Receptor 2 (TLR-2) 
dependent activation of NFB (Wang et al., 2005). IL-6, IL-1 and TNF are 
cytokines which are crucial to the induction of acute phase proteins and 
the acute phase response, a key part of an inflammatory response. IL-1 
and TNF are pyrogens which play an important role in the induction of 
adhesion molecule expression on endothelial cells and the stimulation of 
chemokine production (Murphy et al., 2008).   
 
Interleukin-8 (IL-8) is a pro-inflammatory cytokine and a potent neutrophil 
attractant. VZV infection has been shown to induce the secretion of IL-8 in 
melanoma cells, fibroblasts, a T cell line (Desloges et al., 2008b) and 
human monocytes (Wang et al., 2005) in vitro.  Inhibition of VZV DNA 
replication has no effect on IL-8 release in vitro, suggesting that virus 
entry, release of tegument proteins and/or expression of immediate early 
or early genes are sufficient for the induction of IL-8 secretion (Desloges et 
al., 2008b). The presence of IL-1 or TNF caused a significant induction 
of IL-8 secretion in infected melanoma and fibroblast cells, but had no 
effect on infected T cell line. Treating cells prior to infection with inhibitors 
of NFB, JNK/SAPK or p38/MAPK, revealed that IL-8 expression was not 
dependent on NFB activation in VZV-infected melanoma and T cells. 
However, the JNK/SAPK pathway is required for secretion of IL-8 in VZV 
infected melanoma cells, whilst both the JNK/SAPK and p38/MAPK 
pathways are necessary for IL-8 secretion in a VZV-infected T cell line 
(Desloges et al., 2008b). 
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VZV infection is also associated with the induction of IL-1 production in 
epidermal cells in SCID-Hu mice (Ku et al., 2004). In this model, it was 
demonstrated that Interleukin-1 was expressed constitutively in the 
cytoplasm of epidermal cells in uninfected skin. In VZV infected skin 
xenografts IL-1 was translocated to the nuclei of infected cells but 
remained in the cytoplasm of adjacent, uninfected cells (Ku et al., 2004).  
 
1.7.6.1 Type I (IFN-) and Type II (IFN- and IFN-) Interferons: 
IFN- has been detected in the serum of healthy children with varicella 
and administration of exogenous IFN- to immunocompromised children 
with varicella has been shown to reduce disease severity (Arvin et al., 
1982). Resolution of herpes zoster rash is accompanied by local 
production of IFN- detected in vesicle fluid from cutaneous lesions 
(Stevens et al., 1975). Binding of IFN- to its receptors induces 
phosphorylation of STAT-1 by JAK kinases (Darnell et al., 1994).  Unless 
STAT-1 is phosphoylated, it does not translocate to the nucleus and IFN- 
production is blocked. In VZV infected skin xenografts in the SCID-Hu 
mouse model, phosphorylated STAT-1 was localised to nuclei in 
neighbouring uninfected epidermal cells, but it was not detected in cells 
expressing VZV proteins. STAT-1 was not phosphorylated and remained 
cytoplasmic, as did IFN-, in uninfected skin xenografts. VZV replication 
therefore appears to result in expression of a gene product(s) that 
interferes with STAT-1 activation and thereby inhibits antiviral IFN- 
production in foci of infected skin cells in vivo (Ku et al., 2004).  Although 
this study found that IFN- was down regulated in VZV-infected cells it 
was prominently expressed in neighbouring uninfected epidermal cells (Ku 
et al., 2004). Experiments with neutralizing antibodies against the IFN-/ 
receptor confirmed the role of type-I interferon in immune modulation (Ku 
et al., 2004). 
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IFN- confers cellular resistance against virus infection through at least 
two cellular proteins, double-stranded RNA-activated protein kinase (PKR) 
and 2‟-5‟oligoadenylate synthetase. VZV has been shown to counteract 
the IFN type-1 mediated host defence effectively by circumventing the 
induction of PKR- and RNase L dependent antiviral systems (Desloges et 
al., 2005a, Desloges et al., 2005b). A recent study by Ambagala and 
Cohen (2007) indicates that VZV ORF63 interferes with the PKR pathway. 
The authors found that ORF63 deletion mutant viruses (in which over 90% 
of both copies of ORF63 were deleted) are hypersensitive to human IFN- 
compared to parental virus. Activated PKR phosphorylates the -subunit 
of eukaryotic initiation factor 2 (eIF-2), thereby preventing initiation of 
translation. Cells infected with the VZV ORF63 deletion mutant had 
increased levels of phosphorylated eIF-2 (eIF-2-P) compared to those 
infected with parental virus, suggesting that expression of the ORF63 
protein is necessary to overcome virus-induced phosphorylation of eIF-2. 
In addition, transient expression of IE63 diminished basal levels of eIF-2-
P.  
 
In an in vitro study of lymphocytes the induction of IFN- production by 
VZV was found to be associated with IFN- production and 
phosphorylation of both STAT-1 and STAT-4 (Yu et al., 2005). IFN- can 
restrict VZV replication by its direct antiviral effects, and can be detected in 
the serum of healthy subjects with acute varicella (Arvin et al., 1986b; 
Wallace et al., 1994). IFN- and IFN- inhibit the replication of VZV in vitro 
(Desloges et al., 2005a). IFN- was found to be more effective than IFN-, 
but the level of inhibition of VZV replication achieved by the combination of 
both IFNs was more than additive; thus these two cytokines acted 
synergistically (Desloges et al., 2005a). In the presence of IFN- but not 
IFN-, expression of the IFN-induced, double-stranded RNA-activated 
protein kinase PKR and its phosphorylation were increased, explaining in 
part the inhibition of virus replication by IFNs (Desloges et al., 2005a).   
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1.7.7 Modulation of the NFB Transactivation Pathway: 
NFB possesses the ability to promote the expression of numerous 
proteins involved in innate and adaptive immunity and thus regulates the 
immune response following various stimuli, including infections. NFB 
activation during early stages of viral infection, leads to the expression of 
immune response genes such as those for proinflammatory cytokines 
(IFN-, TNF, IL-6, and IL-8), chemokines (RANTES), and adhesion 
molecules (ICAM-1 and VCAM-1). NFB also strongly induces MHC-I and 
CD80/86 expression on antigen-presenting cells, thus increasing T cell 
activation. Several viruses, including HSV and CMV, have also developed 
strategies to interfere with NFB activation (Amici et al., 2006; Montag et 
al., 2006). 
 
Members of the nuclear factor kappa B (NFB) family of proteins which 
includes NFB1 (p105 processed to p50), NFB2 (p100 processed to 
p52), Rel A (p65), Rel B, and c-rel are key cellular transcription factors. 
The most abundant form of NFB is a heterodimer composed of p50 and 
p65/RelA. In resting cells, NFB proteins are inactive, as the nuclear 
localization signals of p50 and p65 are bound to an inhibitor of NFB (IB) 
known as IB and are sequestered in the cytoplasm (Richmond, 2002).  
The family of IBs also includes IB, -, -, p100, and p105. Following 
signalling, the IB proteins dissociate from the NFB complex as they are 
phosphorylated by the IB kinases (IKKs), ubiquitinated, and degraded by 
the proteasome, thus allowing the activated transcription factor (NFB) to 
translocate to the nucleus where it can bind the unique DNA sequence in 
the promoter region of cytokine responsive genes (Karin and Ben-Neriah, 
2000). 
 
DNA microarrays demonstrated that many NFB responsive genes are 
down regulated in VZV-infected fibroblasts (Jones et al., 2003; Jones, 
2005).  VZV has been shown to inhibit the NFB pathway by sequestering 
p50 and p65 in the cytoplasm of the infected cells after a transient nuclear 
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translocation in vitro (Jones et al., 2006). It was also demonstrated that 
VZV has the ability to inhibit the degradation of IB after exogenous 
stimulation of the NFB pathway by TNF signalling. In human xenografts 
on SCID mice, NFB was retained in the cytoplasm of VZV-infected 
epidermal cells (Jones et al., 2006). VZV inhibits innate responses 
mediated through the NFB pathway in vitro and in vivo, whereas these 
cellular defences are upregulated in adjacent uninfected skin (Jones et al., 
2003; Jones et al., 2006a).  
 
As mentioned previously, VZV induced modulation of ICAM-1 expression 
is now known to be due to the disruption of the NFB signalling pathway 
(El Mjiyad et al., 2007). In melanoma and fibroblasts in vitro VZV is able to 
inhibit NFB nuclear translocation by destabilizing the NFB p65-p50 
heterodimers which are crucial for the TNF induction of the icam-1 gene. 
The NFB subunits p65, p52 and c-Rel are still induced upon VZV 
infection, but the subunit p50 does not translocate in response to TNF. 
Nuclear p65 is no longer associated with p50 and is unable to bind the 
proximal NFB site of the icam-1 promoter. VZV also induces the nuclear 
accumulation of the NFB inhibitor p100 (El Mjiyad et al., 2007).   
 
1.8 Prevention and Treatment: 
1.8.1 Antiviral Therapy: 
There are several drugs which are currently licensed for the treatment of 
VZV disease, including aciclovir (and its prodrug valaciclovir) penciclovir 
(and its prodrug famciclovir), ganciclovir, cidofovir, brivudin and foscarnet 
(Simpson and Lyseng-Williamson, 2006; Boeckh, 2006; Whitley and 
Gnann, 1999). Both valaciclovir and famciclovir are converted within the 
body into their active forms aciclovir and penciclovir respectively. Aciclovir 
is administered either by the oral route or intravenously, depending on the 
severity of the illness. Zoster can also be treated successfully with the oral 
medications famciclovir and valaciclovir. There is a high correlation 
between early treatment (within 24h of onset of rash) and a successful 
outcome (Balfour et al., 1983). Antiviral therapy for varicella does not 
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prevent latent VZV infection. These drugs have different modes of action, 
but all act by inhibiting VZV DNA replication (Whitley and Gnann, 1999). 
 
1.8.2 Varicella Vaccination: 
1.8.2.1 Development of the Varicella Oka Vaccine: 
The live attenuated varicella vaccine was developed by Takahashi and co-
workers in the early 1970s (Takahashi et al., 1974) and is the only 
licenced vaccine available against a herpes virus. Similar live attenuated 
vaccines have been widely used and proven extremely effective for 
immunization against a variety of viruses including polio (Sabin, 1957; 
Sabin and Boulger, 1973), measles (Katz et al., 1960), mumps (Hilleman 
et al., 1968) and rubella (Plotkin et al., 1968; Plotkin, 1972).  
 
The original parental wild type strain of VZV was isolated in Japan in 1971 
from the vesicle fluid of a three year old boy, of the surname Oka who had 
typical chickenpox but was otherwise healthy (Takahashi et al., 1974). 
Attenuation of the virus was achieved at the Biken Institute in Osaka, 
Japan using the classical method of propagation at low temperature in 
vitro, in cells from a species different from that of the natural host.  
 
In addition to the Biken vaccine, Merck and GSK have since produced 
their own forms of the Oka VZV vaccine. Both are derived from the Oka 
strain developed by Takahashi and co-workers. Figure 1.16 summarises 
the differences in propagation between the three brands of vaccine. 
 
1.8.2.2 Comparison of POka and VOka Viruses: 
The vaccine strain (vOka) is not clonal, but instead contains a mixture of 
substrains that differ from one another genetically (Gomi et al., 2002; 
Quinlivan et al., 2004; Quinlivan et al., 2005). Comparison between the 
parental strain (Biken pOka) from which all the mixture of vaccine strains 
derive, has been carried out (Gomi et al., 2000; Gomi et al., 2001; Argaw 
et al., 2000) and revealed that the Oka vaccine virus differs from the 
parent virus at 46 loci (Gomi et al., 2002); only a 0.034% sequence 
difference. The majority of these differences occur in the form of single  
 108 
 
 
Figure 1.16: Attenuation of P-Oka to V-Oka and the Differences in Attenuation Between the Biken, GSK and Merck Vaccines. Attenuation of the virus was achieved using the 
classical method of propagation at low temperature in vitro, in cells from a species different from that of the natural host. Key: HEL-human embryo lung fibroblasts, GPEF- 
guinea pig embryo fibroblast, HFL-human Foetal lung fibroblasts. 
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nucleotide polymorphisms (SNPs), but also include nucleotide additions 
and deletions in variable repeat regions of the genome (Gomi et al., 2002). 
There are only 42 base substitutions, resulting in 20 amino acid (aa) 
conversions and length differences in tandem repeat regions (R1, R3, and 
R4) and in an origin of DNA replication. Amino acid substitutions exist in 
ORFs 6, 9A, 10, 21, 31, 39, 50, 52, 55, 59, 62, and 64. Direct sequencing 
of the vaccine genome revealed that at the majority of the 46 loci, both a 
novel vaccine nucleotide and the parental wild-type virus nucleotide were 
present, (Gomi et al., 2002).   
 
1.8.2.3 Vaccine Virus Attention: 
Although both vOka and pOka have been shown to replicate well in vitro, 
the SCID-Hu mouse model has facilitated studies of the attenuation of 
vOka in vivo (Moffatt et al., 1998a; Moffatt et al., 1998b). VOka and pOka 
have been shown not to differ in their infectivity for human T cells in 
thymus/liver xenografts in vivo (Moffatt et al., 1998b) and recently it has 
been demonstrated in human keratinocytes in vitro that pOka and vOka 
have the same capacity to inhibit the IFN- signaling pathway (Black et al., 
2009). However in skin xenografts, vOka was shown to have a reduced 
capacity to replicate in differentiated human epidermal cells, with lower 
yields of infectious virus, decreased viral protein synthesis and slower 
progression of cutaneous lesions compared to the parental strain (and a 
low passage clinical isolate) which were fully virulent, (Moffatt et al., 
1998a; Moffatt et al., 1998b).  
 
Further investigations of the genetic basis of vOka attenuation have been 
carried out using cosmids to generate chimeric pOka and vOka 
recombinant viruses, which have been evaluated in SCID-Hu skin 
xenografts (Zerboni et al., 2005a). Plaque morphologies and the growth 
kinetics of pOka, vOka and six chimeric pOka/vOka viruses, did not differ 
in vitro, but the pOka/vOka chimeric viruses showed variable virulence in 
skin xenografts. Within vaccine strains there are 15 base substitutions, 
(leading to eight aa differences), located in gene 62/71, but these 
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experiments indicated that ORF62 vaccine changes were not sufficient to 
diminish vOka virulence in skin. In addition, the presence of pOka ORFs 
30–55 in chimeric viruses was sufficient to maintain wild-type infectivity in 
skin, (Zerboni et al., 2005a). 
 
1.8.2.4. Uses of the Varicella Vaccine: 
The Oka Biken vaccine was approved for administration to both high risk 
and healthy children in Japan in 1986, and is also licensed in Korea 
(Asano et al., 1994; Asano, 1996) and Taiwan (Tseng et al., 2003) for 
widespread administration to susceptible children.  
 
VARIVAX™ (Merck & Co., Inc, USA) is currently marketed worldwide in 46 
countries, with around 55 million doses distributed to date, (Galea et al., 
2008). This brand of vaccine was licensed in the US in 1995 for 
vaccination of healthy children, healthy adults (Wise et al., 2000; Sharrar 
et al., 2000), children with leukaemia (LaRussa et al., 1996), and in some 
HIV positive children (Advisory Committee on Immunization Practices, 
1999).  Since 1996, universal vaccination of all children aged 12-18 
months has been recommended in the US (National Advisory Committee 
on Immunization, 1999). To further reduce varicella disease burden, a 
routine two-dose varicella vaccination recommendation has been 
approved by the Centers for Disease Control and Prevention (CDC) 
Advisory Committee on Immunization Practices (ACIP) since 2006; with 
the first dose administered to children aged 12–15 months and a second 
dose at 4–6 years of age (Marin et al., 2007).  
 
Universal vaccination against varicella in the UK is not practised. However, 
there is targeted vaccination of groups at risk of severe varicella 
(Department of Health, 2003). In 2003 the VARILRIX™ and VARIVAX™ 
vaccines were licensed for use in the UK in health care workers (Nardone, 
2003). Licensure and vaccination strategies in Europe are varied 
(reviewed in Sadzot-Delvaux et al., 2008), however, the Society of 
Independent European Vaccination Experts (SIEVE) recommends that the 
immunization of susceptible adolescents needs to be urgently 
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implemented throughout Europe, in addition to the current 
recommendations targeting high-risk patients, their close contacts with a 
negative history of varicella and seronegative health-care workers. A 
universal policy, optimally incorporating a two-dose schedule, will be 
needed to finally reduce the burden of disease of varicella from a societal 
point of view. The SIEVE recommends the implementation of such a policy 
as soon as financially and practically possible, (reviewed in Sengupta et 
al., 2007). 
 
1.8.2.5 Vaccine Efficacy:  
Before vaccine licensure, only one double-blind, placebo-controlled 
efficacy study of the Oka/Merck varicella vaccine was conducted, (Weibel 
et al., 1984).  Almost 1,000 healthy children in the United States were 
immunized with one dose (>17,000pfus) and followed up for several years. 
After nine months of follow-up, the vaccine was found to be 100% 
effective, with only children vaccinated with the placebo developing 
varicella. The children who were given the placebo were then vaccinated, 
and after two years, efficacy was 98% overall. At seven years, 95% had 
remained free from disease. Since the varicella vaccine (which contains a 
minimum of 1,350pfu/dose) was licensed in the United States, several 
effectiveness studies have been carried out (reviewed in Seward et al., 
2008). Data collected from the 19 studies found that overall, one dose of 
varicella vaccine was 84.5% effective (range, 44%–100%) in preventing 
varicella disease and 100% effective in preventing severe disease. 
  
1.8.2.6 The Aim of Universal Vaccination and Achievements Ten Years 
Post Introduction: 
In the long term, it is hoped that with universal vaccination against VZV in 
childhood, varicella and subsequently zoster will be prevented. Before 
implementation of the varicella vaccination program in the States, VZV 
infection resulted in an average of 11,000–13,500 hospitalizations and 
100–150 deaths each year (Galil et al., 2002a; Ratner, 2002; Davis et al., 
2004; Meyer et al., 2000). Since 1996, the annual incidence of varicella in 
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USA has fallen by over 70% in areas of high coverage and associated 
hospital admission rates have also dramatically decreased (Seward et al., 
2002; Zhou et al., 2005; Davis et al., 2004). In Germany use of an age-
structured analytical model has estimated that a routine varicella 
vaccination programme targeting healthy children could prevent 82.7% of 
varicella cases and over 4,700 major complications per year in Germany 
provided the coverage level was 85%. Under these conditions, the 
elimination of varicella is predicted to be achievable within 18 years 
(Wutzler et al., 2002).  
 
Data accumulated 10 years after the varicella vaccine was introduced in 
the States suggests its use so far has been highly effective (Hambleton 
and Gershon, 2005a; Hambleton and Gershon, 2005b; Seward et al., 
2008). A number of recent studies relate increasing vaccine coverage in 
the US to significant reductions in varicella-related consultations, 
hospitalizations and deaths (Davis et al., 2004; Patel et al., 2004; 
Reynolds et al., 2008), in addition to various indicators of reduced varicella 
incidence and VZV transmission, (Hambleton and Gershon, 2005a). The 
safety record of the vaccine also remains after its administration to millions 
of individuals (Wise et al., 2000, Sharrar et al., 2000; Galea et al., 2008; 
Chaves et al., 2008).  
 
1.8.2.7 The Effect of Varicella Vaccination on Rates of Zoster: 
The effects of varicella vaccination on zoster are not yet known and this 
represents one of the major areas of uncertainty in relation to its 
widespread use (Wagenpfeil et al., 2004). Vaccine strain virus can 
certainly establish latent infection and can also reactivate to cause zoster 
(LaRussa et al., 2000; Sharrar et al., 2000), but at a rate that appears 
significantly lower than wild type virus (at least in the 
immunocompromised), (Hardy et al., 1991). Alongside this potential 
protective effect in vaccinees however, must be considered the possibility 
that overall zoster incidence may increase in highly vaccinated populations 
because of the loss of boosting exposures to varicella (Gershon, 1996, 
Thomas et al., 2002, Brisson et al., 2002). This has been demonstrated in 
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a Spanish study (Pérez-Farinós et al., 2007), where the vaccine was first 
introduced in 1997 for use in high risk patients, and recommended for 
vaccination of children of 12 months of age in 1999. Data from this sentinel 
study, conducted in Madrid between 1997-2004, indicated that there was a 
sustained and significant rise in annual incidence of zoster during this time 
period, particularly among the oldest age groups (Pérez-Farinós et al., 
2007).   
 
However, within the ten year time frame since the vaccine has been 
licensed in the USA, the incidence of zoster has remained stable whilst the 
incidence of varicella has decreased (Jumaan et al., 2005). These findings 
revealed that the vaccination-associated decrease in varicella disease has 
not resulted in an increase in the incidence of zoster thus far (Jumaan et 
al., 2005), but these early findings will have to be confirmed as the 
incidence of varicella disease continues to decrease. However, in a recent 
long-term follow-up study on healthy young adults who had been 
vaccinated 10-26 years previously, the incidence of herpes zoster was 
similar to that of the US population in the pre-vaccine era (Hambleton et 
al., 2008). 
  
1.8.3 Development of the Zoster Vaccine: 
Following on from the success of the varicella vaccination, a vaccine 
aimed at boosting pre-existing immunity to prevent herpes zoster was 
developed. The zoster vaccine (ZOSTAVAX; Oka/Merck) was licensed 
in the United States in May 2006, and was recommended for use in adults 
aged ≥60 years by ACIP in October 2006.  It has been estimated that in 
the United States, the vaccine has the potential to prevent 300,000 
outpatient visits, 375,000 medication prescriptions, 9,700 emergency 
department visits, and 10,000 hospitalizations per million vaccine 
recipients (Pellissier et al., 2007).  
 
In a randomized, double-blind, placebo-controlled trial of almost 40,000 
adults, 60 years of age or older, the use of the zoster vaccine reduced the 
incidence of postherpetic neuralgia (PHN) by 66.5 percent (p<0.001), and 
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the incidence of herpes zoster by 51.3 percent (p<0.001) (Oxman et al., 
2005). The minimum potency (19,400 pfus/dose) administered was 14 
times greater than that of the minimum potency of VARIVAX™ (minimum 
of 1,350pfu). Preliminary studies indicated that potencies of this magnitude 
are required to elicit a significant increase in the cell mediated immunity to 
VZV among older adults (Oxman et al., 2005). There are no data to 
suggest that the vaccines aimed at varicella would be efficacious in 
protecting older adults from zoster or PHN.  
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 List of Buffers and Reagents: 
Complete 
Growth Medium 
Culture medium, 10% human serum or FBS; 1% 
penicillin/streptomycin, 1% glutamine 
 
ELISPOT: 
 
Blocking 
solution 
Complete cell culture medium 
Coating buffer 1× PBS 
Dilution buffer 1× PBS, 10% FBS 
Substrate 
solution 
 
BD™ AEC Substrate Reagent Set (AEC (3-amino- 
9-ethyl-carbazole) stock solution: 100mg AEC in 10mL 
DMF (N,N-Dimethylformamide).  
 
Wash buffer I 
 
1× PBS, 0.05% Tween-20 
Wash buffer II  1× PBS  
 
Freezing media 
 
90% FBS,  10% DiMethyl SulfOxide (DMSO) 
 
Maintenance 
media 
 
Culture medium, 2% FBS, 1% Penicillin-Streptomycin–
L-glutamine  
PBS  
 
137mM NaCl, 10mM Na2HPO4, 3mM KCL, 2mM, 
K2HPO4, pH 7.4 
VTM 
 
Modified Hank's balanced salt solution, pH 7.3 (+/- 0.2) 
20mM HEPES,  2% BSA, Amphotericin B (4mg/mL) 
and vancomycin (100mg/mL) 
 
 
Western blot 
 
Blocking buffer 
5% w/v dried skimmed milk powder, 0.05% v/v Tween 
20 in PBS 
 
Wash buffer 
 
0.05% Tween 20 in PBS 
 
2.2 Patient Recruitment and Sample Collection: 
2.2.1 ROVE (Response to Oka Vaccine Evaluation) Study: 
The following research study is based on the introduction of the Oka 
vaccination programme at Bart‟s and the London (BLT) NHS Trust with the 
cooperation of the Trust Occupational Health and BLT Virology 
departments.   
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In June 2005 the occupational database (dating back to March 2000) 
consisted of 1,308 employment screening blood results that were 
serologically negative or equivocal to VZV by standard serology testing 
(Diamedix, USA,). 260 staff were invited to take part in our study: 
Response to Oka Vaccine Evaluation (ROVE).   Ethical permission was 
granted by the East London and the City Health Authority Local Research 
Ethics Committee 3 (05\Q0605\1). A total of 110 BLT staff members were 
recruited for the ROVE study (with thanks to Mrs Fiona Scott). The study 
protocol can be found in appendix 7.1. 
  
Healthcare workers (HCW) who were eligible for varicella vaccination 
according to the Department of Health guidelines (Department of Health, 
2003) were asked to attend the ROVE clinic three times.  This included 
HCWs who had a negative history for varicella and were negative by 
serological testing and those who had recently migrated from the tropics 
with a positive history, but were negative by serological testing. On the first 
visit, the volunteers answered a short questionnaire on demographics and 
history of varicella (see appendix 7.2). Exclusion criteria included 
immunocomprised, e.g: by steroid treatment, and (where applicable) 
pregnancy and/or breastfeeding. Baseline samples were taken.  These 
samples consisted of 3mL of EDTA blood (7.5% 0.072mL), 5mL of clotted 
blood, and 18mL of heparinised blood (sodium heparin 170IU/10mL tube). 
After samples were collected, the HCW was administered subcutaneously 
either the GlaxoSmithKline Oka-RIT (VARILRIXTM) vaccine or the 
Oka/Merck Aventis Pasteur (VARIVAXTM) vaccine (see table 2.1 and 
appendix 7.3).  Each 0.5mL dose of VARIVAX contained a minimum of 
1,350 plaque forming units (pfus) of live attenuated varicella virus, and the 
following inactive ingredients: Sucrose, hydrolysed gelatine, urea, sodium 
chloride, monosodium-L-glutamate, anhydrous disodium phosphate, 
potassium dihydrogen phosphate and potassium chloride. (Aventis 
Pasteur MSD Limited, 2003). Each 0.5mL dose of VARILRIXTM contained 
1,995 (103.3) pfus of live attenuated varicella virus, and the following 
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inactive ingredients: Amino acids, human albumin, lactose, neomycin 
sulphate sorbitol and mannitol (GlaxoSmithKline, 2006).  
 
At the second visit (approximately six weeks after the first visit/vaccination) 
HCWs answered a questionnaire relating to whether any symptoms were 
associated with the previous vaccination, and whether they had come into 
contact with either chickenpox or shingles, (see appendix 7.2). The same 
set of blood samples were collected and the second dose of vaccine (from 
the same manufacturer as the corresponding first dose) was administered 
subcutaneously (see table 2.1 and appendix 7.3). On the third visit, 
(approximately 12 weeks after the first vaccination, and six weeks after the 
second vaccination) the HCW again answered a questionnaire on 
symptoms and contacts and the full repertoire of samples was collected. 
No vaccine was administered at the third visit. Subsequently, 75 study 
participants were recruited for a 1-2 year follow up visit, where again, the 
full set of samples were collected, and a questionnaire was answered by 
the HCW on contacts with chickenpox and shingles since their last visit.   
 
Appendix table 7.4 documents the weeks elapsed between visits for each 
HCW, and thus those individuals who participated in a fourth visit. 
 
Visit 
Number 
Timescale Aim  
Vaccination 
Strategy 
Samples 
Visit 1 
(V1) 
Baseline 
Examine pre-
existing 
immunity 
First dose of 
vaccine 
administered 
Blood 
samples 
collected 
Visit 2 
(V2) 
Six weeks post 
first dose 
Examine 
immune 
response to 
 first dose 
Second dose 
of vaccine 
administered 
Blood 
samples 
collected 
Visit 3 
(V3) 
12 weeks post 
first dose,  
Six weeks post 
second dose 
Examine 
immune 
response to 
second dose 
No vaccine 
administered 
Blood 
samples 
collected 
Visit 4 
(V4) 
12-18 months 
Examine waning 
immunity and 
boosting 
No vaccine 
administered 
Blood 
samples 
collected 
Table 2.1: Summary of ROVE Visits Timings, Vaccine Schedule and 
Sample Collection. 
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2.2.2 Sample Collection in the Case of ROVE Rash Development, Post 
Vaccination:  
If at any point during the study a HCW developed symptoms which they 
thought could be attributed to a varicella rash (one or more cutaneous 
lesions) or suspected a vaccine related event (VRE) (see appendix 7.2) 
the ROVE research nurse was contacted directly by the HCW.  If lesions 
were present the research nurse would carry out a visual examination and 
vesicle fluid from all lesions would be collected using swabs. Swabs were 
then stored in viral transport media (VTM) (see list of buffers and reagents) 
and DNA was extracted within 2h. A full set of blood samples were 
collected, and processed within 2h. 
 
2.3 Sample Processing and Storage:  
2.3.1 ROVE Blood Samples: 
All ROVE blood samples were transported back to the laboratory at room 
temperature (RT) and processed within 2h of being taken.  
 
2.3.2 Whole Blood: 
From the 5mL EDTA tube, 200L of blood was removed for DNA 
extraction (see section 2.3.6). 
 
2.3.3 Plasma Isolation:  
The remaining contents of the EDTA tube were spun at 1,800rpm (500g) 
in a Jouan CR 412 centrifuge at RT for 5min. The resulting plasma layer 
was then aspirated within a class 2 hood using a sterile Pasteur pipette 
into 2 aliquots. The remaining pellet was discarded according to the 
correct safety procedures. 
 
2.3.4 Serum Isolation: 
The 5mL clotted blood tube was spun along side the EDTA tube at 
1,800rpm (500g) in a Jouan CR 412 centrifuge at RT for 5min. The 
resulting serum layer was then aspirated (as described for the plasma 
sample), into 3 aliquots. The remaining pellet was discarded according to 
correct safety procedures. 
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2.3.5 Peripheral Blood Mononuclear Cells (PBMC) Separation: 
The heparinized blood was processed aseptically in a class 2 Trimat hood. 
18mL of heparinized blood was added to equal volumes of phosphate 
buffered saline (PBS) (Sigma, UK) in a sterile 50mL Falcon tube. The 
sample was slowly layered onto 15mL of ficoll (Amersham Pharmacia 
Biotech AB, Sweden). This was centrifuged immediately (25min, 1,800rpm 
(500g), RT, Jouan CR 412). Three quarters of the upper serum layer was 
discarded, and the PBMCs layer was carefully aspirated with a sterile 
Pasteur pipette. 40mL of PBS was added to the PBMCs, mixed and 
centrifuged (12min, 1,500rpm, (350g), RT). The PBS was discarded, and 
the remaining cell pellet gently resuspended in 10mL of PBS and 
centrifuged (5min, 1,500rpm (350g), RT). This step was repeated and the 
final cells pellet was then frozen (see section 2.3.7).  
 
2.3.6 DNA Extraction:  
DNA was extracted from a 200L aliquot of whole blood (see section 
2.3.2) using a QIAamp DNA Mini Kit (Qiagen LTD., UK). For each 
sample, 20L of Protease K, the 200L of sample and 200L of Buffer AL 
were sequentially placed into a 1.5mL microcentrifuge tube. Tubes were 
pulse-vortexed (Vortex 2 Genie, Scientific industries) for 15 seconds and 
incubated at 56oC for 10min in a heating block (Stuart Scientific Test Tube 
Heater Sht 10). All tubes were then briefly centrifuged (Heraeus Biofuge 
Pico, Thermo Fisher Scientific, UK) to remove drops from the inside of the 
lids, after which, 200L of molecular biology grade ethanol (100%) (Sigma, 
UK) was added. Tubes were again pulse vortexed for 15 seconds and 
briefly centrifuged to remove drops from the inside of the lids. The 
contents of the tube was transferred to a QIAamp spin column which were 
then centrifuged (8,000rpm; 5,000g), 1min. The spin column was 
transferred to a fresh collection tube and the collection tube containing the 
AL filtrate was discarded according to correct safety procedures. 500L of 
buffer AW1 was added to the spin column, which was centrifuged 
(8,000rpm (5,000g), 1 min).  The spin column was transferred to a fresh 
collection tube and the collection tube containing the AW1 filtrate was 
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discarded according to correct safety procedures. 500L of buffer AW2 
was added to the column, which was centrifuged (14,000rpm (15,000g), 
3min), placed into a new collection tube and re-centrifuged (14,000rpm 
(15,000g), 1min) to remove any residual buffer AW2. The column was then 
placed into the pre-labelled 1.5mL microcentrifuge tube into which the final 
DNA sample was to be collected. 200L of buffer AE was added to the 
spin column and incubated at RT for 5min. The column was then 
centrifuged (8,000rpm (5,000g), 1min) to elute the DNA, which was stored 
as a single aliquot as mentioned above. The spin column was the 
disposed of according to correct safety procedures. When more than one 
sample was processed at a time, a negative control was employed by 
replacing sample material with 200L of molecular biology grade water 
(Sigma).  
 
2.3.7 Cell Freezing: 
Cell pellets were resuspended in 500L of ice cold freezing media and 
transferred to a 1.8mL cryovial (Nunc). The vial was then immediately 
transferred to an isopropanol bath (Mr Frosty NalgeneTM Cryo 1oC freezing 
container) and frozen at -70oC. After 24h the cells were placed into liquid 
nitrogen storage. 
 
2.3.8 Thawing Cell Aliquots 
Cells were thawed rapidly in a water bath at 37°C.  The cell suspension 
was transferred into a 50mL Falcon tube and washed twice (cells were 
pelleted at 1,600rpm (400g), (Jouan CR 412 centrifuge) for 10min at RT) 
with 50mLs of complete medium. The cells were then resuspended in 
complete medium to the desired concentration.  
 
2.3.9 Viable Cell Counts:  
To determine cell viability, cell counts were carried out by diluting samples 
1/10 in cell culture media or PBS, and subsequently further diluting in 
trypan blue (Sigma) 1/2. Cells were mounted on either a haemocytometer, 
or for ELISPOT and tetramer assays, were counted using disposable 
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„Fastread‟ counting slides (Immune Systems Limited, UK). Cells were 
enumerated by examination on a light microscope and use of a cell 
counter. 
 
2.3.10 Sample Storage: 
All processed samples from the ROVE study were labelled with patient 
number, visit number, date of visit and a description of the sample (e.g. 
serum, plasma, DNA or PBMCs). DNA was stored in 1.5mL eppendorfs at 
-20oC, PBMCs in sterile 1.8mL NUNC cryovials in liquid nitrogen and all 
other blood samples in sterile 1.8mL NUNC cryovials at -70oC.   
 
2.4 Serology Based Assays: 
2.4.1 ELISA Based Assays: 
2.4.1.1 VZV IgG TRFIA. 
Details of the VZV IgG TRFIA assay have been published (Maple et al., 
2006). In brief, this assay used VZV enzyme-linked immunosorbent assay 
grade antigen (The Binding Site, Birmingham, United Kingdom) which was 
a sucrose density gradient centrifugation-purified extract of human embryo 
lung (HEL) cultured VZV strain Ellen. The coating concentration of antigen 
was that which gave a europium count of 400,000 to 600,000 with British 
standard VZV antibody (NIBSC, South Mimms, United Kingdom) at a 
concentration of 50mIU/mL. DELFIA (Dissociation-Enhanced Lanthanide 
Fluorescent Immunoassay) microtiter plates (Perkin Elmer, Cambridge, 
United Kingdom) were coated with antigen at concentrations of 1.0 to 
2.0g/mL (depending on batch) prepared in 0.05M carbonate/bicarbonate 
buffer, pH 9.6. The plates were stored overnight at 4°C and washed four 
times with DELFIA wash buffer (Perkin Elmer, United Kingdom) using a 
DELFIA plate washer (Perkin Elmer, United Kingdom). Sera for testing 
were diluted 1 in 50 in DELFIA assay buffer (Perkin Elmer, United 
Kingdom), and 100L was loaded into appropriate wells. A standard curve 
was run on each plate, prepared from British standard VZV antibody 
diluted in DELFIA assay buffer at concentrations ranging from 50mIU/mL 
to 0.39mIU/mL. The plates were sealed and incubated in a humid chamber 
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for 2h at 37°C and then washed four times, as before. Europium labeled 
anti-human IgG conjugate (Perkin Elmer, United Kingdom) diluted 1 in 500 
in DELFIA assay buffer was added at 100l per well using a multichannel 
pipette. The plates were then incubated for 1h at 37°C and washed four 
times, as before, and 150L DELFIA enhancement solution (Perkin Elmer, 
United Kingdom) was added to all wells. Following 15min of rotating 
incubation at room temperature, in the dark, the plates were read using a 
DELFIA 1234 reader (Perkin Elmer, United Kingdom), and data were 
analyzed using Multicalc software, version 2000 (Wallac Oy, Finland). 
Interpolated antibody concentrations were expressed in mIU/mL. With 
thanks to Dr. Chris Maple, HPA, London, for assistance. 
 
2.4.1.2 VZV IgG Avidity (EUROIMMUN) Assay:      
VZV IgG avidity assays were undertaken using the EUROIMMUN (Lubeck, 
Germany) VZV IgG avidity microplate kit assay according to the 
manufacturer‟s instructions.  In brief, patient samples were diluted 1:101 in 
sample buffer and 100L was loaded, in duplicate, into VZV antigen 
coated wells of a 96 well microtitre plate.  Control samples of high and low 
avidity human anti-VZV IgG were included with the kit and run on each 
plate. After incubation for 30min, (RT), the wells were manually washed 
once, with 450L working strength wash buffer. 200L of urea solution 
was added to one set of sample wells and PBS to the others and the plate 
left at RT for 10min.  The plate was then washed three times and 
horseradish peroxidise-labelled rabbit anti-human IgG added and the plate 
incubated at RT for 30min. Following x3 washes, 100L of 
chromogen/substrate (tetramethylbenzidine/ hydrogen peroxide) solution 
was added and the plate incubated for 15min at RT in the dark.  The 
reaction was stopped by the addition of stop solution (0.5M sulphuric acid) 
to each well and after gentle shaking the plate read at 450nm (reference 
620nm) using a Multiskan Ascent microplate photometer  (Thermo 
Fisher Scientific, USA). The VZV IgG relative avidity index (RAI) of 
samples was calculated by dividing the extinction of the sample with urea 
treatment by the extinction of the sample without urea treatment and 
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expressed as a percentage.  According to the manufacturer RAI <40% 
indicates low avidity antibodies, RAI 40% - 60% values are equivocal and 
RAI >60% represents high avidity antibodies. Samples with VZV specific 
IgG levels below OD: <0.150 after incubation with urea treatment were 
excluded from analyses.  
 
 
 
Figure 2.1 Schematic of TRFIA Reaction. In the final stages of the assay 
an enhancement solution is added which contains a Europium ligand. This 
causes the Europium bound to IgG to dissociate.  Subsequent excitement 
by UV light causes the Europium-ligand complexes to fluorescence. The 
half life of this fluorescence is of the order of several hundredths of a 
micro-second compared to the background fluorescence which is of the 
order of nanoseconds. Once background fluorescence has decayed, a 
time resolved fluorimeter measures the fluorescence of the Europium-
ligand complex, enabling highly sensitive detection. 
 
2.4.2 SDS-PAGE and Western Blotting: 
NuPage LDS 4x Sample Buffer, containing 5% (v/v) -Mercaptoethanol 
(Sigma, UK) was added to the lysates at a ratio of 1:3 and heated at 70°C 
for 10min. Uninfected vero cell lysate and VZV-infected vero cell lysate 
(both Advanced Biotechnologies Inc., USA), were used at concentration of 
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7g/well. 1l/well of MagicMark XP western standard (Invitrogen, UK), 
diluted 1/10 in LDS buffer and 5l/well of Precision plus protein standard 
(Bio-Rad) were used as markers in all gels, to define protein band size. 
Samples and markers were loaded onto a NuPage 10% Bis-Tris SDS 
gel (Invitrogen, UK) and run in a X-Cell Sure Lock Novex Mini Cell 
(Invitrogen) at 200 volts (constant);  (300mAmps), for 50 min in NuPage 
MOPS SDS running buffer, which had 0.25% v/v NuPage Antioxidant 
(Invitrogen) added just prior to electrophoresis. After separation on the gel, 
proteins were transferred to Immobilon-P PVDF Transfer membrane 
0.45m (Millipore) using an X-Cell Sure Lock Novex Mini Cell transfer 
device (Invitrogen). Transfer was performed in NuPage transfer buffer 
(Invitrogen) and a current of 30 volts (constant), (300mAmps) applied for 
1h. Following transfer the membrane was washed in blocking buffer (PBS; 
(Gibco) containing 0.05% v/v Tween 20 and 5% w/v dried skimmed milk 
powder) for 1h at RT or overnight at 4oC, under constant agitation. The 
membranes were then incubated with either a commercial mouse 
monoclonal antibody mixture, containing antibodies specific for seven VZV 
epitopes (Acris Antibodies, Germany), (2mg/mL; see individual results for 
dilution), see chapter 3, section 3.3.5 for protein sizes), or ROVE sera 
diluted in 5% blocking buffer; (see individual results for dilutions), for 1h at 
RT, under constant agitation. Membranes were then then washed 3 times 
for 15min in wash buffer (PBS containing 0.05% v/v Tween 20). After 
washing, the appropriate secondary antibody diluted in 5% blocking buffer; 
(see individual results for dilutions), was applied and incubated with the 
membrane for 1h at RT. The membrane was then washed three times for 
15min in wash buffer and drip-dried.  The membrane was then incubated 
for between 1-5min at RT in ECL advanceTM (Amersham GE Healthcare 
UK). The membrane was again drip-dried and covered with saran wrap 
and placed in a Kodak cassette prior to exposure to HyperfilmTM 
(Amersham GE Healthcare UK).   
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2.4.2.1 Coomassie Staining:  
Following SDS-PAGE, NuPage 10% Bis-Tris SDS gels (Invitrogen, UK) 
were stained in 40mLs/gel of EZBlue Brilliant blue gel saining reagent 
(Sigma, UK), overnight at RT under constant agitation. The following day 
gels were washed x3 in distilled water for up to 1h. Images were then 
visualised on a G:Box gel documentation machine (Synegene, UK), 
using GeneSnap acquisition software (Synegene, UK).  
 
2.4.2.2 Bradford Assay: 
Assays were carried out following the manufactures instructions using 
„Quick Start Bradford Dye Reagent‟ (Bio-Rad, USA). BSA (Sigma, UK) 
was used as a standard and (two fold serial dilutions in PBS), starting at 
concentration of 4mg/mL. Standards and „test proteins‟ were assayed in 
triplicate. Assays were read on a Versamax tunable microplate reader 
(Molecular Devices, USA), and standard curves were plotted using Excel, 
(Microsoft 2003, Reading, UK). 
 
2.4.3 Fluorescent Antibody to Membrane Antigen (FAMA) Technique: 
The FAMA assays were performed in the laboratory of Professor Anne 
Gershon according to the method described (Williams et al., 1974). 
Incubations were carried out for 30min at RT in a humidifying chamber. 
48h post-VZV infection, (90% CPE) 25L of unfixed live human embryonic 
lung cells (at a concentration of approximately 1x105 cells/mL) were 
incubated as specified above with 25L of ROVE sera in 96-well u-
bottomed polyvinylchloride plates (Dynex Technologies, USA). Samples 
were diluted in Minimal essential (Earle‟s) medium, (Invitrogen) and 
ranged from 1:2 to 1:128 for each sample. Positive and negative controls 
consisted of sera from a seropositive lab donor and PBS respectively. 
Following x3 washes in PBS, 25L of Fluorescein-conjugated goat anti–
human IgG (Kirkegaard & Perry Laboratories, USA), diluted 1:10 was 
added and incubated as specified above.  Cells were then washed, 
mounted on slides, and examined by fluorescence microscopy (Lietz 
Ortholux) in a blinded fashion. The end-point titre was the highest dilution 
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that yielded a positive response. There were no positive cells when serum 
from a susceptible person was tested. Fluorescence at a 1:2 dilution of 
test serum and higher was considered positive. With thanks to Sharon 
Steinberg, Columbia University, USA. 
 
2.5 Cell Based Assays: 
2.5.1 IFN- ELISPOT: 
2.5.1.1 Ex vivo Overnight Stimulation on ROVE HCW PBMCs Using 
Whole VZV Lysate as Antigen:  
Human IFN- ELISPOT plates were purchased from BD (UK) and the 
assay was carried out according to manufacturer‟s instructions. Briefly, 
coating (capture) antibody was diluted (according to the certificate of 
analysis) in coating buffer, and 100L of diluted antibody solution was 
added to each well of an ELISPOT plate, which was stored at 4ºC 
overnight. The coating antibody was discarded and wells were washed 
with 200L/well blocking solution. This was discarded and a further 
200L/well blocking solution was added and incubated for 2h at RT.  
 
The blocking solution was discarded and 100L/well of either media alone,  
uninfected vero cell lysate (20g/mL) (Advanced Biotechnologies Inc., 
USA); (negative controls), PHA (5g/mL) (Sigma, UK) (positive control) or 
VZV lysate (20g/mL) (Advanced Biotechnologies Inc., USA) was added 
to triplicate wells/study sample. PBMCs were resuspended as detailed in 
section 2.3.8, diluted to (2x106/mL) and stored on ice for a maximum of 
30min prior to 100L being added to each well (2x105/well), to each assay 
condition, in triplicate. Cells were stored on ice to help minimize cell 
aggregation.  The plate was incubated overnight (16h) at 37ºC, in a 5% 
CO2, humidified incubator. When more than one plate was assayed, plates 
were placed individually on incubator shelves, and not stacked, to allow 
even distribution of heat. Cell culture stages of the ELISPOT were carried 
out under aseptic conditions in a class-II Trimat hood.  
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Following overnight incubation, the cell suspension was then aspirated, 
and wells were washed twice with distilled water.  The wells were allowed 
to soak for 5min at each wash step. This was to lyse and remove any 
remaining cells. The wells were then further washed 3x with 200L/well 
wash buffer I. Detection antibody was then diluted in dilution buffer 
according to the certificate of analysis and added at 100L per well.  The 
plate was incubated for 2h at RT. Detection antibody solution was 
discarded and wells were washed x3 with 200L/well wash buffer I. Wells 
were allowed to soak for 2min at each wash step.  Enzyme Conjugate 
(Streptavidin-HRP) was then diluted in dilution buffer according to the 
certificate of analysis. 100L/well diluted enzyme reagent was added and 
incubated for 1h at RT. The enzyme conjugate solution was discarded and 
wells were washed x4 with 200L/well wash buffer I and allowed to soak 
for 2min at each wash step. Wells were then washed twice with 200L/well 
wash buffer II.  100L of Final Substrate Solution was added to each well.  
 
Spot development was monitored for 1h, and substrate reaction was 
stopped by washing wells with distilled water. The plate was air-dried at 
RT overnight until completely dry. Plates were stored in a sealed plastic 
bag in the dark, until analysis was perforrmed using an automated 
ELISPOT plate reader (Biosystem 5000, BioSys, Germany). The number 
of spot forming units/106 PMBCs was calculated by subtracting the total 
number of spots seen in all negative control wells (if any), from the total 
number of spots in the VZV-stimulated well. The mean of the triplicate 
wells was calculated and presented as the number of SFU/106PBMCs. 
Study participants were classified as having a positive VZV-specific IFN- 
response if the number of SFUs in the VZV lysate stimulated wells was 
greater than the (mean+3SD) of all the negative control wells combined.  
 
2.5.1.2 Assessing PBMC Aggregation at Various Incubation Temperatures 
for ELISPOT Optimisation:  
PBMCs from a healthy donor which had been stored in liquid nitrogen for 
the same period of time as many of the earlier ROVE study time points 
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were thawed rapidly and counted using a disposable counting slide. The 
cells were resuspended in 6mL RPMI and mixed thoroughly by pipetting 
up and down five times. The homogeneous cell suspension was split into 
three equal volumes (comparable to the volumes of which cells would be 
resuspended for use during ELISPOT assays) and incubated at either at 
4oC (on ice), RT and 37oC (5% CO2), for 1h. Cells were then recounted.  
 
2.5.2 DRB1*1501 Specific Peptide Stimulation of PBMCs; T Cell Lines: 
The following assay was carried out under aseptic conditions in a class-II 
Trimat hood. PBMCs were thawed as described previously (section 2.3.8) 
and resuspended cells were seeded in a 24 well plate (Nunc, UK) at 
4x106/well in 2mL complete RPMI 1640 medium. Peptides were added at 
a final concentration of 4g/mL. The plate was then incubated at 37oC in a 
humid incubator, 5% CO2. The PBMCs were fed on day 3 and day 7 by 
carefully removing 1mL of media from each well and replacing with 1mL of 
complete RPMI containing 200IU/mL IL-2 (Sigma, UK). Plates were 
examined under the microscope daily and flow cytometry analysis was 
carried out on day 10.  
 
2.5.3 Flow Cytometry Analysis: 
2.5.3.1 Flow Cytometry Analysis of DRB1*1501 Tetramer and Surface 
Staining on ROVE PBMCs: 
DRB1*1501+ ROVE PBMCs were resuscitated as specified in section 
2.3.8 and the cell pellet was resuspended in 1mL of RPMI and split 
between FACs tubes (100L for compensation tubes, 300L for tetramer 
staining). Cells were repelleted by centrifuging at 1,500rpm (350g) for 
5min at RT. The supernatant was discarded and in the dark, 2L of either 
gE (TSPLLRYAAWTGGLA) or IE63 (QRAIERYAGAETAEY) tetramer 
(Beckman Coulter, iTAg MHC Class II Human SAPE DRB1501/PE) was 
added to each sample and incubated for 1h at 37oC (5% CO2)  in the dark. 
Each sample was then washed with 1mL of PBS (Gibco, UK) and 
centrifuged at 1,500rpm (350g) for 5min at RT. Surface staining was then 
carried out by adding the quantity of fluorochrome conjugated antibody 
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specified in table 2.2 and incubating for 20min at RT in the dark. Each 
sample was then washed and resuspended in 300L of 0.5% PFA (Sigma, 
UK). Samples were stored at 4oC overnight in the dark. 
 
Samples were analysed the following day on a Cyan ADP (Dako) and 
were first gated according to size and granularity (forward and side 
scatter) to select lymphocytes. This was then gated further on live T 
lymphocytes, (viaprobe/7AAD, CD14 and CD19 antibody negative 
staining). This population was then plotted by CD4 and tetramer positivity.  
Unstained cells and fluorochrome compensation tubes were used for each 
run. Data was analysed using Flow Jo (version 8.1.1 Ashland, Oregon, 
USA). 
 
Specificity Amount 
Flourochrome 
conjugate 
Manufacturer 
7 AAD 2L PerCP eBioscience 
CCR4 2L PE-Cy 7 BD Pharmigen 
CCR6 2L FITC R and D 
CCR7 2L PE-Cy7 BD 
CD14 2L PerCP BD Biosciences 
CD19 2L PerCP BD Biosciences 
CD27 2L FITC BD Pharmigen 
CD28 2L APC BD Biosciences 
CD3 2L FITC BD Pharmigen 
CD3 2L PerCP BD Biosciences 
CD3 2L APC BD Pharmigen 
CD4 1L P‟Blue Biolegend 
CD4 2L PerCP BD 
CD4 2L PE BD 
CD45R0 2L APC BD 
CD62L 2L APC BD 
CLA 2L FITC BD 
Viaprobe 5L PerCP BD Biosciences 
 
Table 2.2: Antibodies Used for Surface Staining of PBMCs Prior to Flow Cytometry 
Analysis. Key: 7AAD: 7-amino-actinomycin D (viability stain); CCR; CC Chemokine 
receptor, CD; cluster of differentiation, CLA; Cutaneous lymphocyte  associated, antigen 
(skin homing marker), viaprobe; 7-amino-actinomycin D (viability stain), PerCP; Peridinin 
chlorophyll protein; PE: Phycoerythrin; Cy; Cyanin, FITC; Fluorescein isothiocyanate, 
APC; Allophycocyanin, P‟Blue; Pacific blue. NB: commonly expressed PBMC markers 
(CD3 or CD4) were used for compensation staining.  
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2.6 PCR Based Assays: 
2.6.1 PCR on Vaccine Associated Rash DNA: 
A VZV-vaccine specific PCR was carried using the VZV reference 
laboratory methodology, (with thanks to Mr Gavin Wall), on DNA extracted 
from the vesicles taken from ROVE 1052, three days after the onset of 
rash. 
 
2.7 Statistical Analysis: 
2.7.1 Mixture Modelling: 
Following log10 transformation, mixture modelling was performed in Excel 
(Microsoft 2003, Reading, UK)) using the solver function to fit two normal 
distributions to the data by maximum likelihood. A proportion (p) were 
assumed to be part of low or negative distribution with mean (m1) and 
standard deviation (SD1) and a proportion (1-p) to be part of a positive 
distribution with mean (m2) and standard deviation (SD2). Using the fitted 
distributions, the sensitivity and specificity of different cut-offs could be 
estimated based on the proportions of the two distributions, above (or 
below) the cut-off. 
 
After allocating samples as negative or positive based on the post 
vaccination avidity the mean and SD (log10 scale) was calculated and the 
sensitivity and specificity of different cut-offs calculated using the observed 
proportions that were assigned as negative and positive that were above 
and below the cut-off. 
 
2.7.2 ROC Analysis: 
ROC analysis was performed using Minitab Inc. (2006, Pennsylvania, 
USA). The „gold standard‟ was taken as avidity six weeks (visit 2), with 
≤40% being negative and ≥60% being positive. Samples in between these 
cut-offs (n=3); and individuals with missing values for either six week 
avidity or baseline TRFIA were removed from analysis (n=9); thus ROC 
analysis was carried out using 98 samples. The diagnostic test to be 
considered was log10 TRFIA values at baseline, with the relevant cut-off (< 
cut-off being negative, ≥ cut-off being positive). Cut-offs were applied in 
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log10 0.02 increments from a value of 1.18 up to 4.8, covering the entire 
range of the data. 
 
2.7.3 Calculating the Accuracy of Serological Assays: 
Serological assay parameters were calculated using the following 
formulas: 
  
Reference Assay 
Positive Negative 
„T
e
s
t' 
A
s
s
a
y
 Positive TP FP 
Negative FN TN 
 
Key:   Positive assay reading: TP = true positive  FP = false positive 
Negative assay reading:  FN = false negative TN = true negative 
 Sensitivity = TP/(TP+FN)                            
 Specificity = TN/(TN+FP)                           
 Positive predictive value = TP/(TP+FP)           
 Negative predictive value = TN/(TN+FN)           
 
2.7.4 All Other Statistical Analysis: 
All other analysis was carried out in SPSS (version 15, Chicago; Illinois, 
USA). All p-values were generated by independent 2 tailed t-tests unless 
otherwise stated.  Standard deviations were calculated in Excel, (Microsoft 
XP, Reading, UK). 
 
Fisher‟s exact test was carried out at the following website: 
http://www.langsrud.com/fisher.htm 
Chi squared tests were carried out at the following website: 
http://www.quantpsy.org (Preacher, 2001).  
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  CHAPTER 3: HUMORAL IMMUNE RESPONSES TO VACCINATION 
 
Chapter Summary: 
In this study I have examined the antibody responses of a cohort of 
healthcare workers (HCWs) immunised with the Oka vaccine.  The 
relationship between post immunisation antibody titres and avidity was 
used to evaluate how accurately a new in-house enzyme immunoassay 
was able to discriminate those who were truly non-immune at enrolment 
(true negatives). Further characterisation of the nature of the humoral 
immune response was used to identify groups of subjects, including those 
who may be at risk of waning immunity. The role of ethnicity in the 
magnitude of humoral immune responses to natural infection was also 
investigated.  
 
3.1 INTRODUCTION: 
3.1.1 Antibody Structure and Function:  
Unlike the innate response, the adaptive immune response is highly 
specific and has the ability to improve with each successive exposure. 
Adaptive immune responses are mediated by T and B cells, the latter of 
which produce antibodies (Murphy et al., 2008). Antibodies are B cell 
receptors secreted by terminally differentiated B cells known as plasma 
cells.  
 
3.1.1.1 Antibody Structure and Primary Diversification of Antibody 
Repertoire: 
Antibodies are Y-shaped molecules consisting of three equally sized 
portions which are bound by a flexible tether (see figure 3.1). Antibodies 
are constructed from paired heavy (50kDa) and light (25kDa) polypeptide 
chains, bound by non-covalent and disulphide bonds. The two arms of the 
Y (F‟ab fragment) contain the variable (V) region of the antibody, which 
varies between different antibody molecules. The antigen binding sites are 
found at the tips of the Y and are identical on each arm. The antigen 
specificity of the antigen binding site is determined by complementarity-
determining regions (CDRs), three of which are found in each of the heavy 
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and light chains of the variable region. It is the combination of the CDRs 
from both regions that contribute to the antigen binding site and thus 
determine the antigen specificity. The antigen binds via interactions with 
amino acids within the CDRs. The stem of the Y (Fc fragment) is 
composed solely of the constant (C) region which is considerably less 
variable and interacts with effector cells.  
 
 
Figure 3.1: Structure of Immunoglobulin. Molecules are composed of 
Heavy and Light chains, made up of 4 and 2 domains respectively (VH, 
CH1-CH4 and VL, CL), which are bound by a hinge region. Each chain 
contains variable and constant domains and the variable domains of both 
the heavy and light chain contain the antigen binding site.  
 
The variation in the antigenic binding sites of each antibody cannot be 
encoded for in full in the genome, as this would require more genes than 
there are in the entire genome. Instead the variable region is coded for in 
gene segments, which are assembled in the developing lymphocyte by 
somatic DNA recombination to form a complete V sequence. This process 
is called gene rearrangement. For the light chain the V domain is encoded 
by two DNA segments; a variable (V) gene segment and a joining (J) gene 
segment. The joining of the V and J segment creates an exon which 
encodes the whole of the light chain V region. The heavy chain V domain 
is encoded by three gene segments. In addition to a V and J segment, an 
additional diversity (D) gene segment is encoded, which lies between the 
other two segments. The recombination activating genes (RAG) RAG-1 
and RAG-2 which encode the recombinase proteins RAG-1 and RAG-2, 
are essential for catalyzing immunoglobulin gene rearrangement. There 
are actually numerous copies of all gene segments within the germline 
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DNA. Random selection of just one gene segment (of each type) accounts 
for the vast diversity of V domains found in immunoglobulins.   
 
3.1.1.2 Secondary Diversification of the Antibody Repertoire: 
When the B cell receptor of a naïve B cell encounters the appropriate 
antigen, this results in the upregulation of specific chemokine receptors, 
causing the B cell to migrate to the T-cell-rich area (known as the T-cell 
zone) of lymphoid tissues. In the T cell zone, B cells become fully 
activated as a result of their interaction with CD4+ T helper cells and 
antigen presenting cells.  
 
The secondary phase of antibody diversification occurs in activated B cells 
and includes antibody class (isotype) switching and affinity maturation via 
somatic hypermutation (SHM); (discussed in more detail in section 
3.1.1.2.1). These processes take place in highly specialized and dynamic 
microenvironments known as germinal centres (GC). During T-cell-
dependent antibody responses to exogenous antigen, GCs are formed by 
proliferating B cells in the follicles of peripheral lymphoid tissues (such as 
the tonsils, the spleen, lymph nodes and Peyer‟s patches), (see figure 3.2 
for a schematic of a GC in the context of a lymph node).  The formation of 
GCs and the processes which occur inside of them are yet to be fully 
elucidated (Elgueta et al., 2009). However it is know that the formation of 
these structures requires the interaction of co-stimulatory B cell surface 
receptors with ligands expressed by T cells; specifically CD40, (expressed 
by all B cells), and its ligand CD154 expressed by helper T cells. CD40 
signalling of B cells promotes GC formation; survival of GC-B cells; 
secondary diversification of the antibody repertoire and the formation of 
long-lived plasma cells and memory B cells (Elgueta et al., 2009).   
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Figure 3.2: Schematic Representation of a Germinal Centre, and its 
Location within the Lymph Node. Note; Helper T cells (TFH) play a role in 
antibody class switching and affinity maturation. Centroblasts are 
proliferating B cells which express CXCR4 and undergo SHM; centrocytes 
are non-dividing B cells which express CXCR5. A primary follicle is a 
structure composed of resting B cells within a network of FDCs. Within 
primary follicles, GC-precursor B cells start to rapidly proliferate and push 
the resting B cells aside to form the mantle zone around the GC, creating 
a structure known as the secondary follicle.  Murphy et al., 2008; reprinted 
with permission. 
 
GCs contain many cell types including macrophages, follicular dendritic 
cells (FDCs) and a subset of recently characterised CD4+ T cells known as 
follicular helper T cells (TFH), (King et al., 2008; Elgueta et al., 2009).  
These cells are the true helper cells for antibody responses and have 
recently been shown to be the dominant source of IL-4 (which is crucial for 
antibody class switching), within the lymph node (King et al., 2009b). They 
are distinguishable from other CD4+ T helper subsets due to their 
expression of the chemokine receptor CXCR5 and the costimulatory 
molecule ICOS (Inducible costimulator), along with the production of the 
cytokine IL-21, and the chemokine CXCL13. In addition these cells are 
classified by their migration to B cell follicles and their function in B cell 
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help (King et al., 2008). CXCR5 promotes the co-localization of T and B 
cells in lymphoid follicles, through recognition of its ligand, the chemokine 
CXCL13, which is also produced by FDCs. The cytokine IL-21 is one of 
the most important stimulators of B cell differentiation, proliferation and 
class switching. ICOS engaging with its ligand (ICOS-L; located on B 
cells), induces the production of helper cytokines such as IL-4, (see 
section 3.1.1.2.2 for details of class switching), (King et al., 2008).  
 
After initial contact with antigen-experienced DC, antigen-specific effector 
TFH cells migrate to both the follicular regions of lymphoid organs to form 
stable contacts with antigen-primed B cells and also to germinal centres, 
to form stable contacts with GC B cells. Memory B cells are long lived and 
carry antibody genes that have undergone somatic hypermutation in 
response to antigen encounter. Memory B cells can participate in 
secondary immune responses by developing into plasma cells or returning 
to the germinal centre for further clonal expansion and refinement of 
antibody affinity.  Memory TFH cells persist within the priming environment 
to regulate the antigen-specific memory B cell response to re-challenge 
(King et al., 2008).  
 
Within GCs, cells are organized into two major zones; the dark and light 
zones. In the classical model, the dark zone contains centroblasts, which 
are large, rapidly proliferating B cells which undergo SHM of their antibody 
variable region genes (discussed in section 3.1.1.2.1). Centroblasts are 
suggested to give rise to smaller non-proliferating centrocytes, which 
(along with follicular dendritic cells; FDCs), populate the light zone. FDCs 
are stromal cells with the ability to capture large amounts of antigen in the 
form of immune complexes (antigen:antibody:complement). Immune 
complexes are not internalised by FDCs but remain on the surface of the 
cell in highly ordered units termed iccosomes, where they can be 
recognised by B cell receptors, (Murphy et al., 2008).  
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3.1.1.2.1 Affinity Maturation of Antibodies: 
Somatic hypermutation (SHM) is a process that introduces single 
nucleotide substitutions (point mutations) throughout the rearranged V 
region exon at a very high rate. This process is initiated by an enzyme 
(activation-induced deaminase; AID), which is only expressed in activated 
B cells and results in mutant B cell receptors expression on the surface of 
the B cell. All four bases can be targeted for mutation, and in humans C:G 
pairs and A:T pairs are targeted with approximately equal frequency. AID 
catalyzes targeted deamination of deoxycytidine residues in DNA (and 
also underpins isotype class switching). Deamination changes 
deoxycytidine into deoxyuridine and consequently transforms C:G pairs 
into U:G mispairs.  This can ultimately lead to base excision via base-
excision repair enzymes, introducing a single-strand nick in the DNA at the 
site of the original cytosine, (Murphy et al., 2008).  
 
Some mutant B cell receptors bind antigen with higher affinity than the 
original clone. In the GC, B cell clones (centrocytes) compete with each 
other for interaction with antigen on FDCs and T cell help, (Fazilleau et al., 
2009).  This results in a selective, positive expansion of B cells which have 
surface immunoglobulin that binds antigen with higher affinity and it is 
these clones that are selected to differentiate into antibody secreting 
plasma cells. This process is known as antibody affinity maturation. 
Follicular helper T (TFH) cells are now recognized as the class of helper T 
cells that regulate this process, (McHeyzer-Williams et al., 2009). 
Following contact with antigen-experienced DC, antigen-specific effector 
TFH cells migrate to the appropriate area of the lymphoid organs to form 
stable contacts with both antigen-primed B cells and GC B cells. The 
strength of antigen receptor binding and duration of cellular contact with 
TFH cells is now thought to play a role in the differentiation and survival of 
B cell clones (and memory B cells), (McHeyzer-Williams et al., 2009).  
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3.1.1.2.2 Antibody Class Switching: 
The isotype or class of an antibody is determined by the structure of its 
heavy chain, and thus the Fc fragment and hinge region of each isotype of 
antibody differs. There are five main heavy chain isotypes, denoted by 
lower case Greek letters. The corresponding immunoglobulins are known 
as IgA, IgD, IgE, IgG and IgM. Thus, it is the class of the heavy chain that 
determines the functional properties of the antibody. Different heavy 
chains are produced in a given clone of B cell by linking different heavy 
chain regions (CH) to the rearranged VH gene. During the course of an 
antibody response the activated B cells can switch the expression of CH 
genes by a type of somatic mutation known as class switching.  
 
3.1.1.3. Sources of Antibody Following Primary Antigen Challenge: 
Ultimately, B cells can either differentiate into plasma cells that survive in 
the bone marrow, and continuously secrete antibody or into memory cells 
that can subsequently differentiate into plasma cells upon secondary 
antigenic challenge. Long-lived plasma cells are germinal centre–
experienced cells that survive for months to years in the absence of 
antigen or cell division. The survival of long lived plasma cells is not fully 
understood, but the bone marrow is an environment which provides 
survival signals to these cells, (Wrammet and Ahmed, 2008). 
 
3.1.1.4 Kinetics of Antibody Responses:  
A primary response occurs the first time an individual is exposed to an 
antigen; a secondary response occurs upon subsequent exposure to that 
antigen. Following a primary antigenic challenge there is an initial lag 
phase when no antibody can be detected. This is followed by phases in 
which the antibody titre rises logarithmically to a plateau and finally 
declines again as the antibodies are naturally catabolised or bind to the 
antigen and are cleared from circulation. The secondary response has a 
shorter lag phase and an extended plateau and decline. The plateau in a 
secondary response is typically 10 times greater than in primary response 
(Murphy, 2006).  Primary antibody responses are mediated by IgM and as 
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the immune response continues (and if a secondary response is induced) 
a class and subclass switch in the antibodies produced occurs.  
 
3.1.1.5 Biological Functions of Antibodies: 
IgA, IgG and IgM antibodies have diverse biological activity, (mediated by 
their Fc region), comprising of complement fixation, opsonisation, 
neutralisation and antibody dependent cellular cytotoxicity (ADCC).  The 
Fc fragment of an antibody can bind to Fc receptors (FcRs) expressed on 
various cell types; specifically FcRs bind to IgG antibodies, whilst FcRs 
bind to IgA antibodies and so on. There are three isoforms of FcRs; FcRI 
(CD64), FcRII (CD32) and FcRIII (CD16) which bind with differing 
affinities. Various combinations of these receptors are expressed by a 
range of cells including neutrophils, monocytes and macrophages, NK 
cells, platelets, eosinophils, basophils mast cells and B cells (Gessner et 
al., 1998).  The biological consequences of activating Fc receptors depend 
on the cell type which expresses them. For example, NK cells express 
FcRIII (CD16), which plays a crucial role in antibody dependent cellular 
cytotoxicity (ADCC). This is a process whereby target cells are coated in 
antibody and NK cells are subsequently able to bind to this coating IgG 
antibody via their FcRs. Upon binding, the NK cells degranulate releasing 
perforin and granzymes, which cause the target cell to lyse. During ADCC 
the virus does not need to be phagocytosed to be destroyed.  
 
Neutralizing antibodies exhibit their biological effect by inhibiting viral 
infectivity. This is achieved by antibodies binding to the viral surface 
structures that interact with the cellular receptors involved in viral entry.  
Opsonising antibodies bind to pathogens and facilitate their destruction by 
phagocytic cells. For instance, the F‟ab portion of an opsonising antibody 
binds to the viral antigen, whilst the Fc portion of the antibody binds to an 
FcR on the phagocyte, enabling phagocytosis. Complement activating 
antibodies bind to a target and form a receptor for the first protein of the 
complement system. This can either lead to direct lysis via complement or 
an increase in uptake by phagocytic cells.  
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3.1.1.5.1 Biological Activity of Different Subclasses of IgG: 
IgG is the most abundant immunoglobulin and has several subclasses 
(IgG1, IgG2, IgG3 and IgG4), which are named according to their 
respective abundance in human serum. The half lives of the different 
subclasses vary; IgG3 has a half life of seven days, compared to 21 days 
for the other three subclasses. IgG1 functions are complement fixation, 
neutralisation, opsonisation and ADCC. The IgG3 antibody functions in 
neutralization, opsonisation, and to a lesser extent than IgG1, in ADCC. 
This subclass also has the greatest capacity of all IgG subclasses for 
complement fixation. IgG2 and IgG4 do not activate complement very 
efficiently or bind well to most FcRs and are therefore thought to function 
primarily as neutralising antibodies.  The IgG2 subclass is a major reactant 
to bacterial polysaccharide, and does not act as an opsonin. Likewise, 
IgG4 does not fix complement, participate in ADCC or opsonisation.  
 
3.1.2: Antibodies to VZV: 
The presence of antibodies to VZV in serum has been shown to correlate 
both with a past history of varicella and with protection against subsequent 
infection (Saiman et al., 2001; Williams et al., 1974). During the course of 
varicella IgM antibodies are produced within seven days (Arvin and 
Koropchak, 1980a; Gerna et al., 1979; Van Loon et al., 1992), and have 
been demonstrated to peak during the second week of disease, and then 
progressively decrease in titre until they disappear, usually within two 
months (Gerna et al., 1979).  Primary infection with VZV is also associated 
with production of IgA antibodies within one to five days after onset of 
exanthem and is also usually undetectable by two months post infection 
(Wittek et al., 1983; Van Loon et al., 1992). The roles of these different 
classes of antibodies are discussed in detail in section 3.1.2.2. 
 
During cases of zoster, detection of IgM varies and appears to be 
dependent on the methodology used (Gerna et al., 1979; Namazue et al., 
1986; Arvin and Koropchak, 1980; Van Loon et al., 1992; Doerr et al., 
1987). However IgG and IgA are seen at increased levels compared with 
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those seen during acute varicella (Wittek et al., 1983; Van Loon et al., 
1992; Namazue et al., 1986), and are detectable between one and four 
weeks after onset of zoster, and in some cases are still seen two months 
after the onset of disease (Wittek et al., 1983).  
 
During varicella, IgG, IgM and IgA respond to a range of structural viral 
proteins including capsomers and the viral glycoproteins (Van Loon et al., 
1992; Terada et al., 2002; Bogger-Goren et al., 1984; Arvin and 
Koropchack, 1980; Dubey et al., 1988; Echevarria et al., 1990; Palumbo et 
al., 1984; Schmidt and Gallo, 1984).  Known targets of VZV antibodies are 
discussed in more depth in section 3.1.3. The IgG antibody titres to VZV 
antigens are similar in both acutely and latently infected patients. 
However, in a report where IgM was detected during zoster, antibodies to 
early antigens, membrane antigens and thymidine kinase were detected 
later in zoster than in varicella (Namazue et al., 1986). This suggests that 
the kinetics of antibody responses are different between varicella and 
zoster.  
 
The role of antibodies in these two diseases differs considerably. No 
correlation between VZV-specific antibody titres and the prevention of 
zoster has been demonstrated (Uduman et al., 1975; Brunell et al., 1975), 
but antibodies are known to play an important role in modifying the 
response to varicella. A passive antibody preparation containing VZV IgG 
antibodies (VZIG) which is prepared from high-titre immune human serum 
(Brunell et al., 1975) is used as a post-exposure-prophylactic treatment.  
The preparation is administered to susceptible individuals who have been 
exposed to varicella or zoster and are at risk of serious complications of 
chickenpox (Gershon et al., 1974).   VZIG has been used successfully to 
prevent or modify disease in immunocompromised children, including 
transplant recipients and leukaemia patients (Kavaliotis et al., 1998; 
Pandya et al., 2001; Zaia et al., 1983; Styczynski et al., 2008), otherwise 
healthy adults, including pregnant women (Chapman, 1998; Enders, 1985; 
Enders et al., 1994) and HIV infected individuals (Vafai and Berger, 2001). 
Transplacentally acquired VZV specific IgG antibodies are also known to 
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prevent or modify the severity of varicella during the first six months of life 
(Brunell, 1992).   
 
3.1.2.1 The Role of VZV-Specific Antibodies in the Prevention of Re-
Infection: 
In most individuals, one attack of varicella confers lifelong protection 
against exogenous re-infection and subsequent clinical disease. However, 
despite the presence of detectable serum VZV antibody, clinical and 
subclinical re-infection can occur, as indicated by a rise in antibody titre 
after exposure (Weigle and Grose, 1984). This is particularly common in 
adults who have had varicella but who subsequently have close household 
contact with varicella. A study of 25 immune adults demonstrated that 64% 
of individuals who had had a household exposure experienced a four-fold 
increase in IgG and 70% had significant increases in IgA levels (Arvin et 
al., 1983a).  The first population based surveillance study of the frequency 
of re-infections revealed that 13% of the 1,472 mostly healthy children who 
presented with chickenpox (in California, USA between 1995 and 1999) 
had a previous history of varicella infection (Hall et al., 2002). In a smaller 
study of 21 pregnant women who were exposed to varicella, four 
developed varicella, despite testing seropositive for VZV antibodies prior to 
exposure (Martin et al., 1994).  The largest reported series of cases of 
symptomatic, recurrent varicella due to re-infection included 14 apparently 
immunocompetent children who had intact humoral (and cell mediated) 
immune responses to VZV, each of whom experienced between two and 
five bouts of varicella over a period of years, (Junker et al., 1991). It has 
been suggested that since the magnitude of VZV replication and degree of 
viraemia is reflected in severity of disease expression (Weigle and Grose, 
1984; Malavige et al., 2008b), clinical infection of VZV in individuals who 
have specific humoral (and cell mediated immunity) to VZV may occur if a 
virus load is high enough to overwhelm immune defences (Martin et al., 
1994). In addition, a case report documenting two separate cases of 
zoster (four years apart) within one immunocompetent individual, found 
that in each episode of zoster, a separate genotype of virus was 
reactivated (Taha et al., 2006). A study which examined the avidity of IgG 
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VZV-specifc antibodies (see section 3.1.4 for more details on avidity 
studies) during an outbreak at a geriatric home, also demonstrated that 
one resident who developed varicella (from an index case of zoster), had 
high avidity antibodies during acute infection; signalling existing humoral 
immunity; and therefore re-infection, (Lopez et al., 2008). 
 
3.1.2.2. The Roles of Different Classes and Subclasses of Antibodies 
in VZV Infection: 
3.1.2.2.1 Immunoglobulin G: 
The long lasting humoral immunity to VZV resides in the IgG of the sera 
(Asano et al., 1983; Asano et al., 1985a; Asano et al., 1985b). Following 
primary and recurrent VZV infections IgG1 and IgG3 predominate while 
the occurrence and importance of IgG2 and IgG4 subclasses in the serum 
is reported to differ (Doerr et al., 1987, Sundqvist et al., 1984, Asano et al., 
1987). IgG3 is indicative of recent infection or reactivation of VZV (Doerr et 
al., 1987) and IgG3 levels have been shown to be related to recovery from 
VZV and fall dramatically during convalescence (Asano et al., 1987).  A 
study by Echevarria (et al., 1990) confirmed the dominance of the IgG1 
and IgG3 antibodies in both primary and recurrent VZV infections, and 
Leonard (et al., 1970) demonstrated the presence of IgG1 antibodies in 
the case of natural VZV infection. Doerr‟s study concluded that IgG2 
antibodies are of no significance for humoral immune responses after VZV 
infection, and Leonard‟s study found that IgG4 had very little neutralizing 
activity against the virus.  In contrast to the findings of Doerr and Leonard, 
Echevarria (et al., 1990), found an IgG2 response in a significant number 
of zoster patients, along with IgG4 responses in nearly all zoster cases, 
and 45% of varicella cases.  
 
Only IgG crosses the placenta (IgA, IgD, IgE and IgM are excluded), 
(Kohler and Farr, 1966).  Infants under six months of age may acquire 
varicella more frequently than other viral infections such as measles, 
leading to the suggestion that the VZV antibody transfer across the 
placenta does not provide complete protection against the disease. Thus; 
the subclasses of IgG that are transferred, may shed light onto the role of 
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each subclass in VZV infection. In a study of 46 mothers who were 
seropositive for VZV, all transferred IgG1 antibodies to their infants (Asano 
et al., 1988). In contrast to Doerr‟s findings all of the mothers tested 
positive for VZV-specific IgG4, but all had no, or very low antibody activity 
in IgG2 and IgG3. As IgG2 is not predicted to be protective against VZV 
and IgG3 antibody levels fall rapidly after the initial infection (Asano et al., 
1988) this finding is somewhat expected, but IgG4 is usually present in 
very low concentrations in serum.  
 
3.1.2.2.2 Immunoglobulin A: 
Production of secretory-IgA (s-IgA) is induced in various mucosal surfaces 
including nasal-pharyngeal associated lymphoid tissue and bronchus-
associated lymphoid tissue, upon stimulation with antigen and plays an 
important role in preventing viruses from invading the body; by means of 
viral neutralization (Brown, 1996) and can participate in ADCC.   A 
substantial VZV IgA antibody response is elicited during both primary and 
recurrent VZV infections (Bogger-Goren, et al., 1982; Doerr et al., 1987).  
 
With natural infection, virus has been recovered from throat swabs upon 
the onset of disease (Ozaki et al., 1986; Ozaki et al., 1994), but 
vaccination by-passes replication in the regional lymph nodes around the 
nasopharynx because it is subcutaneously injected. Throat swabs from 
vaccinees in the Ozaki‟s 1994 study were negative for VZV DNA. In a 
study by Tereda (et al., 2000), VZV-s-IgA values were significantly higher 
in matched children after natural chicken pox than in those who had 
received the vaccine, although there was not much difference in total IgA. 
Two of the vaccinees in this study lacked s-IgA altogether. The elderly and 
immunocompromised children in the study who had been naturally 
infected had the same level of s-IgA as the naturally infected children. 
Those who had recently had zoster, or were HCWs (in regular contact with 
VZV) had higher levels of s-IgA. Doerr‟s study also confirmed a boost in 
IgA antibodies following zoster. It has been hypothesized that low or no s-
IgA may be a cause of breakthrough (Tereda et al., 2000).  
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3.1.3 Targets of Humoral Immunity to VZV: 
Research into targets of humoral immunity has primarily focused on the 
glycoproteins which play important roles in fusion, entry and spread of the 
virus (see chapter 1, section 1.5 for details). Tegument proteins (IE62 and 
IE63) that invoke good cell mediated immunity and are transcribed early in 
the viral replication process have also been investigated (Arvin et al., 
1986a; Englund et al., 1990, Sadzot Delvaux et al., 1998), whilst during 
zoster antibodies to thymidine kinase have been documented (Kallander 
et al., 1982). Many of the studies examining targets of adaptive humoral 
immunity have been carried out in small animal models (rabbits, guinea 
pigs and mice) or have used monoclonal antibodies raised in these 
models. Some studies have been carried out using human serum, and 
these are noted in the text where relevant. Table 3.1, summaries the VZV 
proteins (and their function) that are known to induce antibody responses. 
Several glycoproteins (gB, gE and gI) have had antibody epitopes 
identified (see figure 3.3 and table 3.2) and are discussed in more detail.  
 
3.1.3.1 Glycoproteins: 
Antibodies against gB are produced following natural infection and 
vaccination (Harper et al., 1990b), and can neutralize virus (Forghani et 
al., 1990b). Both complement dependent (Edson et al., 1985b) and 
complement independent (Edson et al., 1985b) neutralising antibodies 
against gB have been reported in animals.  A study by Giller (et al., 1989b) 
revealed that this protein served as a potent B cell antigen during both 
acute infection and convalescence. A more in depth study by Kjartansdottir 
(et al., 1996) revealed that a 31-mer-peptide corresponding to a 
hydrophilic segment of the gB reacted with 2 out of 4 varicella and 5 out of 
9 zoster sera, respectively (see table 3.2 for epitope details). One of the 
predominant antibody responses in sera from the elderly is to gB (Vafai et 
al., 1988a).   
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Gene Function Reference 
31 Glycoprotein B 
Harper et al., 1990b; Forghani et al., 1990b;  
Edson et al., 1985b*, Vafai et al., 1988a;  
Giller et al., 1989b; Kutinova et al., 2001* 
Kjartansdottir et al., 1996;  
Haumont et al., 1997;  
37 Glycoprotein H 
Nĕmečková et al., 1996*; Akahori et al., 2009; 
Forghani et al., 1990b; Arvin et al., 1986a;  
Harper et al., 1990b; Kutinova et al., 2001*; 
Montalvo and Grose, 1986a; Ito et al., 1993;  
Vafai et al., 1988a 
40 
Major Nuclear 
Capsid Protein 
Weigle and Grose 1984; Vafai et al., 1988a;  
Vafai et al., 1990    
60 
Glycoprotein L  
(in Complex with 
gH) 
Nĕmečková et al., 1996*; Kutinova et al., 2001* 
62 
Transcriptional 
Activator and 
Tegument Protein 
Arvin et al., 1986a; Englund et al., 1990;  
Lowry et al., 1992*;  Forghani et al., 1990a 
63 
Transcriptional 
Activator and 
Tegument Protein 
Sadzot-Delvaux et al., 1997;  
67 Glycoprotein I 
Vafai et al., 1987*; Vafai et al., 1989*;   
Vafai et al., 1988d*; Vafai et al., 1988a;  
Vafai et al., 1991*  
68 Glycoprotein E 
Ludvikova et al., 1991*; Fowler et al., 1995;   
Kutinova et al., 1996*; Kutinova et al., 2001*;  
Vafai et al., 1988d*; Vafai et al., 1988a; 
Vafai et al., 1989*; Vafai et al., 1991*;  
Vafai, 1993*;   Vafai et al., 1987*; Vafai, 1994;  
Vafai, 1995; Harper et al., 1990b;  
Lowry et al., 1992*; Forghani et al., 1990b,  
Arvin et al., 1986a;  Wu and Forghani, 1997;  
Hatfield et al., 1997 
 
Table 3.1: Function of VZV Proteins which Induce Antibody Responses. 
Key: *Study carried out in animal models, or using mAbs raised in animals; 
all other studies were carried out using human sera. 
 
A comparison of the antibody responses to gB after natural VZV infection 
or after vaccination with live attenuated Oka vaccine determined that there 
was the same order of magnitude of antibody responses in sera from 
individuals with a history of varicella and in vaccinated children (Haumont 
et al., 1997). Antibody levels were comparably higher in individuals given 
booster vaccination. The ratio of anti-gE to anti-gB antibody is highly 
variable from one individual to another but relatively stable over a long 
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period of time for a particular individual, even after a zoster episode 
(Haumont et al., 1997). With respect to neutralizating antibodies, anti-gE 
and anti-gB are equally prevalent in vaccinated children and anti-gE is 
generally, but not always, more abundant than anti-gB in VZV infected 
individuals (Haumont et al., 1997). Antibodies to these two glycoproteins 
appear to predominate amongst the neutralizing antibody response to VZV 
antigens (Haumont et al., 1997). This study also suggested that the 
contribution of anti gB-antibodies to neutralisation may be more important 
than those of gE in the case of vaccination.  
 
Glycoprotein 
aa 
Number 
Sequence Reference 
gB 417-447 HSPQKHPTRNTRSRRSVPVELRANRTITTTS 
Kjartansdottir 
et al., 1996 
gI 55-69 LVFIGEQLPTGTNYS 
Vafai et al., 
1988d 
gI 245-259 VKEGIENHVYPTDMS 
Vafai et al., 
1988d 
 
Table 3.2: Known Antibody Epitopes of gB and gI. The gB epitope was 
identified using sera from varicella and zoster patients, whilst the gI 
epitopes were mapped using mouse mAbs. 
 
Anti-gE antibodies have been shown to mediate ADCC (Ito et al., 1985). 
Ludovikova (et al., 1991) and Kutinova (et al., 1996) have shown that 
recombinant vaccinia viruses expressing gE elicit an antibody response in 
mice which is capable of neutralising VZV infectivity in the presence of 
complement. These findings were supported by the findings of Vafai 
(1993), who demonstrated that a purified, truncated version of gE (511 
aas), expressed in a vaccinia virus vector, was capable of inducing 
complement-dependent neutralising antibodies in rabbits. Further work by 
the author in 1994, again using the recombinant vaccinia virus expression 
system identified new epitopes (see figure 3.3 for details) which were 
recognised by antibodies within human serum (Vafai, 1994). The author 
went on to deliver this as a booster vaccine to a seropositive human 
subject, and demonstrated that neutralising antibodies were produced 
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(Vafai, 1995). An increase in gE antibodies was seen as early as six days 
post immunisation and increased over a 40 day period.  
 
Harper et al., (1990) demonstrated that live attenuated Oka vaccination 
also induces gE antibodies, which are abundant after vaccination and 
natural infection (Harper et al., 1990), and can neutralize virus (Forghani et 
al., 1990b, Arvin et al., 1986a). Wu and Forghani, (1997) later 
characterised the neutralising domains of gE by use of a monoclonal 
antibody (mAb) library and plasmid vectors containing either the whole gE, 
the N-terminal (212 aas) or the Carboxy-terminal (160 aas). Monoclonal 
antibodies with high titre complement-dependent neutralising activities 
bound the N-terminal truncated infected cells, whilst non-neutralising 
mAbs stained the C-terminal truncated infected cells. However the 
complement enhanced neutralising mAbs bound both truncated forms 
indicating that they were reacting with the overlapping region of the 
constructs.  
 
Fowler and colleagues (1995) mapped gE epitopes by inserting 
overlapping fragments of the gE gene into Virus Like Particles (VLPs) of a 
yeast expression system, and tested these against seropositive human 
sera. Pepscan analysis was then used to determine the position of the B 
cell linear epitopes, see figure 3.3 for a schematic of all gE epitopes which 
have been mapped. Using sera from mice and guinea pigs immunized with 
gE-VLPs and pepscan analysis, the authors mapped the dominant 
epitopes, listed as epitopes 5-10 in figure 3.3. These sera also showed 
neutralizing activity against VZV in vitro. These authors also mapped the 
epitopes recognized by neutralizing mAbs 3B3 and IFB9 used for 
diagnostics, as residues 141-161 (3B3) and 71-90 (IFB9). Simultaneously, 
Hatfield and colleagues (et al., 1997) mapped the gE 3B3 epitope to 11 
residues (151-161). 
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Naturally occurring VZV escape mutants which are not recognised by the 
gE 3B3 mAb have been identified in north America and Europe.  The first 
to be discovered was VZV-MSP, which arose through a single aa change 
(aspartic acid into an asparagine (D150N)), which abolished the epitope. 
More importantly, this loss resulted in more virulent virus phenotype; 
capable of accelerated cell-to-cell spread in vitro (Santos et al., 2000; 
Santos et al., 1998) and in vivo in skin implants grafted onto the SCID-Hu 
mouse model (Santos, et al., 2000).  The authors went on to suggest that 
the escape mutation arose due to immunological pressure (Padilla and 
Grose, 2001). In 2002, another variant strain of VZV was isolated from an 
elderly man with herpes zoster in Canada (Tipples et al., 2002), and was 
named VZ-BC. It is likely that these gE mutant viruses arose through 
independent mutation as phylogenetically, they were not closely related. A 
third isolate, identified in Sweden, arose through a single aa change at a 
different position (R152S), (Wirgart et al., 2006), supporting the notion that 
each isolate mutated independently.   
 
Vafai et al., 1987 demonstrated that antibodies against gE and gI could 
neutralize VZV infectivity in vitro. Antigenic cross reactivity between gE 
and gI (determined by the binding of a mAb) mapped to residues 109-123 
on gE and within the first 153 residues on gI (Vafai et al., 1989). See table 
3.2 for the sequences of gI epitopes. Residues 107-121 of that epitope 
had a degree of similarity to the epitopes found on gI: residues 55-69 and 
245-259) (Vafai et al., 1988d). A history of zoster in the elderly has been 
demonstrated to correlate significantly with the presence of antibody to gI 
(Vafai et al., 1988a).  
 
Anti-gH antibodies have been shown to mediate ADCC (Ihara et al., 1991). 
Antibodies against gH are produced after natural infection and vaccination 
(Harper et al., 1990b), and can neutralize virus (Forghani et al., 1990b, 
Arvin et al., 1986a; Akahori et al., 2009).  Immunoblotting experiments 
indicated that the conformational neutralisation epitope was located within 
the tertiary structure of this glycoprotein (Montalvo and Grose, 1986a). The 
epitope elicits a complement independent neutralising antibody response 
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(IgG1) of high magnitude (Forghani et al., 1984, Forghani et al., 1982, 
Grose et al., 1983a, Keller et al., 1984), and is still present when the gH:gL 
complex is formed (Forghani et al., 1994). The epitope is highly conserved 
as the structure is recognised within the vaccine strain vOka, wild type 
strains and laboratory strains of VZV. 
 
Competition blocking experiments using mouse monoclonal antibodies 
indicated that four neutralising antibodies were directed against the same 
or closely related epitope on gH indicating that this is an immunodominant 
neutralisation epitope (Montalvo and Grose, 1986a). The authors also 
identified one non-neutralising antibody that reacted with a different 
antigenic site.  More recent experiments using human monoclonal 
antibodies and immunohistochemistry found that the neutralization domain 
of gH comprised of a cluster of seven conformational-neutralization-
epitopes which prevented cell-to-cell infection in vitro (Akahori et al., 
2009).  
 
In a study carried out in mice and guinea pigs using vaccinia virus vectors 
expressing various glycoproteins (Kutinova et al., 2001), immunisations 
with double recombinants rather than single was more effecitive in raising 
gE, gB and gH neutralising antibodies. Indeed, Nĕmečková (et al., 1996) 
showed that anti-gH neutralizing antibodies could not be induced in mice 
unless gH was expressed with gL in the same cell. This data suggests that 
gH either forms a compound epitope with gL or that co-expression of gL is 
a requirement for surface gH expression. 
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Figure 3.3: The Structure of Glycoprotein E and the Position of Known Antibody Epitopes. 
 
Linear epitopes 1-5 were identified by use of VLPs expressing fragments of gE, peptides from the most immunogenic 
fragment, western blotting, ELISA and pepscan analysis, tested against seropositive sera from varicella and zoster 
patients within 4 months of disease (Fowler et al., 1995).  Epitope 1: Recognised by 3/5 zoster and 2/5 chickenpox sera. 
Epitope 2: All varicella sera reacted strongly, but no zoster sera reacted. Epitope 3: One zoster patient reacted very 
strongly, but residues 71-80 of this epitope were recognised by all chickenpox sera but not by any of the zoster sera. A 
neutralizing mouse monoclonal antibody (IFB9) reacted with sequence 71-90. Epitope 4: All varicella and zoster sera 
tested reacted with this epitope. Epitope 5: All varicella sera and 4/5 zoster sera reacted. Epitopes 6-11 were mapped by 
inserting overlapping fragments of the gE gene into Virus Like Particles (VLPs) of a yeast expression system, and tested 
against seropositive human sera. Pepscan analysis was then used to determine the position of the B-cell linear epitopes. 
Dominant epitopes were confirmed using sera from mice and guinea pigs immunized with gE-VLPs.  These sera also 
showed neutralizing activity against VZV in vitro. In addition the epitopes recognized by neutralizing mAbs 3B3 and IFB9 
used for diagnostics, were mapped to residues 141-161 (3B3) and 71-90 (IFB9), (Garcia-Valcarcel et al., 1997). Epitope 
12: recognised by the mAb 3B3 was determined by recombinant PCR mutagenesis and is found at aa 151-161 (Hatfield 
et al., 1997). Epitope 13: Identified by use of mAb, cloned gene products and immunoprecipitation (Vafai et al., 1988). 
Monoclonal antibodies against this epitope also bind to gI within the first 153 aa (Vafai et al., 1988). Note, residues 107-
121 of this epitope have a degree of similarity to the epitopes found on gI: residues 55-69 and 245-259, (Vafai et al., 
1988).  Fragments 14-16 were identified as immunogenic, using human sera, recombinant vaccinia viruses expressing 
truncated parts of gE and immunoprecipitation. These fragments contained epitopes for several mAbs (Vafai et al., 1994).   
 
Key: IDE BD, Insulin Degrading Enzyme Binding Domain (aa 24-71); gI BD, gI Binding Domain (aa 163-208); SP, Signal 
Peptide; TMD, Transmembrane Domain; CPD, Cytoplasmic Domain. 
NB: Epitopes (1 and 7), (5 and 9) are identical. 
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3.1.3.2 Capsid and Tegument Proteins:  
Antibodies to the major nuclear capsid protein (NCP; encoded by ORF40) are 
induced soon after the onset of varicella rash (Weigle and Grose 1984) and 
are consistently present in VZV seropositive individuals throughout life (Vafai 
et al., 1988d).  One of the predominant antibody responses in sera from the 
elderly is to this protein (Vafai et al., 1988d) and mAbs to VZV NCP are cross 
reactive with HSV-1 NCP (Vafai et al., 1990). This may suggest that infection 
with one virus may help to confer humoral immunity to the other.  
 
Arvin (et al., 1986) demonstrated that IgG antibodies to IE62 were detectable 
in human sera from healthy immune donors, and those in the convalescent 
phase of both varicella and zoster. A study of healthy children who were 
naturally infected with VZV demonstrated that antibodies against IE62 were 
detectable at one month and one year post infection (Englund et al., 1990). 
Antibody responses to IE63 (from serum of naturally immune adults with a 
history of chickenpox) have been demonstrated using the protein expressed 
in bacteria and fused to glutathione-S-transferase (GST) as a stimulating 
agent. Although anti-IE63 specific antibodies were demonstrated by Western 
blot analysis banding in the blots was deemed to be weak (Sadzot-Delvaux et 
al., 1997). Whether any of these antibodies are neutralising has not been 
investigated, but based on the fact that neutralising antibodies target viral 
proteins involved in host cell entry, anti-IE63 antibodies would not be 
expected to have a neutralising function.  
 
3.1.4 Avidity Studies: 
Antibody affinity describes the relative strength of interaction between an 
antibody combining site and antigenic determinant. Avidity or functional 
affinity indicates the overall reaction between a population of antibodies and a 
complex antigen (Griswold, 1987). Avidity testing for the differentiation 
between a primary and an enduring antibody response to infectious disease 
was introduced in 1984 when a simple and reliable method was developed by 
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using enzyme-linked immunosorbent assay (ELISA) and a mild protein-
denaturing agent (Inouye et al., 1984).   
 
IgG avidity is low after primary antigenic challenge but increases 
progressively during subsequent weeks and months due to affinity maturation 
and antigen-driven B cell selection. Low avidity IgG antibodies predominate 
early after primary infection, but avidity increases markedly during 
convalescence (Kangro et al., 1991). In cases of recurrent infection high 
avidity antibodies were found to predominate at all times. An interesting 
finding of this study is that changes in antibody avidity are dependent on the 
peptide to which the antibody is raised. Kangro (et al., 1991) found that 
nuclear assembly proteins (p32 and p36, also known as the nucleoprotein 
complex) had consistently lower avidity responses than glycoprotein 
antibodies.   
 
A case in a South African geriatric home of three residents who were believed 
to have developed varicella following exogenous reinfection revealed some 
interesting results about the role of avidity. Serology samples tested one day 
after each patient was admitted to hospital with a disseminated vesicular rash 
revealed that the avidity of the VZV-IgG antibodies was lower than those of 
primary chickenpox controls, which were in turn expectedly lower than those 
of the zoster controls. Elderly individuals‟ susceptibility to varicella reinfection 
may well be associated with the decay of specific humoral immunity and by 
the presence of low avidity antibodies (Schoub et al., 1992). Another study 
was carried out in immunocompetent children who experienced recurrent 
varicella (each patient had had between two and five episodes of varicella), 
but all had comparable VZV cellular immune responses and total antibody 
levels comparable to controls. However the mean antibody avidity was 
significantly lower than in controls (Junker and Tilley 1994).  These patients 
were able to mount high avidity antibodies to CMV and Rubella, and did not 
experience repeat infection with other agents (Junker and Tilley, 1994).   
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3.1.5 Differences in the Magnitude of the Humoral Immune Response to 
Varicella Vaccine: 
3.1.5.1 Genetic Factors: 
The influence of host factors on the magnitude of the humoral response is 
supported by data showing a significantly greater concordance of VZV 
antibody levels following immunisation with Oka vaccine, between siblings 
than between unrelated individuals (Klein et al., 2007).   A heritable effect on 
antibody levels has also been reported following infection with EBV (Yasui et 
al., 2008), as well as following vaccination against MMR (Ovsyannikova et al., 
2006), hepatitis B (Hennig et al., 2008), influenza (Lambkin et al., 2004) and 
Polio (Paul et al., 2009). 
 
3.1.5.2 Age of Infection: 
Studies in vaccinated children have shown high seroconversion rates of 97%, 
(Watson et al., 1990), with seroconversion rates four to six years later of 95-
100%, (Watson et al., 1994; Watson et al., 1995b). Adult studies suggest that 
antibody responses are not retained at such a high rate (Gershon et al., 1988; 
Lugwig et al., 2006; Ampofo et al., 2002, Saiman et al., 2001; Ndumbe et al., 
1985a). In a study of 34 VZV seronegative nurses who were vaccinated with 
Varilrix and followed for periods of up to 36 months, it was revealed that at 5 
and 12 months post vaccination, 94% of the nurses had seroconverted but at 
3 years, only 64% retained antibody seropositivity (Ndumbe et al., 1985b). In 
a separate study of 187 vaccinated adults, although seroconversion rates 
were 94% after two doses of vaccine, 25% were seronegative at follow-up 
(Gershon et al., 1988).   
 
3.1.5.3 Vaccination Versus Natural Infection: 
Studies have indicated that there are differences in the humoral immune 
response induced by vaccination compared to that of naturally induced 
immunity.  A vaccine study (in children) carried out in the 1980s, revealed that 
although natural infection, subcutaneous immunization, and respiratory 
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inhalation of large doses of vaccine consistently resulted in the development 
of VZV-specific IgG antibodies, which persisted for at least eight to 12 months 
(the length of the study) after either form of infection, the mean IgG antibody 
titres were four- to eight-fold higher after natural infection than after 
immunization. As mentioned earlier, natural infection but not VZV vaccine, 
was associated with the development of serum and nasopharyngeal IgA 
responses to VZV in most subjects (Bogger-Goren et al., 1982). 
 
3.1.5.4 Factors Affecting Vaccine Seroconversion Rates: 
Seroconversion is defined as the change of a serological test result from 
negative to positive, indicating the development of antibodies in response to 
natural infection or immunisation. Rates of seroconversion in subjects 
immunized with the Oka vaccine are dependent on viral titre per dose, relative 
antigen content and the number of vaccine doses administered. In short, the 
higher the viral titre, the higher the response. Weibel (Weibel et al., 1984) 
reported that children who were immunized with 435 plaque forming units 
(pfu) developed an antibody response quicker than those who received only 
42pfu. In several studies, the minimal effective dose required for 
seroconversion rates of 95% in healthy children ranged from 200-500pfu 
(Takahashi et al., 1974; Arbeter et al., 1984; Ozaki et al., 1984a; Horiuchi 
1984). Children receiving 2,650 pfu or more had higher geometric mean 
antibody titres (GMTs) six weeks after immunization compared with those 
who received 950pfu (Johnson et al., 1989). A randomised placebo-controlled 
study in over 500 Finnish children vaccinated between the ages of 10 to 30 
months with either a high-titre (10,000-15,850 pfu) or low titre (1,260-630 pfu, 
partially heat-inactivated) vaccine found that the protective efficacy of the live 
attenuated varicella vaccine was dependent on the vaccine titre administered 
(Varis and Veskari, 1996). Although comparable seroconversion rates of 
100% and 99% were initially recorded in children immunized with either 
vaccine the GMT of post-vaccination varicella antibodies was higher in the 
high titre recipients compared to the low titre recipients. In addition at follow-
 157 
 
up (a mean of 29 months post vaccination), incidence of varicella was 
significantly higher (p=0.005) in the low-titre vaccine group (11% n=19/166) 
compared to the high-titre vaccine group (3% n=5/166). The crude efficacy of 
the high titre vaccine was 88% (CI 72-96%) versus 55% (CI 31%-72%) for the 
low titre vaccine. 
 
As well as live replicating vaccine virus, the vaccine preparations also contain 
incomplete virus particles and dead virus, both of which can stimulate an 
immune response. Reducing the amount of live virus from 1,770 to 80-
160pfu, while maintaining the relative antigen content only reduced 
seroconversion rates from 97 to 92% (Watson et al., 1993). When the pfu 
content was maintained at 1,000pfu, and the antigen content was reduced 
from 96 to 87%, antibody titres produced were equivalent, (Bergen et al., 
1990).  
 
The representative viral titre in a single dose of the commercially available 
varicella vaccines is a minimum of 1,350pfus for VARIVAX and a minimum 
of 1,995pfus for VARILRIXTM. Ninety five percent of healthy children 
seroconvert after one vaccine dose (Kuter et al., 1991; White et al., 1991a; 
Takahashi et al., 1974).  
 
Healthy children given two doses of Oka/Merck varicella vaccine 3 months 
apart, have significantly stronger humoral immune responses 1 year later, 
than children given a single dose (Watson et al., 1995a) and adolescents and 
healthy adults require two doses for 99% seroconversion (Kuter et al., 1995). 
Leukaemic children and children with chronic renal insufficiency require two 
doses for 90% and 98% seroconversion respectively (Hardy et al., 1991; 
LaRussa et al., 1996; Furth et al., 2003). A second dose of varicella vaccine 
has been demonstrated to increase seroconversion rates to 99% (Kuter et al., 
2004; Ngai et al., 1996; Reisinger et al., 2006).  
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3.1.6 Antibodies as a Measure of VZV Immunity and Breakthrough 
Infection:  
One of the shortcomings of the current vaccine is the incidence of 
breakthrough varicella. Breakthrough varicella is generally defined as wild 
type varicella occurring in a vaccine recipient 42 days or more after 
vaccination (Sharrar et al., 2000), and this places the sufferer at risk of wild 
type zoster in the future (Takahashi, 2001). Although mild breakthrough is 
less transmissible than wild type varicella, moderate or severe breakthrough 
disease (more than 50 skin lesions) has been found to be as contagious as 
varicella in the unvaccinated controls (Seward et al., 2004). Thus 
breakthrough also represents a transmission risk within the community.   
 
The clinical symptoms of breakthrough varicella are generally considerably 
milder than those of natural infection. The number of lesions is reduced, in 
both adults and children, usually to no more than 50 (Ampofo et al., 2002, 
Ozaki et al., 2000, Sharrar et al., 2000) and in leukaemic children to generally 
<100 (LaRussa et al., 1996), compared to 250-300 normally seen following 
natural disease (Ross et al., 1962). The incidence and severity of fever is also 
reduced (White et al., 1992; Asano and Takahashi 1977; Bernstein et al., 
1993) as is the overall duration of illness (Bernstein et al., 1993).  
 
Protection of immunized individuals from breakthrough varicella infection 
correlates with the level of VZV antibodies six weeks post-vaccination. 
Vaccine efficacy among children with a six-week post-vaccination antibody 
titre of five glycoprotein-based enzyme-linked immunosorbent assay 
(gpELISA) units or greater was 95.5% compared with 83.5% for subjects with 
a titre of <5 gpELISA units. The latter group were 3.5 times more likely to 
develop breakthrough varicella compared to the former group (Li et al., 2002). 
White and colleges made similar observations and reported that the number 
of varicella lesions in these cases tended to decrease as the six-week 
gpELISA titre increased (White et al., 1992). 
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 The most cited risk factors for breakthrough varicella include; three-five-year 
interval since immunization and immunization at the youngest ages, 
especially 12 months (Lee et al., 2001; Tugwell et al., 2004). The data from 
these studies contrast with studies of vaccine efficacy that were initiated prior 
to widespread vaccination against VZV, which in general were not suggestive 
of declining immunity over long-term follow-up. This discrepancy is most likely 
due to the higher levels of exogenous boosting that existed prior to 
widespread vaccination. However, a study reported by Kuter et al., (2004) 
suggests that the administration of a single dose of varicella vaccine to 
children is associated with higher rates of breakthrough varicella over long-
term follow-up than is a two-dose schedule.  
 
A recent study in the United States (Chaves et al., 2007) which examined 10 
years (1995-2004) of active surveillance data from a sentinel population of 
350,000 subjects suggested that vaccine-induced immunity wanes over time, 
a condition that may result in increased susceptibility later in life, when the 
risk of serious complications may be greater than in childhood. Children 
between the ages of eight to 12 years who had been vaccinated at least five 
years previously and developed breakthrough infection were significantly 
more likely to have moderate or severe disease than were those who had 
been vaccinated less than five years previously (risk ratio, 2.6; 95% 
confidence interval (CI), 1.2 to 5.8). The annual rate of breakthrough varicella 
significantly increased with the time since vaccination, from 1.6 cases per 
1000 person-years (95% CI, 1.2 to 2.0) within one year after vaccination to 
9.0 per 1000 person-years (95% CI, 6.9 to 11.7) at five years and 58.2 per 
1000 person-years (95% CI, 36.0 to 94.0) at nine years.  
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3.1.7 Methodologies for Serology Testing: 
3.1.7.1 Cell and Bead Based Assays: 
The fluorescent antibody to membrane antigen (FAMA) assay measures 
antibodies to viral glycoproteins (Williams et al., 1974) and is the most 
extensively validated assay and correlates best with susceptibility to and 
protection against, clinical varicella infection (Saiman et al., 2001; Williams et 
al., 1974; Iltis et al., 1982; Grose et al., 1979a; Gershon et al., 1994a; 
Gershon et al., 1988; Michalik et al., 2008). Importantly, the presence of 
neutralizing antibody is associated with seropositive FAMA results (≥ 1:4) 
(Grose et al., 1979a). This assay has also been shown to correlate with 
protection from varicella following household exposure; both in naturally 
infected and in vaccinated individuals (Gershon et al., 1994a).  For this 
reason, FAMA is widely regarded as the gold standard against which other 
serological tests are measured.  
 
The assay can either be performed using fixed or unfixed VZV infected 
human fibroblast diploid lung cells (HFDL) or the MeWo melanoma cell line 
(Zaia et al., 1977; Grose et al., 1979a). The increased sensitivity of this 
method is assumed to arise from the preservation of the conformational 
structure of the glycoprotein antigens on the surface of the cells.  In a study of 
86 healthy indviduals with household contact with varicella, 58 who had a 
positive FAMA titre before exposure, did not become ill, whereas the 28 
subjects who were FAMA negative (<1:2 prior to exposure) all developed 
varicella (Gershon et al., 1994a).  Throughout the history of the FAMA assay 
only two cases have been reported where individuals with a positive titre 
subsequently developed varicella, but both were mild cases (Saiman et al., 
2001; Steinberg and Gershon, 1991).  Positive FAMA titres have also been 
shown to correlate with protection in immunized children with leukaemia 
(Gershon et al., 1984b).  
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However this assay is semi-quantitative, not suited for testing large numbers 
of sera, is laborious, cannot be automated, and its interpretation can be 
subjective. Although the test has been established in several laboratories, 
due to these limitations, it is difficult to know if the assay results are 
comparable between laboratories. 
 
The latex agglutination (LA) assay, which uses antigen-coated latex particles, 
has been shown to compare closely with the FAMA assay in a study of 
naturally immune and vaccinated HCWs who had been exposed to household 
varicella (Saiman et al., 2001, Gershon et al., 1994a, Steinberg and Gershon, 
1991). However, false-negative results due to prozone formation may occur 
(Landry and Ferguson, 1993; Unadkat et al,. 1995), whilst false-positive LA 
results have led to failures to vaccinate. In some cases this has resulted in 
the subsequent development of varicella in HCWs with unrecognized 
susceptibility (Saiman et al., 2001; Behrman et al., 2003; Martins et al., 1994). 
 
3.1.7.2 Enzyme-Linked Immuno Sorbent Assays (ELISAs): 
In general there has been a strong correlation between VZV neutralizing 
antibodies and ELISA antibody titre, as observed in studies on sera from 
vaccinated recipients (Provost et al., 1991; Krah et al., 1997). There are at 
least 15 Enzyme-Linked Immuno Sorbent Assays (ELISAs) available for VZV 
testing (Maple et al., 2009c). Most use VZV infected cell lysate as a coating 
antigen, but some use highly purified glycoproteins (gpELISA). Many 
laboratories use non-commercials ELISAs that have whole viral lysate as a 
coating antigen (Behrman et al., 2003; de Ory et al., 2006; Wasmuth and 
Miller, 1990; Maple et al., 2006).  
 
Using the manufacturer‟s cut-offs a range of sensitivities and specificities 
(discussed overleaf) have been reported for VZV ELISAs, but as there have 
been few comparisons with FAMA it is difficult to determine the clinical 
relevance of these cut-offs (Maple et al. 2009a; Maple et al. 2009c).  In brief, 
 162 
 
the results of a diagnostic assay can be classified according to four 
outcomes. These are true positives (individuals who have experienced 
disease and yield a positive assay result); false positives (individuals who 
have not experienced disease yielding a positive result); true negatives 
(individuals who have not experienced disease yielding a negative result) or 
false negative (individuals who have experienced disease yeilding a negative 
result).  The sensitivity of an assay is defined as the proportion of individuals 
who have experienced disease that have a positive test result (true positives), 
whilst the specificity is defined as the proportion of individuals who have not 
experienced disease that have a negative test result (true negatives). 
Therefore, sensitivity is the ability of the assay to ascertain what it is testing 
for and specificity is the ability of the test to reject what it is not testing for. 
Whether an assay is required to have a higher sensitivity or specificity 
depends on the consequences of a false reading.  
 
For example, assays used to screen potential blood donors for transmissible 
infectious diseases require a high sensitivity, as false negative result would 
create a transmission risk. However, if a disease was „mild‟, but the treatment 
had severe side effects, an assay would be required which identified as few 
false positives as possible (thus an assay with a high specificity). If an assay 
used to identify healthcare workers who require varicella vaccination, 
produced false positive readings this would lead to a failure to vaccinate 
susceptible subjects and a failure to potentially eradicate a transmission risk 
to immunocompromised patients. If the assay produced false negatives, this 
would lead to unnecessary vaccination of previously immune individuals and 
create an unnecessary economic burden. Therefore the optimal cut-off for 
such an assay is one that identifies as few false positives as possible (highest 
specificty), with a correspondingly low false negative rate (high sensitivity).   
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A non-commercial ELISA which uses highly purified glycoproteins has been 
developed by Merck and tested extensively in immunised children (Wasmuth 
and Miller, 1990), has proved to be highly sensitive, but has not been tested 
in relation to naturally acquired infection, (Gershon and Krugman, 1975) and 
is not widely available.  The Merck group presented evidence that the 
gpELISA cut-off level of 5 ELISA Units (EU)/mL correlates with protection (Li 
et al., 2002). The study on breakthrough infection in children vaccinated with 
a single dose, showed that 96% of those with an antibody titre of ≥5EUs were 
protected, whereas only 83% who had <5EUs were protected against 
disease. Children with a lower gpELISA reading were 3.5 times more likely to 
develop breakthrough chickenpox. However a recent study of primary vaccine 
failure, (using a FAMA cut-off of 1:4), demonstrated that 76% of children had 
not seroconverted after one dose of vaccine (Michalik et al., 2008). As the 
gpELISA cut-off has demonstrated that 95% of children seroconvert after one 
dose, this cut-off is now thought to be too sensitive; leading to an over 
estimation of seroconversion following vaccination, (Michalik et al., 2008). 
Commercial ELISA tests are considerably less sensitive than either gpELISAs 
or FAMA for the detection of seroconversion after vaccination (Saiman et al., 
2001, Watson et al., 1994). This is likely to be due to the measurement of 
antibodies directed against viral glycoproteins in the case of FAMA (Williams 
et al., 1974) and as a consequence of the more purified and concentrated 
nature of the capture antigen used in the gpELISA, compared to the VZV-
infected cell extracts used in other EIAs, (LaRussa et al., 1987; Provost et al., 
1991). 
 
FAMA, LA and three commercial ELISAs have been validated in clinical 
studies of protection following natural infection (Gershon et al., 1994a, 
LaRussa et al., 1987).  Of 19 VZV naïve subjects who developed varicella 
infection following household exposure, all had a FAMA titre of <1:2 prior to 
infection and all developed FAMA titres of ≥ 1:2 post infection (Gershon et al., 
1994).  The ELISAs tested were less sensitive than FAMA, detecting only 
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between 43-76% of naturally infected subjects with positive FAMA results 
(LaRussa et al., 1987).  The LA results correlated better with FAMA than that 
of the commercial ELISAs (Gershon et al., 1994a). The subjective nature of 
LA and the occurrence of both false-positive and false-negative results 
implies this test is not suitable for routine screening, (Behrman et al., 2003; 
Martins et al., 1994).  
 
3.1.7.3 Time Resolved Fluorescence Immuno Assay (TRFIA): 
The variation and relative insensitivity of most commercially available EIAs 
led to the development of the in house VZV time resolved fluorescence 
immunoassay (TRFIA), (HPA; London). A significant advantage of TRFIA is 
that it uses purified whole-cell antigen extract that is much more readily 
obtained than glycoprotein antigen. The loss in sensitivity due to use of cell 
extract antigen is compensated for by the inherent gains in sensitivity 
achieved through use of fluorescence decay measurement of an Europium 
labelled IgG conjugate (Maple et al., 2006). In the final stages of the assay an 
enhancement solution is added which contains a Europium ligand. This 
causes the Europium bound to IgG to dissociate.  Subsequent excitation by 
UV light causes the Europium-ligand complexes to fluorescence (see figure 
2.1; materials and methods). The half life of this fluorescence is of the order 
of several hundredths of a micro-second compared to the background 
fluorescence which is of the order of nanoseconds. Once background 
fluorescence has decayed, a time resolved fluorimeter can measure the 
fluorescence of the Europium-ligand complex, enabling highly sensitive 
detection. Initial evaluation of the TRFIA assay on serum from healthy adults 
and children derived a cut-off of 93mIU/mL, via mixture modelling of non-
immune and naturally immune populations within that cohort, (Maple et al., 
2006). Using this cut-off, TRFIA was shown to be more sensitive (but less 
specific) than most commercial antibody assays, including the Merck 
gpELISA (Maple et al., 2006), see table 3.3. 
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Assay 
Sensitivity 
(%) 
Specificity 
(%) 
Specificity + 
Sensitivity 
Merck gpELISA 97.8 93.5 191.3 
Behring 98.4 80.7 179.1 
Diamedix 
(Eq=Neg) 
76.4 97.1 173.5 
Table 3.3: Sensitivity and Specificity of Merck gpELISA, Behring and 
Diamedix Assays in Comparison to TRFIA (Cut-Off: 93mIU/mL; Maple et al., 
2006). Key; Eq; Equivocal, Neg; Negative. 
 
 However, in this particular analysis, the concentration of antibodies to Merck 
VZV glycoprotein was determined by interpolation from a standard curve of 
British standard VZV antibody, (which is also used for TRFIA assay). In 
addition, a standard curve of the Merck reference serum was also plotted and 
used for calibration purposes. Using these two methods to standardize units 
between the Merck and TRFIA assays, a negative cut-off 10mIU/mL was 
used for the Merck ELISA.  More recently, repeated testing of eight 
seropositive and two seronegative donors and analysis via receiver operating 
characteristic (ROC) curves calculated a cut-off of 150mIU/mL in naturally 
infected individuals (Maple et al., 2009a).  The specificity and sensitivity of 
this cut-off and a cut-off of 100mIU/mL in comparison to the Merck gpELISA 
(using a cut-off of 5EU/mL) is presented in table 3.4. Regardless of the cut-
off, this assay has not been validated against protection from infection, and 
has not been validated in a vaccinated population. 
 
Cut-Off 
(mIU/mL) 
Sensitivity (%) Specificity (%) Specificity 
+ 
Sensitivity 
% 95%CI 
95%CI 
Range 
% 95%CI 
95%CI 
Range 
100 98.8 
95.8–
99.9 
4.1 88.7 
81.1–
94.0 
12.9 187.5 
150 87.5 
81.5–
92.1 
10.6 94.3 
88.1–
97.9 
9.8 181.8 
Table 3.4: Sensitivity and Specificity of the Two TRFIA Cut-Offs in Naturally 
Immune Adults. A Merck gpELISA cut-off 5EU/mL was used for comparison, 
(Maple et al., 2009a). 
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In summary, there are several methodologies which have been developed to 
measure VZV-specific antibodies, but few assays have been validated 
against protection from infection, and the accuracy of several tests is 
questionable.  Targeted immunisation programmes such as those utilised in 
the UK, require a robust test which generates as few false negative and false 
positive values as possible, in order to ensure that HCWs are no longer 
susceptible to infection, whilst the economic burden of vaccination is kept to a 
minimum. 
 
3. 2 AIMS AND HYPOTHESIS:  
Aims: 
1. Evaluate the UK reference assay (time resolved immunofluorescence 
assay: TRFIA) for the detection of low level naturally induced, and vaccine 
induced VZV-specific antibodies in an adult population.  
2. To use this assay and other methodologies to characterise humoral 
immune responses to vaccination.  
3. To investigate the relationship between ethnicity and antibody titre 
following vaccination.  
Hypothesis:  
The UK reference assay (TRFIA) will have a higher sensitivity than the 
Diamedix assay when assessing VZV-specific IgG titres in this study 
population. 
 
3.3 RESULTS:  
3.3.1 Characteristics of the ROVE Study Population: 
The methods and study design of healthcare worker (HCW) recruitment are 
described in the materials and methods and appendix 7.1. In brief, 110 HCWs 
who tested negative or equivocal by the standard commercial VZV ELISA 
(Diamedix) used at Bart‟s and the London NHS, were recruited.  Two doses 
of vaccine were administered approximately six weeks apart and blood 
samples were taken at baseline, six and 12 weeks post first vaccination. 
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Seventy five study participants were re-recruited approximately 18 months 
post first vaccination, for a follow-up study.  Demographic data (gender, age, 
ethnicity, country of birth, years resided in the UK) for each study participant 
are presented in appendix 7.5.  
 
3.3.1.1 Summary of ROVE Study Participants Demographics: 
Age at baseline is presented in figure 3.4. 
 
 
Figure 3.4: Age at Baseline (Enrolment) for ROVE Study Participants. Age 
has been taken as age at last birthday. 
 
This distribution is skewed slightly towards the younger participants and is 
representative of the local working population. Seventy four percent of the 
participants were female, and the country of origin for the study population 
was diverse.  Figure 3.5 shows the country of origin grouped into continents 
or geographical areas, rather than as separate countries, for ease of analysis. 
The Philippines has been kept as a separate country of origin as the 
frequency of study participants from here was quite high, and previous 
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studies have shown the genetic background of Filipinos is quite distinct from 
other Oriental or Asian races (Keegan et al., 2007).  
 
 
 
 
Figure 3.5: Ethnicity of ROVE Study Participants. Black African and Black 
Caribbean are displayed adjacently in similar shades to illustrate that almost 
43% of the study population were black. Key: ME; Middle Eastern, mixed 
race; Black with Caucasian, Indian subcontinent; Asian. The Caucasian 
population where of European and Australasian origin. 
 
Sixty seven percent (n=74) of study participants were born in the tropics; 
table 3.5 summaries data on the country of birth, age of migration to the UK, 
history of varicella prior to enrolment and any previous vaccination for 
Caucasian and non-Caucasian study participants. Study participants who 
tested equivocal (15-19EU/mL) by Diamedix are also listed.  
 
Caucasians were significantly more likely to report a history of varicella at 
baseline than non-Caucasians (2 test p = 0.02). Of the study participants 
born outside the UK, 72% (n=79), migrated after the age of 15. Four migrated 
at or under the age of five, and seven migrated between the ages of 6-15 
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years old. Subjects with equivocal Diamedix results (n=12) had significantly 
higher baseline titres than those with negative Diamedix results (n=96) 
(independent 2 tailed t-test, p=<0.0001).  
 
 
 
Birth Country 
  UK (n=21) Non-UK (n=89) 
  
XCaucX 
Non 
XCaucX 
Temperate Tropical 
  XCaucX 
Non 
XCaucX 
XCaucX 
Non 
XCaucX 
N 17 4 5 7 2 72 
Age (Years) 
Range 
(Mean) 
 
33 
(21-59) 
 
 
28 
(20-35) 
 
 
36  
(24-50) 
 
 
29  
(23-36) 
 
 
25  
(19-31) 
 
 
33  
(19-61) 
 
Age Migrated 
to the UK; 
Range 
(Mean) 
Not  
Applicable 
25  
(21-39)  
19  
(2-30)  
2  
and  
5 
26 
(1-56) 
Years in UK 
10  
(3-21)  
10  
(4-26)  
14 and 
29 
7 
(0-27)  
Diamedix 
Equivocal 
3 0 0 1 1 7 
History of 
Varicella 
6 (1 
DNK) 
1 2 1 1 
7  (1 
DNK) 
Previous 
Vaccination 
1 0 0 1 0 1 
 
 
Table 3.5: Summary of the Country of Birth, Migration to the UK, History and 
Previous Vaccination for Caucasian and Non-Caucasian Study Participants. 
Key: Cauc; Caucasian, DNK; did not know if they had a history of varicella, 
Equivocal Diamedix values; 15-19EU/mL. Tropical countries of birth were 
defined as lying between the tropics of Cancer and Capricorn (study 
participants born in Australia were omitted from that particular analysis; n=3).   
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3.3.1.2 Characteristics of Humoral Immune Responses to Vaccination:  
Within this study, serology results were obtained using the VZV reference 
antibody test (time resolved immunofluorescence assay: TRFIA). Data for 
each HCWs TRFIA titres at each study visit are presented in appendix 7.6. 
The TRFIA readings at each visit for the study population are summarised in 
figure 3.6.  
 
 
 
Figure 3.6 Comparison of TRFIA VZV-Specific IgG Antibody Titres at Each 
Study Visit. Baseline (visit 1), induced after the first dose of vaccine (six 
weeks; visit 2), the second dose of vaccine (12 weeks; visit 3) and the 18 
month follow-up visit (visit 4). Horizontal bars within box plots represent the 
median value; whiskers represent the lowest data point within 1.5 IQR 
(interquartile range) of the lower quartile and the highest data point within 1.5 
IQR of the upper quartile respectively. Data points falling outside the whiskers 
(outliers) are represented as circles. *** p=<0.0001, (independent 2 tailed t 
test). Descriptive statistics for each visit are presented in appendix 7.7.  
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The mean TRFIA titre for each visit was significantly different from that of the 
other visits p=<0.0001 (one sample, 2 tailed t-test), apart from between visit 2 
and visit 4 (p=0.88). The mean TRFIA value at the 18 month follow-up (visit 
4), was 4-fold above that seen at baseline (visit 1) (72mIU/mL: 295mIU/mL, 
(log101.86: 2.47)).  
 
3.3.2 Evaluation of UK Reference VZV IgG Antibody Assay for Detection 
of Vaccine Induced Antibody and Low Level Antibody: 
As outlined in the chapter introduction, long term follow-up studies allow for a 
correlation between a positive assay result and clinical protection. As long 
term follow-up studies have not been carried out using TRFIA, we made use 
of antibody avidity (measured using the commercially available EUROIMMUN 
assay) and TRFIA titres at six weeks post first vaccination to determine 
humoral immune status. Antibody avidity can be classed as low, 
equivocal/intermediate or high, which with the EUROIMMUN assay is set at 
40%, 41-59% and 60% respectively. As avidity responses mature over 
several months, six weeks is not a sufficient time frame to allow for the 
maturation of high avidity antibodies, thus study participants with high avidity 
antibodies after the first dose of vaccine, were classified as having pre-
existing humoral immunity. In addition, subjects with pre-existing immunity 
were identifiable by a six week TRFIA titre above a certain cut-off (discussed 
in section 3.3.2.2). Developing an avidity assay based on the TRFIA assay 
was not carried out as part of this study, because TRFIA was under 
evaluation. 
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3.3.2.1 Assay Characteristics for TRFIA and Avidity (EUROIMMUN): 
The intra-assay reproducibility for both EUROIMMUN and TRFIA were 
assessed separately.  In each case nine samples with values representing 
the range of results were retested. In both cases the first and second test 
results were significant correlated (paired t-test p=<0.001). For further 
analysis the original result, (not the mean of the two results), was used 
because the number of subjects with repeated results was so small.   
 
To evaluate the relationship between the more sensitive in house assay 
(TRFIA) and the commercial avidity assay (EUROIMMUN), we compared 
results for VZV-specific IgG antibody in the two assays.  Figure 3.7 shows the 
relationship between values generated by the TRFIA assay against the value 
generated from the EUROIMMUN assay (PBS wash), (R2 = 0.70). The results 
indicate a linear relationship which was significantly correlated (paired sample 
t-test; p=<0.0001).  According to the manufacturer‟s instructions, an accurate 
avidity assay cannot be carried out if the concentration of VZV-specific IgG is 
too low. As can be seen from figure 3.7, TRFIA values below 32mIU/mL 
(log101.50) did not correlate as strongly with EUROIMMUM assay values (p = 
0.81). Indeed, for samples with TRFIA values below log102.0 (100mIU/mL), 
the corresponding avidity readings did not correlate significantly (p = 0.25).  
When the values generated by the two assays were re-compared; excluding 
samples with TRFIA values below log102.0 (100mIU/mL), a stronger 
correlation was seen (R2=0.72). Therefore avidity assays were not carried out 
on serum samples with a TRFIA titre of less than 100mIU/mL (log102.0). 
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Figure 3.7: Correlation between VZV-Specific IgG Measured by TRFIA and 
EUROIMMUN Assays.  Log10TRFIA values plotted against EUROIMMUN 
(PBS wash) values. The horizontal red line represents the TRFIA cut-off value 
of log102.0 (100mIU/mL) above which an accurate avidity assay can be 
carried out, the vertical red line represents the EUROIMMUN cut-off value 
0.2, above which an accurate avidity assay can be carried out. 
 
3.3.2.2 Correlation of TRFIA and Avidity Values Six Weeks Post Vaccination: 
Figure 3.8A summarises antibody avidity seen after the first and second dose 
of vaccine and at the 18 month follow-up visit in subjects who had no pre-
existing humoral immunity to VZV (defined by a six week avidity reading 
≤60%); (see appendix 7.8 for data of each HCWs avidity reading, at each 
study visit). Figure 3.8B summaries data on individual study participant‟s 
avidity maturation during the study. Data is presented on the 36 subjects who 
had avidity readings following each dose of vaccine and at the 18 month 
follow-up. There was an overall maturation of avidity at each time point, and 
this was significant between all visits (independent 2 tailed t-test, p=<0.0001). 
Baseline avidity readings are not presented, as few samples contained high 
enough concentrations of VZV-specific IgG (as determined by TRFIA) to allow 
an accurate avidity assay to be carried out.   
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Figure 3.8: Avidity Maturation Seen After Each Dose of Vaccine and at the 
Follow-up Visit for Study Participants with Six Week Avidity <60%. Note; 
baseline data (visit 1) has been excluded as few samples had high enough 
TRFIA values to warrant an accurate avidity reading. Part A: Horizontal bars 
within box plots represent the median value; whiskers represent the lowest 
data point within 1.5 IQR of the lower quartile and the highest data point 
within 1.5 IQR of the upper quartile respectively. Part B: Individual study 
participant‟s avidity maturation during the study. Data is presented on the 36 
subjects who had avidity readings following each dose of vaccine and at the 
18 month follow-up (n=36). *** p=<0.0001, (independent 2 tailed t test). 
Descriptive statistics for each visit are presented in appendix 7.9. 
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Figure 3.8: Avidity Maturation Seen After Each Dose of Vaccine and at the 
Follow-up Visit for Study Participants with Six Week Avidity <60%. (Figure 
legend on opposite page).  
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Six weeks after the first dose of vaccine was administered (visit 2), sera from 
98 patients had a high enough concentration of VZV-specific IgG antibodies 
to carry out a valid avidity assay. These results are plotted against the 
corresponding log10TRFIA value at the same time point in figure 3.9.  
 
 
 
Figure 3.9 Scatter Plot to Show the Relationship Between TRFIA Titres and 
Avidity Levels at Six Weeks After the First Vaccination (Visit 2). The red lines 
represent the avidity and TRFIA cut-offs (60% and log102.60; 400mIU/mL 
respectively) used to classify the data into two distinct populations. Two 
outliers which do not cluster within the two populations are ringed in red.  The 
dashed horizontal line represents the low avidity antibody cut-off of 40%. N = 
98; R2 = 0.86. 
  
Figure 3.9 shows that there was a strong correlation between antibody titres 
and avidity values (R2 = 0.86), and a bimodal distribution in avidity values and 
TRFIA titres six weeks after the first vaccination can be seen. One population 
had avidity values below 60% and TRFIA titres below log102.60 (400mIU/mL) 
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and were classified as primary responders (n=59). The second population 
had avidity and TRFIA readings above 60% and 400mIU/mL respectively and 
were classified as secondary responders (n=37). Demographic and 
serological data for the two outliers, ringed in red in figure 3.9 (study 
participants 1032; high TRFIA, low avidity and 1089; low TRFIA, high avidity) 
are presented in appendices 7.20 and 7.21.  TRFIA titres and avidity values 
for the two populations were significantly different from one another, 
regardless of whether the outliers and the three data points with six week 
avidity values between 41-59% (between the horizontal dashed black and red 
lines) were included or excluded, (independent 2 tailed test; p =<0.0001).  
 
3.3.2.3 Extrapolating a VZV-Specific IgG TRFIA Cut-Off from an Adult 
Population, Using Vaccination as a Tool to Assess Naturally Derived 
Antibody: 
To extrapolate an assay cut-off, the baseline (visit 1) log10 TRFIA titres for 
those classified as primary or secondary responders were plotted (see figure 
3.10). The negatively distributed samples (primary responders) had a mean of 
log101.65 (SD log100.31), whilst the positively distributed samples (secondary 
responders) had a mean of log102.36 (SD log100.43). A cut-off of log102.11 
was taken where the two fitted populations intercepted each other, (as 
indicated by the red arrow).  This cut-off gave a sensitivity of 90% (95% CI 
80-96), and a specificity of 78% (95% CI 61-90). 
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Figure 3.10: Observed and Fitted Positive and Negative Distributions of 
Baseline Samples Classified by Avidity Readings and TRFIA Titres After the 
First Dose of Vaccine (Six Weeks). Three samples with six week avidities of 
41-59% were excluded from this analysis, (n=95). Negative samples were 
classified as samples with avidity readings of 40% and TRFIA titres 
<400mIU/mL (log102.60) after the first dose of vaccine. Positive samples were 
classified as samples with avidity readings of 60% and TRFIA titres of 
>400mIU/mL, after the first dose of vaccine. The red arrow indicates the cut-
off of log102.11 (130mIU/mL); the point where the two fitted populations 
intercept. Figure A shows the two populations plotted separately and figure B 
shows the two populations plotted on the same histogram (using Excel 
Solver). 
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3.3.2.3.1 Defining a Cut-off Using Mixture Modelling: 
Mixture modelling is a methodology that is used to identify sub-groups within 
a heterogeneous population. This approach can therefore be used to 
estimate a cut-off of humoral immunity, by defining sub-populations within an 
antibody profile; (i.e.: seronegative and seropositive). The mixture model (in 
this case; a mixture of two normal distributions) was fitted to the baseline data 
by first creating a histogram with appropriate bin (classification) sizes. The 
solver function in Excel was then used to find the optimal fitted distribution 
(via maximum likelihood), by adjusting (in this case), five parameters (the 
mean and SD of the primary and secondary responder populations, and the 
proportion which fall into these two distributions). Maximum likelihood gives 
the set of parameter values from which the observed data is most likely to 
have been produced and is thus the best fitting mixture (of two normal 
distributions) to the histogram.  This process facilitates the identification of 
sub-populations within the data set, allowing an estimation of an optimal cut-
off value where the fitted sub-populations intercept each other. Mixture 
modelling was applied to the baseline (visit 1) TRFIA VZV-specific IgG titres. 
Data was available for all but two of the participants (study numbers 1061 and 
1110); n=108.  
 
Figure 3.11: Observed and Fitted Counts of ROVE Baseline (Visit 1) Log10 
TRFIA Readings Using Mixture Modelling. N = 108 
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Two peaks can be seen in figure 3.11. The negatively distributed samples 
had a mean of log101.48 (30mIU/mL) (SD log100.20), whilst the positively 
distributed samples had a mean of log102.11 (130mIU/mL), (SD log100.45). 
Using this model it was estimated that 40% of samples were negative at 
baseline and a cut off of approximately log101.8 would be suggested. 
Assigning 95% confidence intervals based on the mixture model was 
attempted using profile likelihood by shifting the negative/positive mean up 
and down and re-fitting until the deviance was significantly different from the 
best fitting model (with a constraint that the proportion in the negative 
distribution was between 20 and 80%). This gave a confidence interval 
around the estimate of 100% specificity of (75%-100%) and around the 
estimate of 51% sensitivity of (29%-95%).  
 
3.3.2.3.2 Comparison between the Six Week Post Vaccination and the 
Mixture Modelling Defined Cut-offs, Using Probability Density Curves: 
Probability density curves plot the fitted distribution (based on the observed 
data) against probability density, rather than the frequency of observed data.  
The probability density is therefore the underlying continuous distribution of 
the fitted data and is independent of sample size. The probability densities of 
the fitted distributions based on both the mixture modelling and on the six-
week post vaccination status (defined using avidity/TRFIA cut-offs), were 
plotted; see figure 3.12.  
 
The mean value of the positive and negative populations in the probability 
density curves based on the six week avidity/TRFIA data were log101.75 and 
log102.45 (56 and 282mIU/mL), whilst those based upon mixture modelling 
were log101.95 and 2.4 (89 and 251mIU/mL) respectively. Cut-offs of 
approximately log102.1 (six week avidity/TRFIA) and log102.3; 200mIU/mL 
(mixture modelling) would be predicted from the probability density curves in 
figure 3.12. The discrepancy in the mixture model cut-offs derived by plotting 
probability densities or frequencies, demonstrates that applying mixture 
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modelling to this data set is not an appropriate method of extrapolating a cut-
off.  
 
Figure 3.12: Comparison of Probability Density Curves for Positive and 
Negative Distributions of Baseline (Visit 1) Samples Using Either Mixture 
Modelling, or Avidity Cohorts Defined After the First Dose of Vaccine (Six 
Weeks). 
 
3.3.2.3.3 Using ROC Analysis to Evaluate an Optimum Cut-Off: 
ROC analysis was used to investigate an optimal cut-off. A receiver (or 
relative) operating characteristic (ROC) curve is a graphical plot of the 
sensitivity versus (1 - specificity) for an assay. The ROC can be represented 
by plotting the fraction of true positives versus the fraction of false positives 
(as determined by a reference assay; in this case, high or low avidity 
antibodies at six weeks, after the first dose of vaccine). Log10 baseline 
antibody titres were ordered and successive cut-offs (increasing by log100.02) 
were applied to the data, for which the sensitivity and specificity was 
calculated. The ROC curve was produced by plotting the true and false 
positives rates for each successive cut-off (see figure 3.13). This process 
allows optimal cut-offs to be selected and suboptimal ones to be rejected.   
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Figure 3.13: ROC Analysis of Baseline TRFIA Readings Classified by 
Immune Status According to Corresponding Six Week Avidity Cut-Off (60%). 
Various Cut-offs are represented on the plot: corresponding log10TRFIA 
readings to the „% of agreement between assays‟ were values 2.12 
(132mIU/mL) or 2.14 (138mIU/mL); „Equally weighting sensitivity and 
specificity‟ were 1.94, 1.96, 1.98 or 2, (87-100mIU/mL) and the „mixture 
modelling‟ cut-off was 1.8 (63mIU/mL). The area under the curve is 0.92. 
 
As discussed earlier, for an assay which is used to identify HCWs who require 
varicella vaccination, equal weighting of sensitivity and specificity is not 
appropriate (blue triangle in figure 3.13). Instead, the cut-off with the highest 
sensitivity and a high specificity is required (the highest true positive rate with 
a low false negative rate). Therefore the cut-offs which fulfil this criteria are 
marked on the ROC curve by the green square in figure 3.13, which 
correspond to the highest agreement between assays (log102.12; 132mIU/mL, 
or log102.14; 138mIU/mL). The mixture model cut-off however gives a higher 
sensitivity (true positive rate) but at the expense of a higher false positive 
rate, thus this cut-off of log101.8 is not appropriate.   
 
Both the probability density curve and the ROC analysis indicated that 
mixture modelling was not an appropriate methodology for selecting an 
optimal cut-off using this data set. Thus the mixture model cut-off was  
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Figure 3.14 Comparison between TRFIA Negative (%) at Each Study Visit, 
Classified by Three TRFIA Cut-Offs. Key: NIA; Cut-off derived from analysis 
of naturally immune adults, VA; Cut-off derived from analysis of vaccinated 
adults.  Black horizontal bars within box plots represent the median values, 
whiskers represent the lowest data point within 1.5 IQR of the lower quartile 
and the highest data point within 1.5 IQR of the upper quartile respectively. 
Data points falling outside the whiskers (outliers) are represented as circles. 
Horizontal dashed-black bar; log101.97; 93mIU/mL (Maple et al., 2006), 
Horizontal red bar; log102.11; 130mIU/mL, horizontal black bar; log102.17; 
150mIU/mL (Maple et al., 2009). Descriptive statistics and the number of 
subjects who were negative at each visit according to the vaccinated adult 
cut-off (130mIU/mL), are presented in appendix 7.25 
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rejected and the six week avidity/TRFIA assigned cut-off of log102.11 
(130mIU/mL) was accepted as the appropriate TRFIA cut-off for vaccinated 
adults. In the following text, titres below and above 130mIU/mL are referred to 
as TRFIA negative and positive respectively. 
 
3.3.3 Assessing Humoral Immune Responses to Vaccination Using the 
TRFIA Cut-Off of 130mIU/mL: 
Figure 3.14 below shows the percentage of TRFIA negative at each study 
visit, classified by the log10 2.11 (130mIU/mL) cut-off and the two published 
TRFIA cut-offs.  
 
V1 V2 V3 V4 Visit Number 
108 108 103 75 N   
  Cut-Off   
66 24 2 13 
Log10 1.97 
(93mIU/mL) 
Maple et al., 
2006 
69 30 4 25 
Log10 2.11 
(130mIU/mL)  
76 37 5 32 
Log10 2.17 
(150mIU/mL) 
Maple et al., 
2009a 
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3.3.3.1 Characteristics of the Humoral Immune Response Following 
Vaccination and at Follow-Up: 
Study participants were classified as either negative (N) or positive (P) 
according to the baseline TRFIA cut-off of log102.11 (130mIU/mL). Sixty 
seven percent (72/106) of individuals were identified as TRFIA negative and 
33% (34/106) as TRFIA positive.  Humoral subsets were classified as either 
primary or secondary responders based on TRFIA/avidity cut-offs of 
log102.60 (400mIU/mL) and 60% respectively after the first dose of vaccine 
(six weeks).  Figure 3.15 summarises the divison of study participants into 
primary and secondary responders and subsequently into each subset whilst 
table 3.6 summarises the cut-offs used to define each subset. Of the TRFIA 
negative cohort, 10% (7/72) were identified as negative secondary 
responders (acronym Negative „Immune‟; NI).  The negative primary 
responder cohort (65/72) were subdivided into those that seroconverted (SC) 
following one dose of vaccine (TRFIA 130mIU/mL); (NSC1; 32/65), 
seroconverted following two doses of vaccine (NSC2; 29/65), or failed to 
seroconvert in response to vaccine. This latter group was classified as Low 
level Responders to vaccine (NLR; 4/65). Those with a positive TRFIA at 
baseline were subdivided into those that exhibited a secondary response to 
the first dose of vaccine (with the acronym Positive „Immune‟ (PI); 29/35) and 
those who made a Low level Response to vaccine (PLR; 6/35). Thus, six 
humoral subsets were identified. Figure 3.16 highlights the clustering of each 
humoral subset after the first dose of vaccine, based on TRFIA and avidity 
readings. Appendices 7.11-7.15 summarise the descriptive statistics on 
TRFIA and avidity data at each study visit, for each humoral subset. 
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Figure 3.15 Schematic of Humoral Subset Classification. Key: NSC1; Negative at baseline, Seroconverted 1 dose, NSC2; 
Negative at baseline, Seroconverted 2 Doses, NLR; Negative at baseline, Low primary Responder, failed to seroconvert 
following two doses (vaccine humoral non-responder), PLR; Positive at baseline, Low Responder, NI; Negative at 
baseline, secondary responder („Immune‟), PI;  Positive at baseline, secondary responder („Immune‟). Four individuals 
were excluded from analysis; two individuals withdrew from the study after the baseline visit, and two outliers (1032 and 
1089).  
 187 
 
  Baseline (Visit 1) Six weeks (Visit 2) 12 weeks (Visit 3) 
N Subset 
TRFIA 
(mIU/mL) 
Avidity (%) (if 
applicable) 
TRFIA 
(mIU/mL) 
Avidity 
(%) 
TRFIA 
(mIU/mL) 
Avidity 
(%) 
32 
P
ri
m
a
ry
 R
e
s
p
o
n
d
e
rs
 
Seroconverted to 
Vaccination 
NSC1 
<130 <60 
130
<60 130   
29 NSC2 <130 
4 
Low Responders 
NLR <130 <40  <130 <40  <130 <40  
6 PLR 130 <60 <400 <60 
  7 
Secondary Responders 
NI <130 60
400 60 
28 PI  130 60
106     
 
Table 3.6: Summary of Humoral Response Subset Classification. Key: NSC1; Negative at baseline, Seroconverted 1 
dose, NSC2; Negative at baseline, Seroconverted 2 Doses, NLR; Negative at baseline, Low primary Responder, failed to 
seroconvert following two doses (vaccine humoral non-responder), PLR; Positive at baseline, Low Responder, NI; 
Negative at baseline, secondary responder („Immune‟), PI;  Positive at baseline, secondary responder („Immune‟), *all 
subjects in this subset had baseline avidities above 40%, but n=6 were <60%, however at 12 weeks these 6 subjects had 
a minimum avidity of 64%. Four individuals were excluded from analysis; two individuals withdrew from the study after the 
baseline visit, and two outliers (1032 and 1089).  
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Figure 3.16: Clustering of each Humoral Subset After the First Dose of 
Vaccine. Key: NSC1; Negative at baseline - Seroconverted to 1st dose, 
NSC2; Negative at baseline - Seroconverted to 2nd dose, NLR; Negative at 
baseline - Low Responder, (failed to seroconvert following two doses: vaccine 
humoral non-responder), PLR; Positive at baseline - Low Responder, NI; 
Negative at baseline, secondary responder („Immune‟), PI;  Positive at 
baseline, secondary responder („Immune‟), 
 
Study participants 1032 and 1089 were outliers according to the six week 
TRFIA/avidity cut-offs of 400mIU/mL (log102.60) and 60% respectively, and 
were excluded from analysis. According to the baseline TRFIA cut-off of 
log102.11 (130mIU/mL), both would be classified as negative at baseline and 
seroconverting following the first dose of vaccine.  However, 1089 could only 
be classified as a secondary responder based on their six week avidity, whilst 
1032 could only be classified into this subset based on their TRFIA titre. 
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Figure 3.17 summaries TRFIA titres at baseline and following each dose of 
vaccine for each subset. The results from the longer term follow-up visit 4 
which occurred approximately 18 months post vaccination, are discussed 
separately in section 3.3.3.4  
 
 
 
Figure 3.17: Summary of Humoral Immune Responses Following Two Doses 
of Vaccine, for Each Subset. The horizontal red line represents the TRFIA 
cut-off of log102.11 (130mIU/mL), horizontal black lines within boxes 
represents the median value; whiskers represent the lowest data point within 
1.5 IQR of the lower quartile and the highest data point within 1.5 IQR of the 
upper quartile respectively. Data points falling outside the whiskers (outliers) 
are represented as circles. A total of 106 study participants are represented. 
Key: NSC1; Negative Seroconverted, 1 dose, NSC2; Negative 
Seroconverted, 2 doses, NLR; Negative Low Responder (humoral non-
responder to vaccine) , PLR; Positive Low Responder, NI; Negative „Immune‟, 
PI;  Positive „Immune‟, V1; Visit 1 (baseline), V2; Visit 2 (six weeks), Visit 3 
(12 weeks), *** p=<0.0001, * p=<0.05, (independent 2 tailed t test).   
 
As can been seen from figure 3.17, for those who were classified as 
seroconverting following vaccination (NSC1 and NSC2), there was a highly 
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significant (p=<0.0001; 2 tailed independent t test) increase in antibody titre 
after each dose of vaccine. Therefore even in study participants who 
seroconverted following one dose of vaccine, a highly significant increase in 
antibody titre was obtained following a second dose of vaccine. Following the 
first dose of vaccine (visit 2; six weeks) the difference in antibody titre 
between these two subsets was highly significant (p=<0.0001), but was no 
longer significant following the second dose of vaccine (visit 3; 12 weeks) 
(p=0.1). For secondary responders (NI and PI) there was a highly significant 
increase following the first dose of vaccine (p=<0.0001), but following the 
second dose, either no significant difference (NI), or a significant decrease 
(p=0.024) (PI) was observed in mean titre. However for low responders (NLR 
and PLR), although the mean increased after each dose of vaccine, this was 
not significant. The log10 TRFIA titres for each low responder at baseline and 
after each dose of vaccine are presented in figure 3.18 
 
 
Figure 3.18: Log10 TRFIA titres at Baseline and after Each Dose of Vaccine 
for Study Participants Classified as Low Responders. (NLR (n=4), PLR 
(n=6)). 
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3.3.3.1.1 Demographic Characteristics for each Subset: 
Demographic data for each humoral subset are summarised in figure 3.19. 
There was no significant difference between the mean age or gender 
between any of the humoral subsets.   
 
 
 
Figure 3.19: Summary of Ethnicity, Gender and Age for Each Humoral 
Subset. Key: NSC1; Negative Seroconverted, 1 dose, NSC2; Negative 
Seroconverted, 2 doses, NLR; Negative Low Responder, failed to 
seroconvert following two doses (vaccine humoral non-responder), PLR; 
Positive Low Responder, NI; Negative „Immune‟, PI;  Positive „Immune‟, 
Cauc; Caucasian (the Caucasian population where of European and 
Australasian origin), Ind; Indian subcontinent, Phil; Filipino, Other; Middle 
Eastern or mixed race (Black with Caucasian). Two subjects withdrew from 
the study, and two subjects were classed as outliers and were excluded from 
this analysis (n=106). There was no significant difference between the mean 
age or gender between cohorts and that of the total study population.  
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Figure 3.20 Summary of Ethnicity, Gender and Age for Subsets which were 
Classified as Seroconverters, Low Responders or Secondary Responders.  
Key: NSC1; Negative Seroconverted, 1st dose, NSC2; Negative 
Seroconverted 2nd doses, NLR; Negative Low Responder, PLR; Positive Low 
Responder, NI; Negative „Immune‟, PI;  Positive „Immune‟, Cauc; Caucasian 
(the Caucasian population where of European and Australasian origin), Ind; 
Indian subcontinent, Phil; Filipino, Other; Middle Eastern or mixed race (Black 
with Caucasian).  
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Data was combined for analysis into those that seroconverted (NSC1 and 
NSC2), were low responders (NLR and PLR) or were secondary responders 
(NI and PI), see figure 3.20. Caucasians were significantly more likely to be 
classified as secondary responders (PI and NI), (2 p=0.003) than non-
Caucasians. Although not significant, there was a suggestion that Black 
(versus non-Black) and Indian subcontinent (versus non-Indian subcontinent) 
were less likely to be classified as secondary responders (2 p=0.066 and 
p=0.057 respectively), whilst Indian subcontinent (versus non-Indian 
subcontinent) were more likely to be classified as seroconverting (2 
p=0.055). 
 
 
Figure 3.20 Summary of Ethnicity, Gender and Age for Subsets which were 
Classified as Seroconverters, Low Responders or Secondary Responders.  
(Figure legend on opposite page). 
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3.3.3.1.2 Characteristics of Primary Responders:  
3.3.3.1.2.1  Characteristics of Primary Responders who Seroconverted 
Following Vaccination (NSC1 and NSC2): 
As mentioned earlier, of the 72 subjects who were TRFIA negative at 
baseline, 65 (90%) were defined as primary responders by avidity and TRFIA 
readings at six weeks.  Thirty two (49%) seroconverted after one dose of 
vaccine (NSC1), and 29 (45%) seroconverted after two doses (NSC2). NSC1 
had significantly higher mean TRFIA titres at both baseline (independent 2 
tailed t test, p=0.008) and after the first dose of vaccine (six weeks, 
p=<0.0001) than NSC2. There was no difference in mean TRFIA titre 
between these two subsets following the second dose of vaccine (12 weeks), 
but avidity readings at this time point were significantly higher for the NSC1 
group, (p=0.005).  The antibody titre seen at the 18 month follow-up was also 
found to differ between these two groups, and is discussed in more detail in 
section 3.3.3.4. 
 
3.3.3.1.2.2 Characteristics of Primary Responders who Made Low Level 
Responses to Vaccine (NLR and PLR): 
Study participants who did not have a significant difference between mean 
TRFIA titres after each dose of vaccine were classified as low responders. Of 
the 72 subjects who were TRFIA negative at baseline, four failed to 
seroconvert following two doses of vaccine (NLR).  The TRFIA values for 
these four vaccine humoral non-responders were 45, 78, 123 and 
126mIU/mL, (log101.65, 1.89, 2.09 and 2.10), and for those samples tested, 
all were low avidity, (11-27%). All four subjects were Black.  A further six 
subjects, who although positive for TRFIA antibodies at baseline, responded 
poorly to each dose of vaccine and were classified as PLR. In all six 
individuals, baseline antibody avidity was low (<40%) and antibody avidity 
remained low at 12 weeks, (26-41%). Five of the six were non-Caucasian 
(two black, one mixed race, two Indian subcontinent).  Although the difference 
in mean TRFIA titre at 12 weeks was significantly different between NLR and 
 195 
 
PLR (p=0.016) the difference between this time point and those of the NSC1 
and NSC2 groups was highly significant (p=<0.0001).  
 
To further explore an association between ethnicity and antibody titre, TRFIA 
titres after two doses of vaccine, (12 weeks; visit 3) were compared for all 
primary responders who were TRFIA negative at baseline (NSC1, NSC2 and 
NLR; n=65), see figure 3.21. Black study participants had significantly lower 
TRFIA titres than non-black at this time point (independent 2 tailed test, 
p=0.009). This was further supported by the finding that after ranking TRFIA 
titres at this time point, black subjects were significantly more likely to fall into 
the bottom quartile than non-blacks (2 p=0.003), and this was still significant 
if NLRs were removed from analysis (2 p=0.017).  
 
 
 
Figure 3.21: Log10 VZV-Specific IgG TRFIA Titres Following Two Doses of 
Vaccine for Primary Humoral Responders who were TRFIA Negative at 
Baseline. Vertical arrows represent the mean value for each cohort.  
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3.3.3.1.2.3  NLRs: Response to a Third Dose of Vaccine: 
Two study participants who failed to seroconvert following two doses of 
vaccine (study numbers 1002 and 1027; NLRs) received a third dose. Study 
number 1002 (African male; 28 years old; no history of varicella prior to 
enrolment), failed to seroconvert with a third dose achieving a final TRFIA of 
just 62mIU/mL. This HCW was not recruited back for the follow-up visit. In the 
case of 1027 (African female; 49 years old; no history of varicella prior to 
enrolment), the HCW experienced what was classified in our study as a 
„vaccine related event‟ (VRE) 12 days after the third dose was administered, 
and was visited by the research nurse. In this case, the VRE was a headache 
and an itchy (but not painful) rash on the left shoulder. Swabs taken from the 
rash site (which did not resemble that of a varicella infection) were negative 
for VZV DNA by PCR analysis. A full set of blood samples was taken at this 
additional time point, a TRFIA of log103.03 (1,074mIU/mL) was recorded. No 
exposure to either varicella or zoster was reported by the HCW prior to their 
third visit, or between administration of the third dose and the VRE. The VZV-
specific IgG level fell to log102.43 (270mIU/mL) two months after the third 
dose was administered. At the follow-up visit (in this case, only 13 months 
post vaccination) their TRFIA level had dropped back down to log102.09 
(123mIU/mL). A third HCW did not return for a third dose of vaccine and 
remained negative at their follow-up visit (log101.77). 
 
3.3.3.1.2.4 NLRs: Responses to Natural Infection: 
Study number 1050 (African male; 36 years old, who did not know if he had 
had varicella before or not, born in Nigeria and migrated to the UK 17 years 
prior to enrolment) also failed to seroconvert after two doses of vaccine, but 
was exposed to varicella via a household contact (his daughter) two days 
prior to his third visit (12 weeks). At this time point, a TRFIA reading of just 
78mIU/mL was obtained. No symptoms were reported following the 
household exposure and a full set of bloods was taken five weeks post 
household contact.  At this time point, the HCW had seroconverted (TRFIA 
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2,118mIU/mL; log103.33; avidity 31%). This study participant was recruited 
back for the follow up visit (17 months post vaccination) and had a TRFIA 
reading of log102.45 (282mIU/mL), with an avidity of 51%.  
 
3.3.3.1.2.5 Secondary Humoral Immune Responses to Vaccination (PI and 
NI): 
Secondary responders were classified as having a six week TRFIA of 
>400mIU/mL and an avidity of >60%, and were subdivided into two further 
subsets based on baseline TRFIA titres. Twenty eight subjects had positive 
baseline TRFIA130mIU/mL (PI), while 7 were negative at baseline (NI). In 
both cases a highly significant increase in the mean TRFIA titre following the 
first dose of vaccine was observed (independent 2 tailed t test, p=<0.0001), 
and secondary responders had significantly higher mean antibody avidity at 
each time point compared to all primary responder subsets (p=<0.0001). Fifty 
percent of Caucasians enrolling in the study were classed as secondary 
responders and this was significant (2 p=0.039). In addition, secondary 
responders were significantly more likely to have grown up in a temperate 
rather than a tropical climate (2 p=0.003). 
 
3.3.3.2 Correlation Between FAMA and TRFIA in Vaccinated Adults; 
Benchmarking Humoral Subsets: 
A positive FAMA score (2) has been shown to correlate with clinical 
protection, and the presence of neutralising antibodies (Gershon et al., 1994a 
and Grose et al., 1979). Sixty four ROVE serology samples, (16 subjects, 4 
visits each), were tested by FAMA (with thanks to Sharon Steinberg and Anne 
Gershon, Columbia University College of Physicians and Surgeons).  FAMA 
and corresponding TRFIA and avidity values for each sample are presented 
in appendix 7.22. The FAMA assays were repeated on five samples, and in 
one case, the FAMA readings did not agree on immune status (<2 first assay, 
2 second assay). This sample was therefore omitted from analysis (n=63). 
There was an 81% (51/63) agreement on assay positive/negative status 
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between the two assays. In comparison to FAMA, TRFIA had a sensitivity of 
81% (39/48) and a specificity of 80% (12/15), see table 3.7. The positive and 
negative predictive values were 93% (39/42) and 57% (12/21) respectively 
(see materials and methods, for formulas).  
 
    FAMA   
  
  Positive 2 Negative <2 Total 
T
R
F
IA
 
(m
IU
/m
L
) 
  
Positive ≥130 39 3 42 
Negative <130 9 12 21 
  Total 48 15 63 
Table 3.7: Comparison of Positive and Negative Status between FAMA and 
TRFIA. 
 
There was a significant difference (independent 2 tailed t-test, p=<0.0001) 
between the mean log10TRFIA titre for samples with positive FAMA scores, 
compared to the mean of samples with negative FAMA scores, see figure 
3.22. The mean log10 TRFIA titre differed significantly for each FAMA score 
(4, 8, >8) (see figure 3.23). For samples with a FAMA of >8 all the 
corresponding TRFIA values (bar one) were above the TRFIA cut-off of log10 
2.11. There was no significant difference between the mean of the negative 
FAMA group (<2) and the lowest of the FAMA positive groups (4), however 
the sample size for the later group was small (n=7), see figure 3.23. 
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Figure 3.22: Correlation between FAMA Assay Negative and Positive Status 
and Log10 TRFIA Titres. Horizontal black lines within boxes represents the 
median value; whiskers represent the lowest data point within 1.5 IQR of the 
lower quartile and the highest data point within 1.5 IQR of the upper quartile 
respectively. The horizontal red line indicates the TRFIA cut-off of log102.11 
(130mIU/mL).  
 
Figure 3.23: Correlation between FAMA Scores and Log10 TRFIA Readings. 
Horizontal black lines within boxes represents the median value; whiskers 
represent the lowest data point within 1.5 IQR of the lower quartile and the 
highest data point within 1.5 IQR of the upper quartile respectively. Data 
points falling outside the whiskers (outliers) are represented as circles. The 
horizontal red line indicates the TRFIA cut-off of log102.11 (130mIU/mL). The 
difference between the mean of the FAMA <2 and FAMA 4 groups was not 
significant.  
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Figure 3.22: Correlation between FAMA Assay Negative and Positive Status 
and Log10 TRFIA Titres. (Figure legend on opposite page). 
 
 
 
 
Figure 3.23: Correlation between FAMA Scores and Log10 TRFIA Readings. 
(Figure legend on opposite page). 
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Representative samples chosen randomly from the humoral subsets were 
tested by FAMA and consisted of secondary responders (PI; n=6 and NI; 
n=1), primary responders who seroconverted (NSC1, n=2, NSC2, n=5) and 
low responder groups (PLR, n=1 and NLR, n=1).   In summary, correlation 
between FAMA and TRFIA was good, with correlation at all time points for 
9/16 study participants.  Both assays agreed on negative/positive status at 
visit 3 (12 weeks, response to second dose of vaccine) for all study 
participants.  Seven individuals; (1001 (PLR), 1013 (PI), 1015 (NSC2), 1017 
(NSC2), 1019 (NSC2), 1026 (NSC2) and 1032 (NI)) showed discrepancies 
between FAMA and TRFIA assay status at one or more time points, see table 
3.8.  
 
Three discrepant results were classified as TRFIA positive/FAMA negative, 
whilst eight samples were classified as TRFIA negative/FAMA positive. For 
two samples, (1032 and 1013), the cause of the discrepancies could be 
explained by assay failure (TRFIA for 1032 and FAMA for 1013) as results for 
these individuals at other visits correlated well.  At three time points (1001, 
visit 1, 1017 visit 2, and 1019 visit 2) discrepant results may be explained by 
borderline TRFIA titres (125, 128, 130mIU/mL). For study participant 1001, 
discrepant assay results were also seen at follow-up (visit 4), and it is not 
possible to predict which assay status is correct.  Strikingly, four out of five 
NSC2 samples tested were discordant at one or more time points, with FAMA 
indicating that each individual was seropositive at six weeks (visit 2). In 
addition, FAMA classified two of these study participants as seropositive at 
baseline, however, for all four NSC2s listed above, only low avidity antibodies 
were seen at any time point, indicating that these subjects did not have pre-
existing humoral immunity at baseline, and therefore that the TRFIA status 
was more likely to be correct at this timepoint.  The two NSC2 individuals that 
were classed as seropositive by FAMA at baseline, had discordant assay 
status at three time points, however both assays agreed that all four NSC2 
were seropositive at 12 weeks (visit 3).  
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V2  700 P 81 8 P Yes 
V3 778 P 85 8 P Yes 
V4 463 P 72 4 P Yes 
1
0
1
5
 
(N
S
C
2
) V1 37 N X 4 P 
None 
No 
V2  96 N 26 4 P No 
V3 429 P 33 8 P Yes 
V4 74 N X >8 P No 
1
0
1
7
 
(N
S
C
2
) V1 64 N X 4 P 
None 
No 
V2  125 N 28 8 P No 
V3 374 P 25 >8 P Yes 
V4 148 P 29 <2 N No 
1
0
1
9
 
(N
S
C
2
) V1 21 N X <2 N 
None 
Yes 
V2  64 N X 8 P No 
V3 326 P 30 8 P Yes 
V4 15 N X <2 N Yes 
1
0
2
6
 
(N
S
C
2
) V1 41 N X <2 N 
None 
Yes 
V2  128 N 26 4 P No 
V3 481 P 34 >8 P Yes 
V4 116 N 28 8 P No 
1
0
3
2
 
(o
u
tl
ie
r:
 
N
S
C
1
/N
I)
 
V1 94 N X 4 P 
None 
No 
V2  823 P 55 8 P Yes 
V3 464 P 80 >8 P Yes 
V4 194 P 81 8 P Yes 
 
Table 3.8: FAMA, TRFIA and Avidity Readings for Study Participants with  
Multiple Assay Discrepancies Throughout the Study.  Key: V1; Visit 1 
(baseline), V2; Visit 2 (six weeks), V3; Visit 3 (12 weeks), V4; Visit 4 (18 
month follow-up), P; positive, N; negative. Assay discrepancies are 
highlighted in Red bold.  
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3.3.3.3 Benchmarking the Subsets Against a History of Varicella at 
Enrolment:  
Eighteen HCWs gave a history of varicella infection prior to enrolment, of 
whom two recalled having the disease twice, two were unable to recall if they 
had chickenpox or not and three had been previously vaccinated; see table 
3.9 and appendix 7.16, for details of which participants reported a history. 
The previously vaccinated individuals have been discussed in the text where 
appropriate, but only one of these three participants completed the study (see 
appendix 7.17 and 7.18 for demographic and serological data on these 
subjects). 
 
Subset  N History of Chickenpox Did Not Know Previous Vaccination 
NSC1 32 0 0 1 
NSC2 29 2 (x1 twice) (7%) 0 0 
NLR 4 0 1 0 
PLR 6 0 0 0 
NI 7 3 (43%) 0 1 
PI   28 12 (x1 twice) (43%) 1 1 
Total 106 17 2 3 
 
Table 3.9: Summary of Subjects who Reported a History of Chickenpox, or a 
Previous Varicella Vaccination, at Enrolment.  
Four subjects were excluded from analysis, (two withdrew from study (1010 
and 1084), and two were humoral subset outliers (1032 and 1089, the latter 
of which reported a history). 
 
Excluding those that did not know if they had previously experienced varicella 
(n=2) and those that had been previously vaccinated (n=3), reporting a 
history at enrolment gave a PPV of 20% and NPV of 83% respectively 
against baseline TRFIA.  Those enrolling with a history were significantly 
more likely to have a positive baseline TRFIA titre than those without a history 
(2 test p= 0.001). In addition, those with a history were significantly more 
likely to have a positive TRFIA titre at the 18 month follow-up visit 
(independent 2 tailed t-test p = <0.0001) than those that enrolled without a 
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history. The two patients with a positive history of chickenpox who were 
TRFIA negative at baseline were in the NSC2 group. Neither had been tested 
by FAMA. Both were Caucasian and one had a history of recurrent 
chickenpox.  Another patient with a history of recurrent chickenpox was 
classified as a positive baseline secondary responder (PI).  
 
3.3.3.4 Antibody Boosting and Waning Immune Responses at 18 Months 
Post Vaccination: 
At the 18 month follow-up visit, (visit 4) no cases of varicella (or herpes 
zoster) were reported. Seventy five subjects participated in the follow-up 
study and were classified according to their 12 week and 18 month TRFIA 
titres. Of these individuals, 27% (20/75) had a negative TRFIA titre and 55/75 
had a positive TRFIA titre at 18 months. The negative cohort was further 
subdivided into those who were TRFIA seropositive at 12 weeks and had thus 
lost seropositive status at follow-up (lost; n=18/20) and those who were 
seronegative at 12 weeks (n=2/20). The cohort which was seropositive at 18 
months was also further subdivided into those that had higher TRFIA titre at 
18 months than 12 weeks (boosted; n=15/55) and those who had a lower 
TRFIA titre at 18 months than 12 weeks (retained; n=40/55). See appendix 
7.19, for which study participants were classified into which follow-up cohorts.  
 
Figure 3.24 is a plot of TRFIA titres at 12 weeks versus 18 months for those 
who lost or retained antibody at 18 months (those with boosted responses 
have been excluded). This figure illustrates that the majority of study 
participants who had a negative TRFIA at follow-up seroconverted after two 
doses of vaccine (NSC2). 
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Figure 3.24: Correlation between TRFIA Titres at 12 Weeks and 18 Months 
for Study Participants who Lost or Retained Seropositive Status. Data are 
coded by humoral subset. Individuals who received a boost in antibody titres 
at follow-up were excluded from analysis. The correlation between 12 week 
and 18 month TRFIA titres was R2 0.52. The horizontal red line represents 
the vaccinated-adult TRFIA cut-off of log102.11 (130mIU/mL). 
 
TRFIA titre at 12 weeks (visit 3) and follow-up (visit 4) for each of the six 
humoral subsets that were identified based on their responses to vaccination, 
are summarised in figure 3.25. 
 
 206 
 
 
Figure 3.25; Comparison between Log10TRFIA Antibody Titres Following Two 
Doses of Vaccine (12 Weeks) and 18 Months Post Vaccination for Each 
Humoral Subset. Key: NSC1; Negative Seroconvert 1st dose, NSC2; Negative 
Seroconvert 2nd doses, NLR; Negative Low Responder, PLR; Positive Low 
Responder, NI; Negative secondary responder („Immune‟), PI; Positive 
secondary responder („Immune‟), V3; Visit 3 (12 weeks), V4; Visit 4 (18 month 
follow-up), *** p=<0.0001, ** p=0.001 or below, * p=0.05 or below 
(independent 2 tailed t test). The horizontal red line represents the 
vaccinated-adult TRFIA cut-off of log102.11 (130mIU/mL), horizontal black 
lines within boxes represents the median value; whiskers represent the lowest 
data point within 1.5 IQR of the lower quartile and the highest data point 
within 1.5 IQR of the upper quartile respectively. Data points falling outside 
the whiskers (outliers) are represented as circles. 
 
As can be seen from figure 3.25, all individuals who were classified as 
secondary responders, were TRFIA positive at follow-up, as were the majority 
of PLR (3/4) and 77% (17/22) of those that seroconverted following one dose 
of vaccine.  Subjects who seroconverted after one dose had significantly 
higher mean TRFIA titre at follow-up than those who seroconverted after two 
doses. Secondary responders had significantly higher follow-up titres than 
primary responders (seroconverters and low responders).  
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3.3.3.4.1 Characteristics of Subjects who Retained Seropositive TRFIA Status 
at 18 Months Post Vaccination: 
Of the study participants who retained a positive TRFIA titre at follow-up, nine 
had a history of varicella at enrolment and one had been previously 
vaccinated. Thirty five percent (14/40) had been classified as secondary 
responders, (NI; 1, PI; 13) and of those classified as primary responders, 52% 
(12/23) had seroconverted after the first dose of vaccine.  As can be seen 
from figure 3.24 and 3.25 all study participants who were secondary 
responders (NI and PI) remained seropositive at follow-up (some of whom 
experienced a boost in antibody response; see section 3.3.3.4.3). 
 
3.3.3.4.2 Waning Humoral Immunity: 
Of the 20 subjects who had antibody titres below the TRFIA cut-off, 90% 
(18/20), had been positive by TRFIA following two doses of vaccine (12 
weeks), whilst two had been classified as NLR (vaccine humoral non-
responders). For the following analysis the two NLR subjects were excluded, 
so that only subjects who had lost positive antibody titre between 12 weeks 
and 18 months could be examined.  Such subjects accounted for 25% of the 
follow-up cohort (18/73). 
 
As illustrated in figure 3.26, the majority (65%; 11/17) were classified as 
seroconverting after two doses of vaccine (NSC2); whilst 29% (n=5) were 
classified as seroconverting after one dose (NSC1). One individual (6%) was 
classified as a PLR, but it is noteworthy that the baseline titre for this 
individual was on the cut-off (130mIU/mL) and this individual still had low 
avidity antibodies at 12 weeks. Thus based on six week avidity and TRFIA 
readings all individuals who had antibody titres below the cut-off at 18 months 
had been a primary responder at enrolment, and those that seroconverted 
after two does were significantly more likely to be TRFIA negative at follow-up 
(2 p=0.003). No study participants in this follow-up cohort reported a history 
prior to enrolment or had received previous vaccination.  
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TRFIA titres at follow-up ranged from log101.18–2.10 (15-126mIU/mL) with a 
mean value of log101.85 (71mIU/mL) S.D: log100.26 and median of log101.95 
(89mIU/mL). Seven subjects had adequate IgG levels to allow an accurate 
avidity assay to be conducted. These readings ranged from 28–73%, with a 
mean of 44% (S.D: 16%) and a median of 41%. Only one of these readings 
was above the 60% cut-off.  For seven subjects, corresponding FAMA 
readings were available, three of which were positive (8, 8, <8). The 
discrepancy in assay results between these assays is discussed in more 
detail in section 3.3.3.2. Neither the mean age, nor the ethnicity of this „lost 
seropositive status‟ cohort, were significantly different from that of the total 
study population; (26% Caucasian, 42% Black, 21% Indian and 11% Filipino, 
with a mean age of 32 years).  
 
 
Figure 3.26 Comparison between Study Participants who Retained or Lost 
TRFIA Seropositive Status at 18 Months Post Vaccination. Key: NSC1; 
Negative Seroconvert 1st dose, NSC2; Negative Seroconvert 2nd doses, PLR; 
Positive Low Responder, NI; Negative secondary responder („Immune‟), PI; 
Positive secondary responder („Immune‟), V3; Visit 3 (12 weeks), V4; Visit 4 
(18 month follow-up). 
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The naturally immune adult cut-off of 150mIU/mL (log102.18) would have 
classified an additional five study participants as negative at follow-up, all of 
whom seroconverted after two doses.  As the majority of those that had lost 
seropositive status at follow-up were classified as seroconverting after two 
doses of vaccine, a comparison was made between the individuals in that 
subset who lost or retained antibody titres at follow-up. During the study, 
there were 29 HCWs who seroconverted after two doses, and 21 were 
available at follow-up. As mentioned earlier, 11 were classified as having lost 
antibody at follow up, whilst nine retained antibody above 130mIU/mL, (one 
subject received a boost to their antibody titre and was excluded from this 
analysis), see figure 3.27 part B. The same analysis was conducted for those 
who seroconverted after one dose of vaccine, although the sample size for 
the TRFIA negative at follow-up cohort was small (n=5), see figure 3.25A.  
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Figure 3.27: Comparison in TRFIA Titres at Each Visit for Subjects who were 
Seropositive or Seronegative 18 Months Post Vaccination who were Either 
Classified as Seroconverting After One or Two Dose(s) of Vaccine.  
Part A; Seroconverted after one dose, Part B; seroconverted after two doses. 
The adult vaccine cut-off of log102.11 (130mIU/mL) is represented by the 
horizontal red line; black horizontal bars within box plots represent the 
median value; whiskers represent the lowest data point within 1.5 IQR of the 
lower quartile and the highest data point within 1.5 IQR of the upper quartile 
respectively. Data points falling outside the whiskers (outliers) are 
represented as circles. Key: V1; Visit 1 (baseline); V2; visit 2 (six weeks), V3; 
Visit 3 (12 weeks), V4; visit 4 (18 month follow-up), *** p=<0.0001, * p=0.05 or 
below (independent 2 tailed t test). 
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Figure 3.27: Comparison in TRFIA Titres at Each Visit for Subjects who were 
Seropositive or Seronegative 18 Months Post Vaccination who were Either 
Classified as Seroconverting After One or Two Dose(s) of Vaccine. (Figure 
legend on opposite page). 
 
 212 
 
 
At baseline, there was no significant difference between the two sub-cohorts 
of the „seroconverted after two doses‟ cohort (independent 2 tailed t test, 
p=0.74). However those that would later be classified as retained at follow-up 
had significantly higher TRFIA titres at both six and 12 weeks (both p=0.04).  
 
For those seroconverted after one dose of vaccine (see figure 3.27 part B), 
again, at baseline, there was no significant difference (independent 2 tailed t 
test, p=0.86). Unlike the „two doses‟ cohort, no significant difference was seen 
at six weeks (p=0.29), but those that would later be classified as retained at 
follow-up had significantly higher TRFIA titres at 12 weeks (p=0.007).  At 
follow-up the difference was highly significant (p=<0.0001).  
 
Although no distinct populations could be identified when plotting 12 week 
and 18 month titres (see figure 3.24), data was combined for the two subsets 
that seroconverted in response to vaccination and TRFIA titres at 12 weeks 
for those who and lost or retained antibody at follow-up were plotted (see 
figure 3.28).  For the combined data, individuals who lost antibody at follow-
up had significantly lower 12 week titres (p=<0.0001). Primary vaccine 
responders with a 12 week TRFIA titre above 500mIU/mL (log102.70) were 
significantly more likely to have an 18 month TRFIA  titre above 130mIU/mL 
(2 p=<0.0001).   
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Figure 3.28: Comparison between 12 week TRFIA (Visit 3) Titres for Study 
Participants who Serconverted after One or Two Doses and were Either 
TRFIA Positive or Negative at Follow-Up (Visit 4). The horizontal red lines 
represent the same point on the y axis, whilst the vertical red arrow indicates 
where these two populations intercept: 500mIU/mL (log102.70). 
 
3.3.3.4.3 Antibody Boosting: 
Fifteen study participants had received a boost to their antibody titres 
between their 12 week visit and their 18 month follow-up visit, with antibody 
increases ranging from 111mIU/mL to 1,642mIU/mL. However, only 47% 
(n=7/15) reported contacts occurring between these time points, all of which 
were occupational exposures. Four subjects recalled multiple exposures, 
three of which were to varicella (ranging from two to six exposures), and one 
subject was exposed to two cases of zoster.  
 
Avidity readings taken at 18 months ranged from 45-95% (with a mean of 
80%, (SD: 15%), and a median of 85%). All but one was seropositive 
following two doses of vaccine (12 weeks); study participant 1050 discussed 
in detail in section 3.3.3.1.2.4. Fifty seven percent (n=9) of those that 
experienced an antibody boost had been classified as secondary responders, 
(PI; n=7 and NI; n=2).  Twenty five percent (n=4) had seroconverted after one 
dose, one had seroconverted after two doses and one was a PLR.  
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3.3.4 Failure to Undergo IgG Antibody Affinity Maturation, 18 Months 
Post Vaccination: 
Of subjects who had low or intermediate avidity antibodies at 12 weeks, 18 
were not reclassified into a higher avidity classification at 18 months (ie: they 
had not matured from low to intermediate, or intermediate to high).  These 
subjects were all primary responders, (NSC1=11/18 (61%), NSC2=5/18 
(28%), PLR=2/18 (11%)). Fifty two percent (11/21) of those who 
seroconverted after one dose of vaccine and were recruited back at follow-up 
had failed to develop high avidity antibodies. Likewise, 45% (5/11) of those 
that seroconverted after two doses had also failed to develop high avidity 
antibodies. Two out of three PLRs had still failed to develop high avidity 
antibodies, but one had an avidity reading of 71%. The two NLRs (vaccine 
humoral non-responders) who were recruited at follow-up had undergone 
antibody affinity maturation, but the antibodies were classed as intermediate 
(12 week avidity readings were 11 and 27%, whilst 18 month readings were 
48 and 51% respectively). 
 
Figure 3.29 illustrates avidity values (part A) and corresponding TRFIA titres 
(part B) at baseline (where applicable), and the six week, 12 week and 18 
month time points for each humoral subset. Table 3.10 summarises the 
percentage of each humoral subset which was classified as low, intermediate 
or high avidity at each study time point. As can be seen from figure 3.29A one 
subject who was classified as PI (based on six week serology readings) had a 
baseline avidity of 48%. At six weeks antibodies had undergone affinity 
maturation and antibodies were classed as high (64%). However, at 12 
weeks and 18 months, the antibodies had not matured their antibody affinity 
further (64% and 65% respectively).  
 
As can be seen from figure 3.29A, secondary responders (NI and PI) had 
higher mean antibody avidity readings than primary responders (NSC1, 
NSC2, NLR and PLR) at six weeks, 12 weeks and 18 months (independent 2  
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Figure 3.29 Comparisons of Avidity Readings and Log10 TRFIA Titres at Each 
Time Point for Each Humoral Subset. The Avidity Cut-offs of 40% and 60% 
and the TRFIA cut-off of Log10 2.11 are represented by the horizontal red 
lines; black horizontal bars within box plots represent the median value; 
whiskers represent the lowest data point within 1.5 IQR of the lower quartile 
and the highest data point within 1.5 IQR of the upper quartile respectively. 
Data points falling outside the whiskers (outliers) are represented as circles. 
Key: V1; Visit 1 (baseline); V2; visit 2 (six weeks), V3; Visit 3 (12 weeks), V4; 
visit 4 (18 month follow-up), *** p=<0.0001, ** p=0.001 or below, * p=0.05 or 
below (independent 2 tailed t test). 
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tailed t test p=<0.0001). At six weeks (visit 2), NLR had significantly lower 
avidity readings than NSC1 (p=0.032). This was seen at 12 weeks (p=0.001) 
and was also seen for NSC2 at this time point (p=0.009). At 12 weeks there 
was also a significant difference in avidity readings between NSC1 and NSC2 
(p=0.007), but the difference at six weeks and 18 months was not significant. 
 
 
Figure 3.29 Comparison of Log10 TRFIA Titres and Avidity Readings at Each 
Time Point for Each Humoral Subset. (Figure on opposite page). 
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Subset NSC1 NSC2 NLR PLR NI PI 
 % in Each Avidity Classification (n) 
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Visit 1 
50 
(1) 
50 
(1) 
0 0 0 0 0 0 0 
100 
(5)  
0 0 0 0 
100 
(1) 
0 
21 
(6) 
85 
(22) 
Visit 2 
94 
(30) 
6 (2) 0 
100 
(22) 
0 0 
100 
(4) 
0 0 
100 
(6) 
0 0 0 0 
100 
(7) 
0 0 
100 
(27) 
Visit 3 
47 
(14) 
50 
(15) 
3 
(1) 
85 
(23) 
11 
(3) 
4 
(1) 
100 
(4) 
0 0 
80 
(4) 
20 
(1) 
0 0 0 
100 
(4) 
0 0 
100 
(25) 
Visit 4 
24 
(5) 
48 
(10) 
28 
(6) 
36 
(4) 
27 
(3) 
36 
(4) 
0 
67 
(2) 
33 
(1) 
67 
(2) 
0 
33 
(1) 
0 0 
100 
(2) 
0 0 
100 
(16) 
 
Table 3.10 Percentage of Each Subset with Low, Intermediate or High Avidity Antibodies at Each Visit.   
Key; NSC1; Negative Seroconvert 1st dose, NSC2; Negative Seroconvert 2nd doses, NLR; Negative Low Responder, PLR; 
Positive Low Responder, NI; Negative secondary responder („Immune‟), PI; Positive secondary responder („Immune‟)
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3.3.5 Western Blotting of Serum from Varicella Vaccinees: 
To analyse the profile of antibodies present in serum from HCWs 18 months 
post immunisation, western blotting of sera was carried out.  The 
concentration of a commercial VZV-infected cell lysate, and the 
corresponding uninfected cell lysate was established using a Bradford assay 
and identical amounts of protein were used for western blot analysis. Figure 
3.30 is an example of a coomassie stained gel, which demonstrates that 
same amount of each lysate was loaded and there were multiple protein 
bands in the uninfected lysate control.  
 
 
Figure 3.30: Coomassie Staining of Lystaes and Markers used for Western 
Blotting. Key: PP; Precision plus proteins standard, VZV; VZV infected vero 
cell lysate, MM; MagicMarkXP standard, Vero; uninfected vero cell lysate. 
7g of each lysate was loaded, and gels were stained with EZBlue 
Coomassie stain. Images were visualised on a G:Box gel documentation 
machine (Synegene, UK), using GeneSnap acquisition software (Synegene, 
UK). 
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In addition to the size of protein bands, (see figure 3.31) the locations of VZV 
proteins within the blot were confirmed using a commercial monoclonal 
antibody, containing a mixture of antibodies specific for seven VZV epitopes 
(located within the nuclear capsid protein (155kDa), IE62 (175kDa), gB (60-
70kDa), a precursor product within gE, as well as fully glycosylated gE (82-
95kDa), gH (100-118kDa), and gI (45-60kDa).  Various concentrations of this 
primary antibody were used (see figure 3.32), in order to visualise the 
different proteins. 
 
 
 
 
Figure 3.31: Schematic of VZV-Specific Bands Identified in Sera from 
Subjects with a History of Varicella under Reducing Conditions. Key; NCP; 
nuclear capsid protein, g; glycoprotein, (referenced from Harper et al., 1988; 
Dubey et al., 1988 and Zweeink et al., 1981). 
 
.  
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Figure 3.32: Western Blot of VZV-Infected Cell and Uninfected Cell Lysate 
with Multiple VZV-Specific Monoclonal Antibodies. The monoclonal antibody 
mix was used at three concentrations to identify various proteins. Key: PP; 
Precision plus proteins standard, VZV; VZV infected vero cell lysate, MM; 
MagicMarkXP standard, Vero; uninfected vero cell lysate, NCP; nuclear 
capsid protein, g; glycoprotein.  Arrows indicate the presumed position of 
NCP (155kDa), gH (100-115kDa), gB (60-70kDa) and gI (45-60kDa). Images 
were generated with a digital Kodak M863 camera. 
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Figure 3.33 Examples of Antibody Detection Using ROVE Follow-Up Serum 
Samples of Varying Avidity.  Key: PP; Precision plus proteins standard, VZV; 
VZV-infected vero cell lysate, MM; MagicMarkXP standard, Vero; 
uninfected vero cell lysate. Arrows indicate the multiple protein bands within 
one sample, which are discussed further in the text. The top arrow is VZV-
specific and is presumed to be gH (100-115kDa). Images were generated 
with a digital Kodak M863 camera. 
 
Serum samples of varying avidity were tested, and results indicated that for 
samples with low avidity antibodies banding could not be detected in 
seropositive samples, as demonstrated in figure 3.33 with serum samples 
1046 and 1088 which had an avidity of less than 40%. Although 1046 had a 
band (55kDa), this cross reacted with the uninfected cell lysate. Multiple 
dilutions of serum samples were used with less stringent washing conditions 
(Tween 20 reduced, wash times reduced), but this had no effect on yielding 
bands in samples with low avidity. Samples with high avidity antibodies 
yielded bands, but the majority were non-specific, reacting with the uninfected 
 222 
 
control lysate and/or the protein marker, as demonstrated with sample 1011 
in figure 3.33. In this sample only one specific band was seen, located 
between 100-120 kDa markers, and thus presumed to be to gH. Other bands 
at 80kDa, 65kDa and 55kDa, which could have been presumed to be gE, 
gB and gI cross reacted with the uninfected control lysate/protein marker.  
 
To assess the optimum TRFIA titre which could be used to detect VZV-
specific proteins in serum with high avidity antibodies in this system, a serial 
two fold dilution of a study participant‟s serum sample was carried out prior to 
the 1/20,000 dilution (see figure 3.34). This revealed that certain VZV-specific 
proteins could be visualised at a higher antibody concentrations, whilst others 
could be visualised at lower concentrations.  
 
 
Figure 3.34 Serial Two Fold Dilution of Vaccinees Serum Sample to Deduce 
the Limit of VZV-Specific IgG that this Western Blotting System could be used 
to Detect. Key: PP; Precision plus proteins standard, VZV; VZV infected vero 
cell lysate, MM; MagicMarkXP standard, Vero; uninfected vero cell lysate. 
Black Horizontal arrows indicate VZV-specific proteins. Images were 
generated with a digital Kodak M863 camera. 
 
As can be seen from figure 3.34, at a concentration of 2,040mIU/mL multiple 
banding could be seen, including a protein presumed to be to NCP (155kDa), 
multiple banding (or very intense luminescence) between 120-50kDa and 
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bands at 37, 35 and 30kDa (thought to be non-glycosylated proteins).  
However at a concentration of 510mIU/mL the NCP and the 35kDa protein 
was no longer detectable, whilst at a concentration of 128mIU/mL a protein at 
80kDa (thought to be gE) was better defined than at higher antibody 
concentrations.  
 
As this system of detection was not suitable on low avidity samples, and 
multiple dilutions would have to be carried out for each high avidity sample in 
order examine the repertoire of VZV-specific bands, this methodology was not 
pursued further. 
  
3.4 DISCUSSION:  
3.4.1 Summary of Main Findings: 
In an effort to provide insight into factors which may influence antibody 
responses and subsequently possible protection against re-infection, the 
differences in antibody titre and avidity maturation were used to group 
individuals by the pattern of their humoral immune response to VZV vaccine.  
Distinct groups of humoral responders were identifiable and certain 
characteristics were found to be associated with different subsets. 
Caucasians (raised in temperate climates) were significantly more likely to 
report a history and be classified as secondary responders than study 
participants raised in the tropics. For those who were identified as primary 
responders, black ethnicity was associated with a significantly lower TRFIA 
titre following two doses of vaccine. Delayed seroconversion (NSC2) was 
associated with an increased risk of developing seronegative status 18 
months post vaccination, as was a 12 week TRFIA titre below 500mIU/mL. 
This study also illustrated that primary responders can take longer than 18 
months to develop high avidity antibody following varicella vaccination and 
that overall there was a good correlation between seronegative/positive assay 
status for TRFIA and FAMA. 
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3.4.2 Defining a TRFIA Cut-Off in an Adult Population Using Vaccination 
as a Tool to Assess Naturally Derived VZV-Specific Antibodies:  
One of the aims of this study was to validate a highly sensitive immunoassay 
for measuring low levels of naturally induced VZV-specific IgG levels in an 
adult population.  In adults, VZV population immunity is typically in excess of 
90% (Lerman et al., 2004), making it difficult to accurately assess an assay 
cut-off in a positively skewed antibody profile. This particular problem was 
overcome in our study, by enrolling subjects who were either negative or 
equivocal by Diamedix. In addition to this, two markers of pre-existing 
humoral immunity were used to define those who were truly negative (primary 
responders) at baseline; avidity readings below 60% and TRFIA titres below 
400mIU/mL (log102.60) at six weeks post first vaccination. This enabled us to 
identify a negative population (defined on the basis of titres obtained following 
natural infection) with greater accuracy, than using the mixture modelling 
methodology. Wide confidence intervals for the mixture model demonstrated 
that the sample size was insufficient to fit a reliable mixture model to this data 
set.  As there was a lot of overlap between the two distributions in the model, 
a sample size of double that which was used would probably be needed.   
 
Because there was a strong correlation between IgG antibody titres 
measured by TRFIA and the EUROIMMUN avidity assays, this was indicative 
that a comparable antibody population was being measured in both assays. 
To our knowledge, this is the first time the properties of antibody avidity and 
titre following vaccine antigen challenge have been used to determine an 
assay cut-off in the baseline population. Moreover, this method was more 
robust for determining a cut-off in a smaller population size than the mixture 
modelling methodology, which was confirmed by probability density curve and 
ROC analysis. 
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The TRFIA cut-off determined in this thesis (130mIU/mL; log102.11) is higher 
than that which was originally derived for this assay (93.3mIU/mL; log101.97), 
using the mixture modelling technique, in healthy adults, (Maple et al., 2006). 
However, more recently ROC analysis and comparison with the Merck 
gpELISA suggested this cut-off was too low and a cut-off of 150mIU/mL 
(log102.18) (Maple et al., 2009a), was suggested.  This level also 
accommodated the high (20%) intra assay variation observed with this assay.    
 
As FAMA is thought to measure neutralising antibody and TRFIA is thought to 
measure total IgG (regardless of antibody function), this would account for 
discrepancies where a high TRFIA titre was obtained for a sample, but the 
corresponding FAMA was low.  The discrepancies seen between TRFIA and 
FAMA suggest that TRFIA suffers from the same drawbacks as other EIAs in 
comparison to FAMA, namely poor discrimination between low positives and 
true negatives around the cut-off.  
 
3.4.3 Study Population Demographics: 
The vaccine study consisted of an ethnically diverse population of healthcare 
workers, of which fewer than 25% were Caucasian. In tropical climates, 
seropositivity in adults is lower than in temperate climates, (Vyse et al., 2004; 
Khoshnood et al., 2006; Garnett et al., 1993; Lokeshwar et al., 2000). Thus, 
when recruiting adults who where seronegative (or equivocal) by the 
Diamedix assay, a skew towards those born and raised in the tropics, was 
expected in our recruited population.   
 
3.4.4 Failure to Seroconvert Following Two Doses of Vaccine in Primary 
Responders: 
The vaccination study examined in this thesis reported a vaccine humoral 
non-responder rate (defined as a failure to seroconvert after two doses of 
vaccine), of 4% (4/103) of the population that completed the study, and 6% of 
those who were primary humoral responders (defined as a six week avidity of 
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<60% and a baseline TRFIA of <130mIU/mL; n=65). Rates of failure to 
seroconvert in children and adults following two doses of varicella vaccine 
have ranged between 4-14% (Gershon et al., 1988; Kuter et al., 2004; Li et 
al., 2002), however a more recent study examining primary vaccine failure 
(i.e. no measurable immune response following vaccination and remaining 
susceptibility) found that in healthy children vaccinated with one dose of 
vaccine found the rate to be higher at 24% (Michalik et al., 2008). The rate of 
failure to seroconvert found in our study is similar to published literature on 
other vaccines. For HBV a rate of 5-10% has been reported and has been 
linked to advanced age (Hollinger, 1989), obesity (Alper et al., 1989, Weber 
et al., 1985), smoking (Shaw et al., 1989) and alcohol consumption (Nalpas et 
al., 1993). In addition an association between HBV primary vaccine failure 
and various HLA types has been reported (DRB1*03, DRB1*07, DQB1*02, 
DPB1*1101), (Milich and Leroux-Roels, 2003; Thursz, 2001). The HLA-
DRB1*0701 allele was also found to be over represented in healthy adults 
who were classified as humoral non-responders following influenza 
vaccination, compared to those who seroconverted (Lambkin et al., 2004). 
Likewise, a high degree of heritability and an HLA association (MHC-I and 
MHC-II) was found amongst primary vaccine failure following measles 
vaccination (Jacobson and Poland, 2004).   
 
Interestingly two of the vaccine humoral non-responders (NLRs) in this study 
seroconverted either following a third dose of vaccine or a household 
exposure to chickenpox. However the HCW who seroconverted following a 
third dose was seronegative at follow-up. The response to the third dose was 
of the magnitude of those seen for secondary responses (although avidity 
was low) suggesting that this was a memory B cell response. However as the 
HCW was seronegative at follow-up this indicates that they lacked long lived 
plasma cells specific for varicella vaccine antigen. Vaccine humoral non-
responders to HBV vaccine have been shown to seroconvert with a booster 
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immunisation (Van der Sande et al., 2007), although in these cases, antibody 
responses were of the same magnitude as primary responses. 
 
With the second HCW (whose CMI response is discussed in chapter 4), this 
subject was able to seroconvert asymptomatically to a household exposure, 
and produce an antibody titre that was of a magnitude seen following primary 
infection (i.e. 10 fold higher), (Bogger-Goren et al., 1982).  In addition, this 
subject retained a seropositive status at follow-up. See chapter 4 discussion 
for suggestions as to why this exposure was asymptomatic.  
 
3.4.5 Humoral Immune Responses and an Association with Ethnicity 
In our vaccination study, no difference in ethnicity was found between those 
who seroconverted following one dose and those who seroconverted 
following two doses. However, as our data indicated that low humoral 
responses to varicella vaccination were associated with ethnicity, it is possible 
that a difference in ethnicity would have been seen with those who 
seroconvert after one dose or two if a larger population size had been 
examined. In addition, there may be differences between the individuals that 
were classified in these two groups which were not measured as part of this 
study. These could possibly be innate immune responses or other genetic 
markers. Being able to identify these differences would be useful as 
individuals who did not seroconvert following primary antigen challenge (one 
dose) were significantly more likely to be TRFIA negative at 18 months. 
 
The data presented in this thesis demonstrated that following varicella 
vaccination, black ethnicity was associated with lower TRFIA titres in primary 
responders. Data from our laboratory has found that there is an association 
between VZV-specific IgG antibody titres and ethnicity following natural 
infection (Ayres, McDonald, Talkuder and Breuer, unpublished). This study 
examined antibody titres in Caucasian women born and raised in the UK with 
titres from Bangladeshi women who were either born and raised in the UK, or 
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born and raised in Bangladesh and had migrated to the UK. Irrespective of 
country of birth and residence, Bangladeshi women had significantly lower 
VZV-specific IgG titres than Caucasian women. This study demonstrated that 
the difference in titre was associated with ethnicity rather than geographical 
factors such as age of infection or seroprevalence, as Bangladeshi women 
born and raised in the UK had comparable seroprevalence rates and age of 
infection to Caucasian women. However, a lower antibody titre following 
vaccination in Asian study participants was not seen in the study presented in 
this thesis. This could be attributable to either the small sample size or a less 
pronounced difference in titre following vaccination compared to that seen in 
black study participants. 
To our knowledge, an association with lower antibody titre following varicella 
vaccination or natural infection and ethnicity has not been reported 
previously. However the influence of host factors on the magnitude of the 
humoral immune response is supported by a study which showed a 
significantly greater concordance of VZV antibody titres following varicella 
vaccination, between siblings than between unrelated individuals (Klein et al., 
2007). A heritable effect on antibody levels has also been reported following 
infection with Epstein Barr Virus (Yasui et al., 2008) and Herpes Simplex 
Virus (Lio et al., 1994), as well as following vaccination against measles, 
mumps, rubella (MMR) (Ovsyannikova et al., 2006), hepatitis B (Henning et 
al., 2008), and influenza (Lambkin et al., 2004).  
 
3.4.6 Negative immune (NI) Humoral Responders: 
Seven secondary responders (n=7) had antibody titres which classified them 
as negative at baseline, despite three reporting previous varicella and one 
reporting prior vaccination. As these individuals had high avidity antibodies 
and a significant increase in VZV-specific IgG titre at six weeks after the first 
antigen challenge, this indicates that these individuals had memory B cells 
specific for VZV that had undergone affinity maturation. However, as these 
subjects were seronegative at baseline this suggests that these individuals 
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either lacked long lived plasma cells which were specific for VZV, or that their 
VZV-specific plasma cells were producing very low titres of antibody.  
 
3.4.7 Failure to Undergo Antibody Affinity Maturation at 18 Months Post-
Vaccination: 
Within the study population were 18 subjects who had failed to undergo 
affinity maturation at 18 months post vaccination (i.e. they had not been 
reclassified into a higher maturation group at this time point).  The time period 
attributed to maturation of high avidity antibodies in immunocompetent 
individuals is reported to be 4 months to CMV infection (Lazzarotto et al., 
1998) and has been reported to occur between 5-6 months in response to the 
mumps vaccine and natural infection (Narita et al., 1998). A report for EBV 
also demonstrated that high avidity antibodies were seen at seven months 
post infection, but this study did not examine antibody avidity in between a six 
week time point (when low avidity antibodies were seen) and this latter time 
point (Robertson et al., 2003).  
 
However there have been several reports which document delayed 
maturation of antibody and the absence of high avidity antibodies to a variety 
of pathogens, in some cases, years post infection. Several reports document 
that CMV-specific antibody affinity maturation (induced following vaccination 
or natural infection) takes place over a much longer period of time than 
previously thought, (24 months in the case of vaccination and up to 23 
months to natural infection) in immunocompromised patients (Marshall and 
Alder, 2003; Lazzarotto et al., 1998). One of the studies reported that gB-
CMV specific antibody affinity maturation was slower following vaccination 
with an attenuated CMV vaccine than with a recombinant-gB vaccine, 
implicating the antigen source as the reason for slow affinity maturation 
(Marshall and Alder, 2003). Another study carried out in immunocompromised 
subjects (systemic lupus erythematosus and rheumatoid arthritis patients) 
showed that these individuals produced low avidity antibodies and restricted 
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class switching to tetanus toxoid compared to healthy controls (Devey et al., 
1987). However a study in healthy subjects in Japan showed that some 
patients immunised with the mumps vaccine failed to produce high avidity 
antibody responses 6 months post immunisation (Narita et al., 1998).  In 
addition, many studies have been carried out on the avidity of antibodies to 
the parasite toxoplama gondii in pregnant women (reviewed in Lefevre-
Pettazzoni et al., 2006) and in one study, low avidity antibodies were still 
detected in some patients six years post infection. The authors suggested 
that anti-parasitic drug treatment may have been responsible for this 
phenomenon (Sensini et al., 1996).  
As explained in this chapter introduction, our understanding of events which 
take place in the germinal centre is rapidly evolving, and one could speculate 
as to which of these process is hampering antibody affinity maturation to 
varicella vaccination, although it is known that humans and mice with 
deficiencies in AID, CD40-CD40L or ICOS have no ability to class switch or 
undergo affinity maturation (King et al., 2008; Elgueta et al., 2009). A study 
carried out on affinity maturation of measles-specific IgG demonstrated that 
age of vaccination affected both antibody avidity and class switching (Nair et 
al., 2007).  Recently a study in dizygotic and monozygotic twins in the 
Gambia demonstrated that environmental rather than genetic factors 
predominantly controlled affinity maturation and the production of high-avidity 
antibodies to tetanus toxoid (Marchant et al., 2006). 
 
Recently, the lack of antibody affinity maturation induced following formalin 
inactivated RSV vaccine administration in mice has been shown to be due to 
poor TLR stimulation (Delgado et al., 2009). TLRs are known to play a crucial 
role in antibody production as TLR signalling is necessary for both DC 
maturation and T-helper and B cell activation (Pasare and Medzhitov, 2005). 
In addition this paper demonstrated that the poor immunogenicity of this 
vaccine was due to the lack of affinity maturation of the antibodies produced 
and not due to the disruption of immunodominant epitopes by formalin, as the 
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quantity of antibodies produced to an immunodominant epitope were shown 
to be the same in mice immunised with WT RSV and the formalin inactivated 
vaccine. 
 
However, numerous publications have previously reported that IgG antibody 
avidity is a suitable tool for distinguishing between current and persistent 
infection for a variety of pathogens (Heldman et al., 1993), including rubella 
virus (Polanec et al., 1994), HIV (Suligoi et al., 2002), West Nile virus (WNV), 
(Levett et al., 2005), dengue virus (DeSouza et al., 2004; Matheus et al., 
2005), as well as various other herpes viruses, including CMV (Blackburn et 
al., 1991; Lazzarotto et al., 2008), EBV (Weissbrich, 1998) and HHV-6 
(Pietiläinen et al., 2009). Our data and that of others suggest that low avidity 
antibodies can still predominate many months after infection/vaccination. 
However, when study participants were classified according to serological 
readings six weeks post first vaccination, a dichotomous population was 
clearly seen, based on both avidity and TRFIA values, indicating that 
secondary responders had high avidity antibodies following natural infection, 
which in those who reported a history occurred a minimum of three years 
previously.  
 
3.4.8 Loss of Seropositive Status 18 Months Post Vaccination and the 
Risk of Breakthrough Infection: 
This study found that 25% of follow-up study participants had converted from 
seropositive to seronegative at this time point. Loss of seropositive status at 
follow-up in 31% and 25% of subjects have been reported in other studies 
(Saiman et al., 2001; Gershon et al., 1998); however the latter study found 
that even those who were seronegative were partially protected. 
 
Breakthrough infections have been correlated with low levels of VZV 
antibodies at six weeks post immunisation and with loss of antibodies over 
time (Li et al., 2002; Ampofo, 2002). Although no breakthrough infections 
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were reported at the 18 month follow-up visit, we believe subjects with 
TRFIAs below 130mIU/mL at this time point are possibly at risk of infection. 
Our data support the notion that low antibody titres at six weeks correlate with 
breakthrough infection as the subset of humoral responders who required two 
doses of vaccine to seroconvert were more likely to seronegative at 18 
months. In addition this study also found that a TRFIA titre below 500mIU/mL 
following two doses of vaccine (12 weeks) was more likely to result in 
seronegative status at follow-up. A similar finding in long term follow-up 
studies of HBV vaccination, demonstrated that peak vaccine-induced IgG 
titres in primary responders were shown to directly correlate with antibody 
decay and subsequent risk of infection (Inskip et al., 1991; Van der Sande et 
al., 2007).  
 
At follow-up, study participant 1019 was seronegative by FAMA, TRFIA (and 
IFN- ELISPOT; see chapter 4 for more details), and thus negative by every 
parameter measured at this time point. It is therefore likely that this subject 
would be susceptible to infection. However, this individual reported an 
occupational shingles contact 84 days (12 weeks) prior to follow-up, which in 
this particular case was at 16 months post vaccination. As there is no 
indication of antibody boosting or CMI, one possibility is that the contact was 
insufficient to allow transmission. DIAMEDIX, FAMA, and TRFIA readings 
agreed this HCW was seronegative at baseline, with a 12 week avidity 
reading of 30%. This HCW was classified as seroconverting after two doses 
during the study. Although (as discussed in chapter 4) seronegative HCWs 
have been shown to be protected from infection, a CMI response has been 
seen in these subjects.  
 
3.4.9 Antibody Boosting at Follow-Up: 
Continued immunity to varicella is thought to be maintained by exogenous 
boosting, where individuals are asymptomatically reinfected throughout their 
lifetime and evidence for this is growing. Repeated cases of zoster within an 
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individual, which were caused by different genotypes of virus is strong 
evidence for this theory (Taha et al., 2006). In a study of vaccinated HCWs 
who lost positive antibody titre following vaccination, re-infection was higher 
following household exposure (18%; 4/22) than occupational exposure (6%; 
8/72), (Saiman et al., 2001). However in this study, all subjects who had a 
boosted antibody titre at follow-up and reported a contact, reported an 
occupational exposure. As 53% of those with boosted antibody titres did not 
report a contact between their 12 week visit and follow-up visit, this means 
that these individuals were either exposed without their knowledge, or they 
had experienced endogenous boosting.  Endogenous boosting of immunity 
has been observed in latently infected patients who have undergone bone 
marrow transplantation (Redman et al., 1997).   
 
3.4.10 Future work: 
It could be hypothesized that there would be a difference in IgG subtypes 
produced by HCWs in different humoral subsets. As outlined in the chapter 
introduction, there is conflicting data on the subtypes which predominate after 
natural infection, and antibody subtype would also be indicative of function. 
Although it was not possible to accurately determine which VZV proteins 
vaccinees were raising antibodies to in this study by Western blotting, cloning 
known immunodominant epitopes into a vaccinia virus expression system 
could facilitate a more precise methodology for examining this. Although VZV 
is a difficult virus to work with in vitro (as it is a highly cell associated and 
generates low titres), complement dependent neutralisation assays would be 
useful in determining the correlation between antibody function, avidity and 
FAMA scores. The presence of neutralising antibodies has been shown to 
correlate with a positive FAMA score (Grose et al., 1979) and studies with 
flavivirus vaccines (yellow fever, Japanese encephalitis and tick-borne 
encephalitis) have also demonstrated that neutralizing antibody correlates 
with protection (Green et al., 2006).  
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CHAPTER 4: CELL MEDIATED IMMUNE RESPONSES TO VACCINATION 
 
Chapter Summary: 
In this chapter VZV-specific IFN- responses were investigated 18 months 
post vaccination, in an attempt to deduce if HCWs were likely to be 
susceptible to VZV infection. In addition, a highly specific methodology (using 
the only existing MHC-II tetramers available for VZV epitopes) was used to 
examine CD4+ T cell responses to vaccination in a subset of our study 
population.  
 
4.1 INTRODUCTION: 
4.1.1 An Introduction to Adaptive Cell Mediate Immunity (CMI): 
T cells are lymphocytes that mature within the thymus. These cells express 
membrane bound receptors (T cell receptors; TCRs) which are composed of 
either  or  chains. These chains are responsible for the specificity of the 
receptor. TCRs recognize peptide antigens presented by major 
histocompatibility complex (MHC) proteins. MHC-I, which is expressed on 
virtually all nucleated cells of the body, presents endogenous peptides, whilst 
MHC-II, expressed on professional antigen presenting cells (DCs, B cells and 
macrophages) presents exogenous peptides. T cells generally express 
either CD4 or CD8; CD8+ T cells recognize peptide in the context of MHC-I, 
whilst CD4+ T cells recognize peptide in the context of MHC-II. T cells with an 
TCR are classified into numerous subsets, defined by several criteria, 
including chemokine receptor expression, location/migration, and function. 
Subsets include cytotoxic CD8+ T cells (Tc) which have the ability to lyse 
target cells; and a range of T helper CD4+ cells, which when activated can 
express various phenotypes including a Th1 (to be discussed later) or Th2 
phenotype, (which amongst other functions produce cytokines that help 
mediate antibody isotype switching), T follicular helper cells (TFH cells), (which 
provide a helper function to B cells and are discussed in more detail in 
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chapter 3, section 3.1.1.2) and T regulatory cells (Tregs) which are generally 
characterized as CD25+, FOXP3+ and suppress immune responses.  
 
Cytotoxic CD8+ T lymphocyte cells (CTLs) have cytoplasmic granules which 
contain perforin and granzymes. These cells are typically involved with 
immune responses to both virally infected and cancer cells. Upon binding to a 
target cell, the contents of the granules are released; perforin creates pores in 
the target cell membrane, causing lysis, and allowing granzymes to enter the 
target cell and induce apoptosis.  Cytotoxic CD4+ T cell clones with the ability 
to lyse target cells in vitro were first described in the early 1980s (Fleischer, 
1984). They have since been found in vitro to several viral infections including 
influenza, HIV and polio virus (Lukacher et al., 1985; Littaua et al., 1992; 
Norris et al., 2001; Mahon et al., 1995), and have been detected directly from 
peripheral blood ex vivo in HIV, CMV and EBV patients, (Appay et al., 2002; 
Zaunders et al., 2004). Studies of clones and cell lines have indicated that 
CD4+ CTLs use the perforin-dependent cytotoxic mechanism, rather than the 
Fas-dependent pathway (Norris et al., 2001; Williams and Engelhard, 1996; 
Echchakir et al., 2000; Yasukawa et al., 2000). Ex vivo analysis of cytotoxic 
CD4+ T cells demonstrated that they have lytic granules containing cytotoxic 
factors such as granzymes and perforin, and that their lytic activity is HLA 
class-II restricted (Appay et al., 2002; Zaunders et al., 2004; Porakishvili et 
al., 2004). 
 
Naïve T cells that have been activated and have differentiated into a Th1 
phenotype are associated with cell-mediated inflammatory reactions and are 
potent producers of IFN-. This cytokine causes upregulation of MHC-II on 
macrophages and DCs as well as promoting macrophage activation and DC 
maturation. IFN- also leads to the expression of inflammatory cytokines 
including IL-1, IL-6, and TNF. The cytokines produced by Th1 cells 
promote the production of IgG1 opsonising and complement fixing antibodies, 
macrophage activation, and antibody dependent cell mediated cytotoxicity. T 
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cells which have differentiated into a Th2 phenotype produce cytokines such 
as IL-4, IL-5, IL-13 and IL-10 and provide optimal help for humoral immune 
responses including IgG4 and IgE switching (see chapter 3, section 3.1.1.2.2  
for more details), mucosal immunity and IgA synthesis. Th2 cells are 
associated with strong antibody and allergic responses.  
 
The kinetics of primary and secondary immune responses are discussed in 
chapter 3, section 3.1.1.4. Naïve T cells traffic through peripheral lymphoid 
organs such as lymph nodes, where they encounter antigen expressing 
mature dendritic cells.  When a T cell encounters its specific antigen it 
becomes activated via TCR signalling and co-stimulation provided by 
membrane bound molecules. Activated T cells undergo clonal expansion and 
differentiation into effector cells. Upregulation of appropriate homing 
receptors allows the effector cells to migrate out of the lymph node and back 
into the blood stream, subsequently trafficking to the site of antigen 
challenge. Following the acute phase of the immune response, the majority of 
the vastly expanded population of effector T cells will apoptose; the 
remainder will become memory cells. Memory T cells are divided into effector 
memory (TEM) and central memory (TCM). TEM are capable of immediate 
effector function upon re-exposure to antigen and are found in peripheral 
tissues particularly epithelia of skin and gut, whilst TCM proliferate to give rise 
to more effector cells and recirculate through secondary lymphoid organs. 
Thus, these two subsets are distinguished by their migratory capacity, state of 
differentiation and ability to proliferate. 
 
4.1.2 The Role of Adaptive Cell Mediated Immunity in Varicella and 
Herpes Zoster: 
VZV-specific T cells are believed to be important in the control of viral 
replication, both during primary infection and in the maintenance of latency 
(Asano et al., 1985a; Arvin et al., 1986b; Park et al., 2004; Saibara et al., 
1993).  Several studies have documented that proliferative T cell responses, 
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(unlike the early production of VZV-specific IgM and IgG antibodies) correlate 
inversely with the severity of clinical varicella infection (Arvin et al., 1986b; 
Asano et al., 1985a; Patel et al., 1979; Gershon and Steinberg, 1979; 
Malavige et al., 2008b), and a study of healthy and immunocompromised 
patients with primary infection found that milder illness was associated with 
the detection of T cell proliferation ex vivo to VZV antigen within three days 
after the appearance of exanthem (Arvin et al., 1986b). The rapid host 
response to primary VZV infection is also associated with rapid termination of 
viraemia in healthy subjects (Arvin et al., 1986b).  
 
With zoster, immunosenescence of the cell mediated immune (CMI) response 
appears to be more important than a waning antibody response in preventing 
virus reactivation, as evidenced by studies investigating the increased risk of 
herpes zoster with ageing (Guess et al., 1985; Opstelten et al., 2002; Thomas 
and Hall 2004).  Numerous studies that have investigated the potential 
decline in immunity to VZV in the elderly have found no reduction in VZV-
specific antibody titres in elderly subjects compared to young adult controls 
(Burke et al., 1982; Hayward and Herberger, 1987; Miller, 1980; Berger et al., 
1981). In contrast, the incidence and severity of herpes zoster and 
postherpetic neuralgia among older adults are closely linked to a progressive 
age-related decline in T cell responses (Burgoon et al., 1957; Ragozzino et 
al., 1982; Galil et al., 1997; Wilson et al., 1992; Buchbinder et al., 1992; 
Miller, 1980; Berger et al., 1981; Burke et al., 1982; Levin et al., 1992). 
 
Strong associations have been observed between the occurrence of herpes 
zoster and low CD4+ T cell count in HIV positive children (Von Seidlein et al., 
1996). Similarly, in breast cancer patients, an inverse correlation between 
VZV re-activation and the total number of T cells transferred with the stem cell 
graft was observed (Zambelli et al. 2002). High incidence of herpes zoster in 
patients with systemic lupus erythematosus (SLE) has been shown to be 
associated with a lower frequency of VZV specific, IFN-+ CD4+ memory T 
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cells (Park et al., 2004), and reduced CD8+ and CD4+ T cell counts have 
been shown to be significantly associated with the onset of zoster in patients 
having undergone autologous peripheral blood progenitor cell transplantation 
(Offidani et al., 2001).  In addition, there is no indication that passive antibody 
prophylaxis reduces the risk of VZV reactivation in high-risk populations, and 
passive antibody administration does not alter the clinical course of herpes 
zoster (Stevens and Merigan, 1980; Brunell et al., 1975).  
 
Reactivation of the virus results in VZV-specific T cell proliferation 
(Ruckdeschel et al., 1977). The number of circulating VZV-specific T cells 
increases immediately as a consequence of the re-exposure to viral antigens 
although the response is decreased in immunocompromised compared to 
otherwise healthy individuals with zoster (Hayward et al., 1991b). Enhanced 
cell mediated immunity persists for a prolonged period after reactivation and 
may explain why second episodes of shingles are very rare (Arvin, 1996a). 
Boosting of VZV-specific CD4+ T cells has been observed in immune adults 
after re-exposure via household contact with children experiencing varicella, 
(Vossen et al., 2004), and zoster cases are lower in those frequently exposed 
to varicella (Thomas et al., 2002).  
 
4.1.3 Variation in T Cell Responses and Factors that Affect T Cell 
Responses in Individuals: 
4.1.3.1 Age: 
Notable differences in VZV-specific T cell responses occur between children 
and adults in response to varicella vaccination. One year after vaccination, 
adults who received two doses had significantly lower VZV-specific T cell 
responses than children who had received just one dose of vaccine, (Nader 
et al., 1995).  As mentioned above, the incidence and severity of herpes 
zoster also increase with age (and thus the subsequent immunosenescence 
of the CMI response); more than half of all persons in whom herpes zoster 
develops are older than 60 years (Hope-Simpson, 1965; Levin et al., 2003b).  
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4.1.3.2 Gender: 
Some epidemiological studies have noted gender differences in the incidence 
of zoster. Recently, Fleming (et al., 2004) evaluated 14,000 cases of zoster 
over eight years and found a consistent female excess of 28% in the rate of 
zoster. A separate, smaller study reported a female prevalence among an 
elderly population of 105 patients with zoster admitted to a study hospital 
(Torrens et al. 1998). However two separate studies which examined zoster 
in 1,075 and 957 cases did not identify gender differences in the incidence of 
zoster (Donahue et al., 1995; Oxman et al., 2005).  Given the importance of 
memory T cells in zoster development, a recent study compared the 
frequencies of VZV-specific memory T cells between 17 males and eight 
females (Klein et al., 2006). Although asymptomatic adults typically had 
minimal fluctuations in their VZV-specific memory T cells over the course of a 
year, the CD4+ T cells responses differed over time between men and 
women. The results suggest the possibility that males maintain higher levels 
of VZV-specific memory T cells than women, even though women exhibited 
episodes of detectable response during the course of the study. The authors 
did acknowledge that the differences observed here could in part, be due to 
the smaller sample size for women. However, gender differences in the 
cytokine responses of memory T cells have been noted for other herpes 
viruses; memory T cells from women have been found to secrete higher 
levels of IFN- and IL-2 in response to both HCMV and HSV as compared to 
men, which might be expected to be associated with higher responder cell 
frequency (RCF) against these viruses and subsequently lower rates of 
reactivation in women (Villacres et al., 2004). 
 
4.1.3.3 Immunosuppression:  
Suppression of the immune system can be caused by multiple factors such as 
anti-cancer therapy, immunosuppressive drug treatment required for organ 
and bone marrow transplantation, and diseases such as lymphoma and 
human immunodeficiency virus (HIV) infection. The incidence and severity of 
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varicella along with the frequency of complications in immunocompromised 
patients with suppressed CMI is higher compared with varicella in healthy 
subjects (Rowland et al., 1995; Rogers et al., 1995; Grant et al., 2002, 
McCluggage et al., 1994; Kim and Haycox, 1999). In contrast no evidence 
exists of more severe varicella in those with abnormal humoral immunity 
(Locksley et al, 1985). Failure of cellular responses to halt the spread of VZV, 
which can often occur in immunocompromised patients, can result in VZV 
visceral dissemination to the lungs, liver, kidneys, and spleen and in 
progressive life-threatening infection (Rowland et al., 1995; Rogers et al., 
1995; Grant et al., 2002).  
 
After cardiac transplantation, herpes zoster infections are more frequent than 
in healthy subjects and depressed or absent cellular responses to VZV 
parallel with that susceptibility (Rand et al., 1977). These findings were 
supported by a later study, in which, immune responses and infections with 
herpes viruses were examined in 36 cardiac transplant recipients. Herpes 
zoster occurred in 22% of patients during the first year after transplantation, 
and in those cases, VZV-specific T cell responses returned thereafter (Pollard 
et al., 1982).  Several studies have demonstrated that intensive anti-cancer 
therapy using bone marrow transplantation (BMT) puts patients at increased 
risk for zoster, increasing both morbidity and mortality of the disease. Reports 
indicate that 14-41% of BMT recipients developed zoster (or subclincal VZV-
viraemia), within a year of transplantation (Schuchter et al., 1989; Locksley et 
al., 1985; Koc et al., 2000; Hogewoning et al., 2001; Wilson et al., 1992). One 
of these studies found that BMT recipients had significantly fewer circulating 
cytotoxic T cells that recognized VZV IE62 or gE than healthy VZV immune 
controls (Wilson et al., 1992). 
 
Herpes zoster is also a frequent complication of lymphoreticular malignancy. 
In a study of normal subjects with recent and remote VZV infection and 
patients with lymphoma, T cell responses were measured before treatment 
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and during long-term remission and then compared with those of normal 
subjects (Arvin et al., 1978b). Despite levels of antibody to VZV that were 
equivalent to those in normal subjects, 44% of the untreated lymphoma 
patients showed a lower T cell transformation response to VZV antigen, than 
the normal patients. Twenty-two percent of lymphoma patients in long-term 
remission continued to have diminished cellular immune responses to VZV 
antigen. Observations in these patient populations and in normal subjects 
with acute herpes zoster suggest that deficiencies in lymphocyte responses 
seen in vitro may correlate with increased susceptibility to clinical infection 
with VZV (Arvin et al., 1978b).   
 
VZV causes severe and/or recurrent varicella or herpes zoster in untreated 
HIV-infected patients (Glesby et al., 1993; Engels et al., 1999). A longitudinal 
study of VZV infections in HIV-infected children found that in 70% of patients 
who had low CD4+ T cells counts at the time of varicella infection went on to 
develop zoster during the course of the study (Gershon et al., 1997). The 
approximate incidence of zoster in HIV-infected individuals, compared to 
uninfected individuals, is approximately ten times greater (Buchbinder et al, 
1992; Veenstra et al, 1995; Morgan et al., 2001), and zoster has been found 
to be a strong predictor of HIV-1 infection in children and young adults in Sub-
Saharan Africa (Lindan et al., 1992; Tyndall et al., 1995; Colebunders et al., 
1988; Naburi and Leppard, 2000). In addition several studies have found the 
incidence of herpes zoster increases as CD4+ T cell counts decrease and HIV 
induced immunosuppression progresses, (Veenstra et al., 1995; Engels et al., 
1999). 
 
4.1.3.4 Genetic Factors:  
Evidence for a heritable contribution to varicella zoster virus disease comes 
from a number of sources, although the role of T cells in these studies was 
not examined per se. In age and sex matched individuals, zoster is four times 
more common in Caucasian than in African American subjects (Schmader et 
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al., 1995), and these findings were supported by later work by the same 
authors when studying multiple elderly cohorts in the same area (Schmader 
et al., 1998a; Schmader et al., 1998b). In a retrospective study it was found 
that black people were at less than half the risk of zoster than Caucasian 
people after adjusting for age and sex, (Thomas and Hall, 2004). However a 
recent report of individuals with incident zoster participating in antiviral trials 
showed that being non-Caucasian and resident in tropical countries were 
independently associated with significantly younger age at zoster, although 
this tendency could simply indicate participation bias or undiagnosed HIV 
infection (Nagasako et al., 2003).  
 
Reports of racial differences in HLA genes and susceptibility to infectious 
diseases such as malaria, tuberculosis and herpes labialis (Tiwari and 
Terasaki, 1981; Hill et al., 1991, Stead et al., 1990, Embil et al., 1975) may 
provide indirect evidence consistent with racial differences in the VZV-specific 
immune response and therefore subsequent development of zoster 
(Schmader et al., 1998a). However studies which have directly examined 
VZV infection and HLA prevalence have been conflicting. An early population-
based study of herpes virus infection and HLA phenotype, conducted during 
the late 1970s revealed that HLA-Bw16 was found less often and HLA-Cw2 
more often, in individuals with histories of herpes labialis than in other 
individuals. However, no strong association was found between HLA and a 
history of herpes zoster or to HSV-2, or HCMV (Blackwelder et al., 1982). 
Similarly, a study carried out in a large and diverse group of individuals to 
examine the relationship between HLA-A, HLA–B and antibodies to a wide 
range of viruses, including the measles virus and VZV revealed that although 
there was a relationship between the presence of the HLA-B15 allele and a 
lack of circulating measles antibodies, there was no association between 
significantly elevated titres to HCMV and VZV and the presence or absence 
of any particular HLA-A or -B antigen (Cuthbertson et al., 1982).  
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An association between HLA and PHN has been suggested. Results from a 
Japanese study on 32 patients with PHN (and 136 healthy controls) found a 
positive association in the susceptibility to VZV and of the development of 
PHN with the HLA class I antigens HLA-A33 and -B44, (the HLA-A33-B44 
haplotype), (Ozawa et al., 1999). Following on from the work of Ozawa, Sato 
(et al., 2002c) found that in addition to HLA-A*3303 and HLA -B*4403, that 
the HLA-DRB1*1302 allele was also significantly associated with PHN.  No 
significant association between PHN and HLA class II alleles (Ozawa et al., 
1999), or between genes in the HLA class III region; (tumour necrosis factor 
alpha (TNFA) promoter, and polymorphisms in the natural killer cell activating 
receptor, NKp30) were demonstrated in these studies (Sato et al., 2002c).  
 
4.1.3.5 Relative Antigen Content of Varicella Vaccine: 
The representative viral titre in a single dose of the commercially available 
varicella vaccines is a minimum of 1,350 pfus for VARIVAX and a minimum 
of 1,995 pfus for VARILRIXTM. As well as live replicating vaccine virus, the 
vaccine preparations also contain incomplete virus particles and dead virus, 
both of which can stimulate an immune response. Studies have been carried 
out to examine the immunogenicity of vaccine preparations with varying ratios 
of live virus and total antigen content, (Watson et al., 1993; Sperber et al., 
1992; Rothstein et al., 1997 and Bergen et al., 1990), but the majority of 
these studies focused on serological responses. In one study of healthy 
children, when plaque forming unit (pfu) content was maintained at 1000 pfu, 
but the relative antigen content was reduced from 96 to 87%, the frequency 
and strength of cell mediated immune responses were drastically reduced, 
although antibody titres were equivalent,  (Bergen et al., 1990).  
 
4.1.4 Nature of the T Cell Response to VZV: 
Both CD8+ and CD4+ T cells are primed during primary VZV infection, but in 
contrast to classic antiviral T cell responses, (including to other herpes 
viruses such as EBV and CMV (Callan et al., 1998; Maini et al., 2000; 
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Sylwester et al., 2005), the response to wild-type and vaccine VZV appears to 
be CD4+ rather than CD8+ dominated (Hayward, 1990; Hayward et al., 1992; 
Huang et al., 1992; Sharp et al., 1992; Vossen et al., 2004; Jones et al., 
2006b; Jones et al., 2007; Malavige et al., 2007; Malavige et al., 2008a; 
Milikan et al., 2006; Milikan et al., 2007; Milikan et al., 2009).  VZV-specific 
CD4+ and CD8+ T cell responses are discussed in more detail in sections 
4.1.4.1 and 4.1.4.2.  Memory T cells specific for VZV have been found at 
lower frequencies, compared with those of other herpes viruses, such as 
HCMV, HSV, and EBV, in healthy immune individuals (Asanuma et al., 2000; 
Khan et al., 2004). Recent ex vivo analysis of IE63 and gE -specific CD4+ T 
cells from naturally immune adults (with no history of reactivation), 
demonstrated evidence of recent cell activation and a mixed central and 
effector memory differentiation phenotype (Jones et al., 2007; Malavige et al., 
2008a).     
 
VZV-specific CD4+ T cells that are induced during primary infection are 
predominantly of the Th1 phenotype and produce high levels of IFN- and 
TNF-, (Zhang et al., 1994; Zhang et al., 1995; Milikan et al., 2007; Jenkins et 
al., 1998a; Asanuma et al., 2000). Such T cell clones have been shown to 
lyse infected cells in vitro (Hayward et al., 1989; Hayward et al., 1986b; 
Huang et al., 1992; Sharp et al., 1992; Milikan et al., 2007). T cell antigen 
specificity has been addressed in a number of studies which have 
documented reactivity to several VZV proteins in healthy naturally immune  
and vaccinated adults, including the regulatory and structural proteins 
encoded by ORF4, ORF10, ORF62, and ORF63 and glycoproteins gB, gC, 
gE, gI and gH (for references and summary see table 4.1).  
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Gene Function Reference 
4 
Transcriptional activator, 
Tegument protein 
Arvin et al., 2002; Jones et al., 2006b; Milikan 
et al., 2007$ 
10 
Transcriptional activator, 
Tegument protein 
Arvin et al., 2002; Milikan et al., 2007$ 
14 Glycoprotein C 
Sharp et al., 1992; Lowry et al., 1992*; 
Milikan et al., 2007$ 
18 
Ribonucleotide reductase 
(small subunit) 
Milikan et al., 2007$ 
29 
Single stranded DNA 
binding protein 
Arvin et al., 2002; Milikan et al., 2007$  
31 Glycoprotein B 
Giller et al., 1989b; Hayward, 1990; Watson 
et al., 1990; Milikan et al., 2007$  
33 Assembly protein 
Welsh et al., 1999; Garcia-Valcarcel et al., 
1997b* 
37 Glycoprotein H 
Arvin et al., 1986a; Giller et al., 1989b; 
Watson et al., 1990 
61 Transcriptional regulator Milikan et al., 2007$ 
62 
Transcriptional activator, 
Tegument protein 
Arvin et al., 1986a; Arvin et al., 1991;  
Frey et al., 2003; van der Heiden et al., 2009; 
Arvin et al., 2002; Sharp et al., 1992;  
Lowry et al., 1992;* Sabella et al., 1993*`; 
Milikan et al., 2007$; Arvin et al., 1987* 
63 
Transcriptional activator, 
Tegument protein, 
Jones et al., 2007; Milikan et al., 2007$ 
Sadzot-Delvaux et al., 1997 
67 Glycoprotein I 
Malavige et al., 2007; Hayward, 1990; Sharp 
et al., 1992; Lowry et al., 1992*;  
Huang et al., 1992; Milikan et al., 2007$ 
68 Glycoprotein E 
Malavige et al., 2008a; Arvin et al., 1986a;  
Arvin et al., 1991; Giller et al., 1989b;  
Sharp et al., 1992;  Lowry et al., 1992*;  
Huang et al., 1992; Welsh et al., 1999; 
Watson et al., 1990; Milikan et al., 2007$
 
Arvin et al., 1987*; Garcia- Valcarcel et al., 
1997a* 
Table 4.1 VZV Proteins which are Targets of T Cell Immune Responses. Key: 
*Study carried out in Guinea pigs or mice (all other studies were carried out 
using human PBMCs, (or T cells recovered from intraocular fluid$).  
 
4.1.4.1 The Role of CD8+ T Cells in VZV Infection: 
Several studies have demonstrated that MHC-I restricted CD8+ T cells were 
capable of responding to VZV antigens (expressed by VZV-infected 
fibroblasts and lymphoblastoid cells), (Hickling et al., 1987; Arvin et al., 1991; 
Sadzot-Delvaux et al., 1997; Milikan et al., 2007). CD8+ T cells have been 
shown to play a role in the response gE as well as IE62 and IE63, and in one 
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study, quantitive analysis of VZV cytotoxicity by limiting dilution assays 
demonstrated that the numbers of circulating virus-specific CD8+ and CD4+ 
CTL precursors were equivalent in naturally immune subjects at least 20 
years after infection (Arvin, et al., 1991). However in another study, VZV-
specific CD8+ T cells were shown to be present in study subjects PBMCs at 
relatively low frequencies after primary infection, but at much higher 
frequencies in zoster patients (Hickling et al., 1987).  
 
More recently, a study from the Arvin laboratory supported the idea that virus-
specific CD8+ T cells may circulate at a relatively low frequency after primary 
infection, as IE62 peptide-specific memory CD8+ T cells were detected only 
after in vitro expansion (Frey et al., 2003). There has been very little work on 
mapping CD8+ T cells epitopes to date; one study has identified HLA-A*02 
restricted IE62 epitopes in naturally immune subjects, (see table 4.2). In brief, 
synthetic 12-mer overlapping peptides were produced to correspond to the 
complete IE62 protein. Single IE62 peptides were combined to prepare 
peptide pools (PPs). The study found that after secondary in vitro stimulation, 
two peptides within a particular pool induced a response in latently infected 
subjects. Furthermore, upon booster vaccination in three individuals, 
increased CD8+ T cell frequencies specific for those peptides resulted, (Frey 
et al., 2003).  
 
Recently, another HLA-A2 restricted IE62 epitope has been mapped (van der 
Heiden et al., 2009), see table 4.2 for details.  This was carried out via the 
use of HLA-A2 pentamers and ex vivo staining of PBMCs from T cell depleted 
allogeneic stem cell transplantation patients experiencing VZV reactivation. 
The epitope was recognized by CD8+ T cells in 42% of patients ex vivo, and 
in a total of 63% (n=12) patients after in vitro expansion.  
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Protein 
aa 
number 
Sequence 
HLA Restriction if 
Known 
Reference 
IE62 445-453 SLPRSRTPI HLA*0201 Frey et al., 2003 
IE62 472-480 SAPLPSNRV HLA*0201 Frey et al., 2003 
IE62 593-601 ALWALPHAA HLA*0201 
van der Heiden et 
al., 2009 
Table 4.2: HLA-A*0201 Restricted CD8+T Cell IE62 Epitopes.  
 
4.1.4.2 The Role of CD4+ T Cells in VZV Infection: 
VZV-specific CD4+ T cells synthesize Th1-like cytokines, such as interleukin-2 
(IL-2) and interferon- (IFN-) (Jenkins et al., 1998a; Zhang et al., 1994), and 
some are capable of MHC-II-restricted cytotoxicity in vitro (Arvin et al., 1991; 
Cooper et al., 1988; Diaz et al., 1989; Hayward et al., 1989; Hayward, 1990). 
EBV transformed human B cells expressing cell surface VZV antigens have 
been shown to be lysed by HLA-DR3 restricted CD4+ T cells in vitro (Hayward 
et al., 1986b). This added support to an earlier finding by Pontesilli (et al., 
1987) that most T cells responding to VZV antigens in culture were CD4+ T 
cells. In addition, a study that was the first to document the infiltration of VZV-
specific T-cells in VZV-induced ocular lesions, found that CD4+ T cells 
predominated over CD8+ T cells (Milikan et al., 2006). Later work by the same 
authors (Milikan et al., 2009) indicated that human retinal pigment epithelial 
cells may play a role as the retina-resident antigen-presenting cells in the 
CD4+ T cell–mediated inflammatory response of VZV-induced uveitis. 
 
4.1.4.3 Targets of CD4+ T Cells 
4.1.4.3.1 Glycoproteins: 
The report by Arvin (et al., 1986a) demonstrated that CD4+ T cells in healthy 
subjects with a diverse HLA background (with naturally acquired VZV 
immunity), could respond to purified gE and gH proteins. In a similar study by 
Giller (et al., 1989b) it was found that purified gH protein did not induce T cell 
responses of the same magnitude to those seen for gE and gB. Giller‟s study 
also revealed for the first time that gB was a potent inducer of T cell immunity, 
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and in the case of acute infection of one adult during the study, gB was the 
predominant T cell inducer. Hayward (1990) demonstrated that CD4+ T cells 
can recognize peptides of gB (and gI; discussed later), but only mount weak 
proliferative responses (see table 4.3). CD4+ cytotoxic T cells from both 
naturally immune and vaccinated healthy adults have been shown to lyse 
autologous lymphoblastoid cell lines infected with vaccinia virus expressing 
either recombinant gC, gE or gI (Sharp et al., 1992).  
 
Diaz (et al., 1989) also showed that CD4+ T cells lysed VZV-infected targets 
after in vitro expansion with gE antigen, and these cells were found to 
circulate in individuals with naturally acquired immunity to VZV. In a second 
study examining CD4+ T cell response to gE peptides, T cells from the 
majority of healthy immune donors recognised carboxy-terminal residues that 
constitute the transmembrane (and thus intracellular anchor segments) of the 
protein. The peptides were recognised from donors with very different MHC-II 
backgrounds. Indeed, two donors with distinct HLA-DR, -DQ, and –DP 
phenotypes responded to all of the gE peptides, although only the HLA-DR 
alleles were published (DRB1 and DRB5 for one individual, and DRB9 and 
DRB6 for the other), (Bergen et al., 1991). More recently three gE epitopes 
were mapped using either PBMCs from naturally immune donors and ex vivo 
and cultured IFN- ELISPOT analysis against successive peptides (Malavige 
et al., 2008a), whilst another was mapped by use of T cell lines derived from 
intraocular fluid samples from patients with VZV-uveitis (Milikan et al., 2007). 
In both cases, HLA restriction was deduced using HLA-specific antibodies 
followed by peptide pulsing of various APC lines of known HLA type. See 
figure 4.1, for more details of identified epitopes. 
 
Huang (et al., 1992), were the first to look at the role of CD4+ T cells in gI 
recognition. Cold target inhibition studies were used to map gI epitopes (see 
figure 4.2), and identified an epitope that lies between position 212-354, and 
that residues 245-259 are the likely candidate peptide for the gI epitope. More 
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recently a study by Malavige (et al., 2007) confirmed that gI is a CD4+ T cell 
target, and demonstrated that VZV gI-specific rapid effector functional 
immune responses are observed in all healthy VZV-seropositive individuals 
with a history of VZV infection. An epitope restricted by HLA-DRB4*01 was 
mapped in this study (see figure 4.2). Glycoprotein I was shown to account for 
9–56.5% (mean, 23.2%) of the total CD4+ IFN+ responses to VZV lysate ex 
vivo (Malavige et al., 2007).  
 
Further data from Huang (et al., 1992) generated using MHC-II restricted 
VZV-specific T cell clones from four naturally immune donors, demonstrated 
that 30 out of a total of 68 clones examined were able to lyse gE expressing 
target cells. Of these 30 clones, 50% were also able to lyse gI expressing 
target cells, demonstrating that gI and gE share a CD4+ T cell epitope. The 
study also found that gE-specific CD4+ cytotoxic T cells outnumber gI-specific 
CD4+ T cells circulating in the peripheral blood of naturally immune donors.  
 
4.1.4.3.2 Tegument Proteins: 
IE62 is one of the key targets of T cell immunity. The report by Arvin (et al., 
1986) demonstrated that T cells (in healthy subjects with a diverse HLA 
background and who had naturally acquired VZV immunity), could respond to 
the IE62 protein. A later study by Bergen (et al., 1991) revealed that IE62 
could elicit potent CD4+ T cell responses to a wide variety of peptides (see 
figure 4.3), which span the length of the protein. Residues from the amino 
terminal half of the IE62 protein tended to be more immunogenic, and were 
reactive in more donors, who were from a diverse genetic background. Using 
the peptides identified as immunogenic by Bergen, Jenkins (et al., 1998a and 
Jenkins et al., 1999) demonstrated that these epitopes could induce CD4+T 
cell responses in naïve donors when presented using autologous DCs. More 
recently two epitopes were mapped by use of T cell lines derived from 
intraocular fluid samples from patients with VZV-uveitis (Milikan et al., 2007), 
 250 
 
with one of these epitopes being recognised by both HLA DRB1*1404 and 
HLA DRB1*0703 restricted T cell lines (Milikan et al., 2007). 
 
Studies carried out in naturally immune adult donors demonstrated that IE63 
is highly immunogenic and elicits a long-term immune response (Sadzot-
Delvaux et al., 1997). In this study, CD4+ Th1 cytotoxic T cells were shown to 
respond to IE63 at frequencies which are equivalent of those seen for IE62 
(Sadzot-Delvaux et al., 1997).  More recently, high frequencies of IE63 
protein-specific T cells were detected ex vivo in naturally immune donors and 
a DRB1*1501 restricted CD4+ T cell epitope was mapped (Jones et al., 2007), 
see table 4.3. 
 
High frequencies of ORF4 protein-specific T cells have also been detected ex 
vivo in individuals up to 52 years after primary infection and identified 
immunogenic regions of the ORF4 protein, including a commonly recognized 
epitope (see table 4.3) which was restricted through HLA-DRB1*07 (Jones et 
al., 2006b). Like the IE63 epitope, the ORF4 epitope was processed and 
presented by keratinocyte cell lines after stimulation with infected cell lysate 
or the live VZV vaccine. The total ORF4 protein responses comprised 
approximately 20% of the total lysate or vaccine stimulated responses, 
suggesting that the ORF4 protein is an immunodominant target antigen. This 
raises the possibility that such T cells have a role in the control of viral 
reactivation.  In a study of healthy immune donors, mean RCFs (75% CD4+ T 
cells, 10% CD8+ T cells) to ORF10 protein were found to be equivalent to 
those invoked by IE62 (Arvin et al., 2002).  
 
4.1.4.3.3 Other Targets: 
In the same study as mentioned previously, the mean RCF to ORF29 protein 
was found to be lower than those of IE62, ORF4 and ORF10 (Arvin et al., 
2002). In a separate study in guinea pigs, immunization with the ORF29 
protein did not prime animals for an enhanced T cell response upon 
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challenge with infectious virus. Thus in this study the ORF29 gene product 
did not elicit protection (Sabella et al., 1993). 
 
A study in mice found that three out of four inbred strains of mice immunised 
with (ORF33) AP-VLPs produced a VZV-specific T cell response (Garcia-
Valcarcel et al., 1997b). A later study of varicella and zoster patients using 
lymphocyte proliferation assays (LPA) against VLPs demonstrated that a 
VZV-specific lymphocyte response to the assembly protein (AP) was 
measurable in some patients (Welsh et al., 1999), but in comparison to the 
response induced by gE fragments (which were recognised by 85% of 
varicella and 75% of zoster patients in this study), AP could not be 
considered a dominant T cell antigen (Welsh et al., 1999).  
 
Glycoprotein/ 
Protein 
aa 
number 
Sequence 
HLA 
Restriction 
(if Known) 
Reference 
gB 139 -149 EITDTIDKFGK  
Hayward, 
1990 
gB 769 -779 LPEGMDPFAEK  
Hayward, 
1990 
IE4 251 - 270 MLYGHELYRTFESYKMDSRI HLA-DRB1*07 
Jones et 
al., 2006b 
IE63 229 -243 QRAIERYAGAETAEY DRB1*1501 
Jones et 
al., 2007 
 
Table 4.3: Glycoprotein B, ORF4 and IE63 CD4+ T Cell Epitopes Identified in 
Naturally Immune Donors. IE4 and IE63 epitopes were identified ex vivo, 
(underlined amino acids are critical for presentation); gB epitopes were 
identified using proliferation and cytotoxicity assays. 
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Figure 4.1: Glycoprotein E CD4+ T Cell Epitopes and their HLA Restriction, Identified in Naturally Immune, Adult Donors. Epitopes 1-
3, 6, 7 and 10 were recognised by CD4+ T cells from 67-92% of donors in lymphocyte proliferation assays. Epitopes 4, 5 and 9 were 
identified ex vivo and following in vitro stimulation. Epitope 8 was mapped using T cell clones from patients with VZV-induced uveitis; 
HLA restrictions are noted above. Key: IDE BD, Insulin Degrading Enzyme Binding Domain (aa 24-71); gI BD, gI Binding Domain (aa 
163-208); SP, Signal Peptide; TMD, Transmembrane Domain; CPD, Cytoplasmic Domain. 
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Figure 4.2: Glycoprotein I CD4+ T Cell Epitopes in Naturally Immune Adult Donors.  
Epitopes 2 and 4 were identified as weakly immunogenic (Hayward, 1990); Huang (et al., 1992) suggest that the shared epitope 
between gE and gI lies between 212-354, and predict the epitope (3) to be at position 245-259. An optimum HLA DRB4*01 restricted 
epitope (1) was identified ex vivo and following in vitro stimulation. 
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Figure 4.3: IE62 CD4
+
 T Cell Epitopes Identified in Either Healthy Naturally Immune, or Vaccinated Donors, or in Patients with VZV-Induced Uveitis. Epitopes 1-5 
were identified as immunogenic (Bergen et al., 1991) and stimulated CD4
+
 T cells from 75-83% of naturally immune donors. Epitopes 2, 3 and 5 also induced an 
immune response in naïve donors whose CD4
+
 T cells were cultured with peptides and autologous DCs (Jenkins et al., 1998). The authors also found that epitope 
6 induced an immune response in 2 out of 3 donors using this methodology, and in a separate study confirmed the importance of epitope 1, 3 and 6 as these 
stimulated CD4
+
 T cell responses in 71-100% of naturally immune and vaccinated donors (Jenkins et al., 1999). Epitpes 7 and 8 were identified using T cell clones 
from patients with VZV-induced uveitis; HLA restriction is noted. 
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4.1.5 Measuring CMI Responses to Vaccination and Naturally Acquired 
Infection: 
There are various methodologies that can be used to measure CMI 
responses, dependent on which T cell subset is to be studied. 
Lymphoproliferation assay (LPA), ELISPOT, Intracellular cytokine flow 
cytometry (ICFC), MHC tetramer analysis, or ELISA for T cell cytokines are all 
methodologies which have been used in the studies discussed above. In 
addition skin testing can also be used to measure CMI (Takahashi et al., 
2001; Asano et al., 1981b; LaRussa et al., 1985; Hata, 1980) and has been 
shown to correlate with IFN- ELISPOTs carried out in the same patients 
(Sadaoka et al., 2008).  
 
In this study both MHC-II tetramer analysis and IFN- ELISPOTs were used 
to measure CMI responses to VOka vaccination. MHC-II (and MHC-I) 
tetramers facilitate the detection and quantification of epitope specific CD4+ 
(and CD8+) T cells respectively. Tetramers are comprised of four 
recombinant, biotinylated, peptide-loaded MHC molecules, bound by a 
fluorescently labelled streptavidin molecule. Incorporating tetramer staining 
into multicolour flow cytometric analysis of whole blood or PBMC samples 
allows for a sophisticated phenotypic analysis of epitope specific T cells 
(Voller and Stern et al., 2008). IFN- ELISPOTs provide a tool to quantitate 
the number of cells producing IFN- in response to an antigen.  
 
4.2. AIMS: 
The aim of this chapter was to measure cell mediated immune (CMI) 
responses to varicella (Oka) vaccination and to determine the relationship 
between CMI, antibody responses and protection from varicella following 
varicella (Oka) vaccination. 
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4.3 RESULTS: 
In this study of vaccinated HCWs, T cell responses were measured ex vivo 
using either a commercial, partially purified, whole VZV lysate as a stimulus in 
overnight IFN- ELISPOT assays, or (in study participants expressing HLA-
DRB1*1501) by use of HLA-DRB1*1501 tetramers complexed with either gE 
or IE63 epitopes (see chapter 2, section 2.5.3.1 for details). In some cases, 
where a second aliquot was available, samples which had tetramer-specific T 
cells ex vivo, were cultured with the corresponding peptide for 10 days and 
the proliferation of tetramer-specific cells was examined. 
 
4.3.1 Ex Vivo VZV-Specific IFN- ELISPOT Optimization; 
The number of PBMCs/well was restricted by the availability of resuscitated 
live PBMCs. Thus, assays were optimized using cell concentrations of 2x105 
PBMCs/well; the lowest concentration of cells previously shown to yield 
reproducible and consistent results (Smith et al., 2001; Jones et al., 2006). 
Concentrations of mitogen and lysates were titrated against resuscitated 
PBMCs from three healthy seropositive donors with a history of varicella or 
zoster >20 years previously (see figure 4.4). The concentration of VZV lysate 
that gave the highest SPFs/106PBMCs was selected (a final concentration of 
10g/mL/well) and the same concentration of uninfected cell lysate was used 
as a negative control.  
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Figure 4.4: Optimisation of IFN- ELISPOT Using PBMCs from Naturally 
Immune Healthy Adults.     Key: PHA; phytohaemoglutinin mitogen. PBMCs 
from healthy seropositive donors (2x105/well) were stimulated with various 
concentrations of either whole VZV-infected Vero cell lysate; uninfected Vero 
cell lysate; PHA mitogen or RPMI media alone. The result is representative of 
three donors. Part A: Processed images (Biosystem 5000 ELISPOT reader) 
of all wells (apart from those stimulated with PHA, where live images are 
presented as there were too many SFUs to count; Part B: Corresponding bar 
graph representing the SFU/106PBMCs. PHA stimulated wells were given an 
arbitrary count of 1000 SFU/106PBMCs as the magnitude of the response 
was uncountable. 10g/mL of VZV lysate generated 112 SFU/106PBMCs; 
(5g/mL = 70SFU/106PBMCs; 2.5g/mL = 28SFU/106 PBMCs).  
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4.3.1.1 Optimizing the Number of PBMCs Available for ELISPOT Assays 
After Thawing: 
As can be seen from table 4.4, (see chapter 2, section 2.5.1.2 for details), 
incubating cells at 4oC was optimal for maximizing the number of live PBMCs 
available. For subsequent ELISPOT assays, cells were incubated on ice 
whilst the plate was prepared for cell addition.  
 
Temperature  
Number of 
Live PMBCs 
at 0min 
Number of 
Live PMBCs 
at 30min 
Total Loss of 
Live PBMCs 
Due to Cell 
Aggregation 
(% of original)  
4oC 1.4x106 1.4x106 0 (100%) 
RT  1.4x106 8x105 6x105 (43%) 
37oC 1.4x106 8x105 6x105 (43%) 
Table 4.4: Loss of Live PBMCs Due to Cell Aggregation, after 30 Minutes 
Incubation at Various Temperatures. PBMCs from a healthy donor were 
resuscitated, counted and split into three equal volumes and incubated at 
various temperatures. Cells were recounted after 30min. 
 
4.3.2 Ex Vivo VZV-Specific IFN- ELISPOT Responses at 18 Months Post 
Vaccination:  
Ex vivo ELISPOT assays were carried out on 18 month follow-up PBMC 
samples (n=75). The number of live PBMCs recovered was not sufficient to 
allow corresponding 10 day cultures to be established. Only 33% (25/75) of 
results were informative with no or low numbers of spot forming units (SFUs) 
in negative control wells, and high levels of IFN- production in response to 
PHA mitogen. A representative image of a PBMC sample which had 
responsive PBMCs and produced a VZV-specific IFN- response is presented 
in figure 4.5. Nineteen of these subjects (76%)  had positive VZV-specific 
IFN- responses (referred to as positive ELISPOT) at this time point, which 
are presented in table 4.5, whilst six were classified as not having a VZV-
specific IFN- response (table 4.7,  discussed later in the text).  See chapter 2 
section 2.5.1 for the definition of a positive response. 
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Figure 4.5: Representative Image of an Ex Vivo IFN- ELISPOT Generated 
Using Responsive PBMCs Which Produced a VZV-Specific IFN- Response 
Following Overnight Stimulation. PBMCs from ROVE study participant 1004 
(18 month follow-up visit), are presented (112SFU/106PBMC). PBMCs were 
either stimulated with PHA mitogen (5g/mL/well), VZV or uninfected lysate 
(10g/mL/well) or RPMI alone. Part A: Processed images (Biosystem 5000, 
ELISPOT reader) of all wells (apart from those stimulated with PHA, where 
live images are presented as there were too many SFUs to count). Part B: 
Corresponding bar graph representing the SFU/106PBMCs. PHA stimulated 
wells were given an arbitrary count of 1000 SFU/106PBMCs as the magnitude 
of the response was uncountable.  The total number of SFUs in the six 
negative control wells were subtracted from the total of SFUs in the three VZV 
stimulated wells and the mean was calculated.  Samples were classified as 
having a positive VZV-specific IFN- response if the number of SFUs in the 
VZV lysate stimulated wells was greater than the (mean+3SD) of the negative 
control wells. In this example the mean of the negative control wells was 0.5, 
and the SD was 0.83, making a cut-off of 3SFU.  
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  Humoral Subset  Serology (18 Months) CMI Demographics 
Study 
Number 
Follow-
Up 
During 
Study 
TRFIA 
(mIU/mL) 
Avidity 
(%) 
FAMA 
SFU/10
6
 
PBMC 
History Ethnicity Gender Age 
1025 N(L) NSC1 65   <2 35 No Ind  M 38 
1026 N(L) NSC1 116 28 8 100 No Phil F 27 
1036 N NLR 59     10 No Black  F 33 
1047 N(L) NSC1 118 56   75 No Ind  F 25 
1027
$
 N NLR 122 48 <2 10 No Black  F 50 
1008 R NSC2 144 73   45 No Ind  F 41 
1009 R PI 717 65 2; 8 35 No Black  F 34 
1017 R NSC2 148 29 <2 15 No Black  F 29 
1029 R PI 574 82 <2 15 No Black  M 20 
1034 R NSC2 138 33   20 No Black  F 38 
1049 R NSC1 334 44   10* No Black  F 29 
1060 R NSC1 210 39   10* No Cauc F 30 
1062 R PI 407 82   30 No Black  F 33 
1090 R PI 422 93   132 x1 Cauc F 19 
1004 Boost PI 1,376 85   112 No Phil F 30 
1020 Boost PI 1,447 87 8 40 DNK Cauc F 24 
1021 Boost NSC2 1,303 84   27 No Ind  F 31 
1031 Boost PI 2,434 90   13 x1 Cauc F 27 
1050 Boost NLR 280 51   42 DNK Black  M 36 
Table 4.5: HCWs who had VZV-Specific IFN- Responses at the 18 Month Follow-Up Visit. Key: NSC1; Negative Seroconverted to one dose, NLR; Negative Low 
Responder; NSC2; Negative seroconverted to two doses, PI; Positive „Immune‟, N; negative at 18 months, N(L); negative, had lost TRFIA titre below 130mIU/mL at 18 
months, R; retained antibody (TRFIA 130mIU/mL) at 18 months, Boost; 18 month TRFIA> 12 week TRFIA,  SFU; spot forming units, History; History of chickenpox at 
enrolment, DNK; did not know, Phil; Filipino, Cauc; Caucasian; Ind; Indian subcontinent, M; male, F; female, *PHA responses for these individuals were low, 
$
HCW 
received a third dose of vaccine. HCWs with values in bold had TRFIA values below 130mIU/mL. Mean; 40 SFU/10
6
PBMCs, median; 30 SFU/10
6
PBMCs, SD 37 
SFU/10
6
PBMCs. See table 4.7 for ELISPOT negative data.   
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Positive ELISPOT readings ranged from 10-132 SFU/106 PBMCs, (mean; 40, 
median; 30 SD 37 SFU/106 PBMCs), but two individuals with counts of 10 
SFU/106PBMCs had low PHA responses in comparison to all other 
individuals (who had mitogen responses classified as „too many to count.‟) 
Thus, in these two cases it is likely that 10 SFU/106PBMCs is an under 
estimate of the true number of VZV-specific IFN- producing cells in the total 
cell population. Thus, excluding these two samples from analysis gave a 
range of 10-132 SFU/106 PBMCs, (mean; 44, median; 35 SD 38 SFU/106 
PBMCs). 
 
4. 3.2.1 Comparison Between VZV-Specific IFN- Responses and VZV-
Specific IgG Titres at 18 Months Post Vaccination: 
There was no correlation between study participants log10 TRFIA titres and 
the number of SFU/106PBMCs at 18 months post vaccination, (R2=0.0097). 
Table 4.6 summarises the ELISPOT and TRFIA assay status at this time 
point. 
 
ELISPOT N TRFIA N 
Positive  19 
Positive 14 
Negative 5 
Negative 6 
Positive 1 
Negative 5 
    Total 25 
 
Table 4.6 Summary of the ELISPOT and TRFIA Assay Status at 18 Months 
Post Vaccination. 
 
4. 3.2.1.1 Positive ELISPOT: 
Of the 19 individuals classified as having a positive ELISPOT reading, 14 
(74%) had corresponding positive TRFIA VZV-specific IgG titres 
(130mIU/mL).  For these 14 individuals, ELISPOT readings ranged from 10-
132 SFU/106PBMC, with a median of 29 SFU/106PBMC whilst TRFIA 
readings ranged from 138-2,434mIU/mL with a median of 415mIU/mL.  Fifty 
percent of this cohort had been classified as secondary humoral responders 
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after the first dose of vaccine, with a positive baseline TRFIA titre (positive 
„immune‟ (PI), n=7), whilst one individual failed to seroconvert following 
vaccination (negative low responder; NLR = 7%), 29% were negative 
seroconverted to two doses (NSC2; n=4), and 14% were NSC1 (n=2). 
 
Three of the 14 reported exposure to VZV in between their 12 week visit and 
their 18 month follow-up visit, in all cases, to two cases of chickenpox. Two 
were household (1034, 1049), and one was occupational (1050). This last 
individual was of particular interest as this was the HCW who was classified 
as a negative low responder, failing to seroconvert following two doses of 
vaccine, but asymptomatically seroconverted when he had a household 
contact with chickenpox. VZV-specific IFN- responses for this participant 
were un-interpretable at 12 weeks (visit 3) and at an additional time point 
taken two months after the household contact. This subject had a VZV-
specific IFN- response of 42 SFUs/106PBMCs, which was above the mean 
value of positive responses, and a TRFIA of 282mIU/ml (log10 2.45) at the 18 
month time point. (Their humoral immune response is discussed at length in 
chapter 3). 
  
Five study participants with positive ELISPOT readings had corresponding 
TRFIA titres which were negative (<130mIU/mL), (highlighted in bold; table 
4.5). Their ELISPOT readings ranged from 10-100 SFU/106PBMCs with a 
median of 35 SFU/106PBMCs. TRFIA readings ranged from 59-122mIU/mL 
with a median of 116mIU/mL. During the study 60% of these participants 
were classified as NSC1 (n=3), whilst 40% were NLR (n=2). Three of the five 
had corresponding FAMA readings and in two of these cases, FAMA scores 
were also negative (<2). Both cases are particularly interesting as study 
number 1025 seroconverted following a natural varicella infection which 
occurred between baseline and their six week visit and study number 1027 
failed to seroconvert despite receiving a third dose of vaccine.   The third of 
the five subjects with a FAMA reading, was classified as positive (FAMA 
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score; 8). It is noteworthy that this individual had one of the highest VZV-
specific IFN- responses of all study participants (100SFU/106PBMC); 
comparable to that seen in latently infected naturally immune donors (see 
figure 4.4).  Within this sub-group of positive ELISPOT/negative TRFIA, the 
two study participants with the lowest scoring positive ELISPOT responses 
were classified as NLR during the study. The remaining three subjects within 
this subgroup seroconverted following the first dose of vaccine.  
 
4.3.2.1.2  Negative ELISPOT: 
Six of the 25 18 month follow up samples with interpretable results were 
classified as not having a VZV-specific IFN- response (negative ELISPOT), 
(see table 4.7 and figure 4.6 for a representative image of a negative 
ELISPOT). 
 
 
Humoral 
Subset 
Serology (18 Months) Demographics 
Study 
Number 
During 
Study 
Follow-
Up 
TRFIA 
(mIU/mL) 
Avidity 
(%) 
FAMA 
Score 
Gender Ethnicity Age History 
1007 NSC2 N (L) 25 -   F Phil 32 No 
1015 NSC2 N (L) 74 - >8 F Black 28 No 
1019* NSC2 N (L) 15 - <2 F Cauc 40 No 
1024 NSC1 N (L) 111 30   M Black 39 No 
1041 NSC2 N (L) 108 73   F Ind   27 No 
1063 PLR R 229 23   M Black 29 No 
 
Table 4.7: Study Participants who had No Measurable VZV-Specific IFN- 
Response at the 18 Month Follow-Up Visit. Key: History; History of 
chickenpox prior to enrolment, NSC1 and NSC2; Negative, Seroconverted to 
one/two doses; PLR; Positive Low Responder (baseline TRFIA >130mIU/mL, 
six week avidity <60% and six week TRFIA <400mIU/mL), N; Negative 
(TRFIA <130mIU/mL at 18 months) N(L); lost TRFIA titre of 130mIU/mL 
between 12 weeks and  18 months, R; retained (TRFIA >130mIU/mL at 18 
months), F; female, M; male, Phil; Filipino, Cauc; Caucasian, Ind; Indian 
subcontinent, *All subjects were born and raised in the tropics apart from 
1019, who was born and raised in the UK. 
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Of the six participants who had negative ELISPOT readings at 18 months 
post vaccination, five (83%) had negative TRFIA titres (<130mIU/mL). Two of 
the five with negative TRFIA titres had a FAMA reading, one of which was 
negative (<2). Thus, this individual (1019) was negative by ELISPOT, TRFIA 
and FAMA at 18 months. Although an ELISPOT reading at 12 weeks was not 
available for this subject, they were positive by both TRFIA and FAMA at that 
time point (326mIU/mL and 8 respectively). Four of the six individuals with a 
negative ELISPOT required two doses of vaccine to seroconvert (NSC2). One 
study participant had a corresponding TRFIA titre which was positive 
(>130mIU/mL), and was classified as a PLR during the study. All study 
participants with a negative ELISPOT had a negative history, but study 
participant 1019 reported an occupational exposure to zoster 84 days prior to 
their follow-up visit, whilst 1063 reported a brief non-household, non-
occupational exposure to chickenpox 119 days prior to follow-up. 
 
 
 
Figure 4.6 Representative Image of an Ex Vivo IFN- Negative ELISPOT 
Response After Overnight Stimulation. PBMCs from ROVE study participant 
1015 (18 month follow-up visit), are presented (0 SFU/106PBMC). PBMCs 
were either stimulated with PHA mitogen (5g/mL/well), VZV or uninfected 
lysate (10g/mL/well) or RPMI alone. Processed images are presented for all 
wells, apart from those stimulated with PHA, where live images are presented 
as there were too many SFUs to count (Biosystem 5000, ELISPOT reader).  
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4.3.3 Ex Vivo and Cultured IE63 and Glycoprotein E Epitope Tetramer 
Specific CD4+ T Cell Responses: 
HLA-DRB1*1501+ tetramers coupled to either gE or IE63 epitopes have been 
used previously to examine the frequencies of CD4+ T cells specific for these 
epitopes in naturally immune adults (Jones et al., 2007; Malavige et al., 
2008a). For seven ROVE study participants who were HLA-DRB1*1501+, ex 
vivo IE63 and gE tetramer specific CD4+ T cell responses were quantified at 
various time points throughout the study, and phenotypic antibody staining 
was carried out for each sample (n=52, with 6 samples stained twice for each 
tetramer, using antibodies to different cell surface markers). The tetramers 
used in this study (with thanks), were designed and optimized by 
collaborators in the laboratory of Dr. Graham Ogg, University of Oxford. 
 
Represenative images of negative control IE63- and gE-tetramer staining, 
carried out in two healthy adult donors, are presented in figure 4.7 (with 
thanks to Dr. Louise Jones and Dr. Graham Ogg (University of Oxford) for 
permission to reproduce these figures). Images generated from the HLA-
DRB1*1501 negative and VZV-seropositive donor are presented in figures 
4.7A and 4.7B, and images for the HLA-DRB1*1501 positive and VZV-
seronegative donor are presented in figure 4.7C and 4.7D. An example of the 
gating used to select live CD14-, CD19-, tetramer specific CD4+ T cells from 
the PBMC population is shown in appendix 7.26. In figure 4.7 A, B and C no 
tetramer-specific CD4+ T cells are present in the gated population of live, 
CD14-, CD19- T lymphocytes. In figure 4.7D a very low percentage 
(0.00023%) of gE-tetramer-specific CD4+ T cells are seen, but these cells are 
not brightly stained. 
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Figure 4.7: Representative Images of Ex vivo IE63- and gE-Tetramer-Specific 
CD4+ T Cells in Populations of Live, CD14-, CD19- T Lymphocytes in a 
Healthy Adult HLA-DRB1*1501 Negative/VZV-Seropositive Donor and a 
Healthy Adult HLA-DRB1*1501Positive/VZV-Seronegative Donor. Event 
counts (given in parentheses) represent the total number of live T 
lymophocytes for each sample of the four donors. With thanks to Dr. Louise 
Jones and Dr. Graham Ogg (University of Oxford) for permission to reproduce 
these figures. 
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4.3.3.1 Comparison between IFN- Responses and Tetramer Staining: 
One of the healthy seropositive donors whose PBMCs were used for 
ELISPOT optimization assays was DRB1*1502+, and although the tetramers 
were a different subtype (DRB1*1501), CD4+ T cells from DRB1*1502 
subjects are also able to bind to the IE63 and gE epitopes presented on the 
DRB1*1501 tetramers. Thus, a comparison between ex vivo VZV-specific 
IFN- responses measured using VZV-infected cell lysate ELISPOT and ex 
vivo frequencies of CD4+ T cells specific for gE and IE63 epitopes measured 
using tetramers and flow cytometry was carried out in this healthy, naturally 
immune, adult donor. As can be seen from figure 4.8 a dose dependent 
response to VZV-infected vero cell lysate was observed, with the number of 
SFU/106PBMCs increasing from 28 (2.5g/mL); 70 (5g/mL) to 112 
(10g/mL). This donor also had tetramer+ CD4+ T cells which accounted for 
0.023% (gE) and 0.057% (IE63) of the live lymphocytes examined. 
 
4.3.3.2: Examining the Frequency of CD4+ Tetramer+ Cells in Low Numbers 
of PBMCs: 
The total numbers of PBMCs/sample that were examined during ex vivo 
tetramer staining was small and ranged from approximately 0.24x106 - 
0.84x106 per „staining set‟ (tetramer + antibodies to cell surface markers).  
Frequencies of tetramer specific CD4+ T cells for each subject at each visit 
are summarised in appendix 7.28. An abbreviated version is presented in 
table 4.8, in the context of corresponding TRFIA titres. As the populations of 
live, CD14-, CD19- lymphocytes examined were so small, for 45% (n=24) of 
samples it was not possible to conclude that the absence of tetramer specific 
CD4+ T cells represented a true absence of such cells from the subject‟s 
peripheral blood. Again due to small sample size, for cases where tetramer 
specific CD4+ T cells were identified, phenotypic analysis was not conducted 
as there were so few cells. However, despite the fact that very small 
populations were analysed, brightly stained, tetramer specific CD4+ T cells 
were visualized in 28 samples, albeit at very low frequencies (see figure 4.9,  
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Figure 4.8: Comparison between Ex Vivo VZV-Specific IFN Responses 
(ELISPOT) and Frequencies of Tetramer-Specific CD4+ T Cells Using PBMCs 
from a DRB1*1502 Naturally Immune Donor. PBMCs from a naturally 
immune, healthy, seropositive, DRB1*1502+ donor were either stimulated 
overnight with commercial VZV lysate prior to ELISPOT (part A and B) or ex 
vivo gE and IE63 tetramer staining was performed (part C). Part A: Processed 
ELISPOT images; Part B: 10g/mL of VZV lysate generated 112 
SFU/106PBMCs; Part C: 0.023% and 0.057% of live lymphocytes were gE 
tetramer+ and IE63+ tetramer CD4+ T cells respectively. Processed images 
are presented in part A for all wells apart from those stimulated with PHA, 
where live images are presented as there were too many SFUs to count.  
Key: PE; Phycoerythrin, P‟Blue; Pacific Blue. 
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for examples of bright tetramer staining gated from populations of 
approximately 2,000 and 5,000 live T lymphocytes).   
 
Samples which contained gE tetramer specific CD4+ T cells had a mean of 
0.022%; (range 0.0006 to 0.042%; median; 0.021, SD 0.012%) of the (live, 
CD14-, CD19-) lymphocyte population, whilst for IE63 the mean was 
significantly higher (independent 2 tailed t test p= 0.049) at 0.057 (range 
0.014-0.212; median; 0.041, SD 0.053).   
 
 
 
Figure 4.9: Representative Images of Low Frequency, Brightly Stained IE63 
Tetramer-Specific CD4+ T Cells Identified in Small Populations of Live, CD14-, 
CD19- T Lymphocytes. Samples from study participant 1088 (follow-up) and 
1028 (12 weeks) are shown, which had populations sizes of approximately 
2,000 and 5,000 respectively. 
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        Glycoprotein E IE63 
Number TRFIA Ex Vivo 
Lines  
(10 Day 
Culture)  
Ex Vivo 
Lines  
(10 Day 
Culture)  
Study 
(Subset) V
is
it
  
T
it
re
 
(m
IU
/m
L
) 
Assay 
Status 
Tetramer 
Present 
N (%) of Live 
T 
Lymphocyte 
Tetramer 
Present 
N (%) of Live 
T 
Lymphocyte 
1001 
(PLR/NL) 
V1 130 Pos SSSCA  (0/4) X SSSCA  (0/4) X 
V2 207 Pos Sample Not Available 
V3 229 Pos Yes 
2/20,000 
(0.010)  
X SSSCA  (0/2000) X 
V4 87 Neg SSSCA  0/6000 (0) 
Non 
Proliferative 
Yes 
3/21,000 
(0.014) 
Proliferative 
1018 
(NSC1/Boost) 
V1 72 Neg SSSCA (0/<100) X SSSCA  (0/<100) X 
V2 176 Pos Yes 
2/6000 
(0.033) 
Non 
Proliferative 
Yes 
4/8000 
(0.051) 
Non 
Proliferative 
V3 398 Pos Yes 
2/31000 
(0.0006) 
Proliferative Yes 
9/27,000 
(0.01) 
Proliferative 
V4 2,040 Pos Yes 
13/38000 
(0.029) 
X Yes 
17/108,000 
(0.016) 
X 
 
Table 4.8 (continued overleaf)             1 of 4 
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        Glycoprotein E IE63 
Number TRFIA Ex Vivo 
Lines  
(10 Day 
Culture)  
Ex Vivo 
Lines  
(10 Day 
Culture)  
Study 
(Subset) 
Visit  
Titre 
(mIU/mL) 
Assay 
Status 
Tetramer 
Present 
N (%) of Live 
T 
Lymphocyte 
Tetramer 
Present 
N (%) of Live 
T 
Lymphocyte 
1028 
(NSC1) 
V1 68 Neg SSSCA (0/<1000) X SSSCA (0/<1000) X 
V2 226 Pos SSSCA (0/<2000) 
Non 
Proliferative 
Yes 
3/1000 
(0.212) 
Non 
Proliferative 
V3 603 Pos Yes 
1/2000 
(0.042) 
X Yes 3/2000 (0.04) X 
V4     Sample Not Available 
1058 
(NSC1/R) 
V1 23 Neg SSSCA (0/<100) X SSSCA  (0/100) X 
V2 262 Pos SSSCA (0/2000) X Yes 
2/2000 
(0.089) 
X 
V3 776 Pos SSSCA (0/<1000) X SSSCA  (0/<500) X 
V4 226 Pos Yes 
5/17000 
(0.034) 
Non 
Proliferative 
Yes 
4/7000 
(0.055) 
Non 
Proliferative 
 
Table 4.8 (continued overleaf)             2 of 4 
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        Glycoprotein E IE63 
Number TRFIA Ex Vivo 
Lines  
(10 Day 
Culture)  
Ex Vivo 
Lines  
(10 Day 
Culture)  
Study 
(Subset) 
Visit  
Titre 
(mIU/mL) 
Assay 
Status 
Tetramer 
Present 
N (%) of 
Live T 
Lymphocyte 
Tetramer 
Present 
N (%) of 
Live 
Lymphocyte 
1067 
(NSC1/R) 
V1a 
55 Neg (Yes) 
3/53,000 
(0.001) 
(Proliferative) 
Yes 
3/57,000 
(0.001) Non-
Proliferative 
V1b 
4/34,000 
(0.002) 
X 
5/38,000 
(0.002) 
V2 180 Pos Yes 
1/5,000 
(0.0188) 
Non-
Proliferative 
Yes 
4/8,000 
(0.05) 
Non-
Proliferative 
V3 546 Pos Yes 
2/7,000 
(0.030) 
X SSSCA 0/3,000 X 
V4 130 Pos Yes 
2/34,000 
(0.0001) 
(Proliferative) Yes 
11/21,000 
(0.005) 
Non-
Proliferative 
1088 
(NSC1/R) 
V1 39 Neg SSSCA 0/<1,000 X SSSCA 0/<500  X 
V2a 
130 Pos 
SSSCA 0/<1,000 
X 
SSSCA 0/<1,000  
X 
V2b SSSCA 0/<1,000 X X 
V3 712 Pos Yes 
1/15,000 
(0.007) 
X Yes 
2/9,000 
(0.022) 
Non-
Proliferative 
V4 231 Pos SSSCA 0/1000 X Yes 
2/1,000 
(0.03) 
X 
 
Table 4.8 (continued overleaf)             3 of 4 
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        Glycoprotein E IE63 
Number TRFIA Ex Vivo 
Lines  
(10 Day 
Culture)  
Ex Vivo 
Lines  
(10 Day 
Culture)  
Study 
(Subset)  
Visit  
Titre 
(mIU/mL) 
Assay 
Status 
Tetramer 
Present 
N (%) of Live 
T 
Lymphocyte 
Tetramer 
Present 
N (%) of Live 
T 
Lymphocyte 
1106 
(NSC1/R) 
V1 101 Neg SSSCA 0/22,000 
Non-
Proliferative 
SSSCA 0/12,000 
Non-
Proliferative 
V2 194 Pos Yes 
1/11,000 
(0.009) 
X SSSCA 0/6,000 X 
V3a 
3,346 Pos Yes 
3/9,000 
(0.034) Non-
Proliferative 
Yes 
5/8,000 
(0.065) Non-
Proliferative 
V3b 
1/5,000 
(0.02) 
1/7,000 
(0.014) 
V4 870 Pos SSSCA 0/<500 X SSSCA 0/<100 X 
Table 4.8                 4 of 4 
Percentage of IE63 and gE Tetramer+, CD4+ T Cells Quantified Ex Vivo and Following Short Term (10 Day) Culture with 
the Corresponding Peptide.  
Key: PLR; Positive Low Responder, NSC1; Negative, Seroconverted after One dose, NL; Negative at follow-up, had Lost 
TRFIA titre (130mIU/mL), R; Retained TRFIA titre (130mIU/mL) at follow-up, V1; visit 1 (baseline), V2; visit 2 (six weeks 
post vaccination), V3; visit 3 (12 weeks post first, six weeks post second vaccination), V4; visit 4 (18 month follow-up), a 
and b; two sets of surface markers were used on these samples, Neg; Negative (<130mIU/mL), Pos; positive 
(130mIU/mL), SSSCA; Sample Size too Small to Conclude tetramer specific CD4+ T cells were Absent from Periphery, 
Yes; tetramer specific CD4+ T cells identified ex vivo were able to proliferate following short term culture, X; T cell lines 
were not set up for these samples, or a second set of surface stains was not used, Live Lymphocytes; total number of live, 
CD14- CD19- lymphocytes, from which tetramer specific CD4+ T cells were gated.  Cell numbers have been rounded off to 
the nearest 1,000 (or in some cases 100 cells), true values are presented in appendix 7.28. 
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For 6/7 individuals, tetramer specific CD4+ T cells were not visualised ex vivo 
at baseline, however, in these cases sample sizes were too small to conclude 
that tetramer specific CD4+ T cells were actually absent from the peripheral 
blood. One subject (1067) had both gE and IE63 tetramer specific CD4+ T 
cells ex vivo at baseline, and is discussed in more detail later in the text. In 
samples with positive TRFIA titres both IE63 and gE tetramer specific CD4+ T 
cells were visualised in 12 samples, whilst in three samples gE tetramer 
specific CD4+ T cells alone were visualised and in four samples IE63 tetramer 
specific CD4+ T cells were visualised. In one case, IE63 tetramer specific 
CD4+ T cells were visualised ex vivo in a sample with a negative TRFIA titre 
at this time point (1001, follow-up visit), and is discussed in more detail later 
in the text. 
 
In addition to tetramer specific CD4+ T cells staining brightly when examined 
ex vivo, in three cases these cells were able to proliferate in response to short 
term culture with the corresponding peptide, the results of which are 
summarised in table 4.8. An example of a comparison between ex vivo 
staining and 10 day culture results (for both gE and IE63 epitope specific 
CD4+ T cells) is shown for ROVE study participant 1018 at the 12 week time 
point (response to second dose of vaccine, visit 3) in figure 4.10. (An example 
of gating used to select tetramer-specific CD4+ T cells following short term 
culture is presented in appendix 7.27). Due to the numbers of live PBMCs 
following resuscitation (counts ranged from approximately 0.17-
2.16x106/well), corresponding mitogen or VZV lysate stimulation was not 
established.  
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Figure 4.10: Glycoprotein E and IE63 Tetramer-Specific CD4+ T Cell Staining 
at 12 weeks (visit 3) for ROVE 1018.  Part A; gE tetramer, Part B; IE63 
tetramer. Both ex vivo (left plots) and 10 day culture (right plots) are shown. 
Two brightly stained gE tetramer specific CD4+ T cells were identified ex vivo 
(0.0006%). Live lymphocytes were plotted by CD4 and tetramer staining. Key: 
PE; Phycoerythrin, P‟Blue; Pacific Blue. 
 
  
From the results presented in figure 4.10, both brightly stained gE and IE63 
tetramer specific CD4+ T cells can be seen ex vivo (although at very low 
frequency) and these corresponded with extensive proliferation of tetramer 
specific CD4+ T cells after 10 days of culture with the corresponding peptide.  
In another case, (1001; follow-up visit; IE63 tetramer), the number of PBMCs 
available for staining after 10 day cultures was very small, but expanded 
brightly stained tetramer specific CD4+ T cells were clearly visible, see figure 
4.11 part A. In this example, CD4+ T cells were able to proliferate in response 
to the IE63 peptide, but not the gE peptide (figure 4.11, part B).   
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Figure 4.11: IE63 and gE Tetramer Specific CD4+ T Cell Staining at 18 
Months Post Vaccination for ROVE Study Participant 1001.  Both ex vivo and 
10 day culture results are shown. Live lymphocytes were plotted by CD4 and 
tetramer staining. Key: PE; Phycoerythrin, P‟Blue; Pacific Blue. 
 
For study participant 1067, their baseline TRFIA was negative, and they 
responded as a primary responder during the study (i.e. six week TRFIA 
<400mIU/mL, avidity <60%). However as mentioned earlier, both IE63 and 
gE tetramer specific CD4+ T cells were identifiable in the baseline sample, 
(see figure 4.12). A higher percentage of IE63 tetramer specific CD4+ T cells, 
than gE tetramer specific cells were seen at baseline (0.01% (IE63) and 
0.004% (gE) of the live lymphocyte population, gated from populations of 
approximately 55,000). However this study participant gave a negative 
history, reported no contacts prior to enrolment and was asymptomatic prior 
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to enrolment, and at all visits throughout the study. This subject was a 27 
years old Indian female, who was born in India and moved to the UK the 
same year as enrolling in the study, and was heterozygous for DRB1*1501; 
(second allele: DRB1*1101).  
 
 
Figure 4.12: IE63 and Glycoprotein E Tetramer Specific CD4+ T Cell Staining 
at Baseline for ROVE Study Participant 1067. Key: PE; Phycoerythrin, P‟Blue; 
Pacific Blue. 
 
Cell numbers examined at six and 12 weeks were very low, but at the follow-
up visit (16 months), cell numbers for the sample stained with gE tetramer 
were comparable to the sample size examined at baseline. Tetramer-specific 
CD4+ T cells were identified, but at a lower frequency than at baseline 
(0.001% for each).   Glycoprotein E tetramer specific CD4+ T cells were able 
to proliferate following short term culture with the gE peptide for the baseline 
and follow-up sample (figure 4.13), although this was not seen with the IE63 
peptide. For both baseline and follow-up staining of gE cell lines, antibody 
staining was not of the same intensity as other lines analysed during the 
same experiment. 
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Figure 4.13: Glycoprotein E Tetramer Specific CD4+ T Cell Staining at 
Baseline and Follow-up for ROVE Study Participant 1067.  A: Baseline; B: 
Follow-up. Both ex vivo and 10 day culture results are presented. Live 
lymphocytes were plotted by CD4 and tetramer staining. Key: PE; 
Phycoerythrin, P‟Blue; Pacific Blue. 
 
 
4.4 DISCUSSION: 
4.4.1 Summary of Results: 
Although baseline VZV-specific IFN- responses were not measured in this 
study and baseline data on gE/IE63 epitope-specific CD4+ T cells was 
severely limited, the results presented in this chapter are consistent with the 
possibility that that the live attenuated varicella vaccination is capable of 
generating VZV-specific IFN- responses and gE/IE63 epitope-specific CD4+ 
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T cell responses in the absence of clinical disease, which are detectable 18 
months post vaccination.  Although there is no published literature on epitope 
specific responses following vaccination, several studies have shown that 
VZV-specific CMI is detectable in adults and children between 1-20 years 
post vaccination (Sharp et al., 2002; Levin et al., 2006; Hayward et al., 1992; 
Asano et al., 1994). The data presented here demonstrate that 76% (19/25) 
of vaccinated HCWs had positive IFN- ELISPOTS at 18 months post 
vaccination, whereas a study in HIV positive children vaccinated with two 
doses found that 83% of study participants had positive CMI at one year 
(Levin et al., 2006). 
 
4.4.2 VZV-Specific IFN- ELISPOT Responses and Corresponding TRFIA 
Titres at 18 Months Post Vaccination:  
In agreement with the findings in this study, several reports have found that 
there is a lack of correlation between antibody titre and corresponding 
measurements of cell mediated immunity in long term studies, both following 
natural varicella infection (Sadaoka et al., 2008) and vaccination, (Trannoy et 
al., 2000; Levin et al., 2008b; Hayward et al., 1992).  However, in this study it 
was found that there was a 76% agreement on assay status (i.e. positive or 
negative by both assays). Twenty percent (5/25) of those with interpretable 
ELISPOT results at follow-up were negative by both assays. This suggests 
that these subjects would be at risk of infection, however, one of these 
individuals had a positive FAMA titre at this time point, which has been shown 
to correlate with clinical protection (Gershon et al., 1994a).  Therefore, in 
subjects who were not tested by FAMA it was not possible to predict if they 
would be at risk of re-infection. However one subject (1019) was found to be 
negative by all three assays at this time point, indicating that they would be at 
risk of re-infection; this subject is discussed in more detail in chapter 3. 
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As IFN- responses at earlier study time points were not available, it is not 
possible to deduce if these subjects failed to mount a VZV-specific IFN- 
response to vaccination (and is therefore possibly indicative of a primary 
vaccine failure), or whether they had lost the response in the time which had 
elapsed since vaccination (and is thus possibly indicative of a secondary 
vaccine failure). In addition, it was not possible to examine a threshold of IFN-
 responses to vaccination in this study, which was indicative of a positive or 
negative CMI response at 18 months post vaccination.  
 
Interestingly, of those that were ELISPOT negative, all were born and raised 
in the tropics, bar one, and 67% (4/6) were classified as NSC2 during the 
study, a humoral subset that we identified as being more likely to have lost a 
positive TRFIA titre at 18 months. However, we were unable to identify factors 
such as age, ethnicity and gender which would predict who would have a 
positive or negative VZV-specific IFN- ELISPOT at 18 months due to small 
sample sizes. 
 
There was a subset of five individuals who were positive by ELISPOT, but 
negative by TRFIA. Two of these subjects, were classified as NLR, and failed 
to seroconvert following two or three doses of vaccine, yet they had 
measurable CMI at 18 months post vaccination, demonstrating that a failure 
to seroconvert to vaccination did not necessarily correlate with a negative 
CMI at follow-up. Some previous studies on varicella vaccine demonstrated 
that seronegative vaccinees were protected from disease, indicating that CMI 
was playing a role in protection (Levin et al., 2003). In addition, two separate 
case reports have documented failure to seroconvert following two or three 
doses of vaccine, but a correspondingly positive CMI in immunocompetent 
HCW (Katial et al., 1999; Ludwig et al., 2006). In one report the HCW was 
negative by commercial VZV IgG ELISA (Wampole) following three dose of 
Varivax vaccine, but had a VZV-specific T cell response (determined by LPA) 
comparable to that of other vaccinees, and in addition had positive FAMA and 
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LA scores (both of which were 8), (Katial et al., 1999).  In the second report 
Dade Behring VZV IgG ELISA and ICFC were used to assess humoral and 
cellular responses respectively (Ludwig et al., 2006). The subject 
seroconverted to the third dose of Varilrix vaccine but had a positive CD4+ T 
cell response after the second dose. This individual was found to be 
seronegative at 18 months, but had retained a positive CMI. At this time point, 
the HCW had an occupational contact with a varicella patient, which included 
a physical examination and daily visitations over a one week period without 
any special protective clothing such as gloves or face mask. Following this 
close contact exposure the HCW remained asymptomatic, but still failed to 
seroconvert.  
 
This last case was in contrast to a case seen during this study, where an 
individual (1050), who failed to seroconvert following two doses of vaccine, 
seroconverted shortly afterwards following a household exposure to varicella, 
(remaining asymptomatic throughout). Although this subject‟s CMI response 
was unknown during the course of the vaccination study, in light of the two 
published case reports, and the fact that this individual‟s antibody response 
was negative by TRFIA at the time of exposure, it is plausible to suggest that 
this subject was protected by a cell mediated-immune response (in 
combination with an innate immune response). This individual was positive by 
both assays 18 months post vaccination.  
 
It is interesting to note that two further subjects who failed to seroconvert 
during the vaccination study (NLR subset) had positive ELISPOT readings at 
18 months post vaccination, whilst those with negative ELISPOTs at this time 
point, were seropositive on completion of the vaccination study (NSC1, NSC2 
and PLR). All study participants who were classified as PI during the study 
had positive ELISPOTs at 18 months, indicating that secondary responders 
were more likely to have positive CMI at follow-up, but failing to seroconvert 
was not predictive of a negative ELISPOT at follow-up.  
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4.4.3 Problems Encountered with the Measurement of CMI after VOka 
Vaccination: 
4.4.3.1 Low Frequencies of IE63 and gE DRB1*1501 Tetramer Specific CD4+ 
T Cells Identified in this Study: 
IE63 and gE tetramer specific CD4+ T cells have been observed in latently 
infected, naturally immune, adult donors ex vivo by others, (Jones et al., 2007 
and Malavige et al., 2008a). In these donors the mean percentage of gE and 
IE63 tetramer positive cells (of the live, CD19-, CD14-, CD4+ lymphocyte 
population) was 0.003% and 0.006% respectively, (Jones et al., 2007; 
Malavige et al., 2008a). This equates to 3 and 6 tetramer positive cells per 
100,000 cells respectively. During acute infection, the median percentages of 
tetramer positive cells identified in adult patients hospitalized with varicella 
were 0.0157% (gE) and 0.007% (IE63), (Malavige et al., 2008b). Thus, even 
during acute infection a minimum of 100,000 live, CD19- CD14- CD4+ 
lymphocytes would need to be examined in order for tetramer specific cells to 
be identified.  Therefore when ex vivo analysis was conducted on sample 
sizes smaller than this during this study, in the absence of tetramer specific 
CD4+ T cells, it was not possible to conclude that the individual actually 
lacked CD4+ T cells specific for that epitope in their peripheral blood, merely 
that they were absent from that particular sample.  However, had acceptable 
sample sizes been examined, as the quantification of CMI is highly specific to 
an individual epitope level, the lack of a response to these two particular 
epitopes is not indicative that the individual is unable to mount responses to 
other VZV epitopes (within these, and other VZV proteins).  
 
It is also plausible that the absence of proliferation following short term culture 
with the corresponding peptide is attributable to the low cell numbers 
examined. In addition as mitogen and VZV lysate controls could not be set up 
in parallel, again due to low cell numbers, it was not possible to distinguish if 
these cells were unable to proliferate specifically in response to the peptide, 
or if these cells would be unable to proliferate in response to any stimulus (for 
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example; a non-proliferative PBMC sample, due to sample degradation in 
long term storage). As the proportion of samples which were found to be 
unresponsive to mitogen stimulation during IFN- ELISPOT analysis was 
high, this is a likely scenario (especially with earlier time points) in cases 
where tetramer specific cells were identified ex vivo, but no proliferative 
response was seen following short term culture.  
 
4.4.3.2 Specificity of Tetramer Staining: 
In many of the FACS plots presented in this chapter as well as in those 
published by collaborators, a small population of tetramer+ CD4- cells can 
sometimes be seen. One explanation for this could be that these cells are 
phagocytic cells that are in the process of engulfing an apoptotic CD4+ T cell 
that is specific for that epitope. However at this stage of flow cytometry 
analysis, dead and phagocytic cells have been gated out of the population 
and reanalysis using „tighter‟ gating on the lymphocyte population and the 
viaprobe negative populations did not eliminate this subset of cells. It could 
be argued that this phenomenon sheds doubt on the specificity this tetramer 
staining, however proliferative responses in this study and in others (Jones et 
al., 2007; Malavige et al., 2008a) have demonstrated that low frequency CD4+ 
tetramer+ cells identified ex vivo have the ability to proliferate following short 
term culture with the corresponding peptide. In addition, experiments by 
collaborators (Jones et al., 2007; Malavige et al., 2008a) demonstrated that 
ex vivo frequencies of tetramer+ CD4+ T cells were significantly higher in HLA-
DRB1*1501 individuals than the frequencies seen in non-HLA-DRB1*1501 
individuals (p=0.0003; IE63 and p=<0.0001 gE), and this difference was also 
seen after short term culture (p=0.0094; IE63), (Jones et al., 2007; Malavige 
et al., 2008a).  
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In agreement with the finding of Jones et al., 2007 and Malavige et al., 2008a, 
the mean frequency of IE63 tetramers specific CD4+ T cells was 
approximately double that of gE. However, the mean frequencies found in this 
study were higher than those reported in latently infected individuals and 
those hospitalised with acute varicella (Malavige et al., 2008a; Malavige et al., 
2008b and Jones et al., 2007). The discrepancies in the 10 fold higher means 
between this study and those of others, is likely to be due to the inaccuracy 
incurred when examining 5-10 fold smaller sample sizes examined in this 
study.  An addition explanation could be that the results presented in this 
thesis examined responses following vaccination as opposed to latently or 
acutely infected individuals. 
 
4.4.4 Discrepant TRFIA and Tetramer Assay Results:  
In this study, it was possible to conclude that proliferative tetramer-specific 
CD4+T cells were present in some samples. Study participant 1001 had a 
population of brightly stained IE63 tetramer-specific CD4+T cells following 
short term culture, but was negative at this time point by TRFIA. Thus as was 
seen with IFN- ELISPOTs responses, there was a discrepancy between a 
negative TRFIA titre and in this case, the presence of epitope specific VZV 
CD4+ T cells at 18 months post vaccination.   A discrepancy was also seen 
with study participant 1067 at baseline.  This subject was classified as a 
primary humoral responder who seroconverted following one dose of vaccine. 
Glycoprotein E tetramer-specific CD4+ T cells were able to proliferate 
following short term culture. However, gE tetramer-specific CD4+ T cells did 
not stain as brightly as for other individuals whose cell lines were analysed 
during the same experiment. The fact that this phenomenon was seen in lines 
established at baseline and 18 months for the same individual suggests that 
this staining pattern is specific to this individual (discussed further below). As 
cells from the same aliquot were used to establish IE63 cell lines, a lack of 
proliferation suggests that the cells identified ex vivo were not specific for this 
epitope. However, tetramer specific CD4+ T cell responses could not be 
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accurately assessed at six weeks and 12 weeks as the total number of live 
lymphocytes examined were several fold lower at these time points in 
comparison to those seen at baseline; (5 and 11 fold lower for IE63 at six 
weeks and 12 weeks respectively and 10 and 8 fold lower at these time 
points for gE).  
 
It was confirmed that the baseline sample was not mislabelled during initial 
sample processing as the other sample processed at the same time, was not 
HLA-DRB1*15+. One possibility that may explain why staining was not as 
bright in this individual, is that this gE epitope may represent a shared CD4+ T 
cell epitope between VZV and HSV, (however the HSV status of this subject 
was not known). Recently DRB1*15+ CD4+ T cell clones developed from a 
patient experiencing acute dengue infection, were shown to be able to cross 
react with both West Nile Virus, Japanese Encephalitis Virus, and to a lesser 
extent to Tick Borne Encephalitis virus and Yellow Fever virus epitopes 
(Moran et al., 2008). If study participant 1067 had HSV-gE specific CD4+ T 
cells that were able to bind to this VZV-gE epitope, (but at a lower affinity than 
CD4+ T cells that were specific for the VZV epitope) this could possibly 
explain why tetramer staining was seen, but at a lower magnitude than for 
other samples in this experiment. However, although cross reactive gB 
antibody epitopes have been identified between VZV and HSV (Kitamaru et 
al., 1986; Edson et al., 1985), no cross reactive epitopes have been reported 
for VZV T cell epitopes.  
 
Assays carried out in naturally immune adult donors as part of this research 
and by others has demonstrated that the presence of low frequency tetramer 
specific CD4+ T cells also corresponds with a positive IFN- ELISPOT 
response, (Jones et al., 2007; Malavige et al., 2008a). In addition, the results 
presented in this chapter and by others (Jones et al., 2007 and Malavige et 
al., 2008a) also demonstrate that low frequencies of tetramer positive cells 
are capable of extensive proliferation, as seen with corresponding short term 
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day cultures. In one case (1018) both proliferative gE and IE63 tetramer-
specific CD4+ T cells, were identified following two doses of vaccine, and in 
another case, proliferative IE63 tetramer-specific CD4+ T cells were identified 
18 months post vaccination, despite this subject being seronegative at this 
time point. 
 
4.4.5 Correlation Between Clinical Protection and CMI: 
Although VZV-specific IFN- ELISPOT has been used to measure CMI in 
naturally immune and vaccinated subjects (Smith et al., 2001; Levin et al., 
2003; Levin et al., 2008; Jones et al., 2006; Jones et al., 2007; Malavige et 
al., 2007; Malavige et al., 2008a; Malavige et al., 2008b) a threshold level of 
protection has not been identified which correlates with clinical protection. 
CMI data has been (or is being) obtained in the course of the vaccine 
approval process for a variety of pathogens including VZV, HIV, HPV, 
influenza A, smallpox, hepatitis C virus, as well as malaria, leishmania and 
tuberculosis (reviewed in Thomas et al., 2009). However in a recent HIV 
vaccine trial carried out in high risk male and female populations, it was 
demonstrated that despite this vaccine being immunogenic and generating 
CMI in the vast majority of study participants this did not correlate with either 
protection from infection, or a reduction in viral load when study participants 
were infected, (Buchbinder et al., 2008; McElrath et al., 2008). CMI was 
measured using numerous methodologies, all of which indicated the vaccine 
induced a strong CMI responses in the majority of study participants; 77% 
(n=258) had ex vivo IFN- responses (with responses ranging from 163-686 
SFUs/106PBMCs to each of the three proteins used in the vaccine); 41% 
(n=58) had HIV-specific CD4+ T cells identified by intracellular cytokine 
staining, (with the median percentage of 88% expressing IL-2, with 72% co-
expressing IFN- or TNF-, or both). In addition, HIV-specific CD8+ T cells 
were identified in 73% (n=117) participants, which expressed either IFN- 
alone or with TNF-. This study indicated that although CMI responses of a 
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high magnitude may be measured in vitro and ex vivo, this does not 
necessarily correlate with clinical protection.   
 
4.4.6 Concluding Remarks: 
The results of this study and of others have confirmed that there are often 
discrepancies between correlates of cell mediated and humoral immunity, 
indicating that both arms of the immune system need to be examined in order 
to gain insight into the possible risk of infection. Despite the fact that CMI is 
important in host defence against varicella, no clinical correlate of CMI and 
protection from infection exists. However, the serology based FAMA assay 
has been shown to correlate with clinical protection (Gershon et al., 1994a) 
and the presence of neutralizing antibodies (Grose et al., 1979). In addition to 
this, separation of PBMCs from blood is laborious and highly technical in 
comparison to processing serum (or plasma) samples. In addition PBMCs, 
(unlike serology samples) are susceptible to degradation in long term or sub-
optimal storage (Smith et al., 2007). Therefore screening HCWs for 
susceptibility to infection is more practically suited to serology based assays.  
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CHAPTER 5: SUMMARY OF KEY FINDINGS AND FUTURE STUDIES: 
 
A serology based assay to assess immune status in heathcare workers is 
preferable to a cell mediated based assay as early studies with Varivax 
demonstrated that antibody titres were a better correlate of efficacy than CMI, 
(Levin et al., 2003b). In addition a positive FAMA score >2 has been shown to 
correlate with clinical protection (Gershon et al., 1994a), and with the 
presence of neutralising antibody (Grose et al., 1979), and as discussed in 
chapter 4, no clinical correlates have been shown for any T cell based 
assays.  As discussed in chapter 3, the only serological assays which have 
been shown to correlate with clinical protection are either not suitable for high 
through put screening (FAMA) or are not widely available (gpELISA). There is 
a need to develop a widely available assay with a correlate of clinical 
protection as VZV immunity wanes over time and exposure to VZV may be 
more likely than for other viruses which do not establish latency, and thus a 
reservoir in the host population. A highly sensitive assay is required to screen 
HCWs to identify those who truly require vaccination, as vaccinating „false 
negatives‟ creates an unnecessary economic burden.  However, a high 
specificity is also required to ensure that „false positives‟ are not excluded 
from vaccination; to eliminate the transmission risk to immunocompromised or 
naïve adult patients.  Therefore, a larger, long term follow-up study of 
healthcare workers is needed to assess if a TRFIA cut-off of 130mIU/mL 
correlates with clinical protection. This study could also be used to assess is a 
TRFIA cut-off of 500mIU/mL after the second dose of vaccine (12 weeks) if a 
useful tool to identify subjects who require booster vaccination. A detailed 
reporting system of contacts would also be useful in assessing protection 
from infection.   
 
This study identified different phenotypes of humoral immune responses to 
vaccination, and an association with ethnicity suggests genetic differences 
may underlie these phenotypic differences. In order to investigate this further, 
a large scale genetic study would need to be undertaken as part of the long 
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term follow-up study. As part of this genetic study, it would be useful to 
investigate innate immune response to vaccination, and whether such 
responses correlate with particular humoral subsets. As discussed in chapter 
3, a lack of affinity maturation may be associated with innate immune 
responses, such as signalling through Toll like receptors. It would therefore 
be of use to attempt to identify any correlates of innate immunity and a lack of 
affinity maturation. Innate immune systems contribute significantly to the 
ability of vaccines to generate adaptive immune responses against pathogens 
and licensed vaccines (such as the live attenuated yellow fever vaccine; YF-
17D) and adjuvants have been shown to activate innate immune signalling 
pathways and receptors, (Querec et al., 2006). In subjects who were unable 
to produce high avidity antibodies many months/years post varicella 
vaccination, investigating whether they could produce high avidity antibodies 
to other pathogens would indicate that this phenomenon was varicella 
vaccine specific. If a lack of affinity maturation was shown to correlate with 
impaired immune responses, alternative adjuvants could be investigated for 
the vOka vaccine in an attempt to increase immunogenicity. 
 
Carrying out a large scale study may also highlight differences that were not 
seen between subsets in this study, (such as age and gender, or a difference 
in ethnicity between primary responders who seroconvert following one or two 
doses of vaccine). Investigating a larger population of Asian HCWs could 
possibly identify if there was an association with lower antibody titre following 
vaccination, as we have shown following natural infection. In order to confirm 
some of the findings of this study, a larger Black population would need to be 
investigated, to examine lower antibody titre in primary responders and 
likelihood of being vaccine humoral non-responders (NLRs).  
 
In addition, a large scale study could be used to phenotype T cell responses 
to vaccination, which was not possible as part of this study due to poor cell 
recovery. As discussed in chapter 4, larger volumes of blood for PBMC 
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analysis and shorter storage times would yield larger numbers of cells for 
tetramer and IFN- ELISPOT analysis.  
 
Recently a „systems biology‟ approach was used to examine innate immune 
response to the yellow fever YF-17D vaccine and identify markers which 
predicted the magnitude of the subsequent adaptive immune response 
(Querec et al., 2009).  Multiple techniques (such as gene expression profiling; 
multiplex analysis of cytokines and chemokines and multiparameter flow 
cytometry), in combination with computational modelling were used to identify 
the genes which correlated with adaptive immune responses. Several genes 
that regulate glucose transport and glycolysis in mammalian cells were found 
to be positive predictors of CD8+ T cell response, (suggesting a possible role 
for glucose metabolism in regulating the CD8+ T cell response), whilst a gene 
encoding for a B cell growth factor receptor was predictive of antibody 
responses to vaccine. However, although this approach facilitated the 
prediction of adaptive immune responses soon after vaccination, these were 
correlates of immunogenicity, and not a correlate of vaccine efficacy. 
However, if such an approach was undertaken in a long term follow-up study, 
it may be possible to correlate markers with clinical protection, rather than just 
immunogenicity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  291 
CHAPTER 6: BIBLIOGRAPHY 
 
Abendroth, A. and A. M. Arvin (2001b). "Immune evasion as a pathogenic mechanism of 
varicella zoster virus." Semin Immunol 13(1): 27-39. 
  
Abendroth, A., I. Lin, et al., (2001a). "Varicella-zoster virus retains major histocompatibility 
complex class I proteins in the Golgi compartment of infected cells." J Virol 75(10): 4878-88. 
  
Abendroth, A., G. Morrow, et al., (2001b). "Varicella-zoster virus infection of human dendritic 
cells and transmission to T cells: implications for virus dissemination in the host." J Virol 
75(13): 6183-92. 
   
Abendroth, A., B. Slobedman, et al., (2000). "Modulation of major histocompatibility class II 
protein expression by varicella-zoster virus." J Virol 74(4): 1900-7. 
  
Akahori, Y., K. Suzuki, et al. (2009). "Characterization of neutralizing epitopes of varicella-
zoster virus glycoprotein H." J Virol 83(4): 2020-4. 
 
Alconada, A., U. Bauer, et al., (1998). Intracellular Transport of the Glycoproteins gE and gI 
of the Varicella-Zoster Virus. gE accelerates the maturation of gI and determines its 
accumulation in the trans-Golgi network. J Biol Chem 273, 13430-13436. 
 
Almeida J.D., A.F. Howatson. M.G. Williams (1962). "Morphology of varicella (chicken pox) 
virus." Virology. 16:353-5. 
 
Alper, C.A., M.S. Kruskall et al. (1989) “Genetic prediction of nonresponse to hepatitis B 
vaccine”. N Engl J Med 321:708-12. 
 
Ambagala, A. P. and J. I. Cohen (2007). "Varicella-Zoster virus IE63, a major viral latency 
protein, is required to inhibit the alpha interferon-induced antiviral response." J Virol 81(15): 
7844-51. 
 
Amici, C., A. Rossi, et al., (2006). "Herpes simplex virus disrupts NF-kappaB regulation by 
blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral 
genes." J Biol Chem 281(11): 7110-7. 
 
Ampofo, K., L. Saiman, et al., (2002). "Persistence of immunity to live attenuated varicella 
vaccine in healthy adults." Clin Infect Dis 34(6): 774-9. 
 
Annunziato, P. W., O. Lungu, et al., (2000). "Varicella-zoster virus proteins in skin lesions: 
implications for a novel role of ORF29p in chickenpox." J Virol 74(4): 2005-10. 
 
Annunziato, P.W., O. Lungu, C. Panagiotidis, (2001). Varicella zoster virus in human and rat 
tissue specimens. Arch Virol Suppl 17, 135-142. 
  
Appay, V., J.J. Zaunders, et al. (2002). "Characterization of CD4(
+
) CTLs ex vivo" J Immunol.  
168: 5954–8. 
 
Arbeit, R. D., J. A. Zaia, et al., (1982). "Infection of human peripheral blood mononuclear cells 
by varicella-zoster virus." Intervirology 18(1-2): 56-65. 
  
Arbeter, A. M., S. E. Starr, et al., (1984). "Varicella vaccine trials in healthy children. A 
summary of comparative and follow-up studies." Am J Dis Child 138(5): 434-8. 
 
Arbeter A.M., S.E Starr, S.A. Plotkin, (1986). "Varicella vaccine studies in healthy children 
and adults." Pediatrics 78(Suppl): 748-56.  
  292 
 
Argaw, T., J. I. Cohen, et al., (2000). "Nucleotide sequences that distinguish Oka vaccine 
from parental Oka and other varicella-zoster virus isolates." J Infect Dis 181(3): 1153-7. 
  
Arvin, A. M. (1992). "Cell-mediated immunity to varicella-zoster virus." J Infect Dis 166 Suppl 
1: S35-41. 
   
Arvin, A. M. (1996a). "Immune responses to varicella-zoster virus." Infect Dis Clin North Am 
10(3): 529-70. 
  
Arvin, A. M. (1996b). "Varicella-zoster virus." Clin Microbiol Rev 9(3): 361-81. 
  
Arvin, A. M. (1997a). "Live attenuated varicella vaccine." Pediatr Ann 26(6): 384-8. 
  
Arvin, A. M. (1997b). "The varicella vaccine." Curr Clin Top Infect Dis 17: 110-46. 
  
Arvin, A.M. (2000a). "Varicella-Zoster virus: pathogenesis, immunity, and clinical 
management in hematopoietic cell transplant recipients." Biol Blood Marrow Transplant 6(3): 
219-30. 
  
Arvin, A. M. (2001a). "Varicella vaccine: genesis, efficacy, and attenuation." Virology 284(2): 
153-8. 
  
Arvin, A. M. (2001b). "Varicella vaccine-the first six years." N Engl J Med 344(13): 1007-9. 
  
Arvin, A. M. (2001c). "Varicella-zoster virus: molecular virology and virus-host interactions." 
Curr Opin Microbiol 4(4): 442-9. 
  
Arvin, A. (2005). "Aging, immunity, and the varicella-zoster virus." N Engl J Med 352(22): 
2266-7. 
  
Arvin, A. (2006). "Investigations of the Pathogenesis of Varicella Zoster Virus Infection in the 
SCIDhu Mouse Model." Herpes 13(3): 75-80. 
 . 
Arvin, A. M., S. Feldman, et al., (1978a). "Human leukocyte interferon in the treatment of 
varicella in children with cancer: a preliminary controlled trial." Antimicrob Agents Chemother 
13(4): 605-7. 
  
Arvin, A. M. and A. A. Gershon (1996). "Live attenuated varicella vaccine." Annu Rev 
Microbiol 50: 59-100. 
  
Arvin, A. and A. Gershon (2006). "Control of varicella: why is a two-dose schedule 
necessary?" Pediatr Infect Dis J 25(6): 475-6 
 
Arvin, A. M., E. Kinney-Thomas, et al., (1986a). "Immunity to varicella-zoster viral 
glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170." J 
Immunol 137(4): 1346-51. 
  
Arvin, A. M. and C. M. Koropchak (1980a). "Immunoglobulins M and G to varicella-zoster 
virus measured by solid-phase radioimmunoassay: antibody responses to varicella and 
herpes zoster infections." J Clin Microbiol 12(3): 367-74. 
  
Arvin, A. M., C. M. Koropchak, et al., (1990). "The T-lymphocyte response to varicella-zoster 
viral proteins." Adv Exp Med Biol 278: 71-81. 
 
  
  293 
Arvin, A. M., C. M. Koropchak, et al., (1986b). "Early immune response in healthy and 
immunocompromised subjects with primary varicella-zoster virus infection." J Infect Dis 
154(3): 422-9. 
  
Arvin, A. M., C. M. Koropchak, et al., (1983a). "Immunologic evidence of reinfection with 
varicella-zoster virus." J Infect Dis 148(2): 200-5. 
  
Arvin, A. M., J. H. Kushner, et al., (1982). "Human leukocyte interferon for the treatment of 
varicella in children with cancer." N Engl J Med 306(13): 761-5. 
   
Arvin, A. M., J. F. Moffat, R. Redman, (1996). "Varicella-zoster virus: aspects of pathogenesis 
and host response to natural infection and varicella vaccine." Adv Virus Res 46: 263-309. 
  
Arvin, A. M., R. B. Pollard, et al., (1978b). "Selective impairment of lymphocyte reactivity to 
varicella-zoster virus antigen among untreated patients with lymphoma." J Infect Dis 137(5): 
531-40. 
 
Arvin, A. M., R. B. Pollard, et al., (1980b). "Cellular and humoral immunity in the 
pathogenesis of recurrent herpes viral infections in patients with lymphoma." J Clin Invest 
65(4): 869-78. 
     
Arvin, A. M., M. Sharp, et al., (2002). "Memory cytotoxic T cell responses to viral tegument 
and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster 
virus." Viral Immunol 15(3): 507-16. 
  
Arvin, A. M., M. Sharp, et al., (1991). "Equivalent recognition of a varicella-zoster virus 
immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ 
or CD8+ phenotype." J Immunol 146(1): 257-64. 
  
Arvin, A. M., S. M. Solem, et al., (1987). "Humoral and cellular immunity to varicella-zoster 
virus glycoprotein gpI and to a non-glycosylated protein, p170, in the strain 2 guinea-pig." J 
Gen Virol 68 (Pt 9): 2449-54. 
  
Asano, Y. (1996). Varicella vaccine: the Japanese experience. J Infect Dis 174(Suppl 3), 
S310-S313. 
 
Asano, Y., P. Albrecht, et al., (1983). "Evaluation of humoral immunity to varicella-zoster virus 
by an enhanced neutralization test and by the fluorescent antibody to membrane antigen 
test.” Arch Virol 75 (3):225-8. 
  
Asano, Y., Itakura N, et al., (1985a). "Viral replication and immunologic responses in children 
naturally infected with varicella-zoster virus and in varicella vaccine recipients." J Infect Dis 
152(5): 863-8. 
 
Asano Y, H. Y., Itakura N, et al., (1987). "Immunoglobulin subclass antibodies to varicella-
zoster virus." Pediatrics 80(6): 933-6. 
  
Asano Y, H. Y., Itakura N, et al., (1988). "Placental transfer of IgG subclass-specific 
antibodies to varicella-zoster virus." J Med Virol 26(1): 1-6. 
 
Asano Y, I. N., Kajita et al., (1990). "Severity of viremia and clinical findings in children with 
varicella." J Infect Dis 161: 1095–8. 
 
Asano, Y., T. Nagai, et al., (1985b). "Long-term protective immunity of recipients of the OKA 
strain of live varicella vaccine." Pediatrics 75(4): 667-71. 
 
  294 
Asano, Y., S. Suga, et al., (1994). Experience and reason: twenty-year follow-up of protective 
immunity of the Oka strain live varicella vaccine. Pediatrics 94, 524-526. 
 
Asano, Y., and M. Takahashi (1977). "Clinical and serologic testing of a live varicella vaccine 
and two-year follow-up for immunity of the vaccinated children." Pediatrics 60(6): 810-4. 
 
Asano Y, Takahashi. M. (1978). "Studies on neutralization of varicella-zoster virus and 
serological follow-up of cases of varicella and zoster." Biken J. 21(1): 15-23 
 
Asano, Y., and M. Takahashi, (1980a). "Studies on the polypeptides of varicella-zoster (V-Z) 
virus. II. Syntheses of viral polypeptides in infected cells." Biken J 23(3): 95-106. 
   
Asano, Y. Takahashi M. (1980b). "Studies of the polypeptides of varicella zoster virus II 
Syntheses of viral polypeptides in infected cells." Biken J 23: 95-106. 
 
Asano, Y., T. Yoshikawa, et al., (1993). "Varicella-zoster virus replication site in internal 
organs of an otherwise healthy child with varicella and sudden death." Acta Paediatr Jpn 
35(4): 348-51. 
 
Asanuma, H., M. Sharp, et al. (2000). "Frequencies of memory T cells specific for varicella-
zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine 
expression." J Infect Dis 181(3): 859-66. 
 
Ayers, K., S.L.R. McDonald, et al., (Unpublished). Running title: “Immunity to Varicella-zoster 
virus is determined by host and environmental factors.”  
 
Baer, R., Bankier, A. T., et al., (1984). "DNA sequence and expression of the B95-8 Epstein-
Barr virus genome." Nature 310: 207-211. 
  
Baiker, A., K. Fabel, et al., (2004a). "Varicella-zoster virus infection of human neural cells in 
vivo." Proc Natl Acad Sci USA 101(29): 10792-7. 
  
Baiker, A., C. Bagowski, et al., (2004b). "The immediate-early 63 protein of Varicella-Zoster 
virus: analysis of functional domains required for replication in vitro and for T-cell and skin 
tropism in the SCIDhu model in vivo." J Virol 78(3): 1181-94. 
 
Balfour, H. H., K.A. McMonigal, B. Bean (1983). "Acyclovir therapy of varicella-zoster virus 
infections in immunocompromised patients." J Antimicrob Chemother Suppl B:169-79. 
 
Batterson, W. and B. Roizman (1983). "Characterization of the herpes simplex virion-
associated factor responsible for the induction of alpha genes." J Virol 46(2): 371-7. 
 
Baudoux, L., P. Defechereux, et al., (2000). "Gene activation by Varicella-zoster virus IE4 
protein requires its dimerization and involves both the arginine-rich sequence, the central 
part, and the carboxyl-terminal cysteine-rich region." J Biol Chem 275(42): 32822-31. 
 
Baxi, M. K., S. Efstathiou, et al., (1995). "The detection of latency-associated transcripts of 
equine herpesvirus 1 in ganglionic neurons." J Gen Virol 76 ( Pt 12): 3113-8. 
  
Behrman, A., D.S. Schmid, et al., (2003). "A cluster of primary varicella cases among 
healthcare workers with false-positive varicella zoster virus titers." Infect Control Hosp 
Epidemiol 24(3): 202-6. 
 
Bender, F. C., J.C. Whitbeck, Ponce de Leon M, Lou H, Eisenberg RJ, Cohen GH. (2003). 
"Specific association of glycoprotein B with lipid rafts during herpes simplex virus entry." J 
Virol 77(17): 9542-52. 
  295 
Berarducci, B., M. Ikoma, et al., (2006). "Essential functions of the unique N-terminal region 
of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the 
pathogenesis of skin infection." J Virol 80(19): 9481-96. 
  
Berarducci, B., J. Rajamani, et al., (2009). "Deletion of the first cysteine-rich region of the 
varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and 
differentially affects cell-cell spread and viral entry." J Virol 83(1): 228-40. 
 
Bergen, R. E., P. S. Diaz, et al., (1990). "The immunogenicity of the Oka/Merck varicella 
vaccine in relation to infectious varicella-zoster virus and relative viral antigen content." J 
Infect Dis 162(5): 1049-54. 
 
Bergen, R. E., M. Sharp, et al. (1991). "Human T cells recognize multiple epitopes of an 
immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus." Viral 
Immunol 4(3): 151-66. 
  
Berger, R., G. Florent, et al., (1981). "Decrease of the lymphoproliferative response to 
varicella-zoster virus antigen in the aged." Infect Immun 32(1): 24-7. 
 
Bernstein, H. H., E.P. Rothstein, et al., (1993). "Clinical survey of natural varicella compared 
with breakthrough varicella after immunization with live attenuated Oka/Merck varicella 
vaccine." Pediatrics 92(6): 833-7. 
  
Besser, J., M. Ikoma, et al., (2004). "Differential requirement for cell fusion and virion 
formation in the pathogenesis of varicella-zoster virus infection in skin and T cells." J Virol 
78(23): 13293-305. 
 
Besser, J., M. H. Sommer, et al., (2003). "Differentiation of varicella-zoster virus ORF47 
protein kinase and IE62 protein binding domains and their contributions to replication in 
human skin xenografts in the SCID-hu mouse." J Virol 77(10): 5964-74  
 
Biron CA, B. K., Sullivan JL. (1989). "Severe herpesvirus infections in an adolescent without 
natural killer cells." N Engl J Med 320(26): 1731-5. 
 
Black A.P., L. Jones, et al., (2009). "Immune evasion during varicella zoster virus infection of 
keratinocytes." Clin Exp Dermatol. 34(8): e941-e944. 
  
Blackwelder, W. C., R. Dolin, et al., (1982). "A population study of herpesvirus infections and 
HLA antigens." Am J Epidemiol 115(4): 569-76. 
 
Boeckh, M. (2006). "Prevention of VZV infection in immunosuppressed patients using 
antiviral agents." Herpes 13 (3): 60-5 
 
Bogger-Goren, S., K. Baba, et al., (1982). "Antibody response to varicella-zoster virus after 
natural or vaccine-induced infection." J Infect Dis 146(2): 260-5. 
 
Bogger-Goren, S., J. M. Bernstein, et al., (1984). "Mucosal cell-mediated immunity to 
varicella zoster virus: role in protection against disease." J Pediatr 105(2): 195-9. 
 
Borchers, K., U. Wolfinger, et al., (1999b). "Latency-associated transcripts of equine 
herpesvirus type 4 in trigeminal ganglia of naturally infected horses." J Gen Virol 80 (Pt 8): 
2165-71. 
 
Boucaud, D., H. Yoshitake, et al. (1998). "The varicella-zoster virus (VZV) open-reading 
frame 29 protein acts as a modulator of a late VZV gene promoter." J Infect Dis 178 (Suppl 
1): S34-8. 
  296 
Bosnjak, L., C. A. Jones, et al., (2005). "Dendritic cell biology in herpesvirus infections." Viral 
Immunol 18(3): 419-33. 
 
Bowden, R. A., M. J. Levin, et al., (1985). "Lysis of varicella zoster virus infected cells by 
lymphocytes from normal humans and immunosuppressed pediatric leukaemic patients." Clin 
Exp Immunol 60(2): 387-95. 
  
Breitfeld, D., L. Ohl et al., (2000). “Follicular B Helper T Cells Express CXC Chemokine 
Receptor 5, Localize to B cell Follicles, and Support Immunoglobulin Production”. J. Exp. 
Med. 192:1545–52 
 
Brisson, M., W. J. Edmunds, et al., (2002). "Varicella vaccine and shingles." J Am Med Assoc 
287(17): 2211; author reply 2211-2. 
 
Brunell, P. A. (1989). "Transmission of chickenpox in a school setting prior to the observed 
exanthem." Am J Dis Child 143(12): 1451-2. 
 
Brunell, P. A. (1992). "Varicella in pregnancy, the fetus, and the newborn: problems in 
management." J Infect Dis 166: Suppl 1:S42-7. 
 
Brunell, P. A., A.A. Gershon, S.A. Uduman, S. Steinberg (1975). "Varicella-Zoster 
Immunoglobulins during Varicella, Latency, and Zoster." J Infect Dis 132(1): 49-54. 
 
Buchbinder, S. P., M.H. Katz, et al. (1992). "Herpes zoster and human immunodeficiency 
virus infection " J Infect Dis 166: 1153-6. 
 
Burgoon, C. F., J. S. Burgoon, G.D. Baldridge (1957). "The natural history of herpes zoster." 
J Am Med Assoc 164(3): 265-9. 
 
Burke, B., Steele R.W, et al., (1982). "Immune responses to varicella-zoster in the aged." 
Arch Intern Med 142(2): 291-3. 
  
Callan, M. F., L. Tan, et al. (1998). "Direct visualization of antigen-specific CD8
+
 T cells 
during the primary immune response to Epstein-Barr virus In vivo." J Exp Med 187(9): 1395-
402. 
 
Card, J. P., Rinaman L., et al., (1993). "Pseudorabies virus infection of the rat central nervous 
system: ultrastructural characterization of viral replication, transport and pathogenesis." J 
Neurosci 13: 2515–2539. 
  
Carpenter, J. E., E. P. Henderson, et al., (2009). Enumeration of an extremely high particle to 
pfu ratio for varicella zoster virus: epub: April 2009 J Virol 2831-2835 
 
Carpenter, J. E., J. A. Hutchinson, et al., (2008). "Egress of light particles among filopodia on 
the surface of Varicella-Zoster virus-infected cells." J Virol 82(6): 2821-35. 
 
Casey, T. A., W. T. Ruyechan, et al., (1985). "Fine mapping and sequencing of a variable 
segment in the inverted repeat region of varicella-zoster virus DNA." J Virol 54(2): 639-42. 
  
Chapman, S. J. (1998). "Varicella in pregnancy." Semin Perinatol. 22(4): 339-46 
 
Chaudhuri, V., M. Sommer, et al., (2008). "Functions of Varicella-zoster virus ORF23 capsid 
protein in viral replication and the pathogenesis of skin infection." J Virol 82(20): 10231-46. 
 
Chaves, S. S., P. Gargiullo, et al., (2007). "Loss of vaccine-induced immunity to varicella over 
time." N Engl J Med 356(11): 1121-9. 
  297 
Chaves, S. S., P. Haber, et al., (2008). "Safety of varicella vaccine after licensure in the 
United States: experience from reports to the vaccine adverse event reporting system, 1995-
2005." J Infect Dis 197 Suppl 2: S170-7. 
 
Che, X., B. Berarducci, et al., (2007). "The Ubiquitous Cellular Transcriptional Factor, USF, 
Targets the Varicella-Zoster Virus ORF10 Promoter and Determines Virulence in Human Skin 
Xenografts in SCIDhu Mice in Vivo." J Virol. 
 
Che, X., M. Reichelt, et al., (2008). "Functions of the ORF9-to-ORF12 gene cluster in 
varicella-zoster virus replication and in the pathogenesis of skin infection." J Virol 82(12): 
5825-34. 
  
Che, X., L. Zerboni, et al., (2006). "Varicella-zoster virus open reading frame 10 is a virulence 
determinant in skin cells but not in T cells in vivo." J Virol 80(7): 3238-48. 
 
Cheatham W.J., T. F. Dolan, et al., (1956). "Varicella: report of two fatal cases with necropsy, 
virus isolation, and serologic studies." Am J Pathol  32(5): 1015-35 
 
Chen, J. J., A. A. Gershon, et al., (2003). "Latent and lytic infection of isolated guinea pig 
enteric ganglia by varicella zoster virus." J Med Virol 70 Suppl 1: S71-8. 
  
Chen, D., and P.D Olivo, (1994). Expression of the varicella-zoster virus origin-binding 
protein and analysis of its site-specific DNA-binding properties. J Virol 68, 3841-3849. 
 
Chen, J. J., Z. Zhu, et al., (2004). "Mannose 6-phosphate receptor dependence of varicella 
zoster virus infection in vitro and in the epidermis during varicella and zoster." Cell 119(7): 
915-26. 
 
Cilloniz, C., W. Jackson, et al., (2007). "The varicella-zoster virus (VZV) ORF9 protein 
interacts with the IE62 major VZV transactivator." J Virol 81(2): 761-74. 
   
Cohen, J. I. (1998). "Infection of cells with varicella-zoster virus down-regulates surface 
expression of class I major histocompatibility complex antigens." J Infect Dis 177(5): 1390-3. 
 
Cohen, J. I., E. Cox, et al., (2004). "The varicella-zoster virus open reading frame 63 latency-
associated protein is critical for establishment of latency." J Virol 78(21): 11833-40. 
  
Cohen, J. I., T. Krogmann, et al., (2005a). "Regions of the varicella-zoster virus open reading 
frame 63 latency-associated protein important for replication in vitro are also critical for 
efficient establishment of latency." J Virol 79(8): 5069-77. 
 
Cohen, J. I., T. Krogmann, et al., (2005b). "Varicella-zoster virus ORF4 latency-associated 
protein is important for establishment of latency." J Virol 79(11): 6969-75. 
 
Cohen, J. I., T. Krogmann, et al., (2007a). "Absence or overexpression of the Varicella-Zoster 
Virus (VZV) ORF29 latency-associated protein impairs late gene expression and reduces 
VZV latency in a rodent model." J Virol 81(4): 1586-91. 
 
Cohen, J. I. and H. Nguyen (1997). "Varicella-zoster virus glycoprotein I is essential for 
growth of virus in Vero cells." J Virol 71(9): 6913-20. 
 
Cohen, J. I. and H. Nguyen (1998). "Varicella-zoster virus ORF61 deletion mutants replicate 
in cell culture, but a mutant with stop codons in ORF61 reverts to wild-type virus." Virology 
246(2): 306-16. 
 
  298 
Cohen, J. I., H. Sato, et al., (2001). "Varicella-zoster virus (VZV) ORF65 virion protein is 
dispensable for replication in cell culture and is phosphorylated by casein kinase II, but not by 
the VZV protein kinases." Virology 280(1): 62-71. 
 
Cohen, J. I. and K. E. Seidel (1993). "Generation of varicella-zoster virus (VZV) and viral 
mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in 
vitro." Proc Natl Acad Sci USA 90(15): 7376-80. 
 
Cohen, J. I. and K. Seidel (1994a). "Varicella-zoster virus (VZV) open reading frame 10 
protein, the homolog of the essential herpes simplex virus protein VP16, is dispensable for 
VZV replication in vitro." J Virol 68(12): 7850-8. 
 
Cohen, J. I. and K. E. Seidel (1994b). "Absence of varicella-zoster virus (VZV) glycoprotein V 
does not alter growth of VZV in vitro or sensitivity to heparin." J Gen Virol 75 (Pt 11): 3087-
93. 
 
Cohen, J. I. and K. E. Seidel (1995). "Varicella-zoster virus open reading frame 1 encodes a 
membrane protein that is dispensable for growth of VZV in vitro." Virology 206(2): 835-42. 
 
Cohen J.I., S.S. Straus, A. Arvin (2007b). "Varicella-zoster virus, replication, pathogenesis 
and management." In: Fields virology, Knipe DM, Howley PM, (editors); 5
th
 Edition (volume 
2): Lippincott-Raven Publishers, Philadelphia, p 2774–2818. 
    
Cohrs, R. J., M. Barbour, et al., (1996). "Varicella-zoster virus (VZV) transcription during 
latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a 
cDNA library enriched for VZV RNA." J Virol 70(5): 2789-96. 
 
Cohrs, R. J., M. P. Hurley, et al., (2003a). "Array analysis of viral gene transcription during 
lytic infection of cells in tissue culture with Varicella-Zoster virus." J Virol 77(21): 11718-32. 
  
Cohrs, R. J. and D. H. Gilden (2003). "Varicella zoster virus transcription in latently-infected 
human ganglia." Anticancer Res 23(3A): 2063-9. 
  
Cohrs, R. J., D. H. Gilden, et al., (2003b). "Varicella-zoster virus gene 66 transcription and 
translation in latently infected human Ganglia." J Virol 77(12): 6660-5. 
  
Cohrs, R. J. and D. H. Gilden (2006). "Prevalence and Abundance of Latently Transcribed 
VZV Genes in Human Ganglia." J Virol. 81(6):2950-6 
 
Cohrs, R. J., D. H. Gilden, et al., (2006). "Comparison of virus transcription during lytic 
infection of the Oka parental and vaccine strains of Varicella-Zoster virus." J Virol 80(5): 
2076-82. 
 
Cohrs, R. J. and D. H. Gilden (2007). "Prevalence and abundance of latently transcribed 
varicella-zoster virus genes in human Ganglia." J Virol 81(6): 2950-6. 
  
Cohrs, R. J., J. Randall, et al., (2000). "Analysis of individual human trigeminal ganglia for 
latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time 
PCR." J Virol 74(24): 11464-71. 
 
Cole, N. L. and C. Grose (2003). "Membrane fusion mediated by herpesvirus glycoproteins: 
the paradigm of varicella-zoster virus." Rev Med Virol 13(4): 207-22.  
 
Collins, T., A.J. Korman, et al., (1984). "Immune interferon activates multiple class II major 
histocompatibility complex genes and the associated invariant chain gene in human 
endothelial cells and dermal fibroblasts." Proc Natl Acad Sci USA 81(15): 4917-21 
  299 
Cooper, E. C., L. K. Vujcic, et al., (1988). "Varicella-zoster virus-specific HLA-restricted 
cytotoxicity of normal immune adult lymphocytes after in vitro stimulation." J Infect Dis 158(4): 
780-8. 
 
Cox, E., S. Reddy, et al., (1998). "Varicella-zoster virus ORF57, unlike its pseudorabies virus 
UL3.5 homolog, is dispensable for viral replication in cell culture." Virology 250(1): 205-9. 
 
Croen, K. D., J. M. Ostrove, et al., (1988). "Patterns of gene expression and sites of latency 
in human nerve ganglia are different for varicella-zoster and herpes simplex viruses." Proc 
Natl Acad Sci USA 85(24): 9773-7. 
 
Cuthbertson, B., H. M. Dick, et al. (1982). "Histocompatibility types and antiviral antibodies in 
a diverse group of individuals." Hum Immunol 4(3): 259-64.  
 
Dahl, H., Marcoccia, J., Linde, A. (1997). "Antigen detection: the method of choice in 
comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in 
human immunodeficiency virus-infected patients." J Clin Microbiol 35: 347-349. 
  
Dahms, NM., Lobel, P., Kornfeld, S. (1989). Mannose 6-phosphate receptors and lysosomal 
enzyme targeting. J Biol Chem 264, 12115-12118. 
 
Darnell, J. E., I.M.  Kerr, G.R. Stark (1994). "Jak-STAT pathways and transcriptional 
activation in response to IFNs and other extracellular signaling proteins." Science 264(5164): 
1415-21. 
 
Davies, J., J. A. Hallworth, et al., (1994). "Characterization and immunogenicity of a 
candidate subunit vaccine against varicella-zoster virus." Med Microbiol Immunol 183(2): 
105-17. 
 
Davis, M. M., M. S. Patel, et al., (2004). Decline in Varicella-Related Hospitalizations and 
Expenditures for Children and Adults After Introduction of Varicella Vaccine in the United 
States. Pediatrics 114: 786-792. 
 
Davison, A; and P. Taylor (1987). "Genetic relations between varicella zoster virus and 
Epstein-Barr virus." J Gen Virol 68 (1067-1079). 
  
Davison, A. J. (1984). "Structure of the genome termini of varicella-zoster virus." J Gen Virol 
65 (Pt 11): 1969-77. 
 
Davison, A. J. (2000). "Molecular evolution of alphaherpesviruses." In A. M. Arvin and A. A. 
Gershon (ed.), Varicella zoster virus.: p. 25-50. 
  
Davison, A. J., C. M. Edson, et al., (1986). "New common nomenclature for glycoprotein 
genes of varicella-zoster virus and their glycosylated products." J Virol 57(3): 1195-7. 
  
Davison, A. J. and J. E. Scott (1986). "The complete DNA sequence of varicella-zoster virus." 
J Gen Virol 67 (Pt 9): 1759-816. 
  
Davison, A. J., D. J. Waters, et al., (1985). "Identification of the products of a varicella-zoster 
virus glycoprotein gene." J Gen Virol 66 (Pt 10): 2237-42. 
  
Davison, A. J. and N. M. Wilkie (1983). "Location and orientation of homologous sequences 
in the genomes of five herpesviruses." J Gen Virol 64 (Pt 9): 1927-42. 
  
Debrus, S., Sadzot-Delvaux, C., et al., (1995). Varicella-zoster virus gene 63 encodes an 
immediate-early protein that is abundantly expressed during latency. J Virol 69, 3240-3245. 
  300 
Defechereux, P., S. Debrus, et al., (1997). "Varicella-zoster virus open reading frame 4 
encodes an immediate-early protein with posttranscriptional regulatory properties." J Virol 
71(9): 7073-9. 
 
Defechereux, P., S. Debrus, et al., (1996). "Intracellular distribution of the ORF4 gene 
product of varicella-zoster virus is influenced by the IE62 protein." J Gen Virol 77 ( Pt 7): 
1505-13. 
 
Defechereux, P., L. Melen, et al., (1993). "Characterization of the regulatory functions of 
varicella-zoster virus open reading frame 4 gene product." J Virol 67(7): 4379-85. 
 
de Ory, F., J. M. Echevarría, et al., (2006). "European seroepidemiology network 2: 
Standardisation of assays for seroepidemiology of varicella zoster virus." J Clin Virol 36(2): 
111-18. 
 
Department of Health. (2003). Chickenpox (varicella) immunisation for health care workers – 
letter (www.doh.gov.uk/jcvi/mins25jan02.htm). 
 
Desloges, N., M. Rahaus, et al., (2005a). "Role of the protein kinase PKR in the inhibition of 
varicella-zoster virus replication by beta interferon and gamma interferon." J Gen Virol 86(Pt 
1): 1-6. 
 
Desloges, N., M. Rahaus, et al., (2005b). "Varicella-zoster virus does not significantly induce 
cell defence mechanism mediated by the 2-5A/RNase L pathway during its replication cycle." 
Med Microbiol Immunol 194 (1-2): 25-31. 
 
Desloges, N., M. Rahaus, et al., (2005c). "The varicella-zoster virus-mediated delayed host 
shutoff: open reading frame 17 has no major function, whereas immediate-early 63 protein 
represses heterologous gene expression." Microbes Infect 7(15): 1519-29. 
 
Desloges, N., M. Rahaus, et al., (2008a). "The phosphorylation profile of protein kinase A 
substrates is modulated during Varicella-zoster virus infection." Med Microbiol Immunol 
197(4): 353-60. 
 
Desloges, N., C. Schubert, et al., (2008b). "Varicella-zoster virus infection induces the 
secretion of interleukin-8." Med Microbiol Immunol 197(3): 277-84. 
 
Devey, M.E., K. Bleasdale, D.A. Isenberg, (1987) “Antibody affinity and IgG subclass of 
responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus 
erythematosus.” Clin Exp Immunol  68(3):562-9. 
 
Diaz, P. S., D. Au, et al., (1991). "Lack of transmission of the live attenuated varicella vaccine 
virus to immunocompromised children after immunization of their siblings." Pediatrics 87(2): 
166-70. 
 
Diaz, P. S., S. Smith, et al., (1988). "Immunity to whole varicella-zoster virus antigen and 
glycoproteins I and p170: relation to the immunizing regimen of live attenuated varicella 
vaccine." J Infect Dis 158(6): 1245-52. 
 
Diaz, P. S., S. Smith, et al. (1989). "T lymphocyte cytotoxicity with natural varicella-zoster 
virus infection and after immunization with live attenuated varicella vaccine." J Immunol 
142(2): 636-41. 
 
Disney, G. H. and R. D. Everett (1990). "A herpes simplex virus type 1 recombinant with both 
copies of the Vmw175 coding sequences replaced by the homologous varicella-zoster virus 
open reading frame." J Gen Virol 71 (Pt 11): 2681-9. 
  301 
Disney, G. H., T. A. McKee, et al., (1990). "The product of varicella-zoster virus gene 62 
autoregulates its own promoter." J Gen Virol 71 (Pt 12): 2999-3003. 
 
Doerr, H. W., M. Rentschler, et al. (1987). "Serologic detection of active infections with 
human herpes viruses (CMV, EBV, HSV, VZV): diagnostic potential of IgA class and IgG 
subclass-specific antibodies." Infection 15(2): 93-8. 
 
Döhner, K., and B. Sodeik (2005). "The role of the cytoskeleton during viral infection." Curr 
Top Microbiol Immunol 285: 67-108. 
 
Dominguez, G., T.R. Dambaugh, et al., (1999) “Human herpesvirus 6B genome sequence: 
coding content and comparison with human herpesvirus 6A.” J Virol 73: 8040-8052. 
   
Donahue, J. C. P., Manson JE, Platt R. (1995). "The incidence of herpes zoster." Arch Intern 
Med 155 (15): 1605-9. 
  
Dubey, L., S. P. Steinberg, et al. (1988). "Western blot analysis of antibody to varicella-zoster 
virus." J Infect Dis 157(5): 882-8. 
 
Duus, K. M. and C. Grose (1996). "Multiple regulatory effects of varicella-zoster virus (VZV) 
gL on trafficking patterns and fusogenic properties of VZV gH." J Virol 70 (12): 8961-71. 
 
Duus, K. M., C. Hatfield, et al., (1995). "Cell surface expression and fusion by the varicella-
zoster virus gH:gL glycoprotein complex: analysis by laser scanning confocal microscopy." 
Virology 210 (2): 429-40. 
 
Echchakir, H., M. Bagot, et al. "Cutaneous T cell lymphoma reactive CD4+ cytotoxic T 
lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for 
specific tumor cell lysis." J Invest Dermatol 2000 115: 74–80. 
  
Echevarria, J. M., A. Tellez, P. Martinez-Martin, (1990). "Subclass distribution of the serum 
and intrathecal IgG antibody response in varicella-zoster virus infections." J Infect Dis. 
162(3): 621-6. 
 
Ecker, JR., Hyman, RW. (1982). Varicella zoster virus DNA exists as two isomers. Proc Natl 
Acad Sci USA 79, 156-160. 
 
Edson, C. M., B. A. Hosler, et al., (1985b). "Cross-reactivity between herpes simplex virus 
glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein." J Virol 56 
(1): 333-6. 
  
Edson, C. M., B. A. Hosler, et al., (1987). "Varicella-zoster virus gpI and herpes simplex virus 
gE: phosphorylation and Fc binding." Virology 161 (2): 599-602. 
 
Eisfeld, A. J., S. E. Turse, et al., (2006). "Phosphorylation of the varicella-zoster virus (VZV) 
major transcriptional regulatory protein IE62 by the VZV open reading frame 66 protein 
kinase." J Virol 80(4): 1710-23. 
 
Eisfeld, A. J., M. B. Yee, et al., (2007). Downregulation of Class I Major Histocompatibility 
Complex Surface Expression by Varicella-Zoster Virus Involves Open Reading Frame 66 
Protein Kinase-Dependent and -Independent Mechanisms. J Virol 81: 9034-9049. 
 
Elgueta, R., M. J. Benson, et al., (2009). Molecular mechanism and function of CD40/CD40L 
engagement in the immune system. Immunol Rev 229: 152-172. 
 
  302 
El Mjiyad, N., S. Bontems, et al., (2007). "Varicella-zoster virus modulates NF-B recruitment 
on selected cellular promoters." J Virol 81(23): 13092-104. 
 
Embil, J. A., R.G. Stephens, F.R. Manuel (1975). "Prevalence of recurrent herpes labialis and 
aphthous ulcers among young adults on six continents." Can Med Assoc J 113(7): 627-30. 
 
Enders, G., E. Miller, et al., (1994). "Consequences of varicella and herpes zoster in 
pregnancy: prospective study of 1739 cases." Lancet 343(8912): 1548-51. 
 
Enders, G. (1985). "Management of varicella-zoster contact and infection in pregnancy using 
a standardized varicella-zoster ELISA test." Postgrad Med J 61 Suppl 4: 23-30. 
 
Engels E.A., P.S. Rosenberg, R.J. Biggar (1999) “Zoster incidence in human 
immunodeficiency virus–infected hemophiliacs and homosexual men,1984–1997.” J Infect 
Dis180:1784–9. 
 
Englund, J. A., A. M. Arvin, et al. (1990). "Acyclovir treatment for varicella does not lower gpI 
and IE-62 (p170) antibody responses to varicella-zoster virus in normal children." J Clin 
Microbiol 28(10): 2327-30. 
 
Erazo, A., M. B. Yee, et al., (2008). "Varicella-zoster virus open reading frame 66 protein 
kinase is required for efficient viral growth in primary human corneal stromal fibroblast cells." 
J Virol 82(15): 7653-65. 
  
Esiri, M. a.nd A. Tomlinson, (1972). "Herpes zoster: demonstration of virus in trigeminal 
nerve and ganglion by immunofluorescence and electron microscopy." J Neurol Sci 15:35–
48. 
 
Etzioni A., C. Eidenschenk., et al., (2005). "Fatal Varicella Associated with Selective Natural 
Killer Cell Deficiency." J Pediatr 146: 423-5. 
 
Felser, J. M., P. R. Kinchington, et al., (1988). "Cell lines containing varicella-zoster virus 
open reading frame 62 and expressing the "IE" 175 protein complement ICP4 mutants of 
herpes simplex virus type 1." J Virol 62(6): 2076-82. 
 
Finnen, R. L., K. R. Mizokami, et al., (2006). "Postentry events are responsible for restriction 
of productive varicella-zoster virus infection in Chinese hamster ovary cells." J Virol 80(21): 
10325-34. 
 
Fleischer, B. (1984). "Acquisition of specific cytotoxic activity by human T4+ lymphocytes in 
culture." Nature 308: 365–7. 
 
Fleming, D. M., K.W. Cross, et al., (2004). "Gender difference in the incidence of shingles." 
Epidemiol Infect 132(1): 1-5. 
 
Forghani, B., Dupuis KW, Schmidt NJ. (1984). "Varicella-zoster viral glycoproteins analyzed 
with monoclonal antibodies." J Virol 52(1): 55-62. 
 
Forghani B, K. Dupuis, N.J. Schmidt (1990b). "Epitopes functional in neutralization of 
varicella-zoster virus." J Clin Microbiol  28(11): 2500-6. 
 
Forghani, B., R. Mahalingam, et al., (1990a). "Monoclonal antibody to immediate early protein 
encoded by varicella-zoster virus gene 62." Virus Res 16(2): 195-210. 
 
Forghani, B., L. Ni, C. Grose. (1994). "Neutralization epitope of the varicella-zoster virus 
gH:gL glycoprotein complex." Virology 199(2): 458-62. 
  303 
Forghani B, N.J. Schmidt et al., (1982). "Serological reactivity of some monoclonal antibodies 
to varicella-zoster virus." Arch Virol. 73(3-4): 311-7.  
  
Fowler, W. J., M. Garcia-Valcarcel, et al., (1995). "Identification of immunodominant regions 
and linear B cell epitopes of the gE envelope protein of varicella-zoster virus." Virology 
214(2): 531-40.  
 
Frey, C. R., M. A. Sharp, et al., (2003). "Identification of CD8
+
 T cell epitopes in the 
immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of 
CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination." J Infect 
Dis 188(1): 40-52. 
  
Fuchs, W., B.G. Klupp, et al., (2002). "The interacting UL31 and UL34 gene products of 
pseudorabies virus are involved in egress from the host-cell nucleus and represent 
components of primary enveloped but not mature virions."  J Virol 76(1): 364-78 
 
Furth, S. L., G.S. Arbus, et al., (2003). "Varicella vaccination in children with nephrotic 
syndrome: a report of the Southwest Pediatric Nephrology Study Group." J Pediatr 142(2): 
145-8. 
 
Gabel, C. A., L. Dubey, et al., (1989). "Varicella-zoster virus glycoprotein oligosaccharides 
are phosphorylated during posttranslational maturation." J Virol 63(10): 4264-76. 
  
Galea, S. A., A. Sweet, et al., (2008). "The safety profile of varicella vaccine: a 10-year 
review." J Infect Dis 197 Suppl 2: S165-9. 
 
Galil, K., P.W. Choo, et al., (1997). "The sequelae of herpes zoster." Arch Intern Med 157: 
1209-13. 
 
Galil K, B. C., Lin F, Seward J. (2002a). "Hospitalizations for varicella in the United States, 
1988 to 1999." Pediatr Infect Dis J 21(10): 931-5. 
 
Galil K, F. E., Mountcastle N, et al., (2002b). "Younger age at vaccination may increase risk 
of varicella vaccine failure." J Infect Dis 186 (1): 102-5. 
 
Galil, K., Lee, B., Strine et al., (2002c). Outbreak of varicella at a day-care center despite 
vaccination. N Engl J Med 347, 1909-1915. 
 
Garcia-Valcarcel, M., W. J. Fowler, et al., (1997a). "Induction of neutralizing antibody and T-
cell responses to varicella-zoster virus (VZV) using Ty-virus-like particles carrying fragments 
of glycoprotein E (gE)." Vaccine 15(6-7): 709-19. 
 
Garcia-Valcarcel, M., W. J. Fowler, et al., (1997b). "Cloning, expression, and immunogenicity 
of the assembly protein of varicella-zoster virus and detection of the products of open reading 
frame 33." J Med Virol 53(4): 332-9. 
 
Garnett, G.P., M. J. Cox, et al., (1993) “The age of infection with varicella-zoster virus in St 
Lucia, West Indies”. Epidemiol Infect 110: 361–372. 
 
Gerna, G., P. M. Cereda, et al., (1979). "Antibody to early antigens of varicella-zoster virus 
during varicella and zoster." J Infect Dis 140(1): 33-41. 
    
Gershon, A. A. (1995). "Varicella-zoster virus: prospects for control." Adv Pediatr Infect Dis 
10: 93-124. 
 
  304 
Gershon, A. A. (2001). "Prevention and treatment of VZV infections in patients with HIV." 
Herpes 8(2): 32-6. 
 
Gershon, A. A., J. Chen, et al., (2008). "A model of lytic, latent, and reactivating varicella-
zoster virus infections in isolated enteric neurons." J Infect Dis 197 Suppl 2: S61-5. 
 
Gershon, A., Cosio L. and Brunell P. A. (1973). "Observations on the growth of varicella-
zoster virus in human diploid cells." J Gen Virol 18: 21–31. 
 
Gershon, MD., and Gershon, AA, (1999). Role of Glycoproteins in varicella-zoster virus 
infection: In Wolff, MH., Schunemann, S., Schmidt, A. Varicella Zoster Virus - Molecular 
Biology, Pathogenesis, and Clinical Aspects. Karger, Switzerland, pp. 43-60. 
 
Gershon, A. A., and S. Krugman (1975). "Seroepidemiologic survey of varicella: Value of 
specific fluorescent antibody test." Pediatrics 56(6): 1005-8. 
 
Gershon, A. A., P. LaRussa, et al., (1992). "Varicella vaccine: the American experience." J 
Infect Dis 166 Suppl 1: S63-8. 
 
Gershon, A. A., P. LaRussa, et al., (1994a). "Detection of antibodies to varicella-zoster virus 
using a latex agglutination assay." Clin Diagn Virol 2(4-5): 271-7. 
 
Gershon, A. A., N. Mervish, et al., (1997). "Varicella-zoster virus infection in children with 
underlying human immunodeficiency virus infection." J Infect Dis 176(6): 1496-500. 
 
Gershon, A. A., D. L. Sherman, et al., (1994b). "Intracellular transport of newly synthesized 
varicella-zoster virus: final envelopment in the trans-Golgi network." J Virol 68(10): 6372-90. 
 
Gershon, A., and Steinberg SP. (1979). "Cellular and humoral immune responses to 
varicella-zoster virus in immunocompromised patients during and after varicella-zoster 
infections." Infect Immun 25: 170–4. 
 
Gershon AA, and S. S. Steinberg (1981). "Antibody responses to varicella-zoster virus and 
the role of antibody in host defense." Am J Med Sci. 282(1): 12-7. 
 
Gershon, A. A., S.P. Steinberg (1989). "Persistence of immunity to varicella in children with 
leukemia immunized with live attenuated varicella vaccine." N Engl J Med 320(14): 892-7. 
 
Gershon, A. A., S.P. Steinberg, P.A. Brunell (1974). "Zoster immune globulin. A further 
assessment." N Engl J Med 290(5 ): 243-5. 
 
Gershon, A. A., S.P. Steinberg, L. Gelb (1984a). "Clinical reinfection with varicella-zoster 
virus." J Infect Dis 149(2): 137-42. 
 
Gershon, A. A., S.P. Steinberg, et al., (1984b). "Live attenuated varicella vaccine. Efficacy for 
children with leukemia in remission." J Am Med Assoc 252(3): 355-62 
 
Gershon, A. A., S. P. Steinberg, et al., (1988). "Immunization of healthy adults with live 
attenuated varicella vaccine." J Infect Dis 158(1): 132-7. 
 
Gershon, A. A. and S. P. Steinberg (1990). "Live attenuated varicella vaccine: protection in 
healthy adults compared with leukemic children. National Institute of Allergy and Infectious 
Diseases Varicella Vaccine Collaborative Study Group." J Infect Dis 161(4): 661-6. 
 
  305 
Ghaffar, F., K. Carrick, B.B Rogers, L.R Margraf, K. Krisher, O. Ramilo (2000). "Disseminated 
infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with 
adenosine deaminase deficiency." Pediatr Infect Dis J 19(8): 764-6. 
 
Gibson, W. and B. Roizman (1972). "Proteins specified by herpes simplex virus. 8. 
Characterization and composition of multiple capsid forms of subtypes 1 and 2." J Virol 10(5): 
1044-52. 
 
Gilden, D. H., R. J. Cohrs, et al., (2003b). "Clinical and molecular pathogenesis of varicella 
virus infection." Viral Immunol 16(3): 243-58. 
 
Gilden, D. H., M. Devlin, et al., (1989). "Persistence of varicella-zoster virus DNA in blood 
mononuclear cells of patients with varicella or zoster." Virus Genes 2(4): 299-305. 
 
Gilden, D. H., A. N. Dueland, et al., (1992). "Varicella-zoster virus reactivation without rash." J 
Infect Dis 166 Suppl 1: S30-4. 
 
Gilden, D. H. and R. I. Katz (2003c). "Surgical induction of zoster in a contralateral 
homologous dermatomal distribution." Arch Neurol 60(4): 616-7. 
  
Gilden, D. H., Y. Shtram, et al., (1982b). "The internal organization of the varicella-zoster 
virus genome." J Gen Virol 60(Pt 2): 371-4. 
  
Giller, R. H., S. Winistorfer, et al., (1989b). "Cellular and humoral immunity to varicella zoster 
virus glycoproteins in immune and susceptible human subjects." J Infect Dis 160(6): 919-28. 
  
Glesby, M.J., R.D. Moore, R.E. Chaisson (1993). “Herpes zoster in patients with advanced 
human immunodeficiency virus infection treated with zidovudine” J Infect Dis 168:1264–8. 
 
Gomi, Y., T. Imagawa, et al., (2000). "Oka varicella vaccine is distinguishable from its 
parental virus in DNA sequence of open reading frame 62 and its transactivation activity." J 
Med Virol 61(4): 497-503. 
 
Gomi, Y., T. Imagawa, et al., (2001). "Comparison of DNA sequence and transactivation 
activity of open reading frame 62 of Oka varicella vaccine and its parental viruses." Arch Virol 
Suppl (17): 49-56. 
 
Gomi, Y., Sunamachi, H., et al., (2002). Comparison of the complete DNA sequences of the 
Oka varicella vaccine and its parental virus. J Virol 76, 11447-11459. 
 
Gonnella, R., A. Farina, et al., (2005). "Characterization and intracellular localization of the 
Epstein-Barr virus protein BFLF2: interactions with BFRF1 and with the nuclear lamina." J 
Virol 79(6): 3713-27 
 
Govero, J., S. Hall, et al., (2007). "Intracellular localization of varicella-zoster virus ORF39 
protein and its functional relationship to glycoprotein K." Virology 358(2): 291-302. 
 
Gowrishankar, K., B. Slobedman, et al., (2007). "Productive varicella-zoster virus infection of 
cultured intact human ganglia." J Virol 81(12): 6752-6. 
 
Grant, R. M., S. S. Weitzman, et al. (2002). "Fulminant disseminated Varicella Zoster virus 
infection without skin involvement." J Clin Virol 24(1-2): 7-12. 
 
Gray, W. L. (2003). "Pathogenesis of simian varicella virus." J Med Virol 70 Suppl 1: S4-8. 
 
  306 
Gray, W. L. (2004). "Simian varicella: a model for human varicella-zoster virus infections." 
Rev Med Virol 14(6): 363-81. 
 
Gray, W. L., R. J. Williams, et al., (1998). "Experimental simian varicella virus infection of St. 
Kitts vervet monkeys." J Med Primatol 27(4): 177-83. 
 
Griffiths, G., Hoflack, B., et al., (1988). The mannose 6-phosphate receptor and the 
biogenesis of lysosomes. Cell 52, 329-341.  
 
Grinfeld, E., R. Goodwin, et al., (2006). "Varicella-Zoster virus gene expression at variable 
periods following death in a rat model of ganglionic infection." Virus Genes. 35(1):29-32 
 
Grinfeld, E., R. Goodwin, et al., (2007a). "Varicella-Zoster virus gene expression at variable 
periods following death in a rat model of ganglionic infection." Virus Genes 35(1): 29-32. 
 
Grinfeld, E. and P. G. Kennedy (2004a). "Translation of varicella-zoster virus genes during 
human ganglionic latency." Virus Genes 29(3): 317-9. 
 
Grinfeld, E. and P. G. Kennedy (2007b). "The pattern of viral persistence in monkeys intra-
tracheally infected with Simian varicella virus." Virus Genes 35(1): 33-37 
 
Grinfeld, E., C. Sadzot-Delvaux, et al., (2004b). "Varicella-Zoster virus proteins encoded by 
open reading frames 14 and 67 are both dispensable for the establishment of latency in a rat 
model." Virology 323(1): 85-90. 
  
Griswold, W. R. (1987). "A quantitative relationship between antibody affinity and antibody 
avidity." Immunol Invest 16(2): 97-106. 
 
Grose, C. (1981b). "Variation on a theme by Fenner: the pathogenesis of chickenpox." 
Pediatrics 68(5): 735-7. 
  
Grose, C. (1989). "Congenital varicella-zoster virus infection and the failure to establish virus-
specific cell-mediated immunity." Mol Biol Med 6(5): 453-62. 
 
Grose, C. (1990). "Glycoproteins encoded by varicella-zoster virus: biosynthesis, 
phosphorylation, and intracellular trafficking." Annu Rev Microbiol 44: 59-80. 
  
Grose, C. (1991). "Glycoproteins of varicella-zoster virus and their herpes simplex virus 
homologs." Rev Infect Dis 13 Suppl 11: S960-3. 
 
Grose, C. (2005). "Varicella vaccination of children in the United States: assessment after the 
first decade 1995-2005." J Clin Virol 33(2): 89-95; discussion 96-8. 
 
Grose, C. and P. A. Brunel (1978). "Varicella-zoster virus: isolation and propagation in human 
melanoma cells at 36 and 32 degrees C." Infect Immun 19(1): 199-203. 
 
Grose, C., B. J. Edmond, et al., (1979a). "Complement-enhanced neutralizing antibody 
response to varicella-zoster virus." J Infect Dis 139(4): 432-7. 
 
Grose, C., B. J. Edmond, et al., (1981). "Immunogenic glycoproteins of laboratory and 
vaccine strains of Varicella-Zoster virus." Infect Immun 31(3): 1044-53. 
 
Grose, C., D. P. Edwards, et al., (1983a). "Monoclonal antibodies against three major 
glycoproteins of varicella-zoster virus." Infect Immun 40(1): 381-8. 
 
  307 
Grose, C., D. P. Edwards, et al., (1984). "Varicella-zoster virus-specific gp140: a highly 
immunogenic and disulfide-linked structural glycoprotein." Virology 132(1): 138-46. 
 
Grose, C., W. E. Friedrichs, et al., (1983b). "Purification and molecular anatomy of the 
varicella-zoster virion." Biken J 26(1): 1-15. 
 
Grose, C., W. E. Friedrichs, et al., (1981). "Cryopreservation of varicella-zoster virions 
without loss of structural integrity or infectivity." Intervirology 15(3): 154-60. 
 
Grose, C., W. Jackson, et al., (1989). "Phosphorylation of varicella-zoster virus glycoprotein 
gpI by mammalian casein kinase II and casein kinase I." J Virol 63(9): 3912-8. 
 
Grose C, and V. Litwin, (1988). "Immunology of the varicella-zoster virus glycoproteins." J 
Infect Dis 157(5): 877-81. 
 
Grose, C. and T. I. Ng (1992). "Intracellular synthesis of varicella-zoster virus." J Infect Dis 
166 Suppl 1: S7-12. 
 
Grose, C., D. M. Perrotta, et al., (1979b). "Cell-free varicella-zoster virus in cultured human 
melanoma cells." J Gen Virol 43(1): 15-27. 
 
Grose, C., S. Tyler, et al., (2004). "Complete DNA sequence analyses of the first two 
varicella-zoster virus glycoprotein E (D150N) mutant viruses found in North America: 
evolution of genotypes with an accelerated cell spread phenotype." J Virol 78(13): 6799-807. 
   
Guess, H. A., D. D. Broughton, et al., (1985) “Epidemiology of Herpes Zoster in Children and 
Adolescents: A Population-Based Study” Pediatrics 76(4): 512-517 
  
Gut, J.P., C. Lablache, et al., (1995) “Symptomatic mumps virus reinfections”. J Med Virol. 
45(1):17-23. 
 
Habermehl, P., A. Lignitz, et al., (1999). "Cellular immune response of a varicella vaccine 
following simultaneous DTaP and VZV vaccination." Vaccine 17(7-8): 669-74. 
  
Hahn, G., Jores, R., Mocarski, ES. (1998). Cytomegalovirus remains latent in a common 
precursor of dendritic and myeloid cells. Proc Natl Acad Sci USA 95, 3937-3942.  
 
Hall, S. L., J. L. Govero, et al., (2007). "Intracellular transport and stability of varicella-zoster 
virus glycoprotein K." Virology 358(2): 283-90. 
 
Hall, S., T. Maupin, et al. (2002). Second Varicella Infections: Are They More Common Than 
Previously Thought? Pediatrics 109: 1068-1073. 
 
Hambleton, S. (2005). "Chickenpox." Curr Opin Infect Dis 18(3): 235-40. 
 
Hambleton, S. and A. M. Arvin (2005a). "Chickenpox party or varicella vaccine?" Adv Exp 
Med Biol 568: 11-24. 
 
Hambleton, S. and A. A. Gershon (2005a). "The impact of varicella vaccination in the United 
States." Semin Pediatr Infect Dis 16(1): 38-43. 
 
Hambleton, S. and A. A. Gershon (2005b). "Preventing varicella-zoster disease." Clin 
Microbiol Rev 18(1): 70-80. 
 
Hambleton, S., M. D. Gershon, et al., (2004). "The role of the trans-Golgi network in varicella 
zoster virus biology." Cell Mol Life Sci 61(24): 3047-56. 
  308 
Hambleton, S., S. P. Steinberg, et al., (2007). "Cholesterol dependence of varicella-zoster 
virion entry into target cells." J Virol 81(14): 7548-58. 
 
Hambleton, S. (2008). "Prevention of varicella and zoster by live attenuated VZV vaccine." 
Front Biosci 13: 2696-704. 
 
Hambleton, S., S.P. Steinberg, et al., (2008). Risk of Herpes Zoster in Adults Immunized with 
Varicella Vaccine. J Infect Dis 197: S196-S199. 
 
Hardy, I., Gershon, A.A. et al., (1991). The incidence of zoster after immunization with live 
attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine 
Collaborative Study Group. N Engl J Med 325, 1545-1550. 
 
Harper, D. R., R. L. Gilbert, et al., (1998). "Molecular biology of varicella-zoster virus. A 
review prepared for the UK Advisory Group on Chickenpox." J Infect 36 Suppl 1: 1-10. 
 
Harper, D. R. and C. Grose (1989). "IgM and IgG responses to varicella-zoster virus p32/p36 
complex after chickenpox and zoster, congenital and subclinical infections, and vaccination." 
J Infect Dis 159(3): 444-51. 
 
Harper, D. R., H. O. Kangro, et al., (1990b). "Antibody responses in recipients of varicella 
vaccine assayed by immunoblotting." J Med Virol 30(1): 61-7. 
 
Harper, D. R., E. A. Sanders, et al., (1995). "Varicella-zoster virus assembly protein p32/p36 
is present in DNA-containing as well as immature capsids." J Med Virol 46(2): 144-7. 
 
Harper DR, K. H., Heath RB. (1988). "Serological responses in varicella and zoster assayed 
by immunoblotting." J Med Virol 25(4): 387-98. . 
  
Harson, R. and Grose, C. (1995). Egress of varicella-zoster virus from the melanoma cell: a 
tropism for the melanocyte. J Virol 69, 4994-5010 
 
Hata, S. (1980). "Skin test with Varicella-zoster virus antigen on herpes zoster patients" Arch 
Dermatol Res 268(1): 65-70. 
 
Hata, A., H. Asanuma, et al., (2002). "Use of an inactivated varicella vaccine in recipients of 
hematopoietic-cell transplants." N Engl J Med 347(1): 26-34. 
 
Hata, A., L. Zerboni, et al., (2001). "Granulysin blocks replication of varicella-zoster virus and 
triggers apoptosis of infected cells." Viral Immunol 14(2): 125-33. 
  
Hatfield, C., K. M. Duus, et al., (1997). "Epitope mapping and tagging by recombination PCR 
mutagenesis." Biotechniques 22(2): 332-7. 
 
Haumont M, J. M., Kangro H, et al., (1997). "Neutralizing antibody responses induced by 
varicella-zoster virus gE and gB glycoproteins following infection, reactivation or 
immunization." J Med Virol 53.(1): 63-8. 
  
Hayakawa, Y., T. Yamamoto, et al., (1986). "Analysis of varicella-zoster virus DNAs of clinical 
isolates by endonuclease HpaI." J Gen Virol 67 (Pt 9): 1817-29. 
  
Hayward, A. R. (1990). "T-cell responses to predicted amphipathic peptides of varicella-
zoster virus glycoproteins II and IV." J Virol 64(2): 651-5. 
 
Hayward, A., A. Boylston, et al., (1988). "Lysis of CD3 hybridoma targets by cloned human 
CD4 lymphocytes." Immunology 64(1): 87-92. 
  309 
Hayward, A. R., K. Buda, et al., (1996). "Varicella zoster virus-specific cytotoxicity following 
secondary immunization with live or killed vaccine." Viral Immunol 9(4): 241-5. 
  
Hayward, A. R., K. Buda, et al., (1994). "Immune response to secondary immunization with 
live or inactivated VZV vaccine in elderly adults." Viral Immunol 7(1): 31-6. 
 
Hayward, A. R., R. Burger, et al., (1991a). "Major histocompatibility complex restriction of T-
cell responses to varicella-zoster virus in guinea pigs." J Virol 65(3): 1491-5. 
 
Hayward, A., R. Giller, et al., (1989). "Phenotype, cytotoxic, and helper functions of T cells 
from varicella zoster virus stimulated cultures of human lymphocytes." Viral Immunol 2(3): 
175-84. 
 
Hayward, A. R. and M. Herberger (1987). "Lymphocyte responses to varicella zoster virus in 
the elderly." J Clin Immunol 7(2): 174-8. 
  
Hayward, A. R., M. Herberger, et al., (1986a). "Cellular interactions in the lysis of varicella-
zoster virus infected human fibroblasts." Clin Exp Immunol 63(1): 141-6. 
 
Hayward, A., M. Levin, et al., (1991b). "Varicella-zoster virus-specific immunity after herpes 
zoster." J Infect Dis 163(4): 873-5. 
 
Hayward, A. R., O. Pontesilli, et al., (1986b). "Specific lysis of varicella zoster virus-infected B 
lymphoblasts by human T cells." J Virol 58(1): 179-84. 
 
Hayward, A., E. Villanueba, et al., (1992). "Varicella-zoster virus (VZV)-specific cytotoxicity 
after immunization of nonimmune adults with Oka strain attenuated VZV vaccine." J Infect 
Dis 166(2): 260-4. 
 
Heineman, T. C. and J. I. Cohen (1994). "Deletion of the varicella-zoster virus large subunit 
of ribonucleotide reductase impairs growth of virus in vitro." J Virol 68(5): 3317-23. 
  
Heineman, T. C. and J. I. Cohen (1995a). "The varicella-zoster virus (VZV) open reading 
frame 47 (ORF47) protein kinase is dispensable for viral replication and is not required for 
phosphorylation of ORF63 protein, the VZV homolog of herpes simplex virus ICP22." J Virol 
69(11): 7367-70. 
  
Heineman, T. C., P. Connolly, et al., (2004). "Conserved cytoplasmic domain sequences 
mediate the ER export of VZV, HSV-1, and HCMV gB." Virology 328(1): 131-41. 
 
Heineman, T. C. and S. L. Hall (2001). "VZV gB endocytosis and Golgi localization are 
mediated by YXXphi motifs in its cytoplasmic domain." Virology 285(1): 42-9. 
 
Heineman, T. C. and S. L. Hall (2002). "Role of the varicella-zoster virus gB cytoplasmic 
domain in gB transport and viral egress." J Virol 76(2): 591-9. 
 
Heineman TC, Krudwug N., Hall SL. (2000). "Cytoplasmic domain signal sequences that 
mediate transport of varicella-zoster virus gB from the endoplasmic reticulum to the Golgi." J 
Virol 74(20): 9421-30. 
 
Heineman, T. C., L. Pesnicak, et al., (2004). "Varicella-zoster virus expressing HSV-2 
glycoproteins B and D induces protection against HSV-2 challenge." Vaccine 22(20): 2558-
65. 
 
Heineman, T. C., M. Schleiss, et al., (2006). "A phase 1 study of 4 live, recombinant human 
cytomegalovirus Towne/Toledo chimeric vaccines." J Infect Dis 193(10): 1350-60. 
  310 
Heineman, T. C., K. Seidel, et al., (1996). "The varicella-zoster virus ORF66 protein induces 
kinase activity and is dispensable for viral replication." J Virol 70(10): 7312-7. 
 
Heise, M. T., M. Connick, H.W. Virgin, (1998). "Murine cytomegalovirus inhibits interferon 
gamma-induced antigen presentation to CD4 T cells by macrophages via regulation of 
expression of major histocompatibility complex class II-associated genes." J Exp Med 187(7): 
1037-46 
 
Heldwein EE, K. C. (2008). "Entry of herpesviruses into mammalian cells." Cell Mol Life Sci. 
65(11): 1653-68. 
 
Henderson, D., and K. Weber (1981). "Immuno-electron microscopical identification of the 
two types of intermediate filaments in established epithelial cells." Exp Cell Res 132(2): 297-
311. 
 
Hennig, B. J., K. Fielding, et al., (2008). "Host genetic factors and vaccine-induced immunity 
to hepatitis B virus infection." PLoS One 3(3): e1898. 
 
Hickling, J. K., L. K. Borysiewicz, et al., (1987). "Varicella-zoster virus-specific cytotoxic T 
lymphocytes (Tc): detection and frequency analysis of HLA class I-restricted Tc in human 
peripheral blood." J Virol 61(11): 3463-9. 
 
Hill, A. B., B. C. Barnett, et al., (1994). "HLA class I molecules are not transported to the cell 
surface in cells infected with herpes simplex virus types 1 and 2." J Immunol 152(6): 2736-41. 
  
Hill, A. V., C. E. Allsopp, et al., (1991). "HLA class I typing by PCR: HLA-B27 and an African 
B27 subtype." Lancet 337(8742): 640-2. 
  
Hilleman, MR., Weibel, RE., et al., (1967). Live attenuated mumps-virus vaccine. IV. 
Protective efficacy as measured in a field evaluation. N Engl J Med 276, 252-258. 
 
Hollinger, F.B. (1989) “Factors influencing the immune response to hepatitis B vaccine, 
booster dose guidelines, and vaccine protocol recommendations”. Am J Med 87:36-40S. 
 
Hondo, R., Y. Yogo, et al., (1987). "Genome variation among varicella-zoster virus isolates 
derived from different individuals and from the same individuals." Arch Virol 93(1-2): 1-12. 
 
Hondo, R. and Y. Yogo, (1988). "Strain variation of R5 direct repeats in the right hand portion 
of the long unique segment of varicella zoster virus DNA." J Virol 62: 2916-2951. 
 
Honess, R., Bodemer W, Cameron KR et al., (1986). "The A+T rich genome of herpesvirus 
saimirir contains a highly conserved gene for thymidylate synthases." Proc Natl Acad Sci 
USA 83: 3604-3608. 
  
Hood, C., A. L. Cunningham, et al., (2006). "Varicella-zoster virus ORF63 inhibits apoptosis 
of primary human neurons." J Virol 80(2): 1025-31. 
  
Hood, C., A. L. Cunningham, et al., (2003). "Varicella-zoster virus-infected human sensory 
neurons re resistant to apoptosis, yet human foreskin fibroblasts are susceptible: evidence 
for a cell-type-specific apoptotic response." J Virol 77(23): 12852-64. 
 
Hoover, S. E., R. J. Cohrs, et al., (2006). "Downregulation of varicella-zoster virus (VZV) 
immediate-early ORF62 transcription by VZV ORF63 correlates with virus replication in vitro 
and with latency." J Virol 80(7): 3459-68. 
 
  311 
Hope-Simpson, R. (1965). "The nature of herpes Zoster: A long term study and a new 
hypothesis." Proc R Soc Med 58: 9-20. 
 
Horiuchi, K. (1984). "Chickenpox vaccination of healthy children: immunological and clinical 
responses and protective effect in 1978-1982." Biken J 2(3): 37-8. 
 
Hsu, L.C., S.R. Lin, et al., (1996) “Ethnic differences in immune responses to hepatitis B 
vaccine.” Am J Epidemiol 143(7):718-24. 
 
Hu H. and J. I. Cohen (2005). "Varicella-zoster virus open reading frame 47 (ORF47) protein 
is critical for virus replication in dendritic cells and for spread to other cells." Virology 337(2): 
304-11. 
 
Huang, J. L., P. C. Sun, et al., (1994). "Herpes zoster in infancy after intrauterine exposure to 
varicella zoster virus: report of two cases." J Formos Med Assoc 93(1): 75-7. 
 
Huang, Z., A. Vafai, et al., (1992). "Specific lysis of targets expressing varicella-zoster virus 
gpI or gpIV by CD4+ human T-cell clones." J Virol 66(5): 2664-9. 
  
Huch, J., G. Morrow et al., (2006) “Varicella-zoster virus inhibits the maturation, function and 
distribution of human dendritic cells.” Abstract presented at: The 7
th
 Annual VZV Satellite 
Workshop, International Herpes Workshop, Seattle, Washington, USA. 
 
Huff, J. L. and P. A. Barry (2003). "B-virus (Cercopithecine herpesvirus 1) infection in humans 
and macaques: potential for zoonotic disease." Emerg Infect Dis 9(2): 246-50. 
  
Ihara, T., M. Ito, et al., (1986). "Human lymphocyte, monocyte and polymorphonuclear 
leucocyte mediated antibody-dependent cellular cytotoxicity against varicella-zoster virus-
infected targets." Clin Exp Immunol 63(1): 179-87. 
  
Ihara, T., T. Kato, et al., (1991). "Antibody response determined with antibody-dependent 
cell-mediated cytotoxicity (ADCC), neutralizing antibody, and varicella skin test in children 
with natural varicella and after varicella immunization." Acta Paediatr Jpn 33(1): 43-9. 
 
Ihara, T., K. Oitani, et al., (1994). "Cytotoxicity against varicella zoster virus infected targets in 
children with acute leukemia." Acta Paediatr Jpn 36(1): 53-6. 
  
Ihara, T., S. E. Starr, et al., (1984). "Human polymorphonuclear leukocyte-mediated 
cytotoxicity against varicella-zoster virus-infected fibroblasts." J Virol 51(1): 110-6. 
  
Iltis, J. P., G.A. Castellano, et al., (1982). "Comparison of the Raji cell line fluorescent 
antibody to membrane antigen test and the enzyme-linked immunosorbent assay for 
determination of immunity to varicella-zoster virus." J Clin Microbiol 16(5): 878-84. 
 
Inchauspe, G., S. Nagpal, et al., (1989). "Mapping of two varicella-zoster virus-encoded 
genes that activate the expression of viral early and late genes." Virology 173(2): 700-9. 
 
Inchauspe, G. and J. M. Ostrove (1989). "Differential regulation by varicella-zoster virus 
(VZV) and herpes simplex virus type-1 trans-activating genes." Virology 173(2): 710-4. 
 
Inouye, S., A. Hasegawn, S. Matsuno, and S. Katow. (1984). "Changes in antibody avidity 
after virus infections: detection by an immunosorbent assay in which a mild protein-
denaturing agent is employed." J. Clin. Microbiol. 20: 525–529. 
 
  312 
Inskip, H.M., A.J. Hall, et al., (1991) “Hepatitis B vaccine in the Gambian Expanded 
Programme on Immunization: factors influencing antibody response.” Int J Epidemiol 20: 
764–769. 
 
Irwin, M., C. Costlow, et al., (1998). "Cellular immunity to varicella-zoster virus in patients with 
major depression." J Infect Dis 178 Suppl 1: S104-8. 
  
Ito, M., S. Bandyopadhyay, et al., (1986). "Interleukin 2 enhances natural killing of varicella-
zoster virus-infected targets." Clin Exp Immunol 65(1): 182-9. 
 
Ito, Y., H. Kimura, et al., (2001). "Investigation of varicella-zoster virus DNA in lymphocyte 
subpopulations by quantitative PCR assay." Microbiol Immunol 45(3): 267-9. 
 
Ito, M., K. Mizutani, et al., (1993). "Inhibition of varicella-zoster virus (VZV) glycoprotein 
expression by a human monoclonal antibody against VZV glycoprotein III." J Infect Dis 
168(5): 1256-9. 
 
Ito, M., K. Mizutani, et al., (1992a). "Flow cytometric analysis of effects of cytokines on the 
expression of varicella-zoster virus glycoproteins." Antiviral Res 18(3-4): 317-26. 
 
Ito, M., T. Nakano, et al., (1991). "Effects of tumor necrosis factor alpha on replication of 
varicella-zoster virus." Antiviral Res 15(3): 183-92. 
 
Ito, M., T. Nakano, et al., (1992b). "Activation of lymphocytes by varicella-zoster virus (VZV): 
expression of interleukin-2 receptors on lymphocytes cultured with VZV antigen." J Infect Dis 
165(1): 158-61. 
  
Ito, M., H. Nishihara, et al., (1995a). "Detection of varicella-zoster virus (VZV) DNA in throat 
swabs and peripheral blood mononuclear cells of immunocompromised patients with herpes 
zoster by polymerase chain reaction." Clin Diagn Virol 4(2): 105-12. 
 
Ito, H., M. H. Sommer, et al., (2005). "Role of the varicella-zoster virus gene product encoded 
by open reading frame 35 in viral replication in vitro and in differentiated human skin and T 
cells in vivo." J Virol 79(8): 4819-27. 
 
Ito, H., M. H. Sommer, et al., (2003). "Promoter sequences of varicella-zoster virus 
glycoprotein I targeted by cellular transactivating factors Sp1 and USF determine virulence in 
skin and T cells in SCIDhu mice in vivo." J Virol 77(1): 489-98. 
 
Ito, M., M. Watanabe, et al., (1995b). "Fas antigen and bcl-2 expression on lymphocytes 
cultured with cytomegalovirus and varicella-zoster virus antigen." Cell Immunol 160(2): 173-7. 
 
Ito, M., M. Watanabe, et al., (1995c). "Increased expression of adhesion molecules (CD54, 
CD29 and CD44) on fibroblasts infected with cytomegalovirus." Microbiol Immunol 39(2): 
129-33. 
 
Ito, M., M. Watanabe, et al., (1996). "Inhibition of natural killer (NK) cell activity against 
varicella-zoster virus (VZV)-infected fibroblasts and lymphocyte activation in response to VZV 
antigen by nitric oxide-releasing agents." Clin Exp Immunol 106(1): 40-4. 
    
Jacquet A., H. M., Chellun. et al., (1998). "The varicella zoster virus glycoprotein B (gB) plays 
a role in virus binding to cell surface heparan sulfate proteoglycans." Virus Res 53:197–207. 
 
Jacquet, A., M. Haumont, et al., (2002). "Immunogenicity of a recombinant varicella-zoster 
virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and 
zoster reactivation." Vaccine 20(11-12): 1593-602. 
  313 
Jenkins, D. E., R. L. Redman, et al., (1998a). "Interleukin (IL)-10, IL-12, and interferon-
gamma production in primary and memory immune responses to varicella-zoster virus." J 
Infect Dis 178(4): 940-8. 
 
Jenkins, D. E., L. L. Yasukawa, et al., (1998b). "Isolation and utilization of human dendritic 
cells from peripheral blood to assay an in vitro primary immune response to varicella-zoster 
virus peptides." J Infect Dis 178 Suppl 1: S39-42. 
  
Jenkins, D. E., L. L. Yasukawa, et al., (1999). "Comparison of primary sensitization of naive 
human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses 
elicited in vivo by varicella vaccination." J Immunol 162(1): 560-7. 
 
Johnson, D. C. and M. T. Huber (2002). Directed Egress of Animal Viruses Promotes Cell-to-
Cell Spread. J Virol 76: 1-8. 
 
Johnson, C., L.P. Rome, et al., (1989). "Humoral immunity and clinical reinfections following 
varicella vaccine in healthy children." Pediatrics 84(3): 418-21. 
 
Jones, J. O. and A.M. Arvin (2003). Microarray Analysis of Host Cell Gene Transcription in 
Response to Varicella-Zoster Virus Infection of Human T Cells and Fibroblasts In Vitro and 
SCIDhu Skin Xenografts In Vivo. J Virol 77: 1268-1280. 
  
Jones, J. O. and A.M. Arvin (2005). "Viral and cellular gene transcription in fibroblasts 
infected with small plaque mutants of varicella-zoster virus." Antiviral Res 68(2): 56-65. 
  
Jones, J. O. and A.M. Arvin (2006a). "Inhibition of the NF-kappaB pathway by varicella-zoster 
virus in vitro and in human epidermal cells in vivo." J Virol 80(11): 5113-24. 
 
Jones, L., A. P. Black, et al., (2006b). "Persistent high frequencies of varicella-zoster virus 
ORF4 protein-specific CD4
+
 T cells after primary infection." J Virol 80(19): 9772-8. 
 
Jones, L., A. P. Black, et al., (2007). "Phenotypic analysis of human CD4+ T cells specific for 
immediate-early 63 protein of varicella-zoster virus." Eur J Immunol 37(12): 3393-403. 
 
Jones, F. and C. Grose (1988). "Role of cytoplasmic vacuoles in varicella-zoster virus 
glycoprotein trafficking and virion envelopment." J Virol 62(8): 2701-11. 
 
Jones, J. O., M. Sommer, et al., (2006c). "Mutational analysis of the varicella-zoster virus 
ORF62/63 intergenic region." J Virol 80(6): 3116-21.  
  
Jumaan, A. O., O. Yu, et al., (2005). "Incidence of herpes zoster, before and after varicella-
vaccination-associated decreases in the incidence of varicella, 1992-2002." J Infect Dis 
191(12): 2002-7. 
  
Junker, A., and P. Tilley (1994). "Varicella-zoster virus antibody avidity and IgG-subclass 
patterns in children with recurrent chickenpox." J Med Virol 43(2): 119-24. 
 
Junker AK, A. E., Thomas EE. (1991). "Recurrent varicella-zoster virus infections in 
apparently immunocompetent children." Pediatr Infect Dis J 10 ((8):): 569-75. 
  
Kallander, C. F., J. S. Gronowitz, et al. (1982). "Human serum antibodies to varicella-zoster 
virus thymidine kinase." Infect Immun 36(1): 30-7. 
 
Kangro, H. O., S. Manzoor, et al., (1991). "Antibody avidity following varicella-zoster virus 
infections." J Med Virol 33(2): 100-5. 
 
  314 
Karin, M., Y. Ben-Neriah (2000). "Phosphorylation meets ubiquitination: the control of NF-B 
activity." Annu Rev Immunol 18: 621-63. 
 
Kato, S., H. Yabe, et al., (1990). "Studies on transfer of varicella-zoster-virus specific T-cell 
immunity from bone marrow donor to recipient." Blood 75(3): 806-9. 
  
Kato, T., K. Kitamura, et al., (1989). "Transcription mapping of glycoprotein I (gpI) and gpIV of 
varicella-zoster virus and immunological analysis of the gpI produced in cells infected with the 
recombinant vaccinia virus." Microbiol Immunol 33(4): 299-312. 
 
Katz, S.L., C.H. Kempe. et al., (1960). "Studies on an Attenuated Measles-Virus Vaccine VIII. 
General Summary and Evaluation of the Results of Vaccination" Am J Dis Child. 100(6): 942-
946. 
 
Katzman, R. B., and R. Longnecker (2003). "Cholesterol-dependent infection of Burkitt's 
lymphoma cell lines by Epstein-Barr virus." J Gen Virol 84(Pt 11): 2987-92. 
  
Kavaliotis, J., I. Loukou, et al. (1998). "Outbreak of varicella in a pediatric oncology unit." Med 
Pediatr Oncol 31(3): 166-9. 
 
Kavaliotis, J., S. Petridou, et al. (2003). "How reliable is the history of chickenpox? Varicella 
serology among children up to 14 years of age." Int J Infect Dis 7(4): 274-7. 
 
Keegan, T.H., S.L. Gomez, et al., (2007) Recent trends in breast cancer incidence among 6 
Asian groups in the Greater Bay Area of Northern California. Int J Cancer. 120 (6): 1324-9 
 
Keller, P. M., A. J. Davison, et al., (1986). "Identification and structure of the gene encoding 
gpII, a major glycoprotein of varicella-zoster virus." Virology 152(1): 181-91. 
 
Keller, P. M., A. J. Davison, et al., (1987). "Identification and sequence of the gene encoding 
gpIII, a major glycoprotein of varicella-zoster virus." Virology 157(2): 526-33. 
  
Keller, P. M., B. J. Neff, et al., (1984). Three major glycoprotein genes of varicella-zoster 
virus whose products have neutralization epitopes. J. Virol 52: 293-297. 
  
Kempf, W., Adams, V., et al.,, (1998). Persistence of human herpesvirus 7 in normal tissues 
detected by expression of a structural antigen. J Infect. Dis 178, 841-845. 
 
Kennedy, P. G. (2002b). "Varicella-zoster virus latency in human ganglia." Rev Med Virol 
12(5): 327-34. 
 
Kennedy, P. G., E. Grinfeld, et al., (2000). "Varicella-zoster virus gene expression in latently 
infected and explanted human ganglia." J Virol 74(24): 11893-8. 
  
Kennedy, P. G., E. Grinfeld, et al., (2001). "Varicella-Zoster virus gene expression in latently 
infected rat dorsal root ganglia." Virology 289(2): 218-23. 
  
Kennedy, P. G., E. Grinfeld, et al., (2005). "Transcriptomal analysis of varicella-zoster virus 
infection using long oligonucleotide-based microarrays." J Gen Virol 86(Pt 10): 2673-84. 
  
Kennedy, P. G., E. Grinfeld, et al., (1998). "Latent varicella-zoster virus is located 
predominantly in neurons in human trigeminal ganglia." Proc Natl Acad Sci USA 95(8): 4658-
62. 
  
Kennedy, P. G., E. Grinfeld, et al., (1999). "Latent Varicella-zoster virus in human dorsal root 
ganglia." Virology 258(2): 451-4. 
  315 
Kennedy, P. G., E. Grinfeld, et al., (2004). "Neuronal localization of simian varicella virus 
DNA in ganglia of naturally infected African green monkeys." Virus Genes 28(3): 273-6.  
 
Kennedy, P. G. and I. Steiner (1994). "A molecular and cellular model to explain the 
differences in reactivation from latency by herpes simplex and varicella-zoster viruses." 
Neuropathol Appl Neurobiol 20(4): 368-74. 
  
Kenyon, T. K., J. I. Cohen, et al., (2002). "Phosphorylation by the varicella-zoster virus 
ORF47 protein serine kinase determines whether endocytosed viral gE traffics to the trans-
Golgi network or recycles to the cell membrane." J Virol 76(21): 10980-93. 
 
Kenyon, T. K., E. Homan, et al., (2003). "Comparison of varicella-zoster virus ORF47 protein 
kinase and casein kinase II and their substrates." J Med Virol 70 Suppl 1: S95-102. 
 
Kenyon, T. K., J. Lynch, et al., (2001). "Varicella-zoster virus ORF47 protein serine kinase: 
characterization of a cloned, biologically active phosphotransferase and two viral substrates, 
ORF62 and ORF63." J Virol 75(18): 8854-8. 
 
Khan, N., A. Hislop, et al., (2004). "Herpesvirus-specific CD8 T cell immunity in old age: 
cytomegalovirus impairs the response to a coresident EBV infection." J Immunol 173: 7481–
9. 
 
Khoshnood, B., M. Debruyne et al., (2006) “Seroprevalence of varicella in the French 
population”. Pediatr Infect Dis J 25: 41–44. 
  
Kim, S.H., and C. Haycox (1999) “Primary disseminated varicella presenting as an acute 
abdomen.” Pediatr Dermatol. 16(3):208-10. 
 
Kimura, H., S. E. Straus, et al., (1997). "Varicella-zoster virus glycoproteins E and I 
expressed in insect cells form a heterodimer that requires the N-terminal domain of 
glycoprotein I." Virology 233(2): 382-91. 
  
Kinchington, P. R., D. Bookey, et al., (1995a). "The transcriptional regulatory proteins 
encoded by varicella-zoster virus open reading frames (ORFs) 4 and 63, but not ORF 61, are 
associated with purified virus particles." J Virol 69(7): 4274-82. 
 
Kinchington, P. R., K. Fite, et al., (2001). "Virion association of IE62, the varicella-zoster virus 
(VZV) major transcriptional regulatory protein, requires expression of the VZV open reading 
frame 66 protein kinase." J Virol 75(19): 9106-13. 
  
Kinchington, P. R., K. Fite, et al., (2000). "Nuclear accumulation of IE62, the varicella-zoster 
virus (VZV) major transcriptional regulatory protein, is inhibited by phosphorylation mediated 
by the VZV open reading frame 66 protein kinase." J Virol 74(5): 2265-77. 
 
Kinchington, P. R., J. K. Hougland, et al., (1992). "The varicella-zoster virus immediate-early 
protein IE62 is a major component of virus particles." J Virol 66(1): 359-66. 
 
Kinchington, P. R., G. Inchauspe, et al., (1988). "Identification and characterization of a 
varicella-zoster virus DNA-binding protein by using antisera directed against a predicted 
synthetic oligopeptide." J Virol 62(3): 802-9. 
 
Kinchington, P. R., P. Ling, et al., (1990). "The glycoprotein products of varicella-zoster virus 
gene 14 and their defective accumulation in a vaccine strain (Oka)." J Virol 64(9): 4540-8. 
  
Kinchington, P. R., W. C. Reinhold, et al., (1985). "Inversion and circularization of the 
varicella-zoster virus genome." J Virol 56(1): 194-200. 
  316 
Kinchington, P. R., J. Remenick, et al., (1986). "Putative glycoprotein gene of varicella-zoster 
virus with variable copy numbers of a 42-base-pair repeat sequence has homology to herpes 
simplex virus glycoprotein C." J Virol 59(3): 660-8. 
 
Kinchington, P. R. and S. E. Turse (1998). "Regulated nuclear localization of the varicella-
zoster virus major regulatory protein, IE62." J Infect Dis 178 Suppl 1: S16-21. 
 
Kinchington, P. R., J. P. Vergnes, et al., (1994). "Transcriptional mapping of the varicella-
zoster virus regulatory genes encoding open reading frames 4 and 63." J Virol 68(6): 3570-
81. 
 
Kinchington, P. R., J. P. Vergnes, et al., (1995b). "Transcriptional mapping of varicella-zoster 
virus regulatory proteins." Neurology 45(12 Suppl 8): S33-5. 
 
King, C., G. Stuart et al., (2008) „T Follicular Helper (TFH) Cells in Normal and Dysregulated 
Immune Responses‟  Annu. Rev. Immunol. 26:741–66 
 
King, C. I. Irah and M. Mohrs (2009). “IL-4-producing CD4
+
 T cells in reactive lymph nodes 
during helminth infection are T follicular helper cells.” J Exp Med 206: 1001-1007. 
 
Kinoshita H, H. R., Taguchi F, Yogo Y (1988). "Variation of R1 repeated sequence present in 
open reading frame 11 of varicella zoster virus strains." J Virol 62: 1097-1100. 
  
Kitamura K, N. J., Campo-Vera H, Ogino T, Yamanishi K. (1986). "Induction of neutralizing 
antibody against varicella-zoster virus (VZV) by VZV gp3 and cross-reactivity between VZV 
gp3 and herpes simplex viruses gB." Virology 149(1): 74-82. 
 
Kjartansdottir, A., Lycke E, Norrby SR. (1996). "B-cell epitopes of varicella-zoster virus 
glycoprotein II." Arch Virol 141((12):): 2465-9. 
  
Klein, N. P., T. H. Holmes, et al., (2006). "Variability and gender differences in memory T cell 
immunity to varicella-zoster virus in healthy adults." Vaccine 24(33-34): 5913-8. 
  
Klein, N. P., B. Fireman, et al. (2007). "A role for genetics in the immune response to the 
varicella vaccine." Pediatr Infect Dis J 26(4): 300-5. 
 
Kleinschmidt-DeMasters, B. K. and D. H. Gilden (2001). "Varicella-Zoster virus infections of 
the nervous system: clinical and pathologic correlates." Arch Pathol Lab Med 125(6): 770-80. 
 
Koc, Y., K.B. Miller, et al., (2000) “Varicella zoster virus infections following allogeneic bone 
marrow transplantation: frequency, risk factors, and clinical outcome.” Biol Blood Marrow 
Transplant.6:44-9. 
 
Koenig, A. and M. H. Wolff (2003). "Infectibility of separated peripheral blood mononuclear 
cell subpopulations by varicella-zoster virus (VZV)." J Med Virol 70 Suppl 1: S59-63. 
 
Koffron, AJ., Hummel, M., et al., (1998). Cellular localization of latent murine 
cytomegalovirus. J Virol 72, 95-103. 
 
Kohler P., R.S Farr (1966). "Elevation of cord over maternal IgG immunoglobulin: evidence 
for an active placental IgG transport." Nature 210(5040):1070-1. 
 
Kolappaswamy, K., R. Mahalingam, et al., (2007). Disseminated Simian Varicella Virus 
Infection in an Irradiated Rhesus Macaque (Macaca mulatta). J. Virol 81: 411-415. 
 
  317 
Kondo, K., Kondo, T., Okuno, et al., (2002). Recognition of a novel stage of betaherpesvirus 
latency in human herpesvirus 6. J Virol 77, 2258-2264. 
 
Koropchak, C. M., G. Graham, et al., (1991). "Investigation of varicella-zoster virus infection 
by polymerase chain reaction in the immunocompetent host with acute varicella." J Infect Dis 
163(5): 1016-22. 
 
Koropchak, C. M., G. Graham, et al., (1992). "Investigation of varicella-zoster virus infection 
by polymerase chain reaction in the immunocompetent host with acute varicella." J Infect Dis 
165(1): 188. 
  
Koropchak, C. M., S. M. Solem, et al., (1989). "Investigation of varicella-zoster virus infection 
of lymphocytes by in situ hybridization." J Virol 63(5): 2392-5. 
  
Krah, D. L., I. Cho, et al., (1997). "Comparison of gpELISA and neutralizing antibody 
responses to Oka/Merck live varicella vaccine (Varivax) in children and adults." Vaccine 
15(1): 61-4. 
 
Kramer, J. M., P. LaRussa, et al., (2001). "Disseminated vaccine strain varicella as the 
acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child." 
Pediatrics 108(2): E39. 
 
Kristensson K, L. E., Röyttä M, et al., (1986). "Neuritic transport of herpes simplex virus in rat 
sensory neurons in vitro. Effects of substances interacting with microtubular function and 
axonal flow [nocodazole, taxol and erythro-9-3-(2-hydroxynonyl)adenine]." J Gen Virol 67 (Pt 
9): 2023-8. 
 
Ku, C. C., J. Besser, et al., (2005). "Varicella-Zoster virus pathogenesis and immunobiology: 
new concepts emerging from investigations with the SCIDhu mouse model." J Virol 79(5): 
2651-8. 
  
Ku, C. C., J. A. Padilla, et al., (2002). "Tropism of varicella-zoster virus for human tonsillar 
CD4
+
 T lymphocytes that express activation, memory, and skin homing markers." J Virol 
76(22): 11425-33. 
 
Ku, C. C., L. Zerboni, et al., (2004). "Varicella-zoster virus transfer to skin by T Cells and 
modulation of viral replication by epidermal cell interferon-alpha." J Exp Med 200(7): 917-25. 
 
Kuhn, M., N. Desloges, et al., (2005). "Varicella-zoster virus infection influences expression 
and organization of actin and alpha-tubulin but does not affect lamin A and vimentin." 
Intervirology 48(5): 312-20. 
 
Kut, E., and D. Rasschaert, (2004 ). "Assembly of Marek's disease virus (MDV) capsids using 
recombinant baculoviruses expressing MDV capsid proteins." J Gen Virol 85(Pt 4): :769-74.
  
Kuter, B., H. Matthews, et al., (2004). "Ten year follow-up of healthy children who received 
one or two injections of varicella vaccine." Pediatr Infect Dis J 23(2): 132-7. 
 
Kuter, B. J., A. Ngai, et al., (1995). "Safety, tolerability, and immunogenicity of two regimens 
of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck 
Varicella Vaccine Study Group." Vaccine 13(11): 967-72. 
 
Kuter, B. J., R.E. Weibel, et al., (1991). "Oka/Merck varicella vaccine in healthy children: final 
report of a 2-year efficacy study and 7-year follow-up studies." Vaccine 9(9): 643-7. 
 
  318 
Kutinova, L., P. Hainz, et al., (2001). "Immune response to vaccinia virus recombinants 
expressing glycoproteins gE, gB, gH, and gL of Varicella-zoster virus." Virology 280(2): 211-
20. 
 
Kyratsous, C. A. and S. J. Silverstein (2007). "BAG3, a host cochaperone, facilitates 
varicella-zoster virus replication." J Virol 81(14): 7491-503. 
 
Lai, L., and W.J. Britt (2003). "The interaction between the major capsid protein and the 
smallest capsid protein of human cytomegalovirus is dependent on two linear sequences in 
the smallest capsid protein." J Virol 77(4): 2730-5 
 
Lambkin, R., P. Novelli, et al., (2004). "Human genetics and responses to influenza 
vaccination: clinical implications." Am J Pharmacogenomics 4(5): 293-8. 
 
Landry, M. L. and D. Ferguson (1993). "Comparison of latex agglutination test with enzyme-
linked immunosorbent assay for detection of antibody to varicella-zoster virus." J Clin 
Microbiol 31(11): 3031-3. 
 
LaRussa, P., Steinberg, S., Gershon, AA. (1996). “Varicella vaccine for immunocompromised 
children: results of collaborative studies in the United States and Canada”. J Infect Dis 174 
(suppl 3), S320-S323. 
 
LaRussa, P., S.P. Steinberg, et al., (1985). "Determination of immunity to varicella-zoster 
virus by means of an intradermal skin test." J Infect Dis 152(2): 869-75. 
  
LaRussa, P., S. Steinberg, et al., (1997). "Transmission of vaccine strain varicella-zoster 
virus from a healthy adult with vaccine-associated rash to susceptible household contacts." J 
Infect Dis 176(4): 1072-5. 
 
LaRussa, P., S. Steinberg, et al., (1987). "Comparison of five assays for antibody to varicella-
zoster virus and the fluorescent-antibody-to-membrane-antigen test." J Clin Microbiol 25(11): 
2059-62. 
  
LaRussa, P., S. P. Steinberg, et al., (2000). "Viral strain identification in varicella vaccinees 
with disseminated rashes." Pediatr Infect Dis J 19(11): 1037-9. 
  
Lazzarotto, T., S. Varani, et al., (1998). „Delayed acquisition of high-avidity anti-
cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant 
recipients.‟ J Infect Dis 178: (4) 1145-9 
 
Lefevre-Pettazzoni, M., S. Le Cam, et al., (2006) “Delayed maturation of immunoglobulin G 
avidity: implication for the diagnosis of toxoplasmosis in pregnant women”. Eur J Clin 
Microbiol Infect Dis 25 (11):687-93 
 
Leisenfelder, S. A., P. R. Kinchington, et al., (2008). "Cyclin-Dependent Kinase 1/Cyclin B1 
Phosphorylates Varicella-Zoster Virus IE62 and Is Incorporated into Virions." J Virol 82(24): 
12116-25. 
 
Leisenfelder, S. A. and J. F. Moffat (2006). "Varicella-zoster virus infection of human foreskin 
fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity." J 
Virol 80(11): 5577-87. 
 
Leonard, L. L., N. J. Schmidt, et al. (1970). "Demonstration of viral antibody activity in two 
immunoglobulin G subclasses in patients with varicella-zoster virus infection." J Immunol 
104(1): 23-7. 
 
  319 
Lerman, Y., G. Chodick, et al. (2004). "Seroepidemiology of varicella-zoster virus antibodies 
among health-care workers and day-care-centre workers." Epidemiol Infect 132(6): 1135-8. 
 
Leuzinger, H., U. Ziegler, Schraner EM, Fraefel C, Glauser DL, Heid I, Ackermann M, Mueller 
M, Wild P. (2005). "Herpes simplex virus 1 envelopment follows two diverse pathways." J 
Virol 79(20): 13047-59. 
 
Levin, M. J., G. Y. Cai, et al., (2003a). "Varicella-zoster virus DNA in cells isolated from 
human trigeminal ganglia." J Virol 77(12): 6979-87. 
 
Levin, M. J., A. A. Gershon, et al., (2006). "Administration of live varicella vaccine to HIV-
infected children with current or past significant depression of CD4
+
 T cells." J Infect Dis 
194(2): 247-55. 
  
Levin, M. J. and A. R. Hayward (1996). "The varicella vaccine. Prevention of herpes zoster." 
Infect Dis Clin North Am 10(3): 657-75. 
  
Levin, M. J., M. Murray, et al., (1992). "Immune response of elderly individuals to a live 
attenuated varicella vaccine." J Infect Dis 166(2): 253-9. 
 
Levin, M. J., M. Murray, et al., (1994). "Immune responses of elderly persons 4 years after 
receiving a live attenuated varicella vaccine." J Infect Dis 170(3): 522-6. 
  
Levin, M. J., J. G. Smith, et al., (2003b). "Decline in varicella-zoster virus (VZV)-specific cell-
mediated immunity with increasing age and boosting with a high-dose VZV vaccine." J Infect 
Dis 188(9): 1336-44. 
  
Levy, O., J.S. Orange, et al., (2003). "Disseminated varicella infection due to the vaccine 
strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells." J 
Infect Dis 188(7): 948-53. 
 
Li, Q., M. A. Ali, et al., (2006). "Insulin degrading enzyme is a cellular receptor mediating 
varicella-zoster virus infection and cell-to-cell spread." Cell 127(2): 305-16. 
 
Li, Q., C. Buranathai, et al., (1997). "Chaperone functions common to nonhomologous 
Epstein-Barr virus gL and Varicella-Zoster virus gL proteins." J Virol 71(2): 1667-70. 
  
Li, S., I.S. Chan, et al., (2002). "Inverse relationship between six week postvaccination 
varicella antibody response to vaccine and likelihood of long term breakthrough infection." 
Pediatr Infect Dis J. 21(4): 337-42. 
 
Li, Q., T. Krogmann, et al., (2007). "The amino terminus of varicella-zoster virus (VZV) 
glycoprotein E is required for binding to insulin-degrading enzyme, a VZV receptor." J Virol 
81(16): 8525-32. 
 
Ling, P., P. R. Kinchington, et al., (1991). "A detailed analysis of transcripts mapping to 
varicella zoster virus gene 14 (glycoprotein V)." Virology 184(2): 625-35. 
 
Lio, D., N. Caccamo, et al., (1994) “Viral antibody titers are influenced by HLA-DR2 
phenotype.” Exp Clin Immunogenet 11: 182-186. 
 
Littaua, R. A., M.B. Oldstone, et al. (1992 ). "A CD4
+
 cytotoxic T lymphocyte clone to a 
conserved epitope on human immunodeficiency virus type 1 p24: cytotoxic activity and 
secretion of interleukin-2 and interleukin-6." J Virol 66: 608–11. 
 
  320 
Litwin, V., W. Jackson, et al., (1992). "Receptor properties of two varicella-zoster virus 
glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI." J Virol 66(6): 
3643-51. 
 
Litwin, V., M. Sandor, et al., (1990). "Cell surface expression of the varicella-zoster virus 
glycoproteins and Fc receptor." Virology 178(1): 263-72. 
 
Locksley R.M., N. Flournoy et al., (1985) “Infection with varicella-zoster virus after marrow 
transplantation.” J Infect Dis. 152(6):1172-81. 
 
Lokshwar, M.R., A. Agrawal, et al., (2000) “Age related seroprevalence of antibodies to 
varicella in India”. Indian Pediatr 37: 714–719. 
  
Lopez, A. S., A. Burnett-Hartman, et al. (2008). "Transmission of a newly characterized strain 
of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West 
Virginia, 2004." J Infect Dis 197(5): 646-53. 
 
Lötzerich, M., Z. Ruzsics, U.H. Koszinowski, (2006). "Functional domains of murine 
cytomegalovirus nuclear egress protein M53/p38." J Virol 80(1): 73-84 
 
Lowry, P. W., C. Sabella, et al., (1993). "Investigation of the pathogenesis of varicella-zoster 
virus infection in guinea pigs by using polymerase chain reaction." J Infect Dis 167(1): 78-83. 
 
Lowry, P. W., S. Solem, et al., (1992). "Immunity in strain 2 guinea-pigs inoculated with 
vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the 
protein product of the immediate early gene 62." J Gen Virol 73 (Pt 4): 811-9. 
 
Lukacher, A. E., L.A. Morrison, et al. (1985). "Expression of specific cytolytic activity by H-2I 
region-restricted, influenza virus-specific T lymphocyte clones." J Exp Med 162: 171–87. 
 
Ludvikova, V., D. Kunke, et al., (1991). "Immunogenicity in mice of varicella-zoster virus 
glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant." J Gen Virol 
72 ( Pt 6): 1445-9. 
 
Ludwig B, K. Allwinn et al., (2006). "Loss of varicella zoster virus antibodies despite 
detectable cell mediated immunity after vaccination." Infection 34:(4): 222-6. 
 
Lungu, O., P. W. Annunziato, et al., (1995). "Reactivated and latent varicella-zoster virus in 
human dorsal root ganglia." Proc Natl Acad Sci USA 92(24): 10980-4. 
 
Lungu, O., C. A. Panagiotidis, et al., (1998). "Aberrant intracellular localization of Varicella-
Zoster virus regulatory proteins during latency." Proc Natl Acad Sci USA 95(12): 7080-5. 
  
Luxton, G. W., S. Haverlock , Coller KE, Antinone SE, Pincetic A, Smith GA. (2005). 
"Targeting of herpesvirus capsid transport in axons is coupled to association with specific 
sets of tegument proteins." Proc Natl Acad Sci USA 102(16): 5832-7 
 
Lynch, JM., Kenyon, TK., et al., (2002). Physical and functional interaction between the 
varicella zoster virus IE63 and IE62 proteins. Virology 302: 71-82. 
Macsween, K.F., Crawford, DH. (2003). Epstein-Barr virus-recent advances. Lancet Infect 
Dis  3: 131-140. 
 
Mahalingam, R., R. Lasher, et al., (1998a). "Localization of varicella-zoster virus gene 21 
protein in virus-infected cells in culture." J Virol 72(8): 6832-7. 
  
  321 
Mahalingam, R., V. Traina-Dorge, et al., (2007). "Simian varicella virus reactivation in 
cynomolgus monkeys." Virology 368(1): 50-9. 
 
Mahalingam, R., M. C. Wellish, et al., (1992). "Localization of herpes simplex virus and 
varicella zoster virus DNA in human ganglia." Ann Neurol 31(4): 444-8. 
 
Mahalingam, R., M. Wellish, et al., (1993). "Quantitation of latent varicella-zoster virus DNA in 
human trigeminal ganglia by polymerase chain reaction." J Virol 67(4): 2381-4. 
   
Mahalingam, R., M. Wellish, et al., (1996). "Expression of protein encoded by varicella-zoster 
virus open reading frame 63 in latently infected human ganglionic neurons." Proc Natl Acad 
Sci USA 93(5): 2122-4. 
 
Mahalingam, R., M. Wellish, et al., (1998b). "Infectious simian varicella virus expressing the 
green fluorescent protein." J Neurovirol 4(4): 438-44. 
 
Mahon, B. P., K. Katrak, et al. (1995). "Poliovirus-specific CD4
+
 Th1 clones with both 
cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus 
infection in transgenic mice expressing the human poliovirus receptor." J Exp Med 181: 
1285–92. 
 
Maini, M. K., N. Gudgeon, L.R. Wedderburn, A.B. Rickinson, P.C. Beverley PC (2000). 
"Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset 
and persist with a variable CD45 phenotype." J Immunol 165(10): 5729-37. 
 
Mainka, C., B. Fuss, et al., (1998). "Characterization of viremia at different stages of varicella-
zoster virus infection." J Med Virol 56(1): 91-8. 
  
Malavige, G. N., L. Jones, et al., (2007). "Rapid Effector Function of Varicella-Zoster Virus 
Glycoprotein I-Specific CD4
+
 T Cells Many Decades after Primary Infection." J Infect Dis 
195(5): 660-4. 
 
Malavige, G. N., L. Jones, et al., (2008a). "Varicella zoster virus glycoprotein E-specific CD4+ 
T cells show evidence of recent activation and effector differentiation, consistent with 
frequent exposure to replicative cycle antigens in healthy immune donors." Clin Exp Immunol 
152(3): 522-31. 
 
Malavige, G. N., L. Jones, et al., (2008b). "Viral load, clinical disease severity and cellular 
immune responses in primary varicella zoster virus infection in Sri Lanka." PLoS ONE 3(11): 
e3789. 
 
Mallory, S., M. Sommer, et al., (1997). "Mutational analysis of the role of glycoprotein I in 
varicella-zoster virus replication and its effects on glycoprotein E conformation and 
trafficking." J Virol 71(11): 8279-88. 
   
Mallory, S., M. Sommer, et al., (1998). "Analysis of the glycoproteins I and E of varicella-
zoster virus (VZV) using deletional mutations of VZV cosmids." J Infect Dis 178 Suppl 1: 
S22-6. 
  
Maple, P.A.C., J. Gray, et al., (2006). "Performance of a time-resolved fluorescence 
immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and 
comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme 
immunoassay." Clin Vaccine Immunol 13(2): 214-8. 
 
  322 
Maple, P.A.C., J. Gray, et al., (2009a). "Performance characteristics of a quantitative, 
standardised varicella zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for 
measuring antibody following natural infection." J Virol Methods 157(1):90-2. 
 
Maple, P.A.C., A. Gunn, et al., (2009b). "Comparison of fifteen commercial assays for 
detecting Varicella Zoster virus IgG with reference to a time resolved fluorescence 
immunoassay (TRFIA) and the performance of two commercial assays for screening sera 
from immunocompromised individuals." J Virol Methods 155(2): 143-9. 
 
Maple, P.A.C., P. Rathod, et al., (2009c). "Comparison of the performance of the LIAISON 
VZV-IgG and VIDAS automated enzyme linked fluorescent immunoassays with reference to 
a VZV-IgG time-resolved fluorescence immunoassay and implications of choice of cut-off for 
LIAISON assay." J Clin Virol 44(1): 9-14. 
  
Marchant, A., M. Pihlgren, et al., (2006) “Predominant influence of environmental 
determinants on the persistence and avidity maturation of antibody responses to vaccines in 
infants” J Infect Dis 193(11):1598-605 
 
Maresova, L., L. Kutinova, et al., (2000). "Characterization of interaction of gH and gL 
glycoproteins of varicella-zoster virus: their processing and trafficking." J Gen Virol 81(Pt 6): 
1545-52. 
 
Maresova, L., T. J. Pasieka, et al., (2001). "Varicella-zoster Virus gB and gE coexpression, 
but not gB or gE alone, leads to abundant fusion and syncytium formation equivalent to those 
from gH and gL coexpression." J Virol 75(19): 9483-92. 
  
Maresova, L., T. J. Pasieka, et al., (2005). "Incorporation of three endocytosed varicella-
zoster virus glycoproteins, gE, gH, and gB, into the virion envelope." J Virol  Retrieved 2, 79,  
 
Marin M., D. Guris, et al., Advisory Committee on Immunization Practices, Centers for 
Disease Control and Prevention (CDC). (2007). "Prevention of varicella: recommendations of 
the Advisory Committee on Immunization Practices (ACIP)." MMWR Recomm Rep 56(RR-4): 
1-40. 
 
Marshall, B.C., and S.P. Adler, (2003) “Avidity maturation following immunization with two 
human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a 
recombinant glycoprotein vaccine (gB/MF59)”. Viral Immunol 16(4):491-500. 
 
Martin, K. A., A. K. Junker, et al., (1994). "Occurrence of chickenpox during pregnancy in 
women seropositive for varicella-zoster virus." J Infect Dis 170(4): 991-5. 
 
Massaer M, H. M., Garcia L, Mazzu L, Bollen A, Jacobs P, Jacquet A. (1999). "Differential 
neutralizing antibody responses to varicella-zoster virus glycoproteins B and E following 
naked DNA immunization." Viral Immunol. 12(3): 227-36.  
  
Matsunaga, Y., K. Yamanishi, et al., (1982). "Experimental infection and immune response of 
guinea pigs with varicella-zoster virus." Infect Immun 37(2): 407-12. 
 
McCluggage W.G., J.D. Fox et al., (1994) “Varicella zoster gastritis in a bone marrow 
transplant recipient.”  J Clin Pathol. 47(11):1054-6. 
 
McDonald, S.L.R., and, J. Breuer, (July 2008) Varicella Zoster: Virus and Disease. In: 
Encyclopedia of Life Sciences (ELS). John Wiley & Sons, Ltd: Chichester. 
 
McGeoch, D. (1989). "The genomes of the human herpesviruses: contents, relationships, 
and evolution." Annu Rev Microbiol. 43: 235-65. 
  323 
McGeoch, D. J. (1987). "The genome of herpes simplex virus: structure, replication and 
evolution." J Cell Sci Suppl 7: 67-94. 
  
McGeoch, D. J. (1990). "Evolutionary relationships of virion glycoprotein genes in the S 
regions of alphaherpesvirus genomes." J Gen Virol 71 ( Pt 10): 2361-7. 
  
McGeoch, D. J., S. Cook, et al., (1995). "Molecular Phylogeny and Evolutionary Timescale 
for the Family of Mammalian Herpesviruses." Journal of Molecular Biology 247(3): 443-458. 
  
McGeoch, D. J., M. A. Dalrymple, et al., (1988). "Structures of herpes simplex virus type 1 
genes required for replication of virus DNA." J Virol 62(2): 444-53. 
   
McGeoch, D. J. and A. J. Davison (1986). "DNA sequence of the herpes simplex virus type 1 
gene encoding glycoprotein gH, and identification of homologues in the genomes of varicella-
zoster virus and Epstein-Barr virus." Nucleic Acids Res 14(10): 4281-92. 
 
McGeoch, D. J., A. Dolan, et al., (2000). Toward a Comprehensive Phylogeny for Mammalian 
and Avian Herpesviruses. J Virol 74: 10401-10406. 
  
Meier, JL., Straus, SE. (1995). Interactions between varicella-zoster virus IE62 and cellular 
transcription factor USF in the coordinate activation of genes 28 and 29. Neurology 45, 
(Suppl 8), S30-32. 
 
Meraz, M. A., White, J.M., et al., (1996). "Targeted disruption of the Stat1 gene in mice 
reveals unexpected physiologic specificity in the JAK-STAT signaling pathway." Cell 84(3): 
431-42. 
 
Mettenleiter, T.C. (2002). Herpesvirus assembly and egress. J Virol 76, 1537-1547. 
 
Mettenleiter, T. C., B.G. Klupp and H. Granzow (2006). "Herpesvirus assembly: a tale of two 
membranes." Curr Opin Microbiol 9(4): 423-9 
 
Meyer, P.A., J.F. Seward et al., (2000). "Varicella mortality: trends before vaccine licensure in 
the United States, 1970-1994." J Infect Dis 182(2): 383-90. 
 
Michael, E.J., Kuck, KM., Kinchington, PR. (1998). Anatomy of the varicella-zoster virus 
open-reading frame 4 promoter. J Infect Dis 178 (Suppl 1), S27-33. 
 
Michalik, D. E., S.P. Steinberg, et al., (2008). "Primary vaccine failure after 1 dose of varicella 
vaccine in healthy children." J Infect Dis 197(7): 944-9. 
 
Milich, D.R and G.G. Leroux-Roels, (2003) “Immunogenetics of the response to HBsAg 
vaccination.”  Autoimmun Rev 2: 248–257 
 
Milikan, J. C., G. S. Baarsma, et al., (2009). "Human ocular-derived virus-specific CD4
+
 T 
cells control varicella zoster virus replication in human retinal pigment epithelial cells." Invest 
Ophthalmol Vis Sci 50(2): 743-51. 
 
Milikan, J. C., P. R. Kinchington, et al., (2007). "Identification of viral antigens recognized by 
ocular infiltrating T cells from patients with varicella zoster virus-induced uveitis." Invest 
Ophthalmol Vis Sci 48(8): 3689-97. 
 
Milikan, J. C., R. W. Kuijpers, et al., (2006). "Characterization of the varicella zoster virus 
(VZV)-specific intra-ocular T-cell response in patients with VZV-induced uveitis." Exp Eye 
Res 83(1): 69-75. 
 
  324 
Miller, A. E. (1980). "Selective decline in cellular immune response to varicella-zoster in the 
elderly." Neurology 30(6): 582-7. 
 
Miller, D. M., B.M. Rahill, et al., (1998). "Human cytomegalovirus inhibits major 
histocompatibility complex class II expression by disruption of the Jak/Stat pathway." J Exp 
Med 187(5): 675-83. 
 
Miwako, I., A. Yamamoto, Kitamura T, Nagayama K, Ohashi M. (2001). "Cholesterol 
requirement for cation-independent mannose 6-phosphate receptor exit from multivesicular 
late endosomes to the Golgi." J Cell Sci 114(Pt 9): 1765-76.  
  
Mo, C., J. Lee, et al., (2002). "The requirement of varicella zoster virus glycoprotein E (gE) for 
viral replication and effects of glycoprotein I on gE in melanoma cells." Virology 304(2): 176-
86. 
 
Mo, C., J. Lee, et al., (2003). "Varicella-zoster virus infection facilitates VZV glycoprotein E 
trafficking to the membrane surface of melanoma cells." J Med Virol 70 Suppl 1: S56-8. 
  
Mo, C., E. E. Schneeberger, et al., (2000). "Glycoprotein E of varicella-zoster virus enhances 
cell-cell contact in polarized epithelial cells." J Virol 74(23): 11377-87. 
  
Mo, C., J. Suen, et al., (1999). "Characterization of Varicella-Zoster virus glycoprotein K 
(open reading frame 5) and its role in virus growth." J Virol 73(5): 4197-207. 
  
Mocarski, E.S., Roizman, B. (1982). Structure and role of the herpes simplex virus  
DNA termini in inversion, circularization and generation of virion DNA. Cell 31, 89-97. 
 
Moffat, J., H. Ito, et al., (2002). "Glycoprotein I of varicella-zoster virus is required for viral 
replication in skin and T cells." J Virol 76(16): 8468-71. 
 
Moffat, J., C. Mo, et al., (2004). "Functions of the C-terminal domain of varicella-zoster virus 
glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo." J Virol 78(22): 
12406-15. 
  
Moffat, J. F., M. D. Stein, et al., (1995). "Tropism of varicella-zoster virus for human CD4
+
 
and CD8
+
 T lymphocytes and epidermal cells in SCID-hu mice." J Virol 69(9): 5236-42. 
 
Moffat, J. F., L. Zerboni, et al., (1998a). "Attenuation of the vaccine Oka strain of varicella-
zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the 
SCID-hu mouse." J Virol 72(2): 965-74. 
  
Moffat, J. F., L. Zerboni, et al., (1998b). "The ORF47 and ORF66 putative protein kinases of 
varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse." 
Proc Natl Acad Sci USA 95(20): 11969-74. 
 
Molyneaux, P. J., S. Parker, et al., (2006). "Use of genomic analysis of varicella-zoster virus 
to investigate suspected varicella-zoster transmission within a renal unit." J Clin Virol 36(1): 
76-8. 
 
Montag, C., J. Wagner, et al., (2006). "Human cytomegalovirus blocks tumor necrosis factor 
alpha- and interleukin-1beta-mediated NF-kappaB signaling." J Virol 80(23): 11686-98. 
 
Montalvo, E. A. and C. Grose (1986a). "Neutralization epitope of varicella zoster virus on 
native viral glycoprotein gp118 (VZV glycoprotein gpIII)." Virology 149(2): 230-41. 
 
  325 
Montalvo, E. A. and C. Grose (1986b). "Varicella zoster virus glycoprotein gpI is selectively 
phosphorylated by a virus-induced protein kinase." Proc Natl Acad Sci USA 83(23): 8967-71. 
 
Montalvo, E. A. and C. Grose (1987). "Assembly and processing of the disulfide-linked 
varicella-zoster virus glycoprotein gpII (140)." J Virol 61(9): 2877-84. 
 
Montalvo EA, Parmley. R., Grose C. (1985). "Structural analysis of the varicella-zoster virus 
gp98-gp62 complex: posttranslational addition of N-linked and O-linked oligosaccharide 
moieties." J Virol. 53(3): 761-70. 
  
Moran, E., C. Simmons et al., (2008) “Preservation of a critical epitope core region is 
associated with the high degree of flaviviral cross-reactivity exhibited by a dengue-specific 
CD4
+
 T cell clone.” Eur J Immunol. 38 (4): 1050-7 
 
Morgan, D., C. Mahe, et al., (2001) “Herpes zoster and HIV-1 infection in a rural Ugandan 
cohort.” AIDS.15(2):223-9 
 
Mori I, and Nishiyama, Y. (2005). "Herpes simplex virus and varicella-zoster virus: why do 
these human alphaherpesviruses behave so differently from one another?" Rev Med Virol. 
15(6): 393-406. 
  
Moriuchi, H., M. Moriuchi, et al., (1995a). "Proteins and cis-acting elements associated with 
transactivation of the varicella-zoster virus (VZV) immediate-early gene 62 promoter by VZV 
open reading frame 10 protein." J Virol 69(8): 4693-701. 
 
Moriuchi, H., M. Moriuchi, et al., (1995b). "The varicella-zoster virus immediate-early 62 
promoter contains a negative regulatory element that binds transcriptional factor NF-Y." 
Virology 214(1): 256-8. 
 
Moriuchi, H., M. Moriuchi, et al., (1995c). "Pseudorabies virus EPO is functionally 
homologous to varicella-zoster virus ORF61 protein and herpes simplex virus type 1 ICPO." 
Virology 209(1): 281-3. 
 
Moriuchi, H., M. Moriuchi, et al., (1994a). "Varicella-zoster virus open reading frame 4 protein 
is functionally distinct from and does not complement its herpes simplex virus type 1 
homolog, ICP27." J Virol 68(3): 1987-92. 
 
Moriuchi, H., M. Moriuchi, et al., (1992). "Varicella-zoster virus open reading frame 61 protein 
is functionally homologous to herpes simplex virus type 1 ICP0." J Virol 66(12): 7303-8. 
 
Moriuchi, H., M. Moriuchi, et al., (1993a). "Varicella-zoster virus (VZV) open reading frame 61 
protein transactivates VZV gene promoters and enhances the infectivity of VZV DNA." J Virol 
67(7): 4290-5. 
 
Moriuchi, H., M. Moriuchi, et al., (1993b). "Varicella-zoster virus open reading frame 10 
protein, the herpes simplex virus VP16 homolog, transactivates herpesvirus immediate-early 
gene promoters." J Virol 67(5): 2739-46. 
 
Moriuchi, M., H. Moriuchi, et al., (1994b). "Varicella-zoster virus (VZV) virion-associated 
transactivator open reading frame 62 protein enhances the infectivity of VZV DNA." Virology 
200(1): 297-300. 
  
Morrow, G., B. Slobedman, et al., (2003). "Varicella-zoster virus productively infects mature 
dendritic cells and alters their immune function." J Virol 77(8): 4950-9. 
 
  326 
Murphy, K., P. Travers, M. Walport (2008) Janeway‟s Immunobiology 7
th
 Edition, New York, 
USA; Garland Science.  
  
Myers, M. G. and B. L. Connelly (1992). "Animal models of varicella." J Infect Dis 166 Suppl 
1: S48-50. 
 
Myers, M. G., H. L. Duer, et al., (1980). "Experimental infection of guinea pigs with varicella-
zoster virus." J Infect Dis 142(3): 414-20. 
 
Nader, S., R. Bergen, et al., (1995). "Age-related differences in cell-mediated immunity to 
varicella-zoster virus among children and adults immunized with live attenuated varicella 
vaccine." J Infect Dis 171(1): 13-7. 
 
Nagasako, E. M., R. W. Johnson, et al., (2003). "Geographic and racial aspects of herpes 
zoster." J Med Virol 70 Suppl 1: S20-3. 
 
Nagler, F. P. and G. Rake (1948). "The Use of the Electron Microscope in Diagnosis of 
Variola, Vaccinia, and Varicella." J Bacteriol 55(1): 45-51. 
 
Nagpal, S. and J. M. Ostrove (1991). "Characterization of a potent varicella-zoster virus-
encoded trans-repressor." J Virol 65(10): 5289-96.  
 
Nair, N., H. Gans, et al., (2007) “Age-dependent differences in IgG isotype and avidity 
induced by measles vaccine received during the first year of life.” J Infect Dis 196(9):1339-45.  
 
Namazue, J., T. Kato, et al., (1986). "Antibody responses to early antigens of varicella-zoster 
virus (VZV) during varicella and zoster." Biken J 29(3-4): 91-7. 
 
Nalpas, B., V. Thepot, et al., (1993) “Secondary immune response to hepatitis B virus 
vaccine in alcoholics”. Alcoholism 17:295-8. 
 
Nardone, A. (2003) and the Health Protection Agency Communicable Disease Surveillance 
Centre, London, England (http://www.eurosurveillance.org/ew/2003/031218.asp) 
 
Narita, M., Y. Matsuzono, et al., (1998) “Analysis of mumps vaccine failure by means of 
avidity testing for mumps virus-specific immunoglobulin G.” Clin Diagn Lab Immunol. 
5(6):799-803. 
 
National Advisory Committee on Immunization. (1999). Statement on recommended use of 
varicella virus vaccine. Canada Communicable Disease Report 25, (ACS-1). (http://www.hc-
sc.gc.ca/hpb/lcdc/publicat/ccdr/99vol25/25sup/acs1.html) 
 
Ndumbe, P. M., J. E. Cradock-Watson, et al., (1985a). "Live varicella immunization in healthy 
non-immune nurses." Postgrad Med J 61 Suppl 4: 133-5. 
  
Ndumbe, P. M., J. E. Cradock-Watson, et al., (1985b). "Immunisation of nurses with a live 
varicella vaccine." Lancet 1(8438): 1144-7. 
 
Ndumbe, P. M., J. Cradock-Watson, et al., (1988). "Natural and artificial immunity to varicella 
zoster virus." J Med Virol 25(2): 171-8. 
 
Ndumbe, P. M. and R. J. Levinsky (1985c). "Immunological cross-reactivities among three 
herpesviruses." J Immunol Methods 83(2): 337-42. 
  
  327 
Ndumbe, P. M. and R. J. Levinsky (1986). "Generation of phenotypically different T cell 
populations by cell-free or cell-bound preparations of varicella zoster virus." Immunol Lett 
13(4): 191-5. 
  
Ndumbe, P. M., K. Wheeler, et al., (1988). "Immunity to varicella zoster virus in children with 
leukaemia." Med Microbiol Immunol (Berl) 177(2): 83-9. 
  
Nemeckova, S., V. Ludvikova, et al., (1996). "Induction of varicella-zoster virus-neutralizing 
antibodies in mice by co-infection with recombinant vaccinia viruses expressing the gH or gL 
gene." J Gen Virol 77 (Pt 2): 211-5. 
  
Newport, M.J., T. Goetghebuer, et al., (2004) “Genetic regulation of immune responses to  
vaccines in early life”. Genes Immun 5: 122-129. 
 
Ng, T. I. and C. Grose (1992). "Serine protein kinase associated with varicella-zoster virus 
ORF 47." Virology 191(1): 9-18. 
 
Ng, T. I., L. Keenan, et al., (1994). "Phosphorylation of varicella-zoster virus open reading 
frame (ORF) 62 regulatory product by viral ORF 47-associated protein kinase." J Virol 68(3): 
1350-9. 
  
Ngai, A. L., B.O. Staehle, et al., 1996). "Safety and immunogenicity of one vs. two injections 
of Oka/Merck varicella vaccine in healthy children." Pediatr Infect Dis J 15(1): 49-54. 
 
Nii, S., Morgan C. and Rose H. M. (1968). "Electron microscopy of herpes simplex virus. II. 
Sequence of development. ." J Virol 2: 517–536. 
 
Niizuma, T., Zerboni, et al., (2003). Construction of varicella-zoster virus recombinants from 
parent Oka cosmids and demonstration that ORF65 protein is dispensible for infection of 
human skin and T cells in the SCID-hu mouse model. J Virol 77, 6062-6065. 
 
Nikkels, A. F., S. Debrus, et al., (1995a). "Localization of varicella-zoster virus nucleic acids 
and proteins in human skin." Neurology 45(12 Suppl 8): S47-9. 
  
Nikkels, A. F., P. Delvenne, et al., (1995b). "Distribution of varicella-zoster virus gpI and gpII 
and corresponding genome sequences in the skin." J Med Virol 46(2): 91-6. 
  
Nikkels, A. F., C. Sadzot-Delvaux, et al., (1998). "Low-productive alpha-herpesviridae 
infection in chronic lichenoid dermatoses." Dermatology 196(4): 442-6. 
 
Nikkels, A. F., C. Sadzot-Delvaux, et al., (2004). "Absence of intercellular adhesion molecule 
1 expression in varicella zoster virus-infected keratinocytes during herpes zoster: another 
immune evasion strategy?" Am J Dermatopathol 26(1): 27-32. 
 
Nogales, E. (2000). "Structural insights into microtubule function." Annu Rev Biochem 69: 
277-302. 
 
Norris, P. J., M. Sumaroka,  et al. (2001). "Multiple effector functions mediated by human 
immunodeficiency virus- specific CD4 (
+
) t-cell clones." J Virol 75: 9771–9. 
  
Offidani, M., L. Corvatta, et al., (2001). "A predictive model of varicella-zoster virus infection 
after autologous peripheral blood progenitor cell transplantation." Clin Infect Dis 32(10): 
1414-22. 
  
  328 
Oh, S. H., S. Bandyopadhyay, et al., (1987). "Cooperation between CD16(Leu-11b)
+
 NK cells 
and HLA-DR
+
 cells in natural killing of herpesvirus-infected fibroblasts." J Immunol 139(8): 
2799-802. 
 
Ojala PM, S. B., Ebersold et al., (2000). "Herpes simplex virus type 1 entry into host cells: 
reconstitution of capsid binding and uncoating at the nuclear pore complex in vitro." Mol Cell 
Biol 20(13): 4922-31. 
 
Oliver, S. L., L. Zerboni, et al., (2008). "Development of recombinant varicella-zoster viruses 
expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root 
ganglia xenografts." J Virol Methods 154(1-2): 182-93. 
 
Olson, J. K., G. A. Bishop, et al., (1997). "Varicella-zoster virus Fc receptor gE glycoprotein: 
serine/threonine and tyrosine phosphorylation of monomeric and dimeric forms." J Virol 
71(1): 110-9. 
 
Olson, J. K. and C. Grose (1997). "Endocytosis and recycling of varicella-zoster virus Fc 
receptor glycoprotein gE: internalization mediated by a YXXL motif in the cytoplasmic tail." J 
Virol 71(5): 4042-54. 
 
Olson, J. K. and C. Grose (1998). "Complex formation facilitates endocytosis of the varicella-
zoster virus gE:gI Fc receptor." J Virol 72(2): 1542-51. 
 
Olson, J. K., R. A. Santos, et al., (1998). "Varicella-zoster virus glycoprotein gE: endocytosis 
and trafficking of the Fc receptor." J Infect Dis 178 Suppl 1: S2-6. 
 
Opstelten, W., J.W Mauritz, et al., (2002) “Herpes zoster and postherpetic neuralgia: 
incidence and risk indicators using a general practice research database” Family Practice 
19(5): 471-475 
 
Ou, Y., K. A. Davis, et al., (2007). "Simian varicella virus expresses a latency-associated 
transcript that is antisense to open reading frame 61 (ICP0) mRNA in neural ganglia of 
latently infected monkeys." J Virol 81(15): 8149-56. 
 
Ovsyannikova, I. G. Dhiman, et al. (2006). "Human leukocyte antigen polymorphisms: 
variable humoral immune responses to viral vaccines." Expert Rev Vaccines 5(1): 33-43. 
 
Oxman, M. N. (2007). "Vaccination to prevent herpes zoster and postherpetic neuralgia." 
Hum Vaccin 3(2): 64-8. 
  
Oxman, M. N., M. J. Levin, et al., (2005). "A vaccine to prevent herpes zoster and 
postherpetic neuralgia in older adults." N Engl J Med 352(22): 2271-84. 
 
Ozaki, T., S. Masuda, et al., (1994). "Investigation of varicella-zoster virus DNA by the 
polymerase chain reaction in healthy children with varicella vaccination." J Med Virol 42(1): 
47-51. 
 
Ozaki, T., T. Matsui, et al., (1984a). "Clinical trial of the Oka strain of live attenuated varicella 
vaccine on healthy children." Biken J 2(3): 39-42. 
 
Ozaki T, Y. Matsui, et al., (1984b). "Viremic phase in nonimmunocompromized children with 
varicella." J Pediatr 104: 85–7. 
 
Ozaki T, Y. Matsui, et al., (1986). "Lymphocyte associated viremia in varicella." J Med Virol 
19: 249–53. 
 
  329 
Ozaki, T., N. Nishimura, Y. Kajita (2000). "Experience with live attenuated varicella vaccine 
(Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic." Vaccine 18(22): 
2375-80. 
 
Ozawa, A., Y. Sasao, et al., (1999). HLA-A33 and -B44 and susceptibility to postherpetic 
neuralgia (PHN). Tissue Antigens 53: 263-268. 
 
Padilla, J. A., Nii S. and Grose C. (2003). "Imaging of the varicella zoster virion in the viral 
highways: comparison with herpes simplex viruses 1 and 2, cytomegalovirus, pseudorabies 
virus, and human herpes viruses 6 and 7." J Med Virol 70 (Suppl. 1): S103–110. 
  
Padilla, J. A. and C. Grose (2001). "Varicella-zoster virus with a lost gE epitope: evidence for 
immunological pressure by the human antibody response." Arch Virol Suppl (17): 27-39. 
 
Palumbo, P. E., A. M. Arvin, et al., (1984). "Investigation of varicella-zoster virus-infected cell 
proteins that elicit antibody production during primary varicella using the immune transfer 
method." J Gen Virol 65 (Pt 12): 2141-7. 
  
Pandya, A., S. Wasfy, et al. (2001). "Varicella-zoster infection in pediatric solid-organ 
transplant recipients: a hospital-based study in the prevaricella vaccine era." Pediatr 
Transplant 5(3): 153-9. 
 
Parham, P., M. J. Androlewicz, et al., (1982). "Monoclonal antibodies: purification, 
fragmentation and application to structural and functional studies of class I MHC antigens." J 
Immunol Methods 53(2): 133-73. 
  
Parham, P. and W. F. Bodmer (1978). "Monoclonal antibody to a human histocompatibility 
alloantigen, HLA-A2." Nature 276(5686): 397-9.  
 
Parham, P., C. E. Lomen, et al., (1988). "Nature of polymorphism in HLA-A, -B, and -C 
molecules." Proc Natl Acad Sci USA 85(11): 4005-9.  
 
Park, H. B., K. C. Kim, et al., (2004). "Association of reduced CD4 T cell responses specific 
to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus 
erythematosus." J Rheumatol 31(11): 2151-5. 
   
Pasieka, T. J., L. Maresova, et al., (2003a). "A functional YNKI motif in the short cytoplasmic 
tail of varicella-zoster virus glycoprotein gH mediates clathrin-dependent and antibody-
independent endocytosis." J Virol 77(7): 4191-204. 
 
Pasieka, T. J., L. Maresova, et al., (2004). "Regulation of varicella-zoster virus-induced cell-
to-cell fusion by the endocytosis-competent glycoproteins gH and gE." J Virol 78(6): 2884-96. 
 
Patel, P., Yoonessi S, et al., (1979). "Cell-mediated immunity to varicella-zoster virus 
infection in subjects with lymphoma or leukemia." J Pediatr Gastroenterol Nutr 94: 223–30. 
 
Pellissier, J. M., M. Brisson, M.J. Levin (2007). "Evaluation of the cost-effectiveness in the 
United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older 
adults." Vaccine 25(49): 8326-37 
 
Perera, L. P., S. Kaushal, et al., (1994). "Varicella-zoster virus open reading frame 4 encodes 
a transcriptional activator that is functionally distinct from that of herpes simplex virus 
homology ICP27." J Virol 68(4): 2468-77. 
 
Perera, L. P., J. D. Mosca, et al., (1992a). "Regulation of varicella-zoster virus gene 
expression in human T lymphocytes." J Virol 66(9): 5298-304. 
  330 
Perera, L. P., J. D. Mosca, et al., (1993). "A major transactivator of varicella-zoster virus, the 
immediate-early protein IE62, contains a potent N-terminal activation domain." J Virol 67(8): 
4474-83. 
 
Perera, L. P., J. D. Mosca, et al., (1992b). "The varicella-zoster virus immediate early protein, 
IE62, can positively regulate its cognate promoter." Virology 191(1): 346-54. 
 
Pérez-Farinós, N., M. Ordobás, et al., (2007) “Varicella and herpes zoster in Madrid, based 
on the Sentinel General Practitioner Network: 1997-2004.” BMC Infect Dis: 15(7):59. 
 
Piskurich, J. F., Wang, Y., et al., (1998). "Identification of distinct regions of 5' flanking DNA 
that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the 
class II transactivator gene." J Immunol. 160(1): 233-40. 
 
Plotkin, S.A. (1972). "Rubella Vaccine." Science 175(4017): 8. 
 
Plotkin S.A., T.H. Ingalls, et al., (1968) "Intranasally administered rubella vaccine." Lancet 
2(7575): 934-6. 
 
Pollard, R. B., A. M. Arvin, et al. (1982). "Specific cell-mediated immunity and infections with 
herpes viruses in cardiac transplant recipients." Am J Med 73(5): 679-87. 
 
Pontesilli, O., P. Carotenuto, et al., (1987). "Processing and presentation of cell-associated 
varicella-zoster virus antigens by human monocytes." Clin Exp Immunol 70(1): 127-35. 
 
Porakishvili, N., L. Kardava, et al., (2004). "Cytotoxic CD4
+
 T cells in patients with B cell 
chronic lymphocytic leukemia kill via a perforinmediated pathway." Haematologica 89: 435–
43. 
 
Preacher K.J., (2001). “Calculation for the chi-square test: An interactive calculation tool for 
chi-square tests of goodness of fit and independence.” [Computer software], available from 
http://www.quantpsy.org. 
 
Provost, P. J., D. L. Krah, et al., (1991). "Antibody assays suitable for assessing immune 
responses to live varicella vaccine." Vaccine 9(2): 111-6. 
 
Puvion-Dutilleul, F., E. Pichard, et al., (1987). "Effect of dehydrating agents on DNA 
organization in herpes viruses." J Histochem Cytochem 35(6): 635-45. 
 
Querec, T.D., R.S. Akondy et al., (2009) “Systems biology approach predicts immunogenicity 
of the yellow fever vaccine in humans”. Nat Immunol 10(1):116-25. 
 
Quinlivan, M. and J. Breuer (2005). "Molecular and therapeutic aspects of varicella-zoster 
virus infection." Expert Rev Mol Med 7(15): 1-24. 
 
Quinlivan, M. and J. Breuer (2006). "Molecular studies of Varicella zoster virus." Rev Med 
Virol 16(4): 225-50. 
 
Quinlivan, M., A. A. Gershon, et al., (2005). "An evaluation of single nucleotide 
polymorphisms used to differentiate vaccine and wild type strains of varicella-zoster virus." J 
Med Virol 75(1): 174-80. 
 
Quinlivan, M. L., A. A. Gershon, et al., (2007). "Natural selection for rash-forming genotypes 
of the varicella-zoster vaccine virus detected within immunized human hosts." Proc Natl Acad 
Sci USA 104(1): 208-12. 
 
  331 
Quinlivan, M. L., A. A. Gershon, et al., (2004). "Rashes occurring after immunization with a 
mixture of viruses in the Oka vaccine are derived from single clones of virus." J Infect Dis 
190(4): 793-6. 
  
Ragozzino, MW., Melton LJ et al., (1982). Population-based study of herpes zoster and its 
sequelae. Medicine (Baltimore) 61, 310-316. 
 
Rahaus, M., N. Desloges, et al., (2003). "Transcription factor USF, expressed during the 
entire phase of varicella-zoster virus infection, interacts physically with the major viral 
transactivator IE62 and plays a significant role in virus replication." J Gen Virol 84(Pt 11): 
2957-67. 
  
Rahaus, M., N. Desloges, et al., (2004). "Replication of varicella-zoster virus is influenced by 
the levels of JNK/SAPK and p38/MAPK activation." J Gen Virol 85(Pt 12): 3529-40.  
 
Rahaus, M., N. Desloges, et al., (2005). "ORF61 protein of Varicella-zoster virus influences 
JNK/SAPK and p38/MAPK phosphorylation." J Med Virol 76(3): 424-33. 
 
Rahaus, M., N. Desloges, et al., (2006). "Varicella-zoster virus influences the activities of 
components and targets of the ERK signalling pathway." J Gen Virol 87(Pt 4): 749-58. 
 
Rahaus, M., N. Desloges, et al., (2007). "Varicella-zoster virus requires a functional 
PI3K/Akt/GSK-3alpha/beta signaling cascade for efficient replication." Cell Signal 19(2): 312-
20.  
 
Rahaus, M. and M. H. Wolff (1999). "Influence of different cellular transcription factors on the 
regulation of varicella-zoster virus glycoproteins E (gE) and I (gI) UTR's activity." Virus Res 
62(1): 77-88. 
 
Rahaus, M. and M. H. Wolff (2000). "Transcription factor Sp1 is involved in the regulation of 
Varicella-zoster virus glycoprotein E." Virus Research 69(1): 69-81. 
  
Rahaus, M. and M. H. Wolff (2003). "Reciprocal effects of varicella-zoster virus (VZV) and 
AP1: activation of jun, fos and ATF-2 after VZV infection and their importance for the 
regulation of viral genes." Virus Res 92(1): 9-21. 
  
Rake, G., H. Blank, et al., (1948). "The Relationship of Varicella and Herpes Zoster: Electron 
Microscope Studies." J Bacteriol 56(3): 293-303. 
  
Rammensee, H. G., J. Bachmann, et al., (1999). SYFPEITHI: database for MHC ligands and 
peptide motifs. Immunogenetics 50: 213-219 (access via: www.syfpeithi.de) 
  
Rand, K. H., L. E. Rasmussen, et al. (1977). "Cellular immunity and herpesvirus infections in 
cardiac-transplant patients." N Engl J Med 296(24): 1372-7. 
 
Ratner, A. (2002). "Varicella-related hospitalizations in the vaccine era." Pediatr Infect Dis J 
21(10): 927-31. 
 
Reddy, S. M., E. Cox, et al., (1998a). "Varicella-zoster virus (VZV) ORF32 encodes a 
phosphoprotein that is posttranslationally modified by the VZV ORF47 protein kinase." J Virol 
72(10): 8083-8. 
 
Reddy, S. M., M. Williams, et al., (1998b). "Expression of a uracil DNA glycosylase (UNG) 
inhibitor in mammalian cells: varicella-zoster virus can replicate in vitro in the absence of 
detectable UNG activity." Virology 251(2): 393-401. 
  
  332 
Redman, R.L., S. Nader, et al., (1997) “Early reconstitution of immunity and decreased 
severity of herpes zoster in bone marrow transplant recipients immunized with inactivated 
varicella vaccine.” J Infect Dis 176(3):578-85  
 
Reichelt, M.,L.  Zerboni et al., (2008) “Mechanisms of varicella-zoster virus 
neuropathogenesis in human dorsal root ganglia.” J Virol. 82(8):3971-83 
 
Reichelt, M., J. Brady, et al., (2009). "The replication cycle of varicella-zoster virus: analysis 
of the kinetics of viral protein expression, genome synthesis and virion assembly at the 
single-cell level." J Virol 83(8): 3904-18. 
 
Reisinger, K. S., M.L. Brown, et al., (2006). "A combination measles, mumps, rubella, and 
varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously 
with MMRII and Varivax." Pediatrics 117(2): 265-72. 
 
Reynolds. M.A., S.S., Chaves, et al., (2008a). The impact of the varicella vaccination 
program on herpes zoster epidemiology in the United States: A review. J Infect Dis 197: 
S224-S227. 
 
Reynolds, A. E., L. Liang, Baines JD. (2004). "Conformational changes in the nuclear lamina 
induced by herpes simplex virus type 1 require genes U(L)31 and U(L)34." J Virol 78(11): 
5564-75. 
 
Reynolds, M. A., B. M. Watson, et al., (2008b). Epidemiology of varicella hospitalizations in 
the United States, 1995-2005. J Infect Dis 197: S120-S126. 
 
Richmond, A. (2002). "Nf-kappa B, chemokine gene transcription and tumour growth." Nat 
Rev Immunol 2(9): 664-74. 
 
Richter, J. Putchler. I., Fleckenstein B, (1988). "Thymidylate synthetase gene of herpesvirus 
aeteles." J Virol 62: 3530-3535. 
 
Rixon, F. J., C. Addison, et al., (1996). "Multiple interactions control the intracellular 
localization of the herpes simplex virus type 1 capsid proteins." J Gen Virol 77(Pt 9): 2251-60 
 
Roberts, C. R., A.C. Weir, et al., (1985). "DNA-binding proteins present in varicella-zoster 
virus-infected cells." J Virol 55(1): 43-53. 
 
Robertson, P., S. Beynon, et al., (2003) “Measurement of EBV-IgG anti-VCA avidity aids the 
early and reliable diagnosis of primary EBV infection.”J Med Virol 70(4):617-23. 
 
Rodriguez, J., Moninger, T., Grose, C. (1993). "Entry and egress of varicella virus blocked by 
same anti-gH monoclonal antibody." Virology 196: 840-844. 
  
Rogers, S. Y., W. Irving, et al. (1995). "Visceral varicella zoster infection after bone marrow 
transplantation without skin involvement and the use of PCR for diagnosis." Bone Marrow 
Transplant 15(5): 805-7. 
 
Roizman, B., Desrosiers, RC., et al., (1992). “The family Herpesviridae: an update.” Arch 
Virol 123, 425-449. 
 
Romero, CH., Meade, PN., et al., (2003). Potential sites of virus latency associated with 
indigenous pseudorabies viruses in feral swine. J Wildl Dis 39, 567-575. 
 
Ross, AH. (1962). Modification of chicken pox in family contacts by administration of gamma 
globulin. N  Engl J Med 267, 369-376. 
  333 
Rothstein, E. P., H.H. Bernstein, et al., (1997). "Dose titration study of live attenuated 
varicella vaccine in healthy children. Pennridge Pediatric Associates." J Infect Dis 175(2): 
444-7. 
 
Rowland, P., E. R. Wald, et al. (1995). "Progressive varicella presenting with pain and 
minimal skin involvement in children with acute lymphoblastic leukemia." J Clin Oncol 13(7): 
1697-703. 
 
Ruckdeschel, J. C., S. C. Schimpff, et al. (1977). "Herpes zoster and impaired cell-associated 
immunity to the varicella-zoster virus in patients with Hodgkin's disease." Am J Med 62(1): 
77-85. 
  
Ruyechan, W. T., T. A. Casey, et al., (1985). "Distribution of G + C-rich regions in varicella-
zoster virus DNA." J Gen Virol 66 (Pt 1): 43-54. 
 
Ruyechan, WT., Hay, J. (2000). DNA replication. In: Arvin, AM., Gershon, AA. In: Varicella-
Zoster Virus and Clinical Management, Cambridge University Press, Cambridge. pp. 51-73. 
 
Ruyechan, W. T., H. Peng, et al., (2003). "Cellular factors and IE62 activation of VZV 
promoters." J Med Virol 70 Suppl 1: S90-4. 
  
Sabella, C., P. W. Lowry, et al., (1993). "Immunization with the immediate-early tegument 
protein (open reading frame 62) of varicella-zoster virus protects guinea pigs against virus 
challenge." J Virol 67(12): 7673-6. 
 
Sabin, A. (1957). "Properties and behavior of orally administered attenuated poliovirus 
vaccine." J Am Med Assoc 164(11): 1216-23. 
 
Sabin, AB., Boulger, LR. (1973). History of Sabin attenuated poliovirus oral live vaccine 
strains. J Biol Stand 1, 115–118. 
 
Sadaoka, K., S. Okamoto, et al. (2008). "Measurement of varicella-zoster virus (VZV)-specific 
cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-
linked immunospot assay." J Infect Dis 198(9): 1327-33. 
 
Sadzot-Delvaux, C., A. M. Arvin, et al., (1998). "Varicella-zoster virus IE63, a virion 
component expressed during latency and acute infection, elicits humoral and cellular 
immunity." J Infect Dis 178 Suppl 1: S43-7. 
  
Sadzot-Delvaux, C., S. Debrus, et al., (1995). "Varicella-zoster virus latency in the adult rat is 
a useful model for human latent infection." Neurology 45(12 Suppl 8): S18-20. 
  
Sadzot-Delvaux, C., P. R. Kinchington, et al., (1997). "Recognition of the latency-associated 
immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes." J 
Immunol 159(6): 2802-6. 
  
Sadzot-Delvaux, C., P. Marc, et al., (1992). "Antibodies to varicella-zoster virus modulate 
antigen distribution but fail to induce viral persistence in vitro." J Virol 66(12): 7499-504. 
 
Sadzot-Delvaux, C., M. P. Merville-Louis, et al., (1990). "An in vivo model of varicella-zoster 
virus latent infection of dorsal root ganglia." J Neurosci Res 26(1): 83-9. 
  
Sadzot-Delvaux, C. and B. Rentier (2001). "The role of varicella zoster virus immediate-early 
proteins in latency and their potential use as components of vaccines." Arch Virol Suppl(17): 
81-9. 
 
  334 
Sadzot Delvaux, C., B. Rentier, et al., (2008). Varicella Vaccination in Japan, South Korea, 
and Europe. J Infect Dis 197: S185-S190. 
  
Sadzot-Delvaux, C., P. Thonard, et al., (1995). "Varicella-zoster virus induces apoptosis in 
cell culture." J Gen Virol 76 (Pt 11): 2875-9. 
 
Saibara, T., T. Maeda, et al. (1993). "Depressed immune functions in the early phase of 
varicella-zoster virus reactivation." J Med Virol 39(3): 242-5. 
 
Saiman, L., P. LaRussa, et al., (2001). "Persistence of immunity to varicella-zoster virus after 
vaccination of healthcare workers." Infect Control Hosp Epidemiol 22(5): 279-83. 
  
Santos, R. A., C. C. Hatfield, et al., (2000). "Varicella-zoster virus gE escape mutant VZV-
MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and 
SCID-hu mice." Virology 275(2): 306-17. 
 
Santos, R. A., J. A. Padilla, et al., (1998). "Antigenic variation of varicella zoster virus Fc 
receptor gE: loss of a major B cell epitope in the ectodomain." Virology 249(1): 21-31. 
 
Sato, H., L. D. Callanan, et al., (2002a). "Varicella-zoster virus (VZV) ORF17 protein induces 
RNA cleavage and is critical for replication of VZV at 37 degrees C but not 33 degrees C." J 
Virol 76(21): 11012-23. 
 
Sato, A., Y. Isaka, et al., (1992). "Human sera from varicella-zoster virus (VZV) infections 
cross-react with human T cell leukaemia virus type 1 (HTLV-1): common epitopes in VZV 
gene 22 protein and HTLV-1 p19 gag protein." J Gen Virol 73 (Pt 11): 2969-73. 
  
Sato, B., H. Ito, et al., (2003a). "Mutational analysis of open reading frames 62 and 71, 
encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects 
on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo." J Virol 77(10): 
5607-20. 
 
Sato, H., L. Pesnicak, J.I Cohen (2003b). "Varicella-zoster virus ORF47 protein kinase, which 
is required for replication in human T cells, and ORF66 protein kinase, which is expressed 
during latency, are dispensable for establishment of latency." J Virol 77(20): 11180-5. 
 
Sato, H., L. Pesnicak, J.I Cohen, (2003c). "Use of a rodent model to show that varicella-
zoster virus ORF61 is dispensable for establishment of latency." J Med Virol 70 Suppl 1: 
S79-81. 
 
Sato, H., L. Pesnicak, et al., (2002b). "Varicella-zoster virus open reading frame 2 encodes a 
membrane phosphoprotein that is dispensable for viral replication and for establishment of 
latency." J Virol 76(7): 3575-8. 
 
Sato, M., J. Ohashi, et al., (2002c). "Association of HLA-A*3303-B*4403-DRB1*1302 
haplotype, but not of TNFA promoter and NKp30 polymorphism, with postherpetic neuralgia 
(PHN) in the Japanese population." Genes Immun 3(8): 477-81. 
 
Sato, B., M. Sommer, et al., (2003d). "Requirement of varicella-zoster virus immediate-early 
4 protein for viral replication." J Virol 77(22): 12369-72. 
 
Sato, H., J. Yamamura, et al., (2003e). "Superiority of varicella skin test antigen over purified 
varicella-zoster virus glycoproteins in monitoring booster response to Oka varicella vaccine." 
Vaccine 22(1): 15-20. 
 
  335 
Sato, M., T. Abe, et al., (2000). "Expression of the Varicella Zoster Virus Thymidine Kinase 
and Cytokines in Patients with Acute Retinal Necrosis Syndrome." Jpn J Ophthalmol 44(6): 
693. 
 
Sato, H., S. Kageyama, et al., (1998). "Immune response to varicella-zoster virus 
glycoproteins in guinea pigs infected with Oka varicella vaccine." Vaccine 16(13): 1263-9. 
  
Sato-Takeda, M.,H. Ihn, et al., (2004). "The human histocompatibility leukocyte antigen (HLA) 
haplotype is associated with the onset of postherpetic neuralgia after herpes zoster." Pain 
110(1-2): 329-36. 
 
Sato-Takeda, M.,I. Takasaki, et al., (2006). "Major histocompatibility complex haplotype is 
associated with postherpetic pain in mice." Anesthesiology 104(5): 1063-9. 
 
Sauerbrei, A. (2007). "Differences in varicella-zoster virus seroepidemiology between 
temperate and tropical regions." Indian J Med Sci 61(3): 123-4. 
 
Sauerbrei, A. and P. Wutzler (2007). "Herpes simplex and varicella-zoster virus infections 
during pregnancy: current concepts of prevention, diagnosis and therapy. Part 1: Herpes 
simplex virus infections." Med Microbiol Immunol 196(2): 89-94. 
 
Sauerbrei, A. and P. Wutzler (2007). "Herpes simplex and varicella-zoster virus infections 
during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: Varicella-
zoster virus infections." Med Microbiol Immunol 196(2): 95-102. 
 
Sawyer, M.H., Chamberlin, C.J., et al., (1994). Detection of varicella-zoster virus DNA in air 
samples from hospital rooms J Infect Dis 169, 91-94. 
 
Schaap, A., J.F. Fortin, et al., (2005). "T-cell tropism and the role of ORF66 protein in 
pathogenesis of varicella-zoster virus infection." J Virol 79(20): 12921-33. 
 
Schaap-Nutt, A., M. Sommer, et al., (2006). "ORF66 protein kinase function is required for T-
cell tropism of varicella-zoster virus in vivo." J Virol 80(23): 11806-16 
 
Schaerli, P., K. Willimann  et al., (2000). “CXC chemokine Receptor 5 Expression Defines 
Follicular Homing T Cells with B Cell Helper Function”. J Exp Med 192:1553–62 
 
Schmader, K., L.K. George, et al., (1998a). "Race and stress in the incidence of herpes 
zoster in older adults." J Am Geriatr Soc 46(8): 973-7. 
 
Schmader, K., L.K. George, et al., (1998b). "Racial and psychosocial risk factors for herpes 
zoster in the elderly." J Infect Dis 178 Suppl 1: S67-70. 
 
Schmader, K., L.K. George, et al., (1995). "Racial differences in the occurrence of herpes 
zoster." J Infect Dis 171(3): 701-4. 
 
Schmader, K., S. Studenski, et al., (1990). "Are stressful life events risk factors for herpes 
zoster?" J Am Geriatr Soc 38(11): 1188-94. 
 
Schmidt, N. J. and D. Gallo (1984). "Class-specific antibody responses to early and late 
antigens of varicella and herpes simplex viruses." J Med Virol 13(1): 1-12. 
 
Schoonbroodt, S., J. Piette, et al., (1996). "Enhancement of varicella-zoster virus infection in 
cell lines expressing ORF4- or ORF62-encoded proteins." J Med Virol 49(4): 264-73. 
 
  336 
Schoub, B. D., N. K. Blackburn, et al. (1992). "Low antibody avidity in elderly chickenpox 
patients." J Med Virol 37(2): 113-5. 
 
Schulz, T.F. (2000). Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): 
epidemiology and pathogenesis J Antimicrob Chemother 45(Suppl T3), 15-27. 
 
Sengupta, N., R. Booy, et al., (2007). "Varicella vaccination in Europe: are we ready for a 
universal childhood programme?" Eur J Pediatr. 167(1):47-55. 
  
Sensini, A., S. Pascoli, et al., (1996) “IgG avidity in the serodiagnosis of acute Toxoplasma 
gondii infection: a multicenter study.” Clin Microbiol Infect 2:25–9 
 
Seward, J.F., M. Marin, et al., (2008). Varicella Vaccine Effectiveness in the US Vaccination 
Program: A Review. J Infect Dis 197: S82-S89. 
 
Seward, J. F., B. M. Watson, et al., (2002). Varicella Disease After Introduction of Varicella 
Vaccine in the United States, 1995-2000. J Am Med Assoc 287: 606-611. 
 
Seward, J. F., J.X. Zhang, et al.,  (2004). "Contagiousness of varicella in vaccinated cases: a 
household contact study." J Am Med Assoc 292(6): 2435-9 
 
Shankar, V., S. Fisher, et al., (2001). "Nucleotide sequence analysis of varicella-zoster virus 
glycoprotein E epitope coding regions." Vaccine 19(28-29): 3830-3. 
  
Sharp, M., K. Terada, et al., (1992). "Kinetics and viral protein specificity of the cytotoxic T 
lymphocyte response in healthy adults immunized with live attenuated varicella vaccine." J 
Infect Dis 165(5): 852-8. 
  
Sharrar, R. G., P. LaRussa, et al., (2000). "The postmarketing safety profile of varicella 
vaccine." Vaccine 19(7-8): 916-23. 
 
Shaw, F.J., H. Guess, et al., (1989) “Effect of anatomic injection site, age and smoking on the 
immune response to hepatitis B vaccination”. Vaccine 7:425-30. 
 
Sheaffer, A. K., W.W. Newcomb, et al., (2001). "Herpes simplex virus DNA cleavage and 
packaging proteins associate with the procapsid prior to its maturation." J Virol 75(2): 687-98. 
  
Shiraki, K., Y. Yoshida, et al., (2003). "Pathogenetic tropism of varicella-zoster virus to 
primary human hepatocytes and attenuating tropism of Oka varicella vaccine strain to 
neonatal dermal fibroblasts." J Infect Dis 188(12): 1875-7. 
 
Shiraki, K. and M. Takahashi (1982). "Virus particles and glycoprotein excreted from cultured 
cells infected with varicella-zoster virus (VZV)." J Gen Virol 61 (Pt 2): 271-5. 
 
Simpson, D., and K.A. Lyseng-Williamson (2006). "Famciclovir: a review of its use in herpes 
zoster and genital and orolabial herpes." Drugs 66(18): 2397-416. 
 
Smith, J. G., H. R. Joseph, et al., (2007). "Establishing Acceptance Criteria for Cell-Mediated-
Immunity Assays Using Frozen Peripheral Blood Mononuclear Cells Stored under Optimal 
and Suboptimal Conditions." Clin Vaccine Immunol 14(5): 527-37.  
 
Smith, J.G., M. Levin, et al., (2003). "Measurement of cell-mediated immunity with a 
Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly 
population receiving a booster immunization." J Med Virol 70 Suppl 1: S38-41. 
  337 
Smith, J.G., X. Liu, et al., (2001). "Development and validation of a gamma interferon 
ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus." Clin 
Diagn Lab Immunol 8(5): 871-9. 
 
Sodeik B, E.M., Helenius A (1997). "Microtubule-mediated transport of incoming herpes 
simplex virus 1 capsids to the nucleus." J Cell Biol 136 (5): 1007-21. 
 
Sommer, M. H., E. Zagha, et al., (2001). "Mutational analysis of the repeated open reading 
frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus." J Virol 75(17): 8224-
39. 
 
Soong, W., J.C. Schultz, et al., (2000). "Infection of human T lymphocytes with varicella-
zoster virus: an analysis with viral mutants and clinical isolates." J Virol 74(4): 1864-70. 
 
Spengler, M., Niesen, et al., (2001). Interactions among structural proteins of varicella zoster 
virus. Arch Virol Suppl 17, 71-79. 
 
Spengler, M.L., Ruyechan, WT., Hay, J. (2000). Physical interaction between two varicella 
zoster virus gene regulatory proteins, IE4 and IE62. Virology 272, 375-381. 
 
Sperber S.J., S.B. Hayden et al., (1992). "Serologic response and reactogenicity to booster 
immunization of healthy seropositive adults with live or inactivated varicella vaccine." Antiviral 
Res. 17(3): 213-22. 
 
Stallings, C.L., G.J. Duigou, et al., (2006). "The cellular localization pattern of Varicella-Zoster 
virus ORF29p is influenced by proteasome-mediated degradation." J Virol 80(3): 1497-512. 
 
Stead, W. W., J.W. Senner, et al., (1990). "Racial differences in susceptibility to infection by 
Mycobacterium tuberculosis." N Engl J Med 322(7): 422-7. 
 
Steinberg, S. P. and A.A. Gershon. (1991). "Measurement of antibodies to varicella-zoster 
virus by using a latex agglutination test." J Clin Microbiol 29(7): 1527-9. 
 
Stevens, D.A., R.A. Ferrington, et al., (1975). "Cellular events in zoster vesicles: relation to 
clinical course and immune parameters." J Infect Dis 131(5): 509-15. 
 
Stevenson, D., K.L. Colman, et al., (1992). "Characterization of the varicella-zoster virus 
gene 61 protein." J Gen Virol 73 (Pt 3): 521-30. 
 
Stevenson, D., K.L. Colman, et al., (1994). "Characterization of the putative protein kinases 
specified by varicella-zoster virus genes 47 and 66." J Gen Virol 75 (Pt 2): 317-26. 
 
Storlie, J., W. Jackson, et al., (2006). "Delayed biosynthesis of varicella-zoster virus 
glycoprotein C: upregulation by hexamethylene bisacetamide and retinoic acid treatment of 
infected cells." J Virol 80(19): 9544-56. 
 
Storlie, J., L. Maresova, et al., (2008). Comparative Analyses of the 9 Glycoprotein Genes 
Found in Wild Type and Vaccine Strains of Varicella Zoster Virus. J Infect Dis 197: S49-S53. 
  
Stow, N.D., H.M Weir and E.C Stow (1990). Analysis of the binding sites for the varicella-
zoster virus gene 51 product within the viral origin of DNA replication. Virology 177, 570-577. 
 
Straus, S.E., H.S. Aulakh, et al., (1981). "Structure of varicella-zoster virus DNA." J Virol 
40(2): 516-25. 
  
  338 
Straus, S.E., J. Hay, et al., (1983). "Genome differences among varicella-zoster virus 
isolates." J Gen Virol 64(Pt 5): 1031-41. 
  
Straus, S. E., J. Owens, et al., (1982). "Molecular cloning and physical mapping of varicella-
zoster virus DNA." Proc Natl Acad Sci USA 79(4): 993-7. 
 
Styczynski, J., P. Reusser, et al. (2008). "Management of HSV, VZV and EBV infections in 
patients with hematological malignancies and after SCT: guidelines from the Second 
European Conference on Infections in Leukemia." Bone Marrow Transplant. 
 
Sundqvist VA, L. A., Wahren B. (1984). "Virus-specific immunoglobulin G subclasses in 
herpes simplex and varicella-zoster virus infections." J Clin Microbiol. 20 (1): 94-8. 
 
Sylwester, A. W., B.L Mitchell, et al., (2005). "Broadly targeted human cytomegalovirus-
specific CD4
+
 and CD8
+
 T cells dominate the memory compartments of exposed subjects." J 
Exp Med 202(5): 673-85. 
 
Taha, Y., F.T. Scott, et al., (2006). "Reactivation of 2 genetically distinct varicella-zoster 
viruses in the same individual." Clin Infect Dis 43(10): 1301-3. 
 
Takahashi, M., T. Otsuka, et al., (1974). Live vaccine used to prevent the spread of varicella 
in children in hospital. Lancet 2, 1288-1290. 
 
Takahashi, K., S. Sonoda, et al., (1989). "Predominant CD4 T-lymphocyte tropism of human 
herpesvirus 6-related virus." J Virol 63(7): 3161-3. 
  
Takahashi, M. (1984). "Development and characterization of a live varicella vaccine (Oka 
strain)." Biken J 27(2-3): 31-6. 
 
Takahashi, M. (2004). "Effectiveness of live varicella vaccine." Expert Opin Biol Ther 4(2): 
199-216. 
  
Takahashi, M., Y. Hayakawa, et al., (1985). "Attenuation and laboratory markers of the Oka-
strain varicella-zoster virus." Postgrad Med J 61 Suppl 4: 37-46. 
 
Takahashi, M., T. Iketani, et al., (1992). "Immunization of the elderly and patients with 
collagen vascular diseases with live varicella vaccine and use of varicella skin antigen." J 
Infect Dis 166 Suppl 1: S58-62. 
  
Takahashi, M., H. Kamiya, et al., (2001). "Immunization of the elderly to boost immunity 
against varicella-zoster virus (VZV) as assessed by VZV skin test reaction." Arch Virol Suppl 
(17): 161-72. 
  
Takahashi, M., S. Okada, et al., (2003). "Enhancement of immunity against VZV by giving 
live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody 
assay." Vaccine 21(25-26): 3845-53. 
 
Talukder, Y. S., G. Kafatos, et al., (2007). "The seroepidemiology of varicella zoster virus 
among pregnant Bangladeshi and white British women in the London Borough of Tower 
Hamlets, UK." Epidemiol Infect: 135(8):1344-53 
 
Telford EA, W. M., McBride K, Davison AJ. (1992). "The DNA sequence of equine 
herpesvirus-1." Virology 189(1): 304-16. 
 
Terada, K., T. Niizuma, et al. (2000). "Low induction of varicella-zoster virus-specific 
secretory IgA antibody after vaccination." J Med Virol 62(1): 46-51. 
  339 
Terada, K., T. Niizuma, et al., (2002). "Responses of varicella zoster virus (VZV)-specific 
immunity in seropositive adults after inhalation of inactivated or live attenuated varicella 
vaccine." Vaccine 20 (31-32): 3638-43. 
 
Thomas, S. L., and A.J. Hall (2004). "What Does Epidemiology Tell us About Risk Factors for 
Herpes Zoster." Lancet 4: 26-33. 
 
Thomas, SL., Wheeler, JG., Hall, AJ. (2002). Contacts with varicella or with children and 
protection against herpes zoster in adults: a case-control study. Lancet 360, 678-682. 
 
Thursz, M., (2001) “MHC and the viral hepatitides”. QJM 94: 287–291. 
 
Tibbetts, S. A., J. Loh, et al., (2003). "Establishment and maintenance of gammaherpesvirus 
latency are independent of infective dose and route of infection." J Virol 77(13): 7696-701. 
 
Tipples, G. A., G. M. Stephens, et al., (2002). "New variant of varicella-zoster virus." Emerg 
Infect Dis 8(12): 1504-5. 
 
Tischer, B. K., B. B. Kaufer, et al., (2007). "A self-excisable infectious bacterial artificial 
chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein 
encoded by ORF9." J Virol 81(23): 13200-8. 
  
Tiwari, J. L and P.I. Terasaki, (1981). "HLA-DR and disease associations." Prog Clin Biol Res 
58 151-63. 
 
Topp KS, M. L., LaVail JH. (1994). "Microtubule polarity in the peripheral processes of 
trigeminal ganglion cells: relevance for the retrograde transport of herpes simplex virus." J 
Neurosci. 14(1): 318-25. 
 
Torigo, S., T. Ihara, et al., (2000). "IL-12, IFN-gamma, and TNF-alpha released from 
mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella." 
Microbiol Immunol 44(12): 1027-31. 
 
Torrens, J., D. Nathwani, et al., (1998). "Acute Herpes zoster in Tayside: demographic and 
treatment details in immunocompetent patients 1989-1992." J Infect 36(2): 209-14. 
 
Tseng, H., Tan, HF., Chang, CK. (2003). Varicella vaccine safety, incidence of breakthrough, 
and factors associated with breakthrough in Taiwan. Am J Infect Control 31, 151-156. 
 
Tsolia, M., A. A. Gershon, et al., (1990). "Live attenuated varicella vaccine: evidence that the 
virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. 
National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study 
Group." J Pediatr 116(2): 184-9. 
   
Tugwell, B. D., L.E. Lee, Gillette H, Lorber EM, Hedberg K, Cieslak PR. (2004). "Chickenpox 
outbreak in a highly vaccinated school population." Pediatrics 113(3): 455-9. 
 
Tyring, S. K., F. Diaz-Mitoma, et al., (2006). "Safety and tolerability of a high-potency zoster 
vaccine in adults >/=50 years of age." Vaccine. 25(10):1877-83 
  
Uduman SA, G. A., Brunell PA. (1975). "Should patients with zoster receive zoster immune 
globulin?" J Am Med Assoc 234(10): 1049-51. 
 
Unadkat, P., B. Newman, R.S. Tedder (1995). "The detection of varicella zoster antibodies by 
simultaneous competitive EIA and its comparison with radioimmunoassay, latex agglutination 
and antiglobulin type EIA." J Virol Methods. 2(3): 145-52. 
  340 
 
Vafai, A. (1993). "Antigenicity of a candidate varicella-zoster virus glycoprotein subunit 
vaccine." Vaccine 11(9): 937-40. 
 
Vafai, A. (1994). "Antibody-binding sites on truncated forms of varicella-zoster virus gpI(gE) 
glycoprotein." Vaccine 12(14): 1265-9. 
 
Vafai, A. (1995). "Boosting immune response with a candidate varicella-zoster virus 
glycoprotein subunit vaccine." Vaccine 13(14): 1336-8. 
 
Vafai, A. and M. Berger (2001). "Zoster in patients infected with HIV: a review." Am J Med Sci 
321(6): 372-80. 
 
Vafai, A., B. Forghani, et al., (2000). "Stability of a varicella-zoster virus glycoprotein E 
epitope." Arch Virol 145(1): 85-97. 
 
Vafai, A., K. Jensen, et al., (1989). "Existence of similar antigenic-sites on varicella-zoster 
virus gpI and gpIV." Virus Res 13(4): 319-36. 
 
Vafai, A., R. Mahalingam, et al., (1988a). "Detection of antibodies to varicella-zoster virus 
proteins in sera from the elderly." Gerontology 34(5-6): 242-9. 
  
Vafai, A., M. Wellish, et al., (1987). "Induction of antibody against in vitro translation products 
encoded by varicella-zoster virus glycoprotein genes." Virus Res 7(4): 325-33. 
 
Vafai, A., Z. Wroblewska, et al., (1990). "Antigenic cross-reaction between a varicella-zoster 
virus nucleocapsid protein encoded by gene 40 and a herpes simplex virus nucleocapsid 
protein." Virus Res 15(2): 163-74. 
 
Vafai, A., Z. Wroblewska, et al., (1988d). "Recognition of similar epitopes on varicella-zoster 
virus gpI and gpIV by monoclonal antibodies." J Virol 62(8): 2544-51. 
 
Vafai, A. and W. N. Yang (1991). "Neutralizing antibodies induced by recombinant vaccinia 
virus expressing varicella-zoster virus gpIV." J Virol 65(10): 5593-6. 
  
Vandersmissen, G., G. Moens, et al. (2000). "Occupational risk of infection by varicella zoster 
virus in Belgian healthcare workers: a seroprevalence study." Occup Environ Med 57(9): 621-
6.  
 
van der Heiden, P. L., R. de Boer, et al., (2009). "Identification of varicella-zoster virus-
specific CD8 T cells in patients after T-cell-depleted allogeneic stem cell transplantation." J 
Virol 83(14): 7361-4. 
 
van der Sande, M.A., P.A. Waight, et al., (2007) “Long-term protection against HBV chronic 
carriage of Gambian adolescents vaccinated in infancy and immune response in HBV 
booster trial in adolescence.” PLoS ONE 2: e753 
 
van Loon, A. M., J. T. van der Logt, et al., (1992). "Antibody-capture enzyme-linked 
immunosorbent assays that use enzyme-labelled antigen for detection of virus-specific 
immunoglobulin M, A and G in patients with varicella or herpes zoster." Epidemiol Infect 
108(1): 165-74. 
 
Veenstra, J., A. Krol  et al., (1995) “Herpes zoster, immunological deterioration and disease 
progression in HIV-1 infection.” AIDS. 9(10):1153-8. 
 
  341 
Varis T., and T. Vesikari (1996). “Efficacy of high-titer live attenuated varicella vaccine in 
healthy young children” J Infect Dis. 174 (Suppl 3):S330-4. 
 
Villacres, M. C., J. Longmate, C. Auge, D.J. Diamond (2004). "Predominant type 1 CMV-
specific memory T-helper response in humans: evidence for gender differences in cytokine 
secretion." Hum Immunol 65(5): 476-85. 
 
Vittone, V., E. Diefenbach, Triffett D, Douglas MW, Cunningham AL, Diefenbach RJ. (2005). 
"Determination of interactions between tegument proteins of herpes simplex virus type 1." J 
Virol 79(15): 9566-71. 
 
Vollers, S. S., L.J. Stern (2008). "Class II major histocompatibility complex tetramer staining: 
progress, problems, and prospects." Immunology 123(3): 305-13. 
 
Von Seidlein, L., Gillette SG, Bryson Y, Frederick T, Mascola L, Church J, Brunell P, Kovacs 
A, Deveikis A, Keller M. (1996). "Frequent recurrence and persistence of varicella-zoster 
virus infections in children infected with human immunodeficiency virus type 1." J Pediatr: 
128(1): 52-7. 
 
Vossen, M. T., M. H. Biezeveld, et al., (2005a). "Absence of circulating natural killer and 
primed CD8
+
 cells in life-threatening varicella." J Infect Dis 191(2): 198-206.  
 
Vossen, M. T., M. R. Gent, et al., (2004). "Development of virus-specific CD4
+
 T cells on 
reexposure to Varicella-Zoster virus." J Infect Dis 190(1): 72-82. 
 
Vossen, M. T., M. R. Gent, et al., (2005b). "Persistent detection of varicella-zoster virus DNA 
in a previously healthy child after severe chickenpox." J Clin Microbiol 43(11): 5614-21. 
 
Vyse, A. J., N. J. Gay, et al., (2004). "Seroprevalence of antibody to varicella zoster virus in 
England and Wales in children and young adults." Epidemiol Infect 132(6): 1129-34. 
 
Waclawski, E. R. and M. Stewart (2002). "Susceptibility to varicella-zoster virus in applicants 
for nurse training in Scotland." Commun Dis Public Health 5(3): 240-2. 
 
Wagenpfeil, S., A. Neiss, P. Wutzler (2004). "Effects of varicella vaccination on herpes zoster 
incidence." Clin Microbiol Infect. 10(11): 954-60. 
 
Wallace, M. R., I. Woelfl, et al., (1994). "Tumor necrosis factor, interleukin-2, and interferon-
gamma in adult varicella." J Med Virol 43(1): 69-71. 
 
Walters, M. S., C. A. Kyratsous, et al., (2008). "Nuclear import of the varicella-zoster virus 
latency-associated protein ORF63 in primary neurons requires expression of the lytic protein 
ORF61 and occurs in a proteasome-dependent manner." J Virol 82(17): 8673-86. 
 
Wang, J. P., E. A. Kurt-Jones, et al., (2005). "Varicella-zoster virus activates inflammatory 
cytokines in human monocytes and macrophages via Toll-like receptor 2." J Virol 79(20): 
12658-66. 
 
Wang, Z. H., M. D. Gershon, et al., (2001). "Essential role played by the C-terminal domain of 
glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions 
of glycoproteins with tegument." J Virol 75(1): 323-40. 
   
Wang, Z., Gershon, MD., et al., (1998). Intracellular transport of varicella-zoster virus 
glycoproteins. J Infect Dis 178(Suppl 1), S7-S12. 
  342 
Wang, Z.H., Gershon, MD., Lungu, O., Zhu, Z., Gershon, AA. (2000). Trafficking of varicella-
zoster virus glycoprotein gI: T
338
-dependent retention in the trans-Golgi network, secretion, 
and mannose 6-phosphate-inhibitable uptake of the ectodomain. J Virol 74, 6600-6613. 
 
Wasmuth, E. H., W.J. Miller (1990). "Sensitive enzyme-linked immunosorbent assay for 
antibody to varicella-zoster virus using purified VZV glycoprotein antigen." J Med Virol 32(3): 
189-93. 
 
Watson, B., C. Boardman, et al., (1995a). "Humoral and cell-mediated immune responses in 
healthy children after one or two doses of varicella vaccine." Clin Infect Dis 20(2): 316-9. 
 
Watson, B., R. Gupta, et al., (1994). "Persistence of cell-mediated and humoral immune 
responses in healthy children immunized with live attenuated varicella vaccine." J Infect Dis 
169(1): 197-9. 
  
Watson, B., P. M. Keller, et al., (1990). "Cell-mediated immune responses after immunization 
of healthy seronegative children with varicella vaccine: kinetics and specificity." J Infect Dis 
162(4): 794-9. 
  
Watson, B., E. Rothstein, et al., (1995b). "Safety and cellular and humoral immune responses 
of a booster dose of varicella vaccine 6 years after primary immunization." J Infect Dis 
172(1): 217-9. 
 
Watson B, Soppas D, et al., (1993). "The effect of decreasing amounts of live virus, while 
antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine." J 
Infect Dis. 168(6): 1356-60. 
 
Weber, J.D., W.A. Rutala, et al., (1985) “Obesity as a predictor of poor antibody response to 
hepatitis B plasma vaccine.” J Am Med Assoc 254:3187-9. 
 
Weibel, R.E., Neff, BJ., et al., (1984). Live attenuated varicella virus vaccine. Efficacy trail in 
healthy children. N Engl J Med 310: 1409-1415. 
 
Weigle, K. A. and C. Grose (1984). "Molecular dissection of the humoral immune response to 
individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and 
reactivation." J Infect Dis 149(5): 741-9. 
  
Welch, H.M., Bridges, et al., (1992). Latent equid herpesviruses 1 and 4: detection and 
distinction using the polymerase chain reaction and co-cultivation from lymphoid tissues. J 
Gen Virol 73, 261-268. 
 
Weller T.H., H.M. Witton, E.J. Bell (1958). "The etiologic agents of varicella and herpes 
zoster; isolation, propagation and cultural characteristics in vitro." J Exp Med 108(6): 843–
868. 
  
Welsh, M. D., D. R. Harper, et al., (1999). "Ability of yeast Ty-VLPs (virus-like particles) 
containing varicella-zoster virus (VZV)gE and assembly protein fragments to induce in vitro 
proliferation of human lymphocytes from VZV immune patients." J Med Virol 59(1): 78-83. 
  
Westlund, B., Dahms, NM., Kornfeld, S. (1991). The bovine mannose 6-phosphate/insulin-
like growth factor II receptor. Localization of mannose 6-phosphate binding sites to domains 
1-3 and 7-11 of the extracytoplasmic region. J Biol Chem 266, 23233-23239. 
 
Whealy, M. E., Card J. P., et al., (1991). "Effect of brefeldin A on alphaherpesvirus 
membrane protein glycosylation and virus egress." J Virol 65: 1066–1081. 
 
  343 
White, T. M. and D. H. Gilden (2003). "Varicella virus-mononuclear cell interaction." Adv Virus 
Res 62: 1-17. 
  
White, T. M., D. H. Gilden, et al., (2001). "An animal model of varicella virus infection." Brain 
Pathol 11(4): 475-9. 
 
White, C. J., B. J. Kuter, et al., (1991). "Varicella vaccine (VARIVAX) in healthy children and 
adolescents: results from clinical trials, 1987 to 1989." Pediatrics 87(5): 604-10. 
 
White, C. J., B.J. Kuter, et al., (1992). "Modified cases of chickenpox after varicella 
vaccination: correlation of protection with antibody response." Pediatr Infect Dis J 11(1): 19-
23. 
 
White, T. M., R. Mahalingam, et al., (1997). "Identification of simian varicella virus 
homologues of varicella zoster virus genes." Virus Genes 15(3): 265-9. 
 
Whitley, R. J. and J.W. Gnann (1999). "Herpes zoster: focus on treatment in older adults." 
Antiviral Res. 44(3): 145-54. 
 
Whitely, R.J., and J. Hillard, (2007). Cercopithecine Herpes Virus 1 (B Virus). (In: Fields 
Virology, (5
th
 Edition), Editors; Knipe, D.N., P.M. Howley, Lippincott Williams and Wilkins, 
Publishers, Philadelphia, pp. 2889-2903. 
 
Williams, V., A. A. Gershon, and P. A. Brunell. (1974). "Serologic response to varicella-zoster 
membrane antigens measured by indirect immunofluorescence." J Infect Dis 130: 669–672. 
 
Williams, N. S., and V.H. Engelhard, (1996). "Identification of a population of CD4
+
 CTL that 
utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism " J Immunol 156: 
153–9. 
 
Wilson, A., M. Sharp, et al., (1992). "Subclinical varicella-zoster virus viremia, herpes zoster, 
and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow 
transplantation." J Infect Dis 165(1): 119-26. 
 
Winkler, MT., Doster, A., Jones, C. (2000). Persistence and reactivation of bovine 
herpesvirus 1 in the tonsils of latently infected calves. J Virol 74, 5337-5346. 
  
Wirgart, B. Z., V. Estrada, et al., (2006). "A novel varicella-zoster virus gE mutation 
discovered in two Swedish isolates." J Clin Virol 37(2): 134-6. 
 
Wise, R. P., M. E. Salive, et al., (2000). "Postlicensure safety surveillance for varicella 
vaccine." J Am Med Assoc 284(10): 1271-9. 
 
Wittek, A. E., A. M. Arvin, et al., (1983). "Serum immunoglobulin A antibody to varicella-
zoster virus in subjects with primary varicella and herpes zoster infections and in immune 
subjects." J Clin Microbiol 18(5): 1146-9. 
  
Wolfstein, A., C.H. Nagel, Radtke K, Döhner K, Allan VJ, Sodeik B. (2006). "The inner 
tegument promotes herpes simplex virus capsid motility along microtubules in vitro." Traffic 
7(2): 227-37. 
 
Wroblewska, Z., D. Gilden, et al., (1985). "Affinity-purified varicella-zoster virus glycoprotein 
gp1/gp3 stimulates the production of neutralizing antibody." J Gen Virol 66 (Pt 8): 1795-9. 
 
  344 
Wutzler, P., Neiss, A., et al., (2002). Can varicella be eliminated by vaccination? Potential 
clinical and economic effects of universal childhood varicella immunisation in Germany. Med 
Microbiol Immunol (Berlin) 191, 89-96. 
 
Xia, D., Srinivas, et al., (2003). Varicella-zoster virus open reading frame 21, which is 
expressed during latency, is essential for virus replication but dispensable for establishment 
of latency. J Virol 77, 1211-1218 
 
Yao, Z. and C. Grose (1994). "Unusual phosphorylation sequence in the gpIV (gI) component 
of the varicella-zoster virus gpI-gpIV glycoprotein complex (VZV gE-gI complex)." J Virol 
68(7): 4204-11. 
  
Yao, Z., W. Jackson, et al., (1993a). "Identification of the phosphorylation sequence in the 
cytoplasmic tail of the varicella-zoster virus Fc receptor glycoprotein gpI." J Virol 67(8): 4464-
73. 
 
Yamagishi, Y., T. Sadaoka, et al., (2008). "Varicella-zoster virus glycoprotein M homolog is 
glycosylated, is expressed on the viral envelope, and functions in virus cell-to-cell spread." J 
Virol 82(2): 795-804 
  
Yamanishi, K., Y. Matsunaga, et al., (1980). "Immune response of guinea pigs to varicella 
vaccine strain (OKA) and wild strains." Biken J. 23(1): 53-5. 
 
Yang, M., J. Hay, et al., (2004). "The DNA element controlling expression of the varicella-
zoster virus open reading frame 28 and 29 genes consists of two divergent unidirectional 
promoters which have a common USF site." J Virol 78(20): 10939-52. 
 
Yang, M., H. Peng, et al., (2006). "Promoter activation by the varicella-zoster virus major 
transactivator IE62 and the cellular transcription factor USF." J Virol.  80(15): 7339-53. 
 
Yasui, Y., N. Hamajima, et al., (2009). "Association of Epstein-Barr virus antibody titers with a 
human IL-10 promoter polymorphism in Japanese women." J Autoimmune Dis 5(2). 
 
Yasukawa, M., H. Ohminami, et al., (2000). "Granule exocytosis, and not the fas/fas ligand 
system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(
+
) as well as 
CD8(
+
) cytotoxic T lymphocytes in humans." Blood 95: 2352–5. 
 
Ye, M., K. M. Duus, et al., (1999). "Varicella-zoster virus Fc receptor component gI is 
phosphorylated on its endodomain by a cyclin-dependent kinase." J Virol 73(2): 1320-30. 
  
Yoshii, H., K. Sadaoka, et al., (2008). "Varicella-zoster virus ORF58 gene is dispensable for 
viral replication in cell culture." J Virol 5: 54. 
 
Yoshiike, T., Y. Aikawa, et al., (1991). "HLA-DR antigen expression on peripheral T cell 
subsets in pityriasis rosea and herpes zoster." Dermatologica 182(3): 160-3. 
 
Yu, H. R., R. F. Chen, et al., (2005). "IL-12-independent Th1 polarization in human 
mononuclear cells infected with varicella-zoster virus." Eur J Immunol 35(12): 3664-72. 
 
Zaia, J. A., M. J. Levin, et al., (1983). "Evaluation of varicella-zoster immune globulin: 
protection of immunosuppressed children after household exposure to varicella." J Infect Dis 
147(4): 737-43. 
  
Zaia, J. A. and M.N. Oxman (1977). "Antibody to varicella-zoster virus-induced membrane 
antigen: immunofluorescence assay using monodisperse glutaraldehyde-fixed target cells." J 
Infect Dis 134(4): 519-30. 
  345 
Zak-Prelich, M., Borkowski, JL., et al., (2002). The role of solar ultraviolet irradiation in zoster. 
Epidemiol Infect 129, 593-597. 
 
Zambelli, A., D. Montagna, et al., (2002). "Evaluation of infectious complications and immune 
recovery following high-dose chemotherapy (HDC) and autologous peripheral blood 
progenitor cell transplantation (PBPC-T) in 148 breast cancer patients." Anticancer Res 
22(6B): 3701-8. 
 
Zapata, H. J., M. Nakatsugawa, et al., (2007). "Varicella-zoster virus infection of human 
fibroblast cells activates the c-Jun N-terminal kinase pathway." J Virol 81(2): 977-90. 
 
Zaunders, J. J., W.B. Dyer, et al., (2004). "Identification of circulating antigen-specific CD4
+
 T 
lymphocytes with a CCR5
+
, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in 
CMV infection." Blood 103: 2238–47. 
 
Zerboni, L., S. Hinchliffe, et al., (2005a). "Analysis of varicella zoster virus attenuation by 
evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the 
SCIDhu mouse model." Virology 332(1): 337-46. 
  
Zerboni, L., C. C. Ku, et al., (2005b). "Varicella-zoster virus infection of human dorsal root 
ganglia in vivo." Proc Natl Acad Sci USA 102(18): 6490-5. 
 
Zerboni, L., S. Nader, et al., (1998). "Analysis of the persistence of humoral and cellular 
immunity in children and adults immunized with varicella vaccine." J Infect Dis 177(6): 1701-
4. 
 
Zerboni, L., M. Reichelt, et al., (2007). "Aberrant infection and persistence of varicella-zoster 
virus in human dorsal root ganglia in vivo in the absence of glycoprotein I." Proc Natl Acad 
Sci USA 104(35): 14086-91. 
 
Zerboni, L., M. Sommer, et al., (2000). "Varicella-zoster virus infection of a human CD4-
positive T-cell line." Virology 270(2): 278-85. 
 
Zhang, Y., M. Cosyns, et al., (1994). "Cytokine production in varicella zoster virus-stimulated 
limiting dilution lymphocyte cultures." Clin Exp Immunol 98(1): 128-33. 
  
Zhang, Y., T. Kimura, et al., (2003). "Multiplex polymerase chain reaction for detection of 
herpes simplex virus type 1, type 2, cytomegalovirus, and varicella-zoster virus in ocular viral 
infections." Jpn J Ophthalmol 47(3): 260-4. 
  
Zhang, Y., C. J. White, et al., (1995). "Cytokine production in varicella-zoster virus-stimulated 
lymphocyte cultures." Neurology 45 (12 Suppl 8): S38-40. 
 
Zhang, Z., J. Rowe, et al., (2007). "Genetic analysis of varicella-zoster virus ORF0 to ORF4 
by use of a novel luciferase bacterial artificial chromosome system." J Virol 81(17): 9024-33.
  
Zhou, Z. H., D.H. Chen, et al., (1999). "Visualization of tegument-capsid interactions and 
DNA in intact herpes simplex virus type 1 virions." J Virol 73(4): 3210-8 
 
Zhou, F., R. Harpaz, et al., (2005) “Impact of varicella vaccination on health care utilization*. 
J Am Med Assoc 294:797-802.  
 
Zhu, Z., Gershon, MD., et al., (1995). Envelopment of varicella-zoster virus: targeting of viral 
glycoproteins to the trans-Golgi network. J Virol 69: 7951-7959. 
  346 
Zhu, Z., Hao, Y., et al., (1996). Targeting of glycoprotein I (gE) of varicella-zoster virus to the 
trans-Golgi network by an AYRV sequence and an acidic amino acid-rich patch in the 
cytosolic domain of the molecule. J Virol 70, 6563-6575. 
 
Zweerink, H.J., Morton, D.H., et al., (1981). Restriction endonuclease analysis of the DNA 
from varicella-zoster virus: stability of the DNA after passage in vitro. J Gen Virol 55, 207-
211.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  347 
CHAPTER 7: APPENDICES 
 
7.1  ROVE Study Protocol      349 
7.2 ROVE Study Questionnaires and VRE Form   356 
7.3  Vaccine Brand Administered to Each Study Participant  362 
7.4  Length of Time between Visits for Each Study Participant 366 
7.5  Demographic Data for Each Study Participant   370 
7.6  TRFIA Titre (mIU/mL and log10) for Each Study Participant  
at Each Visit        374 
7.7      Summary of TRFIA Readings for Each Visit during the  
Study         377 
7.8      Avidity Readings (with Corresponding TRFIA) Titre for  
Each Study Participant at Each Visit    378 
7.9       Summary of Avidity Readings for Each Visit during the  
Study         381 
7.10  Classification of Each Study Participant, Number of Doses  
Required to Seroconvert and Diamedix Screening Results 382  
7.11 Descriptive Statistics for TRFIA and Avidity Values for  
the NSC1 Subset       386 
7.12 Descriptive Statistics for TRFIA and Avidity Values for  
the NSC2 Subset       387 
7.13 Descriptive Statistics for TRFIA and Avidity Values for the  
PLR Subset        388 
7.14  Descriptive Statistics for TRFIA and Avidity Values for the  
NI Subset        389 
7.15 Descriptive Statistics for TRFIA and Avidity Values for the  
PI Subset        390 
7.16 History of Chickenpox or Varicella Vaccination Prior to  
Study Enrolment for Each Study Participant   391 
7.17  Demographic Data of HCWs who were Previously  
Vaccinated Prior to Enrolment in the ROVE Study  394 
 
  348 
7.18 HCWs who were Previously Vaccinated Prior to Enrolment  
in the ROVE Study       395 
7.19  Classification of Each Study Participant at Follow-up with 
Corresponding Humoral Subset Classification During the  
Study         396 
7.20  Summary of Serological Data (TRFIA Titres, Avidity and  
FAMA Scores) for Humoral Subset Outliers   400 
7.21 Summary of Demographics, Immune Status during Study  
and Exposure Data, for the Two Humoral Subset Outliers 401 
7.22 FAMA with Corresponding TRFIA (mIU/mL) and Avidity (%)  
Values for 16 ROVE Study Participants at Four Time Points 402 
7.23 Vaccine Related Rash      403 
7.24  Confirmation of a Vaccine Related Rash in ROVE Study  
Participant 1052       404 
7.25  Summary of Positive TRFIA Status at each Study Time  
Point, Classified According to the TRFIA cut-off of  
log10 2.11 (130mIU/ml)      404 
7.26 An Example of Gating Used to Identify Tetramer+ CD4+ T  
Cells Ex Vivo        405 
7.27 An Example of Gating Used to Identify Tetramer+ CD4+ T  
Cells Following Short Term Culture    406 
7.28  Percentage of Tetramer+, CD4+ T Cells Quantified Ex Vivo  
and Following 10 Days of Culture with the Corresponding  
Peptide        407 
 
 
 
 
 
 
 
 
 
 
  349 
Appendix 7.1: ROVE Study Protocol 
 
 
             
   
Responses to Oka Vaccine Evaluation studies 1 and 2  
(ROVEs 1 and 2) 
 
Aims:  
1. To determine whether a subset of viruses in the vaccine are 
responsible for complications (rash). 
2. To evaluate the process whereby single vaccine viruses are found in 
rash vesicles despite a mixture of viruses being inoculated in the 
vaccine itself  
3. To evaluate the relationship between development of rash and the  
immune response in blood and saliva 
4. To evaluate the host factors, including HLA  which might contribute to 
poor immune response or complications   
Background:  
Since December 2003 a programme of immunisation of seronegative 
healthcare workers has been introduced in the UK.  The main aims of the 
programme were to prevent staff infecting seronegative patients and to 
reduce the cost to trusts associated with prevention of chickenpox in staff and 
patients.   However, since chickenpox even in healthy adults, is a serious 
disease, the programme is directly of benefit to the healthcare workers 
themselves. Almost without exception, seronegative adults acquire 
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chickenpox naturally over time, either from household contact or in the case 
of healthcare workers occasionally from occupational exposure1. 
Complications from natural chickenpox, including pneumonitis and 
encephalitis, are over 100 times more common than in children and mortality 
is at least 20 times higher1.  By contrast the Oka vaccine is very safe for 
adults. Serious complications requiring hospitalisation have been reported in 
fewer than one in 10,000 subjects as compared to 1 in 400 in wild type 
infection1.   No vaccine related deaths in adults and children have been 
recorded in 40 million doses administered in the USA as compared with a 
mortality of 1 in 4,000 in adults infected with wild type chickenpox. Inadvertent 
immunisation of 362 pregnant women has resulted in no congenital infections 
or abnormalities1. 
 
The main side effect of the Oka vaccine is a rash, which occurs in 5-10% of 
adults1.  Although vaccine rashes are mild (a median of 60 lesions versus 300 
in wild type infection) they can be inconvenient for the health care worker, 
who may need to be off work, and costly for their trust.   
 
Preliminary evidence suggests that the viruses that cause rashes may not be 
representative of the mixture of viruses in the original vaccine, suggesting the 
possibility that a selective biological process is occurring. Some of the rash 
viruses my have a biological advantage for growth in skin, while others 
appear to have acquired mutations, which have enabled them to escape from 
the immune system.  Understanding the basis for rash formation after 
vaccination may enable us to improve the safety and efficacy of the vaccine 
formulation.  Such improvements are likely to improve vaccine uptake among 
health care workers that will be of benefit for them and their patients. 
 
Reference:  
1. Gershon A, Takahashi M, Seward J.Varicella vaccine. In: Plotkin  S, Orenstein W, 
eds. Vaccines. 4th ed. Philadelphia: Saunders, 2003:783–823. 
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Inclusion Criteria:  
1. All seronegative Healthcare workers  receiving Oka vaccine  
   [ROVES 1] 
2. All Health care workers who develop fever, local blister, disseminated 
rash, or other complication following vaccination.  ROVES 1 and 
ROVES 2 (patients not enrolled at baseline but who agree to 
participate if a vaccine related event occurs). 
 
Baseline Visit: 
All healthcare workers are given Oka vaccine dose 1 as usual  
All health care workers are given the Oka information sheet PLS as usual. 
 
ROVE 1 Only: 
1. Consent healthcare worker for inclusion in the study 
2. Consent healthcare worker for informing their GP of the study   
3. Compete questionnaire V1  
4. Obtain baseline samples (three blood samples totaling 20mLs will be 
taken, see below) 
– Serum for baseline VZV antibody testing   
– CPT blood (bottles available from HPA Varicella Ref Lab*) for 
baseline cellular immunity to varicella 
– EDTA for VZV viral load if necessary 
– Salivary swab 
5. Send blood and questionnaire in pack by courier to HPA VZV 
reference laboratory* 
6. Send letter to GP  
 
GIVE FIRST DOSE VACCINE  
– Note Batch Manufacturer. 
– Retain vaccine vial until final visit. 
– Issue HCW with ROVE study card (overleaf). 
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Vaccine Related Event (VRE)1 occurring during weeks 1-6: 
ROVEs 1 (Patients Already Enrolled): 
1. Administer Vaccine Related Event questionnaire 
2. Obtain Samples :  
Three blood samples totalling 20mls will be taken(see below) 
a. Fluid/crusts from at least 3 vesicles in separate saline pots 
EDTA blood 
b. CPT sodium heparin blood 
c. Serum for baseline VZV antibody testing 
d. CPT blood (bottles available from HPA Varicella Ref Lab*)for 
baseline cellular immunity to varicella 
e.  EDTA for VZV viral load if necessary 
f.   Salivary swab 
3. Send blood and questionnaire in pack by courier to HPA VZV 
reference laboratory* 
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ROVEs 2 (For Patients Who Were Not Enrolled at Baseline):  
1. Consent healthcare worker for inclusion in the study 
2. Consent healthcare worker for informing their GP of the study   
3. Complete questionnaire V1  
4. Complete questionnaire for Vaccine Related Events 
5. Obtain samples (three samples totalling 20mls will be taken, see 
below) 
a. Fluid/crusts from at least 3 vesicles in separate saline pots 
EDTA blood 
b. CPT sodium heparin blood 
c. Serum for VZV antibody testing 
d. CPT blood (bottles available from HPA Varicella Ref Lab*)for 
cellular immunity to varicella 
e. EDTA for VZV viral load  
f. Salivary swab 
6. Send blood and questionnaire in pack by courier to HPA VZV 
reference laboratory* 
7. Send letter to GP  
 
Patients whose rashes are found to be due to wild type virus can be 
counselled that they have had ordinary chickenpox and now have natural 
protection.  In these cases, there will be no need to administer the second 
dose of vaccine.  Please note, this advice should be given to all patients with 
post vaccine rashes due to wild type virus irrespective of whether they are in 
the study or not. 
 
 
Visit 2 Week 6: GIVE SECOND DOSE VACCINE 
– Note Batch Manufacturer. 
– Retain vaccine vial until final visit. 
– Issue HCW with ROVE study card (below). 
 
1. Complete questionnaire V2  
2. Obtain samples (three blood samples totalling 20 mls will be taken, see 
below) 
a. Serum for VZV antibody testing   
b. CPT blood (bottles available from HPA Varicella Ref Lab*) for 
cellular immunity to varicella 
c. EDTA for VZV viral load  
d. Salivary swab 
3. Send blood and questionnaire in pack by courier to HPA VZV 
reference laboratory* 
4. Ensure HCW has ROVE card 
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Vaccine Related Event (VRE)1 Occurring During Weeks 6-12:  
ROVEs 1 (Patients Already Enrolled):  
 
1. Administer Vaccine Related Event questionnaire 
2. Obtain Samples : (three blood samples totalling 20mls will be taken, 
see below) 
a. Fluid/crusts from at least 3 vesicles in separate saline pots 
EDTA blood 
b. CPT sodium heparin blood 
c. Serum for baseline VZV antibody testing 
d. CPT blood (bottles available from HPA Varicella Ref Lab*)for 
baseline cellular immunity to varicella 
e. EDTA for VZV viral load if necessary 
f. Salivary swab 
3. Send blood and questionnaire in pack by courier to HPA VZV 
reference laboratory* 
 
ROVEs 2 (For Patients Who Were Not Enrolled At Baseline):  
1. Consent healthcare worker for inclusion in the study 
2. Consent healthcare worker for informing their GP of the study   
4. Complete questionnaire V1  
5. Complete questionnaire for Vaccine Related Events 
6. Obtain samples (three blood samples totalling 20mls will be taken, see 
below) 
a. Fluid/crusts from at least 3 vesicles in separate saline pots 
EDTA blood 
b. CPT sodium heparin blood 
c. Serum for VZV antibody testing 
d. CPT blood (bottles available from HPA Varicella Ref Lab*)for 
cellular immunity to varicella 
e. EDTA for VZV viral load  
f. Salivary swab 
7. Send blood and questionnaire in pack by courier to HPA VZV 
reference laboratory* 
8. Send letter to GP  
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Week 12-18: all HCWs in ROVES 1 and 2: 
 
1. Complete questionnaire V2  
2. Obtain samples (three blood samples totalling 20mls will be taken (see 
below) 
a. Serum for VZV antibody testing   
b. CPT blood (bottles available from HPA Varicella Ref Lab*) for 
cellular immunity to varicella 
c. EDTA for VZV viral load  
d. Salivary swab 
3. Send blood and questionnaire in pack by courier to HPA VZV 
reference laboratory* 
 
Extra work for OHD: 
1. Consenting HCW at baseline 
2. Extra visit at 12-18 weeks to check seroconversion 
3. Blood samples at 0,6,12 weeks and if rash appears 
 
Advantages for HCW and OHD:   
1. Confirmation of seroconversion to VZV 
2. Investigation of vaccine related events 
 
 
1. Definition of vaccine related event 
Pyrexia/Flu like symptoms 
Inoculation blister 
Rash (localised or generalised) 
Other including pneumonitis, encephalitis, hepatitis requiring admission 
to hospital. 
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Appendix 7.2: ROVE Study Questionnaires and VRE Form: 
 
Responses to Oka Vaccine Evaluation Study (ROVE) 
(V1) Baseline Questionnaire (1st Dose of Vaccine)   
         
Study No:_______     
 
Date __/___/____   Hospital:  ______________    Surname______________ 
 
First Name_____________Ethnicity:____________   Sex:  _____   
 
Country of Birth:_____________                           Age of entry to 
UK:_____________ 
 
Contact Phone No:_______________                      DOB___/___/_______   
 
VZV antibody negative pre-vaccination:              Yes        Equivocal         
 
Have you had Chickenpox? Yes    Age:________________     No   Don’t Know   
 
Name and manufacturer of screening assay:           ____________________ 
 
Vaccine 1st dose                 
Manufacturer:     GlaxoSmithKline / Aventis Pasteur (please delete one)   
Batch /lot  Number of _________________        Date of  vaccination ___/___/____ 
Recent Chickenpox or Shingles contacts  (last 4 weeks)      Yes        No   
If yes: 
Chickenpox Household?  Yes      Number of days since contact1 ___   
 
                    Occupational?  Yes        Number of days since contact1 ____  
 
      Other (describe)_________________ Number of days since contact1 ____ 
 
Shingles   Household?  Yes      Number of days since contact1 ____  
 
                    Occupational?  Yes        Number of days since contact1 ____ 
      Other (describe) _________________   Number of days since contact1_____ 
 
Samples: 2 Sodium Heparin   1 Serum     1 EDTA     1  Saliva   
_________________________________________________________________ 
1. Days since first contact  
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Responses to Oka Vaccine Evaluation Study (ROVE) 
Vaccine Related Events Form     
 
VRE No: _______          
 
Study No:_______     Date __/___/____  Hospital:  
 
Date of last  vaccination ___/___/____ 
 
Manufacturer:     GlaxoSmithKline / Aventis Pasteur (please delete one)   
 
Batch /lot  Number of ___________________ 
 
Date of onset of symptoms ___/_____/___ 
 
Nature of symptoms  
 
Rash at injection site:                  No. of Lesions:   ___       
 
Localised rash NOT inj. site:       No. of Lesions:  ___        
 
Generalised rash:                No. of lesions _______       
 
Pyrexia/flu like symptoms:_______________                Temp:_____ C      
 
Other :______________________________________________________ 
 
Swab  of inoculation site X 1   
 
Swab of lesion 1 in saline X 1    2Swab of lesion 2 in separate saline pot X 1   
 
Swab of lesion 3  X   in separate saline pot 
 
Samples:   2 Sodium Heparin   1 Serum     1 EDTA    1  Saliva   
  
Date of recovery__/___/_____            
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Responses to Oka Vaccine Evaluation Study (ROVE) 
(V2) Six Week Visit Questionnaire (2nd dose of Vaccine) 
 
 
Study No:_______     Date __/___/____     Hospital: _________ 
 
No. of weeks since previous vaccination?  _____ 
 
Manufacturer:     GlaxoSmithKline / Aventis Pasteur (please delete one)   
 
2nd Batch /lot  Number of _______________Date of 2nd vaccination ___/___/____ 
 
 
Any Chickenpox or Shingles contacts since last dose?                     Yes      No   
 
Chickenpox Household?  Yes       Number of days since contact1 ___   
 
                    Occupational?  Yes        Number of days since contact1 ____  
 
      Other (describe)_________________  Number of days since contact1 ____ 
 
Shingles   Household?  Yes       Number of days since contact1 ____  
 
                    Occupational?  Yes         Number of days since contact1 ____ 
 
      Other (describe) _________________     Number of days since 
contact1_____ 
 
Post vaccination complications?                                     Yes      No           
 
If Yes: Was vaccine related event form filled in ?                      Yes      No   
 
V2    Samples:   2 Sodium Heparin    1 EDTA    1 Serum   1  Saliva   
 
_________________________________________________________________ 
1.Days since first contact  
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Responses to Oka Vaccine Evaluation Study (ROVE) 
(V3) 12-18 Week Visit Questionnaire (Final Visit) 
 
  
Study No:_______     Date __/___/____  Hospital:____________  
 
 
No. of weeks since previous vaccination?  _____ 
 
Any Chickenpox or Shingles contacts since last dose?                     Yes      No   
 
Chickenpox Household?  Yes       Number of days since contact1 ___   
 
                    Occupational?  Yes        Number of days since contact1 ____  
 
      Other (describe)_________________  Number of days since contact1 ____ 
 
Shingles   Household?  Yes       Number of days since contact1 ____  
 
                    Occupational?  Yes         Number of days since contact1 ____ 
 
      Other (describe) _________________     Number of days since 
contact1_____ 
 
Post vaccination complications?                                     Yes      No           
 
If Yes: Was vaccine related event form filled in ?                      Yes      No   
 
 
V3 Samples:   2 Sodium Heparin   1 Serum     1 EDTA   1  Saliva   
 
________________________________________________________________ 
1. Days since first contact 
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Responses to Oka Vaccine Evaluation Study (ROVE) 
(V4) 18 Month Visit Questionnaire (Follow-up Visit) 
 
 
Study No:_______   Date __/___/____  Hospital:  ______________    
 
Surname______________                    First Name_____________ 
   
Contact Phone No:_______________ 
 
Number of months since 2nd vaccination   __________ 
 
Have you had any Chickenpox or Shingles contacts since vaccination?  
             Yes       No   
 
If yes: 
 
Chickenpox       Number of contacts ___   
 
         Household?  Yes     Number of weeks since last contact ___   
 
         Occupational?  Yes      Number of weeks since last contact ___  
  
 Other (describe)__________ 
Number of weeks since last contact ___  
 
Shingles       Number of  contacts ___  
   
         Household?  Yes     Number of weeks since last contact ___   
 
         Occupational?  Yes      Number of weeks since last contact ___  
  
Other (describe)__________ 
                                                  Number of weeks since last contact ___   
 
Have you had Chickenpox or Shingles since your last visit?  
Yes       No   
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If yes: 
Chickenpox    Yes              Number of weeks since illness  ___   
 
         Severity of rash ___________________________________  
Complications _____________________________________ 
 
   Number of days lost from work  ___  
  
Shingles   Yes              Number of weeks since illness  ___   
         Severity of rash ___________________________________  
       Location of Rash ___________________________________ 
Complications _____________________________________ 
 
   Number of days lost from work  ___ 
 
Did you transmit the virus to anyone else?          Yes       No  
If yes: 
Member of household  1._________  Age___ 
                                Number of days after your infection  ___ 
                          2.__________  Age__ 
                                               Number of days after your infection  ___ 
            3.__________  Age___  
                                 Number of days after your infection  ___ 
Patient         1.__________  Age___  
                                               Number of days after your infection  ___ 
                          2.__________  Age__ 
                                               Number of days after your infection  ___ 
Other       1.__________  Age___ 
         Number of days after your infection  ___                                     
2.__________  Age__ 
         Number of days after your infection  ___ 
Other relevant 
details_________________________________________________ 
                                 
                                                 
Samples: 2 Sodium Heparin  2 Serum     1 EDTA    1 Saliva  
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Apendix 7.3: Vaccine Brand Administered to Each Study Participant: 
Study 
Number 
Brand of 
vaccine  
Vaccine Batch 
Number First 
Dose 
Vaccine Batch Number 
Second Dose 
1001 Merck HV50280 HW04720 
1002 Merck HV50280 HW04720 
1003 GSK AD06A0431 AD06A0531 
1004 GSK AD06A0431 AD06A0531 
1005 GSK AD06A0431 AD06A0531 
1006 GSK AD06A0531 AD0680531 
1007 GSK AD06A0531 AD06A0531 
1008 GSK AD06A0531 AD06A0531 
1009 GSK AD06A0531 AD06A0531 
1010 Merck HV50280 Withdrew from study 
1011 Merck HW04720 HW04720 
1012 Merck HW04720 HW04720 
1013 Merck HV50280 HW04720 
1014 Merck HV40280 HW04720 
1015 Merck HV50280 HW04720 
1016 Merck HV50280 HW04720 
1017 Merck HV50280 HW04720 
1018 Merck HV50280 NA29040 
1019 Merck HV50280 HW04720 
1020 Merck HV04720 HW04720 
1021 Merck HV50280 HW04720 
1022 Merck HV50280 HW04720 
1023 Merck HV50280 HW04720 
1024 Merck HW04720 NA29040 
1025 Merck HW04720 HW04720 
1026 Merck HW04720 HW04720 
1027 Merck HW04720 HW04720 
1028 Merck HW04720 NA29040 
1029 Merck HW04720 NA29040 
1030 Merck HW04720 NA29040 
1031 Merck HW04720 NA29040 
1032 Merck HW04720 NA29040 
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Study 
Number 
Brand of 
vaccine  
Vaccine Batch 
Number First 
Dose 
Vaccine Batch Number 
Second Dose 
1033 Merck HW04720 NA29040 
1034 Merck HW04720 NA29040 
1035 Merck HW04720 HW04720 
1036 Merck HW04720 HW04720 
1037 Merck HW04720 NA29040 
1038 Merck HW04720 HW04720 
1039 Merck HW04720 NA29040 
1040 Merck HW04720 NA29040 
1041 Merck HW04720 NA29040 
1042 Merck HV50280 NA29040 
1043 Merck HW04720 NA29040 
1044 Merck HW04720 NA29040 
1045 Merck NA29040 NA29040 
1046 Merck HW04720 NA29040 
1047 Merck HW04720 NA29040 
1048 Merck HW04720 NA29040 
1049 Merck HW04720 NA29040 
1050 Merck NA29040 NA29040 
1051 Merck NA29040 NA29040 
1052 Merck NA29040 Withdrew from study 
1053 Merck NA29040 Withdrew from study 
1054 Merck NA29040 NA29040 
1055 Merck NA29040 NA29040 
1056 Merck NA29040 NA29040 
1057 Merck NA29040 NA29040 
1058 Merck NA29040 NA29040 
1059 Merck NA29040 NA29040 
1060 Merck NA29040 NA29040 
1061 Merck NA29040 NA29040 
1062 Merck NA29040 NA29040 
1063 Merck NA29040 NA29040 
1064 Merck NA29040 NA29040 
1065 Merck NA29040 NA29040 
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Study 
Number 
Brand of 
vaccine  
Vaccine Batch 
Number First 
Dose 
Vaccine Batch Number 
Second Dose 
1066 Merck NA29040 NA29040 
1067 Merck NA29040 NA29040 
1068 Merck NA29040 NA29040 
1069 Merck NA29040 NC38010 
1070 Merck NA29040 NC38010 
1071 Merck NA29040 NC38010 
1072 Merck NA29040 NC38010 
1073 Merck NA29040 NC38010 
1074 Merck NA29040 NC38010 
1075 Merck NA29040 NC38010 
1076 Merck NA29040 NC38010 
1077 Merck NA29040 NC38010 
1078 Merck NA29040 NC38010 
1079 Merck NA29040 NC38010 
1080 Merck NA29040 NC38010 
1081 Merck NA29040 NC38010 
1082 Merck NA29040 NC38010 
1083 Merck NA29040 NC38010 
1084 Merck NC38010 Withdrew from study 
1085 Merck NC38010 NC38010 
1086 Merck NC38010 NC38010 
1087 Merck NC38010 NC38010 
1088 Merck NC38010 NC38010 
1089 Merck NC38010 NC38010 
1090 Merck NC38010 NC38010 
1091 Merck NC38010 NC38010 
1092 Merck NC38010 NC38010 
1093 Merck NC38010 NC38010 
1094 Merck NC38010 NC38010 
1095 Merck NC38010 NC38010 
1096 Merck NC38010 NC38010 
1097 Merck NC38010 NC38010 
1098 Merck NC38010 NC38010 
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Study 
Number 
Brand of 
vaccine  
Vaccine Batch 
Number First 
Dose 
Vaccine Batch Number 
Second Dose 
1099 Merck NC38010 NC38010 
1100 Merck NC38010 NC38010 
1101 Merck NC38010 NC38010 
1102 Merck NC38010 NC38010 
1103 Merck NC38010 NC38010 
1104 Merck NC38010 NC38010 
1105 Merck NC38010 NC38010 
1106 Merck NC38010 NC38010 
1107 Merck NC38010 NC38010 
1108 Merck NC38010 NC38010 
1109 Merck NC38010 NC38010 
1110 Merck NC38010 NC38010 
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Appendix 7.3: Manufacture Brand of Vaccine Received by Each Study 
Number Enrolled in the ROVE Study Between July 2005–November 2006. 
Key: GSK; GlaxoSmithKline.  
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Appendix 7.4: Length of Time between Visits for Each Study Participant: 
 
  Visit 2 Visit 3 Visit 4 
Study Number 
Weeks Elapsed 
Since First 
Dose 
Weeks Elapsed 
Since Second 
Dose 
Months 
Elapsed Since 
Second Dose 
1001 7 6 18 
1002 7 7 - 
1003 6 6 27 
1004 6 7 21 
1005 8 6 18 
1006 6 6 - 
1007 7 6 18 
1008 6 8 21 
1009 7 8 18 
1010 
Withdrew from 
study 
Withdrew from 
study 
- 
1011 6 8 21 
1012 7 7 - 
1013 7 6 16 
1014 8 
Withdrew from 
study 
- 
1015 6 7 17 
1016 6 6 25 
1017 6 6 17 
1018 7 6 16 
1019 6 6 16 
1020 8 8 16 
1021 6 6 18 
1022 6 6 16 
1023 5 9 17 
1024 6 8 18 
1025 8 7 17 
1026 6 11 17 
1027 6 9 13 
1028 7 8 - 
1029 6 6 17 
1030 6 6 - 
1031 6 10 18 
1032 6 7 17 
Appendix 7.4 continued      1 of 4 
  367 
  Visit 2 Visit 3 Visit 4 
Study Number 
Weeks Elapsed 
Since First 
Dose 
Weeks Elapsed 
Since Second 
Dose 
Months 
Elapsed Since 
Second Dose 
1033 6 7 - 
1034 6 7 19 
1035 7 7 19 
1036 6 9 17 
1037 6 6 - 
1038 6 7 - 
1039 9 7 19 
1040 9 7 - 
1041 8 7 18 
1042 6 6 - 
1043 6 6 - 
1044 6 7 - 
1045 7 7 - 
1046 7 9 18 
1047 7 7 20 
1048 6 7 18 
1049 6 6 17 
1050 6 8 17 
1051 6 6 - 
1052 7 
Withdrew from 
study 
- 
1053 7 
Withdrew from 
study 
- 
1054 7 7 16 
1055 6 7 - 
1056 7 12 18 
1057 7 10 16 
1058 7 8 16 
1059 6 6 - 
1060 7 6 16 
1061 7 6 16 
1062 6 6 16 
1063 7 9 16 
1064 7 7 16 
1065 6 7 19 
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  Visit 2 Visit 3 Visit 4 
Study Number 
Weeks Elapsed 
Since First 
Dose 
Weeks Elapsed 
Since Second 
Dose 
Months 
Elapsed Since 
Second Dose 
1066 8 
Withdrew from 
study 
- 
1067 6 7 16 
1068 6 7 - 
1069 8 7 15 
1070 6 7 15 
1071 6 6 16 
1072 6 8 17 
1073 6 12 - 
1074 10 6 14 
1075 6 7 16 
1076 7 7 14 
1077 9 13 - 
1078 6 6 - 
1079 6 6 - 
1080 6 6 - 
1081 8 13 15 
1082 6 6 - 
1083 6 7 17 
1084 
Withdrew from 
study 
Withdrew from 
study 
16 
1085 7 13 16 
1086 7 15 - 
1087 6 9 15 
1088 6 10 15 
1089 6 8 16 
1090 6 11 16 
1091 6 9 14 
1092 6 7 14 
1093 8 6 - 
1094 7 6 14 
1095 6 6 15 
1096 6 7 - 
1097 8 9 14 
1098 7 10 14 
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  Visit 2 Visit 3 Visit 4 
Study Number 
Weeks Elapsed 
Since First 
Dose 
Weeks Elapsed 
Since Second 
Dose 
Months 
Elapsed Since 
Second Dose 
1099 8 10 14 
1100 6 7 14 
1101 6 7 - 
1102 6 7 14 
1103 6 7 - 
1104 6 7 - 
1105 6 6 12 
1106 7 10 14 
1107 7 7 12 
1108 9 9 12 
1109 6 8 13 
1110 10 8 12 
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Appendix 7.4: Length of Time between Visits for ROVE Study Participants.  
Key: - Did not participate at Visit 4 (18 month follow up). 
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Appendix 7.5: Demographic Data for Each Study Participant: 
ROVE 
Study 
Number 
Gender 
Age at 
Enrolment
£ 
Ethnicity 
Birth 
Country 
Age 
Relocated 
to UK 
Years 
Resided 
in UK 
1001 M 35 Cauc Australia        21 14 
1002 M 28 Black Af Nigeria          25 3 
1003 F 23 
Black 
Cbn 
Trinidad         18 6 
1004 F 30 Phil Philippines      28 2 
1005 F 31 Phil Philippines      29 2 
1006 F 44 
Black 
Cbn 
Jamaica          40 5 
1007 F 32 Phil Philippines      30 2 
1008 F 41 Ind Sub Trinidad         26 15 
1009 F 34 
Black 
Cbn 
UK               0 35 
1010 M 29 Ind Sub India            25 4 
1011 F 35 Phil Philippines      8 27 
1012 M 40 
Black 
Cbn 
Trinidad         20 21 
1013 F 46 Cauc UK               0 46 
1014 F 21 Cauc UK               0 21 
1015 F 28 Black Af Zimbabwe         23 5 
1016 F 37 
Black 
Cbn 
Grenada          33 4 
1017 F 29 
Black 
Cbn 
Jamaica          28 1 
1018 F 33 Phil Philippines      31 3 
1019 F 40 Cauc UK               0 40 
1020 F 24 Cauc UK               0 25 
1021 F 31 Ind Sub India            29 3 
1022 F 31 Cauc 
Hong 
Kong        
2 29 
1023 F 42 Black Af Nigeria          21 22 
1024 M 39 Black Af Uganda           28 11 
1025 M 38 Ind Sub India            29 9 
1026 F 27 Phil Philippines      27 0 
1027 F 49 Black Af Ghana            46 4 
1028 M 20 
Black 
Cbn 
Montserrat       10 10 
1029 F 38 Black Af Ghana            27 11 
1030 M 47 Black Af Nigeria          44 4 
1031 F 27 Cauc UK               0 28 
1032 M 35 Black Af Uganda           28 8 
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ROVE 
Study 
Number 
Gender 
Age at 
Enrolment
£ 
Ethnicity 
Birth 
Country 
Age 
Relocated 
to UK 
Years 
Resided 
in UK 
1033 F 28 
Black 
Cbn 
Trinidad         21 7 
1034 F 38 Black Af Ghana            31 7 
1035 F 24 Black Af Nigeria          14 10 
1036 F 33 
Black 
Cbn 
Trinidad         19 14 
1037 F 34 Black Af Ghana            24 11 
1038 F 44 Ind Sub Mauritius        39 5 
1039 F 29 
Black 
Cbn 
Jamaica          24 5 
1040 F 28 Other Iran             2 26 
1041 F 27 Ind Sub India            24 3 
1042 F 30 
Black 
Cbn 
Jamaica          26 5 
1043 F 21 Black Af Ghana            12 9 
1044 F 32 Other 
South 
Africa     
26 6 
1045 F 30 Phil Philippines      24 6 
1046 F 28 Other 
South 
Africa     
21 8 
1047 F 25 Ind Sub India            25 1 
1048 M 44 Black Af Nigeria          41 3 
1049 F 29 
Black 
Cbn 
Tobago           24 6 
1050 M 36 Black Af Nigeria          19 17 
1051 M 36 Ind Sub Mauritius        31 5 
1052 F 31 Ind Sub India            31 1 
1053 F 29 Cauc UK               0 29 
1054 F 28 Ind Sub Bangladesh       1 27 
1055 M 34 Black Af Nigeria          32 2 
1056 F 25 Phil Philippines      25 1 
1057 M 58 Phil Philippines     29 29 
1058 F 39 Cauc UK               0 39 
1059 F 43 Black Af Ghana            39 5 
1060 F 30 Cauc Germany          20 11 
1061 M 61 
Black 
Cbn 
Trinidad         56 5 
1062 F 33 Black Af Nigeria          29 4 
1063 M 29 Black Af Ghana            20 9 
1064 F 24 Cauc UK               0 24 
1065 F 24 Ind Sub India            23 1 
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ROVE 
Study 
Number 
Gender 
Age at 
Enrolment
£ 
Ethnicity 
Birth 
Country 
Age 
Relocated 
to UK 
Years 
Resided 
in UK 
1066 M 35 Ind Sub India            30 6 
1067 F 27 Ind Sub India            27 1 
1068 M 34 Ind Sub Sri Lanka        34 1 
1069 F 29 Black Af 
Sierra 
Leione    
25 4 
1070 M 29 Cauc UK               0 30 
1071 F 25 Ind Sub India            24 2 
1072 F 27 Cauc UK               0 27 
1073 F 30 Black Af Ghana            25 5 
1074 F 34 
Black 
Cbn 
Jamaica          27 7 
1075 F 32 Black Af Burundi           26 6 
1076 F 29 Cauc UK               0 30 
1077 F 30 
Black 
Cbn 
Jamaica          24 7 
1078 F 44 Cauc Eire             24 21 
1079 M 40 Black Af Nigeria          35 6 
1080 M 32 Black Af Ghana            26 6 
1081 F 19 Black Af Nigeria          11 8 
1082 F 23 Ind Sub Switzerland      12 12 
1083 M 28 Cauc UK               0 29 
1084 F 22 Black Af 
Sierra 
Leione    
17 6 
1085 F 40 Ind Sub India            36 4 
1086 F 22 Black Af Germany          18 5 
1087 F 31 Ind Sub Bangladesh       26 5 
1088 M 21 Cauc UK               0 22 
1089 F 25 
Black 
Cbn 
Jamaica          20 6 
1090 F 19 Cauc Ecuador          5 14 
1091 F 26 
Black 
Cbn 
Montserrat       17 9 
1092 M 45 Cauc UK               0 45 
1093 F 41 Black Af Ghana            37 4 
1094 M 22 Ind Sub UK               0 23 
1095 F 26 Cauc UK               0 27 
1096 M 33 Ind Sub UK               0 33 
1097 F 27 Ind Sub India            27 1 
1098 F 19 Ind Sub UK               0 20 
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ROVE 
Study 
Number 
Gender 
Age at 
Enrolment
£ 
Ethnicity 
Birth 
Country 
Age 
Relocated 
to UK 
Years 
Resided 
in UK 
1099 F 25 Ind Sub India            24 2 
1100 F 31 
Black 
Cbn 
Trinidad         26 5 
1101 F 32 Black Af Ghana            20 13 
1102 M 23 Cauc Spain            21 3 
1103 F 33 Cauc Australia        28 6 
1104 F 29 Cauc Russia           23 6 
1105 M 59 Cauc UK               0 59 
1106 F 28 Cauc Australia        26 2 
1107 M 29 Ind Sub India            28 1 
1108 F 31 Cauc UK               0 32 
1109 F 50 Cauc Portugal         39 11 
1110 F 20 
Black 
Cbn 
Jamaica          15 6 
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Appendix 7.5: Demographic Data for Each ROVE Study Participant.  
Key: F; Female, M; Male, £ Age has been taken as the age at their last 
birthday rather than decimalised (e.g. 26 rather than 26.86), Cauc; 
Caucasian, Black Af; Black African, Black Cbn, Black Caribbean, Phil; 
Pilipino, Ind sub; Indian subcontinent. 
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Appendix 7.6: TRFIA Titre (mIU/mL and log10) for Each Study Participant 
at Each Visit 
 
Baseline  
(Visit 1)  
Six Weeks (Visit 
2) Immune 
Response to 
First Dose of 
Vaccine 
12 weeks 
 (Visit 3) Immune 
Response to 
Second Dose of 
Vaccine 
18 Month Follow-
Up  
(Visit 4) 
ROVE 
Study 
Number 
 Log10 
TRFIA 
TRFIA 
mIU/mL 
 Log10 
TRFIA 
TRFIA 
mIU/mL 
Log10 
TRFIA 
TRFIA 
mIU/mL 
Log10 
TRFIA 
TRFIA 
mIU/mL 
1001 2.11 130 2.32 209 2.36 229 1.94 87 
1002 1.79 62 1.95 89 1.65 45 -  -  
1003 1.68 48 1.94 87 2.41 257 2 100 
1004 2.33 214 3.09 1230 3.02 1023 3.14 1380 
1005 2.33 214 3.32 2089 3.24 1738 2.84 692 
1006 1.74 55 2.54 347 2.65 447  - -  
1007 1.4 23 1.93 85 2.8 631 1.4 23 
1008 1.3 20 1.91 81 2.64 437 2.16 145 
1009 3 1000 3.11 1288 2.95 891 2.86 724 
1010 1.34 22 WFS WFS WFS WFS WFS WFS 
1011 3.19 1549 3.58 3802 3 1000 2.71 513 
1012 2.09 123 2.32 209 3 1000  - -  
1013 2.26 182 2.85 708 2.89 776 2.67 468 
1014 2.16 145 3.13 1349  WFS WFS   - -  
1015 1.57 37 1.98 95 2.63 427 1.87 74 
1016 1.88 76 2.49 309 3 1000 2.63 427 
1017 1.81 65 2.1 126 2.57 372 2.17 148 
1018 1.86 72 2.25 178 2.6 398 3.31 2042 
1019 1.32 21 1.81 65 2.51 324 1.18 15 
1020 2.81 646 3.15 1413 3 1000 3.16 1445 
1021 1.51 32 1.75 56 2.67 468 3.11 1288 
1022 1.18 15 1.45 28 2.62 417 1.54  35 
1023 2.42 263 3.22 1660 2.93 851 2.78 603 
1024 1.54 35 2.17 148 2.45 282 2.05 112 
1025 1.36 23 2.12 132 2.51 324 1.81 65 
1026 1.61 41 2.11 130 2.68 479 2.06 115 
1027 1.82 66 2.07 117 2.1 126 2.09 123 
1028 1.83 68 2.35 224 2.78 603  - -  
1029 2.97 933 3.05 1122 2.93 851 2.76 575 
1030 2.26 182 3.11 1288 3 1000  - -  
1031 3.18 1513 3.48 3020 3.31 2042 3.39 2455 
1032 1.97 93 2.92 832 2.67 468 2.29 195 
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Baseline  
(Visit 1)  
6 Weeks  
(Visit 2)  
Immune 
Response to First 
Dose of Vaccine 
12 weeks  
(Visit 3)  
Immune 
Response to 
Second Dose of 
Vaccine 
18 Month  
Follow-Up  
(Visit 4) 
ROVE 
Study 
Number 
Log10 
TRFIA 
TRFIA 
mIU/mL 
 Log10 
TRFIA 
TRFIA 
mIU/mL 
Log10 
TRFIA 
TRFIA 
mIU/mL 
 Log10 
TRFIA 
TRFIA 
mIU/mL 
1033 1.86 72 2 100 2.26 182  - -  
1034 1.45 28 2.06 115 2.76 575 2.14 138 
1035 1.57 37 2.19 155 2.57 372 2.05 112 
1036 1.65 45 1.86 72 2.09 123 1.77 59 
1037 1.84 69 1.93 85 3.13 1349  - -  
1038 2.36 229 2.83 676 3.13 1349  -  - 
1039 1.89 78 1.91 81 2.15 141 1.95 89 
1040 1.62 42 2.35 224 3 1000  - -  
1041 1.64 44 1.69 49 2.37 234 2.03 107 
1042 1.86 72 2.56 363 2.61 407  - -  
1043 1.48 30 1.56 36 2.38 240  - -  
1044 2.28 191 2.95 891 2.86 724 - -  
1045 2.16 145 2.84 692 3.27 1862  - -  
1046 2.6 398 2.26 182 3.34 2188 2.84 692 
1047 1.48 30 2.58 380 2.74 550 2.07 117 
1048 1.49 31 2.36 229 2.34 219 3.27 1862 
1049 1.79 62 2.55 355 2.84 692 2.52 331 
1050 1.26 18 1.46 29 1.89 78 2.45 282 
1051 2.26 182 2.63 427 2.8 631  - -  
1052 1.28 19 2.43 269 WFS WFS   - -  
1053 1.58 38 2.83 676 WFS  WFS  - -  
1054 1.53 34 2.1 126 2.51 324 2.15 141 
1055 2.27 186 2.36 229 2.6 398 -  -  
1056 1.93 85 2.29 195 2.48 302 2.51 324 
1057 2.47 295 3 1000 3.16 1445 2.78 603 
1058 1.36 23 2.42 263 2.89 776 2.35 224 
1059 1.86 72 2.16 145 2.47 295  - -  
1060 1.56 36 2.26 182 2.9 794 2.32 209 
1061 * *  2.13 135 3.1 1259 2.34 219 
1062 2.29 195 2.86 724 3.01 1023 2.61 407 
1063 2.13 135 2.09 123 2.45 282 2.36 229 
1064 2.56 363 3.17 1479 2.93 851 2.89 776 
1065 1.3 20 2.45 282 3.03 1072 2.53 339 
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Baseline  
(Visit 1)  
6 Weeks  
(Visit 2) 
 Immune 
Response to First 
Dose of Vaccine 
12 weeks  
(Visit 3)  
Immune 
Response to 
Second Dose of 
Vaccine 
18 Month  
Follow-Up  
(Visit 4) 
ROVE 
Study 
Number 
 Log10 
TRFIA 
TRFIA 
mIU/mL 
 Log10 
TRFIA 
TRFIA 
mIU/mL 
 Log10 
TRFIA 
TRFIA 
mIU/mL 
 Log10 
TRFIA 
TRFIA 
mIU/mL 
1066 2.11 130 2.53 339  WFS WFS  -  - 
1067 1.74 55 2.26 182 2.74 550 2.11 130 
1068 1.2 16 1.92 83 2.83 676  - -  
1069 1.41 26 1.62 42 2.89 776 2.16 145 
1070 1.49 31 1.93 85 3.1 1259 2.33 214 
1071 1.2 16 2.22 166 2.66 457 2.45 282 
1072 2.76 575 3.47 2951 2.82 661 2.89 776 
1073 1.28 19 1.96 91 2.35 224 -  -  
1074 2.29 195 3.12 1318 2.92 832 2.35 224 
1075 2.45 282 3.64 4365 3.14 1380 3 1000 
1076 2.06 115 3.35 2239 3.21 1622 3.28 1905 
1077 1.61 41 2.38 240 2.34 219 -  -  
1078 2.2 158 3.88 7586 2.94 871 -  -  
1079 1.89 78 2.56 363 2.94 871 -  -  
1080 2.52 331 3.32 2089 3.04 1096 -  -  
1081 3.4 2512 3.21 1622 3.06 1148 3.28 1905 
1082 1.23 17 1.93 85 2.69 490  - -  
1083 2.47 295 3.79 6166 3.3 1995 3.5 3162 
1084 1.65 45 WFS WFS WFS WFS  - -  
1085 2.16 145 2.48 302 2.45 282 2.76 575 
1086 1.62 42 2.19 155 2.48 302  - -  
1087 1.93 85 2.36 229 2.91 813 3.01 1023 
1088 1.59 39 2.11 130 2.85 708 2.36 229 
1089 2 100 2.37 234 3.15 1413 2.99 977 
1090 2.31 204 2.99 977 3.07 1175 2.63 427 
1091 1.58 38 2.52 331 2.62 417 2.34 219 
1092 1.4 25 1.69 49 2.4 251 1.68 48 
1093 1.61 41 2.91 813 2.99 977 -  -  
1094 1.81 65 2.93 851 3.05 1122 2.65 447 
1095 1.26 18 1.89 78 2.81 646 2.42 263 
1096 1.86 72 3.24 1738 3.4 2512  - -  
1097 1.26 18 2.33 214 2.9 794 2.44 275 
1098 1.34 22 2 100 2.58 380 1.67 47 
Appendix 7.6 continued                                                                                            3 of 4 
  377 
 
 
Baseline  
(Visit 1)  
Six Weeks 
 (Visit 2) 
Immune 
Response to 
First Dose of 
Vaccine 
12 weeks  
(Visit 3)  
Immune 
Response to 
Second Dose of 
Vaccine 
18 Month  
Follow-Up  
(Visit 4) 
ROVE 
Study 
Number 
Log10 
TRFIA 
TRFIA 
mIU/mL 
Log10 
TRFIA 
TRFIA 
mIU/mL 
 Log10 
TRFIA 
TRFIA 
mIU/mL 
 Log10 
TRFIA 
TRFIA 
mIU/mL 
1099 1.18 15 2.22 166 2.98 955 2.61 407 
1100 1.48 30 1.62 42 2.68 479 2.05 112 
1101 1.67 47 1.9 79 2.45 282  - -  
1102 1.23 17 1.58 38 2.54 347 2.1 126 
1103 1.77 59 3.33 2138 WFS WFS  -  -  
1104 1.34 22 1.77 59 2.71 513  - -  
1105 2.13 135 2.73 537 2.76 575 2.47 295 
1106 2 100 2.29 195 3.52 3311 2.94 871 
1107 1.23 17 1.92 83 3.35 2239 2.37 234 
1108 2.38 240 3.34 2188 3.08 1202 3.08 1202 
1109 1.86 72 3.03 1072 2.92 832 2.93 851 
1110 *  *  2.04 110 2.99 977 2.64 437 
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Appendix 7.6: TRFIA Titre (mIU/mL and log10) for Each Study Participant at 
Each Visit 
Key; * sample not available for testing (study participant difficult to bleed), 
 - Did not participate in follow up visit, WFS: withdrew from study.  
 
Visit Number N 
Range Log10 (mIU/mL) Mean 
Log10 
(mIU/mL) 
SD Log10 
(mIU/mL) Minimum Maximum 
Visit 1 
(Baseline) 
108 1.18 (15) 3.40 (2,512) 1.86 (72) 0.49 (3) 
Visit 2  
(Six weeks) 
108 1.45 (28) 3.88 (7,586) 2.46 (288) 0.57 (4)  
Visit 3  
(12 weeks) 
103 1.65 (45) 3.52 (3,311) 2.78 (603) 0.33 (2) 
Visit 4  
(18 months) 
75 1.18 (15) 3.50 (3,162)  2.47 (295) 0.49 (3) 
Appendix 7.7 Summary of TRFIA Readings for Each Visit During the 
Study. Data is presented as Log10 values, with corresponding mIU/mL units 
shown in parentheses. (See corresponding figure 3.6). 
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Appendix 7.8: Avidity Readings (with Corresponding TRFIA) Titre for 
Each Study Participant at Each Visit 
 
Baseline  
(Visit 1)  
Six Weeks  
(Visit 2) Immune 
Response to First 
Dose of Vaccine 
12 weeks  
(Visit 3) Immune 
Response to 
Second Dose of 
Vaccine 
18 Month Follow-
Up  
(Visit 4) 
ROVE 
Study 
Number 
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
1001 130   209 15 229 38 87  X 
1002 62  X 89 11 45 19  - -  
1003 48  X 87 34 257 46 100  X 
1004 214 41 1230 87 1023 88 1380 85 
1005 214 59 2089 84 1738 79 692 84 
1006 55  X 347 24 447 50  - -  
1007 23  X 85 20 631 33 23 X 
1008 20  X 81 31 437 36 145 73 
1009 1000 48 1288 64 891 51 724 65 
1010 22  X WFS  WFS WFS WFS  - -  
1011 1549 89 3802 74 1000 87 513 90 
1012 123 33 209 25 1000 35 -   - 
1013 182 70 708 81 776 85 468 87 
1014 145 64 1349 85  WFS WFS   - -  
1015 37  X 95 26 427 33 74  X 
1016 76  X 309 48 1000 55 427 65 
1017 65  X 126 28 372 25 148 29 
1018 72  X 178 35 398 44 2042 81 
1019 21  X 65 8 324 30 15  X 
1020 646 84 1413 83 1000 91 1445 87 
1021 32  X 56 20 468 27 1288 84 
1022 15  X 28 23 417 19  - -  
1023 263 83 1660 95 851 96 603 95 
1024 35  X 148 4 282 20 112 30 
1025 23  X 132 21 324 31 65 X  
1026 41  X 130 26 479 34 115 28 
1027 66  X 117 6 126 11 123 48 
1028 68  X 224 17 603 55 -   - 
1029 933 86 1122 81 851 80 575 82 
1030 182 68 1288 75 1000 80  - -  
1031 1513 89 3020 86 2042 92 2455 90 
1032 93  X 832 55 468 80 195 81 
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Baseline  
(Visit 1)  
6 Weeks (Visit 2) 
Immune 
Response to First 
Dose of Vaccine 
12 weeks (Visit 3) 
Immune 
Response to 
Second Dose of 
Vaccine 
18 Month 
Follow-Up  
(Visit 4) 
ROVE 
Study 
Number 
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
1033 72  X  100 15 182 25 - -  
1034 28  X 115 10 575 27 138 33 
1035 37  X 155 21 372 40 112 35 
1036 45  X 72 X  123 12 59  X 
1037 69  X 85 5 1349 30 - -  
1038 229 73 676 86 1349 99 -  -  
1039 78  X 81 22 141 27 89 X  
1040 42  X 224 11 1000 43 -   - 
1041 44  X 49 36 234 33 107 73 
1042 72  X 363 34 407   - -  
1043 30  X 36 13 240 32 - -  
1044 191 53 891 92 724 89      - -  
1045 145 54 692 69 1862 87 - -  
1046 398 42 182 22 2188 31 692 34 
1047 30  X 380 41 550 53 117 56 
1048 31  X 229 39 219 53 1862 79 
1049 62  X 355 22 692 43 331 44 
1050 18  X 29 13 78 27 282 51 
1051 182 73 427 80 631 94 - -  
1052 19  X 269 32 WFS  WFS       - -  
1053 38  X 676 85  WFS WFS  - -  
1054 34  X 126 30 324 35 141 57 
1055 186 35 229 30 398 41 - -  
1056 85  X 195 27 302 37 324 45 
1057 295 71 1000 84 1445 87 603 90 
1058 23  X 263 13 776 21 224 45 
1059 72  X 145 11 295 21 - -  
1060 36  X 182 40 794 43 209 39 
1061  * *  135 21 1259 43 219 88 
1062 195 65 724 79 1023 80 407 82 
1063 135 10 123 15 282 26 229 23 
1064 363 78 1479 79 851 86 776 78 
1065 20  X 282 19 1072 59 339 55 
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Baseline  
(Visit 1)  
6 Weeks (Visit 2) 
Immune 
Response to First 
Dose of Vaccine 
12 weeks (Visit 3) 
Immune 
Response to 
Second Dose of 
Vaccine 
18 Month 
Follow-Up  
(Visit 4) 
ROVE 
Study 
Number 
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
1066 130 42 339 17 WFS   WFS  - -  
1067 55  X  182 15 550 35 130 49 
1068 16  X 83 24 676 48 -  -  
1069 26  X 42 X  776 35 145 51 
1070 31  X 85 12 1259 61 214 62 
1071 16  X 166 18 457 47 282 42 
1072 575 78 2951 82 661 74 776 87 
1073 19  X 91 14 224 37 - -  
1074 195 52 1318 74 832 80 224 84 
1075 282 75 4365 90 1380 91 1000 93 
1076 115 79 2239 95 1622 88 1905 92 
1077 41  X 240 18 219 23 - -  
1078 158 72 7586 86 871 83 - -  
1079 78  X 363 17 871 29 - -  
1080 331 68 2089 93 1096 88 - -  
1081 2512 69 1622 84 1148 88 1905 90 
1082 17  X 85 X  490 40  - -  
1083 295 85 6166 96 1995 93 3162 95 
1084 45  X  WFS WFS  WFS  WFS  -  -  
1085 145 44 302 34 282 27 575 71 
1086 42  X 155 18 302 35  - -  
1087 85  X 229 18 813 42 1023 78 
1088 39  X 130 17 708 27 229 19 
1089 100 49 234 93 1413 93 977 94 
1090 204 61 977 86 1175 76 427 93 
1091 38  X 331 34 417 36 219 45 
1092 25  X 49 X  251 31 48  X 
1093 41  X 813 65 977 70 - -  
1094 65  X 851 85 1122 86 447 93 
1095 18  X 78 X  646 34 263 37 
1096 72  X 1738 96 2512 95  - -  
1097 18  X 214 28 794 52 275 57 
1098 22  X 100 14 380 24 47  X 
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Baseline  
(Visit 1)  
6 Weeks (Visit 2) 
Immune 
Response to First 
Dose of Vaccine 
12 weeks (Visit 3) 
Immune 
Response to 
Second Dose of 
Vaccine 
18 Month 
Follow-Up  
(Visit 4) 
ROVE 
Study 
Number 
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
TRFIA 
mIU/mL 
 
Avidity 
(%)  
1099 15 X  166 23 955 53 407 59 
1100 30  X 42  X 479 42 112 41 
1101 47  X 79 11 282 15 - -  
1102 17  X 38  X 347   126  40 
1103 59  X 2138 81  WFS WFS  - -  
1104 22  X 59  X 513 9 -       - 
1105 135 69 537 91 575 84 295 91 
1106 100 42 195 11 3311 60 871 72 
1107 17  X 83 14 2239 39 234 33 
1108 240 82 2188 88 1202   1202  74 
1109 72  X 1072 85 832   851  74 
1110  * *  110 36 977   437  48 
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Appendix 7.8: TRFIA Data (mIU/mL) and the Corresponding Avidity Readings 
(%) for Each ROVE Study Participant, at Each Study Visit.  
Key; X: TRFIA too low to allow accurate avidity to be carried out, *sample not 
available for testing (study participant difficult to bleed), - Did not participate in 
follow up visit, WFS: withdrew from study. 
 
 
Visit Number N 
Range (%) 
Mean (%) Median (%) SD (%) 
Minimum Maximum 
Visit 2 
(Six weeks) 
64 4 55 20 21 11 
Visit 3 
(12 weeks) 
67 9 80 36 35 13 
Visit 4 
(18 months) 
38 19 88 52 50 19 
Appendix 7.9: Summary of Avidity Readings for Each Visit during the 
Study. (See corresponding figure 3.8). 
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Appendix 7.10: Classification of Each Study Participant, Number of 
Doses Required to Seroconvert and Diamedix Screening Results.  
ROVE 
Study 
Number 
Six Week 
Avidity 
60% 
Dose Required for 
Seroconversion 
If Seronegative at 
Enrolment 
Humoral Subset 
Diamedix from 
Occupational 
Health  
1001 No Positive B‟line  PLR  Neg 
1002 No NLR NLR Neg 
1003 No Two NSC2 Neg 
1004 Yes Positive B‟line  PI Neg 
1005 Yes Positive B‟line  PI Neg 
1006 No One NSC1 Neg 
1007 No Two NSC2 Eq 
1008 No Two NSC2 Neg 
1009 Yes Positive B‟line  PI Neg 
1010 X  WFS WFS Neg 
1011 Yes Positive B‟line  PI Neg 
1012 No One NSC1 Neg 
1013 Yes Positive B‟line  PI Eq 
1014 Yes Positive B‟line  PI Neg 
1015 No Two NSC2 Neg 
1016 No* One NSC1 Neg 
1017 No Two NSC2 Neg 
1018 No One NSC1 Neg 
1019 No Two NSC2 Neg 
1020 Yes Positive B‟line  PI Neg 
1021 No Two NSC2 Neg 
1022 No Two NSC2 Neg 
1023 Yes Positive B‟line  PI Neg 
1024 No One NSC1 Neg 
1025 No One NSC1 Neg 
1026 No One NSC1 Neg 
1027 No NLR NLR Neg 
1028 No One NSC1 Neg 
1029 Yes Positive B‟line  PI Eq 
1030 Yes Positive B‟line  PI Neg 
1031 Yes Positive B‟line  PI Eq 
1032 No* One 
Outlier 
NSC1/NI 
Neg 
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ROVE 
Study 
Number 
Six Week 
Avidity 60% 
Dose Required 
for 
Seroconversion 
If Seronegative 
at Enrolment 
Humoral 
Subset 
Diamedix from 
Occupational 
Health  
1033 No Two NSC2 Neg 
1034 No Two NSC2 Neg 
1035 No One NSC1 Neg 
1036  X NLR NLR Neg 
1037 No Two NSC2 Neg 
1038 Yes Positive B‟line  PI Eq 
1039 No Two NSC2 Neg 
1040 No One NSC1 Neg 
1041 No Two NSC2 Neg 
1042 No One NSC1 Neg 
1043 No Two NSC2 Neg 
1044 Yes Positive B‟line  PI Neg 
1045 Yes Positive B‟line  PI Eq 
1046 No Positive B‟line  PLR Neg 
1047 No* One NSC1 Neg 
1048 No One NSC1 Neg 
1049 No One NSC1 Neg 
1050 No NLR NLR Neg 
1051 Yes Positive B‟line  PI Neg 
1052 No One NSC1 Neg 
1053 Yes One NI Neg 
1054 No Two NSC2 Neg 
1055 No Positive B‟line  PLR Neg 
1056 No One NSC1 Neg 
1057 Yes Positive B‟line  PI Eq 
1058 No One NSC1 Neg 
1059 No One NSC1 Neg 
1060 No One NSC1 Neg 
1061 No Two" WFS Neg 
1062 Yes Positive B‟line  PI Neg 
1063 No Two
&
 PLR Neg 
1064 Yes Positive B‟line  PI Neg 
1065 No One NSC1 Neg 
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ROVE 
Study 
Number 
Six Week 
Avidity 60% 
Dose Required 
for 
Seroconversion 
If Seronegative 
at Enrolment 
Humoral 
Subset 
Diamedix from 
Occupational 
Health  
1066 No Positive B‟line  PLR Neg 
1067 No One NSC1 Neg 
1068 No Two NSC2 Neg 
1069  X Two NSC2 Neg 
1070 No Two NSC2 Neg 
1071 No One NSC1 Neg 
1072 Yes Positive B‟line  PI Eq 
1073 No Two NSC2 Neg 
1074 Yes Positive B‟line  PI Eq 
1075 Yes Positive B‟line  PI Neg 
1076 Yes Positive B‟line  NI Neg 
1077 No One NSC1 Neg 
1078 Yes Positive B‟line  PI Neg 
1079 No One NSC1 Neg 
1080 Yes Positive B‟line  PI Eq 
1081 Yes Positive B‟line  PI Neg 
1082 X  Two NSC2 Neg 
1083 Yes Positive B‟line  PI Neg 
1084 X  WFS  WFS Neg 
1085 No Positive B‟line  PLR Neg 
1086 No One NSC1 Eq 
1087 No One NSC1 Neg 
1088 No One NSC1 Neg 
1089 Yes One 
Outlier 
(NSC1/NI) 
Neg 
1090 Yes Positive B‟line  PI Eq 
1091 No One NSC1 Neg 
1092  X Two NSC2 Neg 
1093 Yes One NI Neg 
1094 Yes One NI Neg 
1095  X Two NSC2 Neg 
1096 Yes One NI Neg 
1097 No One NSC1 Neg 
1098 No Two NSC2 Neg 
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ROVE 
Study 
Number 
Six Week 
Avidity 60% 
Dose Required 
for 
Seroconversion 
If Seronegative 
at Enrolment 
Humoral 
Subset 
Diamedix from 
Occupational 
Health  
1099 No One NSC1 Neg 
1100 X  Two NSC2 Neg 
1101 No Two NSC2 Neg 
1102  X Two NSC2 Neg 
1103 Yes One NI Neg 
1104 X  Two NSC2 Neg 
1105 Yes Positive B‟line  PI Neg 
1106 No One NSC1 Neg 
1107 No Two NSC2 Neg 
1108 Yes Positive B‟line  PI Neg 
1109 Yes One NI Neg 
1110 No Two" NSC2 Neg 
Appendix 7.10 continued             4 of 4 
 
Appendix 7.10: Classification of Each Study Participant, Number of Doses 
Required to Seroconvert and Diamedix Screening Results.  
Seroconversion was classified as a TRFIA reading of 130mIU/mL (log102.11).  
Subset classification was based on baseline TRFIA of 130mIU/mL, Six week avidity 
readings of 60% and TRFIA of 400mIU/mL (log102.60). Diamedix screening results 
(assayed when the HCW joined BLT NHS trust) were obtained from the occupational 
health database.  
Key: X: Visit 1 and 2 TRFIA readings were too low to allow accurate avidity readings 
to be taken, WFS; withdrew/withdrawn from study, Positive b‟line; positive TRFIA at 
baseline, SC1; Seroconverted following one dose, SC2; Seroconverted following two 
doses, „Immune‟; True secondary responder, Neg; negative (<15EU/mL) Eq; 
equivocal (15-19EU/mL), *Avidity readings were below 60%, but they were above 
low cut-off of 40%, “baseline (visit 1) serology was not available, but were classified 
according to subsequent serology readings, & this HCWs had log10 TRFIA readings 
of 2.13 at baseline, 2.09 at six weeks, and 2.45 at 12 weeks, and was classified as 
seroconverting after 2 doses, these two individuals were classified as outliers and 
did not group with the two populations seen at six weeks (primary responders = 
avidity <60%, TRFIA < log102.60; 400mIU/mL; secondary responders = avidity >60%, 
TRFIA > log102.60; 400mIU/mL), and were excluded from analysis. (1032 had a six 
week avidity reading was below 60% (55%), but experienced a nine fold increase in 
antibody titre following the first dose of vaccine (log102.92; 832mIU/mL), suggesting 
this individual was actually a false negative; 1089 had a baseline TRFIA of log102.00; 
100mIU/mL and an intermediate avidity of 49%, at six weeks avidity was at 93% 
although the corresponding TRFIA reading was below the log102.60 cut-off at 
log102.37; 234mIU/mL. 
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  Log10 TRFIA (mIU/ml) Avidity (%) 
  
n 
Range 
Mean SD Median n 
Range 
Mean SD Median 
  Minimum Maximum Minimum Maximum 
Baseline 
(Visit 1) 
32 1.18 (15) 
2.09 
(123) 
1.6 
(40) 
0.25 
1.62 
(42) 
2 33 42       
Six 
Weeks 
(Visit 2) 
32 
2.11 
(130) 
2.92 
(832) 
2.35 
(224) 
0.18 
2.34 
(219) 
32 4 55 24 12 22 
12 
Weeks 
(Visit 3) 
31 
2.34 
(219) 
3.52 
(3,311) 
2.75 
(562) 
0.25 
2.74 
(550) 
30 20 80 42 14 43 
18 
Months 
(Visit 4) 
22 1.81 (65) 
3.31 
(2,042) 
2.46 
(288) 
0.39 
2.4 
(251) 
21 30 81 49 19 45 
Appendix 7.11: Descriptive Statistics for TRFIA and Avidity Values for the NSC1 Subset. Study participants were 
classified into this subset if their baseline TRFIA readings were below log102.11; 130mIU/mL, (negative) and (if applicable) 
their corresponding avidity value was <60%. Their six week TRFIA was 130mIU/mL value with a corresponding avidity 
below 60% (seroconverted following one dose of vaccine).  
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  Log10TRFIA (mIU/ml) Avidity (%) 
  
n 
Range 
Mean SD Median n 
Range 
Mean SD Median 
  Minimum Maximum Minimum Maximum 
Baseline 
(Visit 1) 
29 1.18 (15) 1.89 (78) 
1.47 
(30) 
0.21 
1.43 
(27) 
0           
Six 
Weeks 
(Visit 2) 
29 1.45 (28) 
2.11 
(130) 
1.89 
(78) 
0.17 
1.92 
(83) 
22 5 36 20 9 20 
12 
Weeks 
(Visit 3) 
29 
2.15 
(141) 
3.35 
(2,239) 
2.65 
(447) 
0.27 
2.63 
(427) 
27 9 61 32 10 33 
18 
Months 
(Visit 4) 
21 1.18 (15) 
3.11 
(1,288) 
2.05 
(112) 
0.43 
2.1 
(126) 
13 62 84 51 18 48 
Appendix 7.12: Descriptive Statistics for TRFIA and Avidity Values for the NSC2 Subset. Study participants were 
classified into this subset if their baseline TRFIA readings were below log102.11; 130mIU/mL (negative), and (if applicable) 
their corresponding avidity value was <60%. Their six week TRFIA was <130mIU/mLvalue with a corresponding avidity 
below 60%, with 12 week TRFIA readings 130mIU/mL (seroconverted following two doses of vaccine). 
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  Log10TRFIA (mIU/ml) Avidity (%) 
  
n 
Range 
Mean SD Median n 
Range 
Mean SD Median 
  Minimum Maximum Minimum Maximum 
Baseline 
(Visit 1) 
6 
2.11 
(130) 
2.6 (397) 
2.24 
(174) 
0.21 
2.13 
(135) 
5 10 44 37 14 42 
Six 
Weeks 
(Visit 2) 
6 
2.09 
(123) 
2.53 
(337) 
2.31 
(204) 
0.16 
2.32 
(209) 
6 15 34 20 6 17 
12 
Weeks 
(Visit 3) 
5 
2.36 
(229) 
3.34 
(2,192) 
2.69 
(490) 
0.45 
2.53 
(339) 
5 26 41 36 10 35 
18 
Months 
(Visit 4) 
4 1.94 (87) 
2.84 
(687) 
2.38 
(240) 
0.45 
2.36 
(229) 
3 23 71 41 35 21 
Appendix 7.13: Descriptive Statistics for TRFIA and Avidity Values for the PLR Subset. Study participants were 
classified into this subset if their baseline TRFIA readings  log102.11; 130mIU/mL (positive) with a corresponding avidity 
of <60%. In addition, their six week TRFIA was below log102.60; 400mIU/mL (low responder) with a corresponding avidity 
below 60%. The six HCWs in this subset were 1001, 1046, 1055, 1063, 1066, 1085. 
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  Log10TRFIA (mIU/ml) Avidity (%) 
  
n 
Range 
Mean SD Median n 
Range 
Mean SD Median 
  Minimum Maximum Minimum Maximum 
Baseline 
(Visit 1) 
7 1.58 (38) 
2.06 
(115) 
1.82 
(66) 
0.17 
1.84 
(68) 
1 79        
Six 
Weeks 
(Visit 2) 
7 
2.83 
(676) 
3.35 
(2,239) 
3.09 
(1,230) 
0.21 
3.03 
(1,072) 
7 65 96 85 10 85 
12 
Weeks 
(Visit 3) 
5 
2.92 
(832) 
3.4 
(2,512) 
3.12 
(1,318) 
0.17 
3.1 
(1,259) 
4 70 95 85 11 87 
18 
Months 
(Visit 4) 
3 
2.65 
(447) 
3.28 
(1,905) 
2.96 
(912) 
0.26 
2.96 
(912) 
2 92 93    
Appendix 7.14: Descriptive Statistics for TRFIA and Avidity Values for the NI Subset. Study participants were 
classified into this subset if their baseline TRFIA readings were below log102.11; 130mIU/mL (negative), and their six week 
TRFIA was above log102.60; 400mIU/mL with a corresponding avidity above 60% (secondary responder; immune). The 
seven HCWs in this subset were 1053, 1076, 1093, 1094, 1096, 1103 and 1109. 
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  Log10 TRFIA (mIU/ml) Avidity (%) 
  
n 
Range 
Mean SD Median n 
Range 
Mean SD Median 
  Minimum Maximum Minimum Maximum 
Baseline 
(Visit 1) 
28 
2.13 
(135) 
3.4 
(2,512) 
2.49 
(309) 
0.34 
2.36 
(229) 
28 41 89 71 12 71 
Six 
Weeks 
(Visit 2) 
28 
2.63 
(427) 
3.88 
(7,586) 
3.18 
(1,514) 
0.32 
3.13 
(1,349) 
28 64 96 84 7 84 
12 
Weeks 
(Visit 3) 
27 
2.76 
(575) 
3.31 
(2,042) 
3.02 
(1,047) 
0.15 
3.01 
(1,023) 
26 51 99 86 6 87 
18 
Months 
(Visit 4) 
20 
2.35 
(224) 
3.5 
(3,162) 
2.89 
(776) 
0.3 
2.84 
(692) 
20 65 95 73 8 72 
Appendix 7.15: Descriptive Statistics for TRFIA and Avidity Values for the PI Subset. Study participants were 
classified into this subset if their baseline TRFIA readings were above log102.11; 130mIU/mL (positive), with a 
corresponding avidity of >60%. Their six week TRFIA values were above log102.60; 400mIU/mL with a corresponding 
avidity above 60% (secondary responders; immune).  
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Appendix 7.16: History of Chickenpox or Varicella Vaccination Prior to 
Study Enrolment for Each Study Participant 
 
 History of Chickenpox   
ROVE 
Study 
Number 
History of 
Chickenpox 
Age of 
Chickenpox* 
Number of 
Years Since 
Chickenpox$ 
Additional 
Vaccination 
1001 No      
1002 No     Third dose 
1003 No      
1004 No       
1005 Once 12 19   
1006 No       
1007 No      
1008 No       
1009 No      
1010 No     
1 Year 
Previously 
1011 No      
1012 No       
1013 No      
1014 No       
1015 No      
1016 No       
1017 No      
1018 No       
1019 No      
1020 Unknown       
1021 No      
1022 No       
1023 Once 16 26   
1024 No       
1025 No      
1026 No       
1027 No    Third dose 
1028 No       
1029 No      
1030 No       
1031 Once <1 year 26   
1032 No       
Appendix 7.16 continued        1 of 4 
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 History of Chickenpox   
ROVE 
Study 
Number 
History of 
Chickenpox 
Age of 
Chickenpox* 
Number of 
Years Since 
Chickenpox$ 
Additional 
Vaccination 
1033 No      
1034 No       
1035 No      
1036 No       
1037 No      
1038 No       
1039 No      
1040 No       
1041 No      
1042 No       
1043 No      
1044 Once < 1 year 31   
1045 No      
1046 No       
1047 No      
1048 No       
1049 No      
1050 Unknown       
1051 Once < 1 year 35   
1052 No       
1053 No    
1 Year 
Previously 
1054 No       
1055 No      
1056 No       
1057 Once 40 18   
1058 No       
1059 No      
1060 No       
1061 No      
1062 No       
1063 No      
1064 Once 3 21   
1065 No       
Appendix 7.16 continued        2 of 4 
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 History of Chickenpox   
ROVE 
Study 
Number 
History of 
Chickenpox 
Age of 
Chickenpox* 
Number of 
Years Since 
Chickenpox$ 
Additional 
Vaccination 
1066 No       
1067 No      
1068 No       
1069 No      
1070 Twice 15 14   
1071 No      
1072 No       
1073 No      
1074 No     
1 year 
Previously 
1075 Twice 8 24   
1076 Once 6 23   
1077 No      
1078 Once <1 year 43   
1079 No      
1080 No       
1081 No      
1082 No       
1083 Once 5 23   
1084 No       
1085 No      
1086 No       
1087 No      
1088 No       
1089 Once 22 3   
1090 Once 3     
1091 No      
1092 No       
1093 No      
1094 Once 9 13   
1095 No      
1096 No       
1097 No      
1098 No       
Appendix 7.16 continued        3 of 4 
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 History of Chickenpox   
ROVE 
Study 
Number 
History of 
Chickenpox 
Age of 
Chickenpox* 
Number of 
Years Since 
Chickenpox$ 
Additional 
Vaccination 
1099 No      
1100 No       
1101 Once < 1 year 31   
1102 No       
1103 No      
1104 No       
1105 No      
1106 No       
1107 No      
1108 Once 3 28   
1109 Once 6 44   
1110 No       
Appendix 7.16        4 of 4 
 
Appendix 7.16: History of Chickenpox or Varicella Vaccination Prior to Study 
Enrolment for Each Study Participant. Data on additional vaccination within 
the ROVE study is also given.  
Key: *In cases where study participants experienced varicella twice, the age 
is given of the last episode, <1 year; chickenpox under the age of 1 year old, 
$ In cases where study participants experienced varicella twice, the age is 
given since the last episode, Previous; Previously vaccinated, see appendix 
8.17 and 8.19 for details, Third dose; third dose administered during the 
ROVE study.  
 
 
Study 
Number 
Gender Age Ethnicity 
Birth 
Country 
Years 
UK 
1010 Male 29 
Indian 
subcontinent 
India 4 
1053 Female 29 Caucasian UK 29 
1074 Female 34 Black Jamaica 7 
Appendix 7.17: Demographic Data of HCWs who were Previously 
Vaccinated Prior to Enrolment in the ROVE Study. 
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Previous 
vaccination 
ROVE 
Vaccination  
Serology   
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C
o
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m
e
n
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1010 GSK 
1 
dose 
Merck 
1 
dose 
1.34 
(22) 
NA WFS WFS WFS WFS WFS WFS 
Developed 
fever and 
general 
malaise after 
1st dose  
1053 GSK 
2 
doses 
Merck 
1 
dose 
1.58 
(38) 
NA 
2.83 
(676) 
85% WFS WFS WFS WFS 
Seroconveted 
after 1st dose 
1074 GSK 
2 
doses 
Merck 
2 
doses 
2.29 
(195) 
52% 
3.12 
(1,318) 
74% 
2.92 
(832) 
80% 
2.92 
(832) 
66% 
Requested 
2nd dose as 
different 
brand of 
vaccine to 
previous 
course 
Appendix 7.18: HCWs who were Previously Vaccinated Prior to Enrolment in the ROVE Study. Key: WFS; withdrew 
from study, NA; Not applicable. Three HCWs were vaccinated one year prior to enrollment into the ROVE study, whilst 
employed at other NHS trusts.
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Appendix 7.19: Classification of Each Study Participant at Follow-up 
with Corresponding Humoral Subset Classification During the Study: 
 
ROVE 
Study 
Number 
Humoral Subset 
Classification at 18 
Month Follow-Up 
1001 PLR  Negative 
1002 NLR - 
1003 NSC2 Negative 
1004 PI Boost 
1005 PI Retained 
1006 NSC1 - 
1007 NSC2 Negative 
1008 NSC2 Retained 
1009 PI Retained 
1010 WFS - 
1011 PI Retained 
1012 NSC1 - 
1013 PI Retained 
1014 PI - 
1015 NSC2 Negative 
1016 NSC1 Retained 
1017 NSC2 Retained 
1018 NSC1 Boost 
1019 NSC2 Negative 
1020 PI Boost 
1021 NSC2 Boost 
1022 NSC2 Negative 
1023 PI Retained 
1024 NSC1 Negative 
1025 NSC1 Negative 
1026 NSC1 Negative 
1027 NLR Negative 
1028 NSC1 - 
1029 PI Retained 
1030 PI - 
1031 PI Boost 
1032 Outlier NSC1/NI Retained 
 
Appendix 7.19 continued                  1 of 4 
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ROVE 
Study 
Number 
Humoral 
Subset 
Classification at 18 
Month Follow-Up 
1033 NSC2 - 
1034 NSC2 Retained 
1035 NSC1 Negative 
1036 NLR Negative 
1037 NSC2 - 
1038 PI - 
1039 NSC2 Negative 
1040 NSC1 - 
1041 NSC2 Negative 
1042 NSC1 - 
1043 NSC2 - 
1044 PI - 
1045 PI - 
1046 PLR Retained 
1047 NSC1 Negative 
1048 NSC1 Boost 
1049 NSC1 Retained 
1050 NLR Boost 
1051 PI - 
1052 NSC1 - 
1053 NI - 
1054 NSC2 Retained 
1055 PLR - 
1056 NSC1 Boost 
1057 PI Retained 
1058 NSC1 Retained 
1059 NSC1 - 
1060 NSC1 Retained 
1061 WFS Retained 
1062 PI Retained 
1063 PLR Retained 
1064 PI Retained 
1065 NSC1 Retained 
 
               Appendix 7.19 continued                        2 of 4 
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ROVE 
Study 
Number 
Humoral 
Subset 
Classification at 18 
Month Follow-Up 
1066 PLR - 
1067 NSC1 Retained 
1068 NSC2 - 
1069 NSC2 Retained 
1070 NSC2 Retained 
1071 NSC1 Retained 
1072 PI Boost 
1073 NSC2 - 
1074 PI Retained 
1075 PI Retained 
1076 NI Boost 
1077 NSC1 - 
1078 PI - 
1079 NSC1 - 
1080 PI - 
1081 PI Boost 
1082 NSC2 - 
1083 PI Boost 
1084 WFS - 
1085 PLR Boost 
1086 NSC1 - 
1087 NSC1 Boost 
1088 NSC1 Retained 
1089 
Outlier 
(NSC1/NI) 
Retained 
1090 PI Retained 
1091 NSC1 Retained 
1092 NSC2 Negative 
1093 NI - 
1094 NI Retained 
1095 NSC2 Retained 
1096 NI - 
1097 NSC1 Retained 
1098 NSC2 Negative 
                  
Appendix 7.19  continued                      3 of 4 
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ROVE Study 
Number 
Humoral 
Subset 
Classification at 18 
Month Follow-Up 
1099 NSC1 Retained 
1100 NSC2 Negative 
1101 NSC2 - 
1102 NSC2 Negative 
1103 NI - 
1104 NSC2 - 
1105 PI Retained 
1106 NSC1 Retained 
1107 NSC2 Retained 
1108 PI Boost 
1109 NI Boost 
1110 NSC2 Retained 
                 Appendix 7.19                          4 of 4 
  
Appendix 7.19: Classification of Each Study Participant at Follow-up with 
Corresponding Humoral Subset Classification During the Study. 
Key: WFS; withdrew/withdrawn from study, NSC1; TRFIA negative at 
baseline, seroconverted following one dose, NSC2; TRFIA negative at 
baseline seroconverted following two doses, PI; TRFIA positive at baseline, 
„immune‟ (secondary responder), - HCW did not participate in follow-up visit, 
Negative; HCW had a TRFIA titre below log102.11 (130mIU/mL) at follow-up, 
Retained; HCW had retained an TRFIA titre at or above 130mIU/mL; Boost; 
HCWs had TRFIA titres above 130mIU/mL at 12 weeks, and TRFIA titres had 
increased at 18 months, these two individuals were classified as outliers and 
did not group with the two populations seen at six weeks (primary responders 
= avidity <60%, TRFIA < log102.60; 400mIU/mL; secondary responders = 
avidity >60%, TRFIA >log102.60; 400mIU/mL), and were excluded from 
analysis.  
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    Study Number 
    1032 1089 
Baseline  
(Visit 1) 
Log10TRFIA (mIU/mL) 1.97 (94) 2.00 (101) 
Avidity (%) N/A 49 
FAMA 4 N/A 
Six Weeks  
(Visit 2) 
Log10TRFIA (mIU/mL) 2.92 (823) 2.37 (236) 
Avidity (%) 55 92 
FAMA 8 N/A 
12 Weeks 
 (Visit 3) 
Log10TRFIA (mIU/mL) 2.67 (464) 
3.15 
(1,424) 
Avidity (%) 80 93 
FAMA >8 N/A 
18 Month 
Follow-Up  
(Visit 4) 
Log10TRFIA (mIU/mL) 2.29 (194) 2.99 (980) 
Avidity (%) 81 93 
FAMA 8 N/A 
 
Appendix 7.20: Summary of Serological Data (TRFIA Titres, Avidity and 
FAMA Scores) for Humoral Subset Outliers. 
Key: N/A; not applicable as corresponding TRFIA <100mIU/mL, or FAMA not 
performed on these samples. (1032 had a six week avidity reading was below 
60% (55%), but experienced a nine fold increase in antibody titre following 
the first dose of vaccine (log102.92; 832mIU/mL), suggesting this individual 
was actually a false negative; 1089 had a baseline TRFIA of log102.00; 
100mIU/mL and an intermediate avidity of 49%, at six weeks avidity was at 
93% although the corresponding TRFIA reading was below the log102.60 cut-
off at log102.37; 234mIU/mL. 
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    Study Number 
    1032 1089 
Im
m
u
n
e
 
S
ta
tu
s
  
Baseline Diamedix Negative Negative 
Baseline TRFIA Negative Negative 
Baseline FAMA Positive N/A 
Six Week Avidity Unclassified Previously Immune 
C
la
s
s
if
ic
a
ti
o
n
 
D
u
ri
n
g
 S
tu
d
y
 Doses Required to 
Seroconvert 
One One 
Humoral Subset 
SC1/False 
Negative 
SC1/False  
Negative 
18 Month 
Classification 
Immune (Retained) Immune (Retained) 
D
e
m
o
g
ra
p
h
ic
s
 Gender Male Female 
Ethnicity Black Black 
Country of Birth Uganda Jamaica 
Age (Years) 35 25 
Years Resided in 
the UK 
8 6 
H
is
to
ry
 History of C'Pox No Yes 
Age C'pox (Years) N/A 22 
Previous 
Vaccination 
No No 
E
x
p
o
s
u
re
 D
u
ri
n
g
 
S
tu
d
y
 
Basline (Visit1) None 
Occuptational HZ;  
3 Days Prior 
Six Weeks (Visit 2) 
Occuptational HZ; 
28 Days Prior 
None 
12 Weeks (Visit 3) None None 
18 Month Follow-
Up (Visit 4) 
X4 Occupational 
HZ; Last Exposure 
35 Days Prior 
None 
 
Appendix 7.21: Summary of Demographics, Assay Status during Study 
and Exposure Data, for the Two Humoral Subset Outliers. 
Key: HZ; herpes zoster, C‟Pox; chickenpox, Diamedix negative; <15EU/mL, 
TRFIA negative; <130mIU/mL (log102.11), FAMA positive; >2, N/A; not 
applicable, SC1; seroconverted after one dose. 
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Appendix 7.22: FAMA with Corresponding TRFIA (mIU/mL) and Avidity 
(%) Values for 16 ROVE Study Participants at Four Time Points 
Study 
Number 
and 
Humoral 
Subset  
VISIT TRIFIA AVID FAMA 
  
Study 
Number 
and 
Humoral 
Subset 
VISIT TRIFIA AVID FAMA 
1001 
(PLR) 
V1 130 28 <2   
1020 
(PI) 
V1 639 84 >8 
V2  207 15 8   V2  1406 83 >8 
V3 229 38 8   V3 1000 91 >8 
V4 87 X 8   V4 1447 87 8 
1005 
(PI) 
V1 215 59 4;4   
1022 
(NSC2) 
V1 15 X <2 
V2  2068 84 >8   V2  28 23 2;(<2) 
V3 1744 79 >8   V3 415 19 8 
V4 695 70 8   V4 35 X <2 
1009 
(PI) 
V1 1000 48 >8   
1023 
(PI) 
V1 263 83 >8; 8 
V2  1282 64 >8   V2  1647 95 >8 
V3 885 51 >8   V3 844 96 >8 
V4 717 36 2;8   V4 604 77 >8 
1013 
(PI) 
V1 183 70 <2   
1025 
(NSC1) 
V1 23 X <2 
V2  700 81 8   V2  132 21 >8 
V3 778 85 8   V3 322 31 8 
V4 463 72 4   V4 65 X <2 
1015 
(NSC2) 
V1 37 X 4   
1026 
(NSC2) 
V1 41 X <2 
V2  96 26 2;4   V2  128 26 4 
V3 429 33 8   V3 481 34 >8 
V4 74 X >8   V4 116 28 8 
1017 
(NSC2) 
V1 64 X 4   
1027 
(NLR) 
V1 66 X <2 
V2  125 28 8   V2  118 6 <2 
V3 374 25 >8   V3 126 11 <2 
V4 148 29 <2   V4 122 48 <2 
1018 
(NSC1) 
V1 72 X <2   
1029 
(PI) 
V1 942 86 >8 
V2  176 35 4   V2  1123 81 >8 
V3 398 44 >8   V3 856 80 >8 
V4 2040 81 >8   V4 574 72 >8 
1019 
(NSC2) 
V1 21 X <2   1032 
Outlier 
(NI/NSC1) 
 
V1 94 X 4 
V2  64 X 8   V2  823 55 8 
V3 326 30 8   V3 464 80 >8 
V4 15 X <2   V4 194 81 8 
 
Key; Visit: V1 – baseline, V2: 6 weeks, V3: 12 weeks; V4 18 month Follow up, 
NSC1/2; Negative-seroconverted after one/two dose(s), NLR; Negative low 
responder (humoral non-responder to vaccine), NI; Negative immune (secondary 
responder), PLR; positive low responder PI; positive immune (secondary responder), 
FAMA: <2 = negative, X: Avidity was not carried out as TRFIA reading was too low to 
allow accurate avidity assay to be carried out.  Values in red represent discordant 
negative/positive status between assays. 
 403 
 
Appendix 7.23: Vaccine Related Rash: 
One study participant developed a vaccine related rash 13 days after 
receiving one dose of Merck vaccine (lot NA29040). The HCW was a 31 year 
old female of Indian ethnicity, who was born and raised in India and had lived 
in the UK for one year prior to the study. At enrolment this individual gave a 
negative history of varicella and was deemed Negative at enrolment with a 
TRFIA reading of log101.28; (19mIU/ml).  
 
The individual was visited by the ROVE research nurse three days after the 
onset of symptoms. The HCW had a mild rash consisting of five lesions; one 
on the forehead, one on each arm, and one on both the spine and abdomen 
and also reported feeling tired at the onset of symptoms. The research nurse 
recorded a body temperature of 37.8oC; the lesions were examined and 
swabbed and a full set of blood samples were taken. Vesicle swabs were 
transported to the laboratory in saline and DNA was extracted within 2h of 
collection. As can be seen from appendix 7.24 vaccine virus DNA was 
obtained from all vesicle fluids. The date of recovery was noted as 10 days 
after the onset of symptoms. The TRFIA reading obtained from serum drawn 
three days after the rash developed was 30mIU/ml and VZV specific IgM was 
also detected. Six weeks after the subject was first vaccinated, their antibody 
titre had risen log102.43 (269mIU/ml) with an avidity of 32%. The HCW was 
subsequently withdrawn from the study and the second dose of vaccine was 
not administered.  
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Appendix 7.24: Confirmation of a Vaccine Related Rash in ROVE Study 
Participant 1052. Agarose Gel of sma1 PCR carried out on DNA extracted 
from blood and fluid of vaccine related rash vesicles from ROVE study 
participant 1052. Key: WT +ve; wild type positive, -ve; negative, bp; base pair. 
 
 
  
Baseline  
(Visit 1) 
Six weeks  
(Visit 2) 
12 weeks  
(Visit 3) 
18 Month 
Follow-Up 
 (Visit 4) 
  
Negative Positive  Negative Positive  Negative Positive  Negative Positive  
% 69 31 30 70 4 96 25 75 
n 74 34 32 76 4 99 19 56 
Appendix 7.25: Summary of Positive TRFIA Status at each Study Time 
Point, Classified According to the TRFIA cut-off of log102.11 
(130mIU/ml). (See corresponding figure 3.14). 
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Appendix 7.26: An Example of Gating Used to Identify Tetramer+ CD4+ T Cells Ex Vivo. Lymphocytes were identified 
by size and granularity (using forward and side scatter); live lymphocytes (T cells) were identified as Viaprobe, CD14 and 
CD19 (PerCP) negative and subsequently plotted by CD4 (P‟ Blue) against tetramer (PE). Key: PerCP; Peridinin 
chlorophyll protein, PE; Phycoerythrin, P‟Blue; Pacific Blue. 
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Appendix 7.27: An Example of Gating Used to Identify Tetramer+ CD4+ T Cells Following Short Term Culture. 
Lymphocytes were identified by size and granularity (using forward and side scatter); live lymphocytes (T cells) were 
identified as Viaprobe, CD14 and CD19 (PerCP) negative and subsequently plotted by CD4 (P‟ Blue) against tetramer 
(PE). Key: PerCP; Peridinin chlorophyll protein, PE; Phycoerythrin, P‟Blue; Pacific Blue. (1018, visit 3, gE). 
 
 407 
 
    Glycoprotein E IE63 
Number Ex Vivo Lines (10 Day Culture)  Ex Vivo Lines (10 Day Culture)  
Study (Subset) Visit  
Population 
Size 
% Tet+ 
(n) 
Population 
Size 
% Tet+ 
(n) 
Population 
Size 
% Tet+ 
(n) 
Population 
Size 
% Tet+ 
(n) 
1001 (PLR/NL) 
V1 4 0 (0) X X 4 0 (0) X X 
V2 Sample Not Available 
V3 19,199 0.010 (2) X X 2,325 0 (0) X X 
V4 5,946 0 (0) 13,931 0 21,721 
0.022 
(5) 
968 4.545 
1018 
(NSC1/Boost) 
V1 96 0 (0) X X 45 0 (0) X X 
V2 6,082 0.033 (2) 15,766 0 7,778 
0.051 
(4) 
4,853 0 
V3 31,160 
0.0006 
(2) 
573,134 3.24 27,431 0.01 (9) 807,500 3.98 
V4 37,671 
0.029 
(13) 
X X 107,873 
0.016 
(17) 
X X 
1028 (NSC1) 
V1 571 0 (0) X X 733 0 (0) X X 
V2 1,758 0 (0) 9,114 0.0219 1,412 
0.212 
(3) 
4,860 0.103 
V3 2,269 0.042 (1) X 2,090 
0.144 
(3) 
X 
V4 Sample Not Available 
1058 (NSC1/R) 
V1 81 0 (0) X X 111 0 (0) X X 
V2 2,771 0 (0) X 2,249 
0.089 
(2) 
X 
V3 348 0 (0) X X 354 0 (0) X X 
V4 17,213 0.034 (5) 725,763 0.004271 7,225 
0.055 
(4) 
463,239 0.002375 
Appendix 7.28                                                                                                                                                                      (1 of 2) 
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    Glycoprotein E IE63 
Number Ex Vivo Lines (10 Day Culture)  Ex Vivo Lines (10 Day Culture)  
Study 
(Subset)  
Visit  
Population 
Size 
% Tet+ 
(n) 
Population 
Size 
% Tet+ 
(n) 
Population 
Size 
% Tet+ 
(n) 
Population 
Size 
% Tet+ 
(n) 
1067 
(NSC1/R) 
V1a 52,632 0.01 (6) 569,995 0.51 56,546 0.004 (3) 73,892 0.0298 
V1b 34,838 0.021 (7) X X 38,090 0.024 (9) X X 
V2 5,308 
0.0188 
(1) 
9,640 0.0519 7,712 0.05 (4) 7,416 0.027 
V3 6,771 0.030 (2) X X 3,389 0 (0) X X 
V4 34,390 0.003 (3) 860,968 0.12 20,804 0.001 (3) 265,168 0.0211 
1088 
(NSC1/R) 
V1 884 0 X X 477 0 (0) X X 
V2a 987 0 (0) 
X X 
881 0 (1) 
X X 
V2b 691 0 (0) X X 
V3 14,736 0.007(1) X X 9,299 0.022 (2) 25,537 0.117 
V4 1,000 0 (0) X X 1,199 0.03 (2) X 
1106 
(NSC1/R) 
V1 21,602 0 (0) 12,783 0.0548 11,635 0 (0) 216,890 0.012 
V2 11,248 0.009 (1) X X 5,544 0 (0) X X 
V3a 8,779 0.034 (3) 
8,403 0 
7,689 0.065 (5) 
11,348 0 
V3b 4,972 0.02 (1) 6,913 0.014 (1) 
V4 209 0 (0) X X 95 0 (0) X X 
Appendix 7.28                                                  2 of 2   
Appendix 7.28 Percentage of Tetramer
+
, CD4
+
 T Cells Quantified Ex Vivo and Following 10 Days of Culture with the Corresponding Peptide.  
Key: PLR; Positive Low Responder, NSR1; Negative, „Susceptible‟ Responded to One dose, V1; visit 1 (baseline), V2; visit 2 (s ix weeks post vaccination), 
V3; visit 3 (12 weeks post first, six weeks post second vaccination), V4; visit 4 (18 month follow-up), a and b; two sets of surface markers were used on these 
samples, X; T cell lines were not set up for these samples, or a second set of surface stains was not used. The number of tetramer
+
 cells are expressed as a 
percentage of the population size (total number of live, CD14
-
 CD19
-
 lymphocytes). 
